COMPREHENSIVE MASS SPECTROMETRY STUDIES FOR STRUCTURAL CHARACTERIZATION AND QUANTITATIVE DETERMINATION OF HETEROGENEOUS CARBOHYDRATE MOIETIES DERIVED FROM GLYCOPROTEINS FOR THERAPEUTIC PROTEIN DEVELOPMENT AND BIOMARKER DISCOVERY by Gashash, Ebtesam
Georgia State University 
ScholarWorks @ Georgia State University 
Chemistry Dissertations Department of Chemistry 
5-6-2019 
COMPREHENSIVE MASS SPECTROMETRY STUDIES FOR 
STRUCTURAL CHARACTERIZATION AND QUANTITATIVE 
DETERMINATION OF HETEROGENEOUS CARBOHYDRATE 
MOIETIES DERIVED FROM GLYCOPROTEINS FOR THERAPEUTIC 
PROTEIN DEVELOPMENT AND BIOMARKER DISCOVERY 
Ebtesam Gashash 
Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss 
Recommended Citation 
Gashash, Ebtesam, "COMPREHENSIVE MASS SPECTROMETRY STUDIES FOR STRUCTURAL 
CHARACTERIZATION AND QUANTITATIVE DETERMINATION OF HETEROGENEOUS CARBOHYDRATE 
MOIETIES DERIVED FROM GLYCOPROTEINS FOR THERAPEUTIC PROTEIN DEVELOPMENT AND 
BIOMARKER DISCOVERY." Dissertation, Georgia State University, 2019. 
https://scholarworks.gsu.edu/chemistry_diss/162 
This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ 
Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized 
administrator of ScholarWorks @ Georgia State University. For more information, please contact 
scholarworks@gsu.edu. 
COMPREHENSIVE MASS SPECTROMETRY STUDIES FOR STRUCTURAL 
CHARACTERIZATION AND QUANTITATIVE DETERMINATION OF 
HETEROGENEOUS CARBOHYDRATE MOIETIES DERIVED FROM GLYCOPROTEINS 
FOR THERAPEUTIC PROTEIN DEVELOPMENT AND BIOMARKER DISCOVERY 
 
 
by 
 
 
EBTESAM GASHASH 
 
Under the Direction of Peng Georgie Wang, PhD 
 
ABSTRACT 
Among a wide range of post-translational modifications, O- and most frequently N-linked 
glycosylation has been attracting most of the researchers’ attention. Glycoproteins are common in 
all eukaryotic living cells and play essential roles covering the spectrum from those imperceptible 
to those critical for an organism to survive. There is ample indication that aberrant glycosylation 
may affect many biological phases during the protein life-cycle. Recent state-of-the-art mass 
spectrometry techniques allow thorough explorations of complex carbohydrate moieties derived 
from biological molecules. These techniques extend the scientists’ ability to enhance the efficacy 
of carbohydrate-based drugs as well as discovering early glycan-based biomarkers associated with 
numerous acute diseases.  
In this dissertation, two mass spectrometry techniques, covered in Chapter 1, have been 
employed for qualitatively and quantitatively characterizing protein-derived carbohydrate 
moieties, including N- and O-glycopeptides as well as free glycans derived from biological 
specimens. In Chapter 2, an RP-LC-MS/MS system functionalized with multiple fragmentation 
performances, specifically CID and HCD, is utilized to survey all probable N- and O-glycosites 
along the backbone of a coagulation factor, human plasma von Willebrand Factor, with full 
characterization of covalently linked N- and O-glycoforms.  N-glycosite occupancy varied along 
the protein backbone chain. 181-characterized glycoforms are specified into either N- or O-
glycosites. Noteworthy, two previously unreported N-glycosites within domain D’(TIL’-E’) are 
occupied with N-glycoforms. In Chapter 3, MALDI-TOF technique is utilized to explore aberrant 
N-glycosylation in the frontal cortex (FC) region extracted from Alzheimer Disease (AD) patients’ 
brains in comparison with age-matched individuals. AD FC N-glycome exhibits a significant 
decrease in galactosylation and fucosylation as well as sialylation compared to normal FC. Eight 
N-glycoforms, detected across all cases, are significantly differentiated between the examined 
cohorts. Also, high mannose, hybrid, complex, and truncated N-glycans are considerably changed 
in disease tissues. In Chapter 4, altered N-glycosylation of soluble serum glycoproteins derived 
from colon cancer (CC) patients’ blood sera is characterized by MALDI-TOF. N-glycome of CC 
glycoproteins shows an increase in aglactosylation, fucosylation, and sialylation, especially 
sialylated core-fucosylated species. The knowledge of this work (Chapter 5) might improve our 
perception of disease pathogenesis or enhance the efficacy of current therapy treatments 
 
INDEX WORDS: LC-MS/MS, MALDI-MS, Glycosylation, CID, HCD, Plasma von Willebrand 
Factor (VWF), Occupancy, HILIC, Alzheimer’s disease (AD), frontal cortex (FC). Colon 
Cancer.  
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1 CHAPTER 1. INTRODUCTION TO GLYCOMIC AND GLYCOPROTEOMIC 
ANALYSIS  
1.1 Introduction 
Glycosylation is one of the most common co- and post-translational modifications (PTMs) of 
proteins. Carbohydrate moieties cover the surface of all eukaryotic living cells and have essential 
roles in cell communications and self-functions.1 Therefore, body health enormously depends on 
perfection in the glycosylation process, and thus many illnesses including diabetes,2 congenital 
disorder of glycosylation (CDG),3 or inflammatory diseases such as neurodegenerative diseases 
(NDDs)4-7 and cancer8, 9 have involved reflection of blemishes in this process.  For comprehending 
the root of carbohydrate-mediated cell communications, protein bindings, or biological functions, 
grasp extensive details of glycoprotein structure is necessary. Because of the inevitable diversity 
of carbohydrate structures and other PTM processes taking place on protein, the task is 
challenging. That is, a thorough analysis of glycoprotein structure must be able to identify peptide 
sequence, distinguish attached glycan sites, and elucidate glycan structures. 
Recently, mass spectrometry (MS) is a promising technique employed to profile intact glycans 
in addition to prototypically digested glycopeptides.10, 11 The latter MS-based approach reveals not 
only the glycosylation position along the protein backbone but also the structure of the attached 
glycoforms (microheterogeneity).12 For decades, glycoconjugates are attracting the scientific 
community attention as potential biomarkers for numerous diseases13, 14 and as a critical PTM 
quality for engineered therapeutic proteins.15, 16 Several tandem MS techniques including collision-
induced dissociation (CID), High-energy collision dissociation (HCD), or electron capture/transfer 
dissociation (ECD, ETD) have been employed for glycomics, glycoproteomics or proteomics. 
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Each MS fragmentation technique has characteristically preferential cleavages17-20 so that distinct 
structural information, however, can be obtained for the same protein. Thus, one technique is 
insufficient for a comprehensive depiction of the glycoprotein structure. Although CID-based 
tandem MS technique has been successfully utilized for profiling global glycoforms,21 a 
combination of tandem MS analyses of intact glycopeptides after proteolytic digestion is an 
idealistic strategy that reveals correlative and simultaneous information on both portions and 
carbohydrate conjugates, including attachment sites.22, 23 In this research work, we have employed 
multiple MS-based techniques to characterize the quality of the glycosylation pattern in a 
therapeutic protein and determine apparent changes in this biological process caused by a 
pathological disease development. 
1.2 Glycosylation and its biological importance 
Among a wide range of PTMs experimentally and putatively reported on Swiss-port 
database, O-linked glycosylation and most frequently N-linked glycosylation PTM have been 
attracting researchers’ attention.24 It is estimated that more than half of all human proteins are 
glycosylated to modulate the functionality of these proteins.25 Glycosylation is one of the most 
common co- and post-translational modification (PTM) of proteins in all eukaryotic living cells.26 
Based on the amino acid attached to the carbohydrate moiety, glycosylation can be classified into 
two broad classes: N-linked and O-linked glycosylation. In N-glycosylation, the glycan portion, 
starting with β-N-Acetylglucosamine (GlcNAc), is covalently linked to Asparagine (Asn or N) 
within a peptide consensus sequence of NX(S/T/C), in which X is any amino acid except proline 
(Pro or P). The symbols S, T and C are Serine (Ser), threonine (Thr) and Cysteine (Cys), 
respectively. All N-linked glycans consist of a conserved core containing five monosaccharides 
(Asn-GlcNAc2Man3), in which Man represents Mannose monosaccharide. Unlike N-linked 
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glycans, the first monosaccharide, α-N-Acetylgalactosamine (GalNAc), befalls on the hydroxyl 
group of the side chain of either S or most commonly T on the peptide for O-glycans.27 
 
Figure 1.1: N-glycan common structures linked to a consensus amino acid sequence (N-S/T/C) on the protein backbone in 
eukaryotic cells.  
All N-glycoforms share the same core with five monosaccharides. ◼ N-acetylglucosamine (GlcNAc), ⚫ Mannose (Man),  ⚫ 
Galactose (Gal),  ◆ N-acetylneuraminic acid (Neu5Ac), and  Fucose (Fuc).  
Among all eukaryotic cells, biosynthetic steps of N-glycan are highly well-maintained. The 
glycosylation process begins on the cytoplasmic side of the endoplasmic reticulum (ER), on which 
a 7-member oligosaccharide is attached to lipid dolichol-phosphate; two GlcNAc and five Man.  
After being flipped to the luminal side of the ER, a single block of dolichol-anchored 14-member 
oligosaccharide are assembled step by step by a series of specific glycosyltransferases (GTs). The 
premature glycoforms are, then, block transferred to the Asn side chain within the sequon N-X-
S/T/C of the nascent protein by oligosaccharyltransferase (OST). Later, the glycosylated portion 
undergoes further trimming by a series of glycosidases as well as elongation and decoration by 
subsequent actions of Golgi GTs to infuse a mature glycosylated protein adorned with 
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oligomannose, complex or hybrid N-glycans.26, 28 Figure 1.1 shows the common N-glycan 
structures created in eukaryotic cells and the preserved core across all structures. 
Unlike N-glycosylation, the biosynthesis of newborn O-glycans is restricted to the cis-Golgi 
compartment. In this subcellular section, poly-peptidyl-αGalNAc transferase (ppGalNAcT) adds 
the first monosaccharide, α-GalNAc, to the side chain of either S or T residues on the backbone of 
the processed glycoprotein to produce Tn antigen. As shown in Figure 1.2, the first attached α-
GalNAc residue (Tn-antigen) can be sialylated on C6 position (STn-antigen), galactosylated on C3 
(Core 1, so-called T antigen), then substituted with β-GlcNAc on C6 after C3 galactosylation (Core 
2) or substituted with β-GlcNAc on C3 or C6 (Core 3, or Core 6). Multiple O-glycan cores are 
generated by sequential actions of GTs. Depending on the availability of donor substrates and the 
activities of GT enzymes and glycosidases at the subcellular compartment, both N- and O-glycans 
can be further modified to generate different branches of complex carbohydrate moieties that can 
be capped with specific epitopes such as ABH(O)-antigens, 26, 28 as shown in Figure 1.3. 
After all, carbohydrates cover the surface of all eukaryotic living cells and play essential 
roles, including the spectrum from those imperceptible to those critical for an organism to survive. 
Glycan-mediated biological functions are divided into two categories: functions depend on the 
glycan structure or modulation of the attached molecules, and functions depend on specific 
recognition of glycans (glycan-binding proteins, GBPs).27 Nowadays, it increasingly becomes 
evident that imperfections of the glycosylation process are firmly associated with different diseases 
such as inflammatory diseases29, cancer30, diabetes31 or congenital disorder of glycosylation 
(CDG)32. In the case of cancer, aberrant glycosylation is undoubtedly accompanying tumor growth 
and malignancy, as reported in several studies.8, 9, 13 Herein, the potentiality of using glycans and 
glycan-associated molecules as tools in disease diagnosis and prognosis is unimpeachable. 
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Therefore, it is necessary to determine glycan-based alterations in a glycoprotein structure not only 
for discovering early disease biomarkers but also for evaluating the glycoprotein-based drug 
quality and safety.  
 
Figure 1.2: Biosynthesis of basic O-linked oligosaccharides cores covalently attached to S or T side chains within a 
protein backbone in eukaryotic cells. 
◼ GalNAc, ◼ GlcNAc, ◆ Neu5Ac (Sialic acid), and  Fuc 
 
Figure 1.3: Some terminal extension epitopes that cap the reducing end of either N- or O-glycoforms attached to the protein 
backbone in eukaryotic cells. 
◼ N-acetylgalactosamine (GalNAc),  ⚫ Galactose (Gal) and  Fucose (Fuc). 
1.3 Therapeutic proteins and glycosylation 
Regarding biopharmaceutical production, therapeutic agents of therapeutic proteins are the 
fastest developing representatives in this field.33 An example of such proteins is von Willebrand 
Factor (VWF) besides other coagulation factors such as FV, FVII, FVIII, FIX, and FXI, which 
play essential roles in Hemostasis process, so-called blood coagulation. Patients with insufficiency 
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in one or more of these factors suffer from bleeding illnesses correlated to the defective protein.34 
For instance, patients diagnosed with Von Willebrand Disease (VWD), a bleeding disorder caused 
by deficiency or defect of VWF, are usually treated with plasma concentrate VWF.35 Also, 
Hemophilia A (HA), an X-linked congenital bleeding disorder characterized by a lack of or 
dysfunction of coagulation factor VIII (FVIII), is initially treated by the intravenous replacement 
therapy with plasma-derived FVIII (pdFVIII). Because of the risk of viral infections and blood-
disease transmission, pdFVIII is replaced with recombinant FVIII (rFVIII). However, the major 
complication accompanying treatment with such engineered proteins is developing neutralizing 
antibodies, termed inhibitors.36 Glycosylation may modulate the therapeutic protein 
immunogenicity and mediate the immune system interactions. Such engineered proteins are 
accompanied with foreign carbohydrate epitopes such as α-Gal and N-glycolylneuraminic acid 
(Neu5Gc), 37, 38 yeast mannans,39 or plant glycoforms40 that affect the protein functions and may 
induce immunogenic responses. Thus, disciplinary micro-heterogenous structure, including PTM 
glycosylation, is critical for safe protein-based therapy. 
VWF plays two core functions in the primary hemostasis process.34 In addition to platelet 
activation at sites of vascular injury, VWF stabilizes FVIII and maintains its level in the plasma 
by preventing proteolytic activation and thus clearance from bloodstream by protein C. The mature 
form of VWF contains multiple subunits, each containing 2,050 amino acids (AAs), constructing 
multimers linked together by multiple disulfide bonds localized on carboxylic acid termini.41 The 
mature protein is heavily glycosylated with twelve N-glycosylation sites and ten S and T residues 
covalently linked to O-glycoforms. These sites are most likely close to the binding sites, including 
FVIII, P-selectin, platelet glycoprotein Ibα and IIbIIIα (GPIbα and GPIIbIIIα) and collagen, and 
the multimerization or dimerization locations. Apropos glycosylation at these sites is essential for 
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effective interactions of the protein with other macrobiological molecules and hence adequately 
intrinsic activity.42, 43 Also, appropriate occupancies at these glycosylation sites is vital for 
adequate functions during the protein life-cycle.44, 45 Therefore, paramount efforts have been 
exerted to determine structural layers that define the protein functionality. 
MALDI-TOF/TOFa with off-line separation has been utilized for site-specific analysis of 
VWF glycome. In a recent study, Solecka et al. (2016) have reported that the major population of 
ten VWF O-glycosites were di-sialyl core 1 O-glycan. However, sulfated core 2 O-glycans were 
unequally dispersed among putative glycosylation sites. Some of these sites rarely dwell with Tn 
antigen.46 In terms of N-glycome mapping of human plasma VWF, N-glycosylation sites were 
occupied by various N-glycoform structures decorated with lactosamine extension, ABH antigens, 
sulfated antennae, terminal and bisecting GlcNAc residues.47 Implementation of such advance MS 
technique, MALDI-TOF/TOF, along with off-line separation for analyzing proteolytically 
digested glycopeptides led to a discovery of a new N-glycosite, Asn2635, that showed heavy 
glycosylation. 47 This site had been reported unoccupied before the employment of such advance 
MS technique. Moreover, unlike small drugs, the large VWF protein, as well as similar therapeutic 
glycoproteins, are susceptible to a wide range of undesirable modifications during the protein 
expression, purification, long-term storage, and administration processes. 48, 49 Any defect in the 
protein structure can, in principle, influences its safety, efficacy, and activity.50 
After all, disciplinary production of a therapeutic protein that is heavily glycosylated is 
challengeable. That is, glycosylation is a non-template-driven biological process, and it depends 
on the production system used to generate the protein.51 Moreover, O-glycosylation is a post-
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folding event and no common consensus sequence directing the glycosylation position on S or T 
residues along the protein backbone.28 With recent advance in MS techniques, more effort is 
necessary to enhance our perception of such therapeutic proteins in terms of glycosylation sites, 
occupancy, and structural alterations to get into the core of protein pharmaceuticals. Hence, in this 
research work, we aim to simultaneously determine both N- and O-glycan microheterogeneity of 
a commercially available plasma VWF protein by using a combination of state-of-the-art tandem 
MS techniques. Effective glycopeptide enrichment alongside with on-line separation on RP-
UPLC-MSb will provide profound structural information that is necessary for wise production of 
such large and complex therapeutic protein.  
1.4 Neurodegenerative diseases and glycosylation 
By 2018, 50 million people worldwide were living with dementia, and this number is 
expected to be tripled by 2050. The total estimated worldwide cost of dementia is about a trillion 
US$ that is forecast to double by 2030. Most dementia cases were attributed to Alzheimer’s 
Disease (AD), which causes more deaths in US than breast cancer and prostate cancer altogether.52 
This devastating disease is one of the most common aging-related neurodegenerative disorders 
(NDDs), including Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral 
sclerosis (ALS), and multiple sclerosis. It is escorted with cognitive and functional deficits in the 
brain that is accompanied by behavioral changes.53-54  Although about a hundred drugs have been 
tested since 1998, only four have been authorized for managing some symptoms accompanying 
dementia, but only for some people.52  
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Noteworthy, most of NDDs are characterized with aberrant glycosylation.55 Over past 
decades, the protein that plays the most significant part in the disease developments is still an 
arguable topic among scientists.52 If not all, most of these AD-key diagnostic proteins are 
glycosylated.54, 56, 57 However, the pathological roles of PTMs, in particularly glycosylation, have 
remained poorly understood. Recent advances in MS-based approaches have increasingly exposed 
the alterations of these AD-key proteins that are intensely involved in the disease onset and 
progression.58,59 
1.4.1 Theories of Alzheimer’s Disease  
The etiology of AD is complicated, and much remains to be entirely enlightened. However, 
the disease is differentiated with the occurrence of two primary histopathological brain lesions.  
According to the amyloid hypothesis, the pathological process of AD is progressively promoted 
decades before the preclinical phase testing diagnostic accumulation of amyloid-β (Aβ) peptide in 
the brain. 60 The proteolytic cleavage of the transmembrane amyloid precursor protein (APP) by 
mutated α-secretase (β-secretase) or BACE-1 and γ-secretase generates debris of Amyloid β 
peptides (Aβ) with various lengths (Aβ-40 and Aβ-42 AAs), leaving an intercellular soluble 
fragment, APPβ. The action of γ-secretase on C-terminus of the membrane-bound APP produces 
an intracellular APP fragment.60, 61 Pinpointing critical factors that affect biological processing, 
sorting and secretion of APP are essential for understanding the initiative mechanism that leads to 
the cascade neurotoxicity in AD brains.  
The amyloid theory, however, is immature since it incompletely reflects the pathological AD 
stags and explains the disease severity.62 Hyperphosphorylation of tau protein (p-tau), a soluble 
protein essential for microtubule (MT) assembly, is another critical protein preclinically 
observable for the disease diagnosis. The phosphorylated protein is detached from the MT to form 
10 
aggregation and fibrillization of itself, including intracellular accumulations of paired helical 
filaments (PHF) that turn to neurofibrillary tangles (NFT) at advanced stages.63, 64 Most 
neuroprotective strategies have been proposed based on the phosphorylation theory of tau 
pathology.62 Up to date, quality of cerebrospinal fluid (CSF), debris of Aβ peptides and levels of 
p-tau are the most established criteria that are anticipated for AD biomarkers.54 However, these 
biomarkers are limited to the availability of postmortem brain tissues as well as the capability of 
the spectroscopy instruments used for diagnosing procedures. Discovering sensitive biomarkers 
detectable years before the disease diagnosis is still in demand for developing adequate protection 
and treatment strategies.  
1.4.2 Aberrant glycosylation in Alzheimer’s Disease 
Among all PTMs that regulate the protein functionalities, glycosylation is the most 
commonly reported, especially O- and N-linked glycans.24. Glycosylation is prevalent in all 
eukaryotic living cells and plays essential roles covering the spectrum from those imperceptible to 
those critical for an organism to survive.27 The functional glycoforms are quite diverse and regulate 
various biological processes, including protein folding, trafficking, secretion, activity, and 
interactions with other biological micro- and macro-molecules.65 Several AD-related 
biomolecules, including APP, tau, BACE-1 (β-secretases), α- and γ-secretases, Apolipoprotein E 
(ApoE), and Triggering receptor expressed on myeloid cells 2 (TREM2, R47H), are 
glycosylated.56 
The AD-key protein, APP, has been reported with two N-glycosylation sites and modified 
with mucin-type O-glycans and O-GlcNAcylation on S and T residues along the protein 
backbone.66-69 Altered glycosylation might play a regulating role of Aβ peptide production. For 
example, secretion of APP because of the cleavage by secretases occurs after O-glycosylation.69 
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Regarding N-glycosylation, the most common glycan modifications on APP are core-fucosylation 
and bisecting.70 The mutated form of human APP exhibit an increase in these N-glycan epitopes.66 
The higher contents of bisecting GlcNAc residues is contributed to upregulation of N-
acetylglucosaminyltransferase III (Gn-T-III) in AD brains, which is an adaptive response to protect 
the brain from additional Aβ production.66 A recent study on AD and mild cognitive impairment 
(MCI) has confirmed that CSF N-glycome profiling is associated with an increase in bisecting 
GlcNAc and a decrease in the overall sialylation degree.71 
On the other hand, MS-based experiment revealed three O-glycosites decorated with 
sialylated core 1 O-glycans on thirty-seven glycopeptides derived from different series of APP/ 
Aβ lengths in human CSF.72 The common O-glycan structure, (Neu5Ac)1-
2Hex(Neu5Ac)HexNAc-O-, was occasionally modified with O-acetylation or lactonization on 
terminal Neu5Ac residues. This sialylation pattern observed on Tyr10 residues of Aβ peptides was 
2.5 times higher in AD patients compared to normal.72 Moreover, the membrane-bound aspartic 
protease, BACE1 (β-secretase), the leading cause of producing neurotoxic Aβ peptides, was 
responsible for cleaving β-galactoside α2,6-sialyltransferase-1 (ST6Gal1).73 This observation 
might explain the overall reduction in the sialylation level in human CSF fluid in AD brains.74-71 
However, hypersialylation of NFTs and granulovacuolar degenerations (GVDs) derived from p-
tau was reported, while the core of dystrophic neurites of senile plaques was utterly desialylated 
in AD brains.75 The contradictory sialylation between CSF fluid and accumulated tangles in AD 
brains rises an indication for further investigating changes in the glycosylation quality in discrete 
parts of the brain. 
Among γ-secretase subunits, nicastrin is the only N-glycosylated subunit with 16 potential 
N-glycosites that play an indispensable role in the enzyme activity such as interaction with the 
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catalytic subunit, presenilin (PSEN-1/2).76 α-Secretase, on the other hand, is mediated by ADAM 
family proteins, such as ADAM10, to produce soluble APP (sAPPα) and non-toxic Aβ peptides. 
ADAM10 contains four potential N-glycosites that regulate the enzyme activity.77 The cytosolic 
form of Tau protein was reported with O-GlcNAcylation, while N-glycosylated form was observed 
only observed in AD brains.78 This notice suggests a critical role of aberrant N-glycosylation in 
tau-related AD pathology. Altered O-GlcNAcylation in autopsied postmortem tissues from grey 
matter of the mid-frontal gyrus of AD (stage V or VI) was also noticeable compared to controls.58 
At all rate, our perception of AD pathomechanisms is still inadequate. Detailed glycan structure 
analysis covering the glycome quality at discrete parts of AD brains is necessary.  
1.5 Malignant diseases and Glycosylation 
Aberrant glycosylation has been defined as a hallmark associating cancer diseases.13 A new 
perspective in cancer research has focused on glycobiological mechanisms underlying the 
malignant progression and metastasis as well as clinical implications.9 The majority of FDA 
approved biomarkers currently used for clinically diagnosing malignant tumors are glycoproteins, 
including AFP for liver cancer, PSA for prostate cancer, CA125 for ovarian cancer, and CEA for 
colon cancer.9 Within the past five years, glycosylation-based variations have been introduced as 
potential cancer hallmarks. These involved the overall changes in the core- and terminal-
fucosylation, sialylation, galactosylation and bisecting beside the presence of specific epitopes 
such as Sialyl Lewis A and X structures or LacNAc motifs.13, 79, 80  
Also, several types of malignant tumors including prostate, colon, breast, lung, gastric, and 
esophageal cancer are characterized with overexpression of tumor-associated antigens (T-, Tn- and 
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STn- antigens), which promote tumor metastasis.81, 82 Recent advances in MS, interfaced with CEc, 
HPLC or UPLC, have introduced more glycomics-based biomarker studies with high credibility.13  
In developed countries, colon cancer (CC) is one of the leading causes of cancer-related 
deaths. The disease is developed from a small polyp in its early stages until it is spreading to 
various organs at metastatic stages.83 Until now, most of the CC cases are detected at metastatic 
stages, in which the survival within five years is less than 10%.84 Unfortunately, the sensitivity 
and specificity of current screening methods, such as colonoscopy, barium enema, or 
sigmoidoscopy, are insufficient, invasive and costly. However, biological specimens, such as 
blood and other fluids, can be used to target biomarkers that are more sensitive and specific as well 
as less invasive compared to traditional approaches.85  Recently glycomics and glycoproteomics 
have been attracted the researchers’ attention in CC research to discover promising 
glycan/glycoprotein candidate biomarkers.86-88 That is, protein glycosylation plays critical roles 
during various biological processes, including cell signaling, cell adhesion, proliferation or 
immune responses.89 
It is unsurprising that alteration in protein glycosylation is well-recognized as a cause or a 
result of the malignancies during tumor development. For instance, altered N-glycosylation, 
including a decrease of bisecting GlcNAc and an increase of sulfated and paucimannosidic glycans 
as well as a high level of sialylated Lewis epitopes have been reported in primary colorectal 
carcinoma (CRC) tissues. 90 In a recent study, CRC plasma N-glycome showed a decrease in only 
two core fucosylated bi-antennary N-glycans.91 However, the overall changes in the glycosylation 
quality in plasma is still inadequate. On the other hand, in a detailed study of plasma 
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Immunoglobulin (IgG) derived from CRC patients, core-fucosylated neutral glycans have been 
reported with high level, while the corresponding sialylated forms showed a decrease across 
examined cohorts.92 In the same study, IgG N-glycome was associated with a decrease in 
galactosylation and sialylation in CRC cases.92 Herein, glycosylation changes as an indication for 
disease development is a matter of contention and still underestimated, but more research efforts 
might enhance our knowledge of deviations in enzymatic pathways involved in such a delicate 
process. 
1.6 Glycan release from glycoproteins 
The first step in glycomics-based methodologies is an effective release of global 
glycoforms covalently attached to the protein backbone. Several enzymatic- and chemical-based 
approaches have been developed for glycan release.93 However, intact oligosaccharide requires 
different release strategies regarding the natural difference in the protein-sugar linkage between  
N- and O-glycans. For N-glycan release, several enzymes are available, the most popular among 
which is peptide-N-(N-acetyl-β-glucosaminyl)asparagine amidase, so-called PNGase F (N-
glycanase).94 This enzyme cleaves intact N-glycans, including hybrid, high mannose and complex, 
except those with core Fuc α-(1,3) attachment to the innermost GlcNAc.95 Unlike N-glycans, an 
enzymatic release of O-linked glycans is problematic because the analogous endoglycosidase is 
unavailable. The commercially available endo-GalNAc-ase D, so-called O-glycanase, has high 
substrate specificity and unable to cleave all modified O-glycan structures, except the unmodified 
disaccharide structure Core 1 (Gal-β-1,3-GalNAc).96 Thus, the use of this enzyme is of minimal 
value for releasing O-linked glycans. 
Therefore, cleavage of all O-glycan structures is most likely chemical-based, such as 
hydrazinolysis and alkaline-catalyzed β-elimination.93 Although hydrazinolysis is universal for 
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both N- and O-glycan types and produces free reducing termini, the procedure is accompanied by 
several complications. The used anhydrous hydrazine is highly toxic and explosive.97 Also, the 
final oligosaccharide product of hydrazinolysis requires re-N-acetylation to retrieve the intact 
glycans.98 Thus, alkaline-based β-elimination methods have been commonly utilized for glycan 
release, particularly convenient for O-glycans. The traditional reaction elimination occurs in 
NaOH solution in the presence of NaBH4 (Carlson β-elimination)
99 or NH3·BH4.100 Although the 
latter introduces volatile reagents that are compatible with downstream MS analyses and 
overcomes the drawback of extensive desalting steps in Carlson approach. However, both release 
procedures produce alditols that are unavailable for subsequent derivatization on the reducing end 
beside the susceptibility to the undesired ‘peeling’ reaction in the absence of reducing agents.100 
Therefore, non-reductive β-elimination is achievable by 28% NH4OH saturated with (NH4)2CO3. 
The final non-reduced product is glycosylamine that can be converted to a free glycan by the 
addition of boric acid drops.101 Moreover, ammonium carbamate has been lately utilized for glycan 
release with the probability of minimum undesired by-products.102 The reaction time can be 
minimized by using Microwave in the presence of a mild base, such as dimethylamine (DMA) 
which is also incorporated to the peptide site.103 
1.7 Strategies for carbohydrate moiety enrichment 
MS analysis of intact glycopeptides (glycoproteomics) after proteolytic digestion is an 
idealistic strategy that reveals correlative and simultaneous information not only for attached 
glycan isoforms but also for glycosylation sites.104 Theoretically, employed quantitative 
techniques in proteomics are also applicable to glycoproteomics. However, Numerous challenges 
are accompanying the LC-MS/MS analysis of glycoproteins. First and foremost, glycoproteins in 
biological systems are most likely present in low abundances compared to non-glycosylated 
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proteins.  Thus, glycopeptide ionization is suppressed in the presence of abundant relatively 
hydrophobic peptides besides the ionization competition with co-eluting peptides. Moreover, 
microheterogeneity of glycan moieties raises the glycoprotein complexity with the inconsistency 
of the glycosylation degree so that the abundant of a glycoprotein form is far low than the total 
protein abundance. All together limits the ability to identify glycosylation sites along with glycan 
structures. Thus, prior efficient enrichment approach is crucial to overcoming most of these 
difficulties before LC-MS/MS analysis of glycoproteins.105  
Various enrichment approaches have been developed for sensitive and informative 
glycomics and glycoproteomics.106 Enrichment of free glycoforms is easily accomplished by solid-
phase extraction (SPE) using C18 cartridges or non-porous graphitized (non-PGC) carbon 
columns.107 A combination of reversed-phase C18 adsorbent and porous graphitized carbon (PGC) 
adsorbent was utilized to purify highly hydrophilic and hydrophobic N-glycopeptides.108 
Moreover, many SPE-based enrichment methods such as lectin-specific affinity,46 boronate 
affinity,109 hydrazide chemistry (HC),110 and separation techniques based on hydrophilic 
interactions111 and PGC have been utilized in glycoproteomics, each of which has its pros and 
cons.  
Although lectin-affinity strategies are the most common methods exploited for glycoprotein 
and glycopeptide isolation, subtle variations are noticeable in the glycosylation profile because of 
inevitably low affinity and specificity of lectins.105, 112 Hence, a combination of lectins is required 
to enrich the majority of targeted glycoproteins from biological fluid mixtures.105,113 On the other 
hand, the HC-based enrichment strategy is universal for all glycan structures. However, the main 
disadvantage of this technique is information loss of intact glycopeptides because of the intrinsic 
enrichment principle of HC.110 On the other hand, PGC-based separation is able to separate 
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oligosaccharide isomers.114, 115 However, PGC was unsuitable for enriching long trypsin-digested 
glycopeptides beside the unvoidable co-elution of accompanying peptides.116 Thus, integrated C18-
PGC separation was employed to overcome the drawback of missing highly hydrophobic 
glycopeptides. 108, 117 
Unlike the approaches mentioned above, HILC is considered as a promising enrichment 
technique that captures glycoprotein/glycopeptide independently of the attached glycoforms.105 In 
a recent study, a soluble nanopolymer, poly (amidoamine) dendrimer (PAMMA), functionalized 
with ZIC-HILIC material was combined with Filter-aided Sample Preparation (FASP) for 
simultaneous desalting and enrichment of digested glycopeptides.118 In terms of sensitivity and 
university, HILIC-based LC-MS separation showed superiority over boronic acid methods, 
preferred to capture high mannose-containing peptides.116 Therefore, HILIC materials have been 
attracting researchers’ attention because of the practical superiority over other enrichment systems 
for hydrophilic and ionizable peptides, regardless of the glycan structure.119 In short, an efficient 
enrichment procedure before MS analysis is essential for sensitive and informative glycomics and 
glycoproteomics. 
1.8 Derivatization of carbohydrates for glycomics analysis 
MS analysis of native glycoforms is hampered by the inherent physical and chemical 
properties of glycans. Because of the high hydrophilicity in nature, glycans tend to show low ion 
yields either in positive or negative modes. Also, the lack of intrinsic chromophores or 
fluorophores hinders a sensitive and structural informative determination of native glycoforms. 
Therefore, various derivatization strategies have been employed, including reductive amination, 
Michael addition, hydrazide labeling, and permethylation.120 Labeling reagents initially developed 
for HPLC, introduced to the reducing end of free glycoforms, originally have aromatic structures 
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to enable UV or florescent detections.121 Beside enhancing the glycoform hydrophobicity for RP 
separation, labeling the reducing end usually enhances ionization efficiency in ESId and 
MALDI.122 The traditional standard for glycan labeling is reductive amination, in which a 
condensation reaction occurs between a primary amine group on the label and the aldehyde group 
on the reducing carbohydrate moiety. The result is an imine or Schiff base that is converted to a 
secondary amine by a reducing agent.120, 123 The most widely applied agents are 2-aminobenzoic 
acid (2-AA), 2-aminobenzamide (2-AB), 2-aminopyridine (PA), 1-aminopyrene-3,6,8-trisulfonic 
acid (APTS), and 2-aminonaphthalence trisulfonic acid (ANTS) in the presence of reducing 
agents, mostly cyanoborohydride.122 Labeling on the reducing end of glycans is also performed 
with reagents such as 1-phenyl-3-methyl-5-pyrazolone (PMP) in alkaline conditions, so-called 
Michael addition.124 The reaction condition is suitable to avoid the considerable risk of sialic acid 
loss under acidic media intrinsic to reductive amination.120 Although the product PMP bis-
derivative has a strong absorbance at 245 nm with a detection limit of 1 pmol,125 with acceptable 
performance on RP-C18 column as well as suitable for MALDI-MS,
126 MS quantifications is still 
unreliable.127 Recent developments in glycomics involved a combination of release and labeling 
strategies by a novel one-pot reaction in the presence of pyrazolone analogs,128-130 so-called β-
elimination in the presence of pyrazolone analogs (BEP). Immobilized O-glycopeptides derived 
from ovarian cancer cells were subjected to BEP.131 This approach allows simultaneous release 
and labeling of O-glycans, preventing the unwanted “peeling” reaction. Hydrazide labeling is 
another procedure, in which a hydrazine derivative containing a chromophore, fluorophore, biotin, 
charge, etc., reacts with the reducing end of a free oligosaccharide to produce a hydrazone that has 
                                                 
d ESI: Electrospray Ionization 
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analytical advantages.132 Although this labeling procedure is suitable for both N- and O-glycans, 
an additional reductive step is required to stabilize the final product.132 
The derivatization approaches mentioned above occur on the reducing end of released 
glycans. However, acidic glycoforms, capped with sialic acid residues on the non-reducing end, 
exhibit inadequate ionization in MS profile along with neutral species. In positive MS mode, it is 
difficult to detect neutral glycans along with negatively-charged sialylated forms simultaneously. 
Permethylation enables analyzing acidic oligosaccharides in positive mode along with neutral 
species as metal adducts.133,134 Although the permethylation procedure is considered laborious and 
less reproducible, MS signals of precursor ions in MS1 and fragments in MS2 or even higher have 
noticeably intensive intensities compared to those obtained from native glycans.135 Enhanced MS 
signals are attributed to the polarity reduction results from introducing methyl groups (CH3-, 14 
Da) to all applicable functional groups, including -OH, -NHCOCH3, -NH2, and -COOH.
136 Hence, 
permethylation of carbohydrate moieties is the most widely accepted strategy for identifying 
biomarkers in several diseases by MS because it allows sensitive detection,137, 138 simultaneous 
determination of neutral and acidic species, and informative fragmentations regarding linkage 
positions.132 
The first simple permethylation procedure was introduced in 1964 by Hakomori.139 The 
carbohydrate moieties reacted with methyl iodide (CH3I) in the presence of dimethylsulfoxide 
(DMSO) and catalyzed by methyl-sulfinyl carbanion, prepared by NaOH. This reaction converts 
-OH, -COOH, and -NH to -OCH3, -COOCH3 and -NCH3, respectively. Hakomori’s method had 
been adapted using different bases, such as KOH and LiOH, to produce the carbanion reagent.140, 
141 Until 1984, when a simple, rapid, and quantitative permethylation procedure was published by 
Ciucanu and Kerek, using finely divided NaOH in replace of methyl sulfinyl carbanion.142 
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Although oxidative degradation has been observed under certain conditions, this drawback can be 
avoided by introducing NaOH to oligosaccharides prior to the addition of CH3I,
143 adding a trace 
of water, or using N,N-dimethylacetamide as a reaction solvent.144 
Although in-solution permethylation has been well-suited for carbohydrate analyses by 
MS,107,145 another problem associated with this procedure is the presence of a series of +30 Da 
ions in MS spectra. This observation is a result of competition between a side product, iodomethyl 
methyl molecules, and CH3I for reacting with -OH groups covalently attached to carbohydrate 
moieties.146 To avoid over-methylation, solid-phase permethylation (SPP) has been successfully 
introduced for a very small amount of carbohydrates using micro-spin columns or fused-silica 
capillaries packed with fine NaOH.133 Also, SPP using macro-spin columns filled with NaOH 
beads has been adapted for high-throughput derivatization of glycans prior to MS.134, 147 However, 
a recently reported approach, a spin column free (SCF) permethylation, was comparable or even 
better than some widely-used SPP and oxidative degradation was claimed eliminated.148 However, 
the latter protocol introduces a large amount of salts during the neutralization step before 
liquid/liquid (L/L) extraction beside more salts resulted from dissolved NaOH beads, which may 
lead to sample loss, especially low abundant species. Furthermore, isotopic permethylation by 
light/heavy CH3I of carbohydrate moieties derived from biological samples have been reported for 
relative quantification.149, 150  Afterall, permethylation has superiority over most derivatization 
approaches for MS-based quantitative studies of carbohydrate moieties for disease-biomarker 
discovery.71, 151, 152 That is, permethylation is the best choice for carbohydrate quantification 
because of the enhanced sensitivity, which is better than that generated by native carbohydrates in 
MS1, and informative tandem MS2.149, 150, 132 Nevertheless, practical cautious is necessary for 
successful derivatization and thus glycomics analysis. 
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1.9 Mass spectrometry techniques for glycosylation analysis 
MS techniques, especially most widely used ESI-MS and MALDI-MS, have been utilized for 
glycomics and glycoproteomics analyses of glycoproteins derived from biological specimens.153-
157 In terms of glycoproteomic, inclusive clarification of a glycoprotein structure is a challengeable 
task on multiple phases,158 including the revelation of attachment sites, carbohydrate moieties 
profiling and structural depiction, and finally characterization of microheterogeneity.159 In fact, 
the diversity of glycan compositions beside various possibilities of monosaccharide linkages 
introduce complexity and nature microheterogeneity to the protein structure, which means multiple 
glycoforms are covalently attached to the same amino acid residue.160 Numerous methods have 
been employed for analyzing glycoproteins. However, in a site-specific manner, MS technique is 
the most promising approach that enables illuminating the structural diversity derived from 
carbohydrate moieties attached to the same site along the protein backbone.119,161 In this level of 
resolution, the covalent bond between a carbohydrate portion and the corresponding amino acid 
within a proteolytically digested glycopeptide is maintained for subsequent tandem MS analysis.162 
Complementary tandem MS methods such as collision-induced dissociation (CID), high-energy 
collision dissociation (HCD), or electron capture/transfer dissociation (ECD, ETD), provide useful 
and informative fragmentation of the glycopeptides.17-20 
Regarding fragmentation mechanisms, each MS/MS technique has its distinct preferential 
cleavages. In CID technique, so-called ion trap CID, the isolated precursor ion is dissociated by 
collision with inert gas atoms. Conversion of kinetic energy into internal vibrational energy, 
exceeding a certain energy threshold, leads to cleave covalent bonds along targeted peptides. 
Because the energy randomly distributes over all the peptide, the weakest bonds, usually peptide 
backbone, are the predominantly broken bonds with y- and b-ions in the absence of PTMs. Hence, 
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CID is most widely used for protein sequencing and identification, but it is unsuitable for liable 
PTMs.163 That is, in the presence of glycosylation PTM, CID technique is barely able to obtain 
information about the peptide sequence; hence, glycosylation-related fragments dominate MS 
spectra.10 However, in a recent effort, O-glycosylation sites and glycoforms were identified by 
comparing retention time shifts (Rt) and LC-CID-MS spectra of two groups containing 
nonspecifically enzymatic-digested O-glycopeptides, a group of which were deglycosylated.164 
Also, Toyama et al. (2012) constructed CID energy-resolved oxonium ion profiles, in which 
relative abundance of fragments are plotted against applied CID energies, for several standard 
glycopeptides analyzed on a QqQ-MS analyzer. Determination of the glycan portion stability and 
differentiation among glyco-isomers can be achieved by comparing their CID breakdown curves. 
Besides, monitoring m/z 138 ([GlcNAc-CH6O3]
+) fragment, instead of m/z 204.09 ([GlcNAc]+) 
fragment, is suggested as a signature for glycopeptides carrying either mannose, hybrid, or 
complex glycoforms.165 
In contrast to CID, beam-type CID, so-called HCD with higher activation energy and shorter 
activation time has been employed for peptide sequencing to generate abundant y-ions while b-
ions are further fragmented into smaller species. In respect of glycopeptides, diagnosing ions with 
specific m/z (e.g., HexNAc, m/z 204; HexNAcHex1, m/z 366) have high MS2 accuracy and low 
mass cut-off restriction, which allows utilizing these ions to designate the presence of 
glycosylation.104, 166 Recently, HCD technique has been effectively employed for the qualitative 
and quantitative determination of N- and O-glycan microheterogeneity of recombinant human 
erythropoietin (rEOP) without pre-cleavage of glycans.167 In another study, the oxonium ion 
profile of synthetic O-glycopeptides was investigated by using HCD at different collision energies 
on a hybrid LTQ-Orbitrap-MS. Comparable with CID investigation, oxonium ion profiles 
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exhibited dependence on glycoform structures carried on a glycosylated site.168 Complete 
identification of site-specific glycoforms carried on close-distance glycosites is still, however, 
challengeable when HCD technique has been used alone unless effective enzymatic digestion 
precedes MS analysis, or a complementary tandem technique, such as ETD, accompanies the high 
activation fragmentation.162,22  
An alternative tandem MS technique for peptide ion dissociation is electron-based 
fragmentation, such as ETD and ECD. Unlike CID, these techniques induce random breakage of 
the peptide backbone (N-Cα) to generate c- and z-type fragment ions while the glycan portion 
remains intact. Hence, the peptide sequences can be determined in simultaneous with glycosylation 
sites in the MS spectrum.10 In a recent study, ETD technique was efficiently utilized to determine 
phosphorylation PTM and microheterogeneity of multiple adjacent O-glycosites along long tryptic 
peptides derived from bovine fetuin.162  More recent studies have applied alternating MS2 
techniques, such as CID/ETD169 or CID/ETD/HCD,170 to improve peptide identification and 
enable otherwise problematic analysis of PTMs, like glycosylation.171  
1.10 Quantitative approaches in glycomics and glycoproteomics 
Analysis of glycans and glycan conjugates is increasingly applied in numerous biological 
studies, including clinical and pharmaceutical production. In the last decades, advances in MS 
techniques have enhanced qualitative and quantitative approaches not only for proteomics but also 
for PTM investigation (e.g., glycosylation). Quantitative approaches employed in proteomics, such 
as label-free, chemical stable isotope, and metabolic stable isotope labeling, have also been 
adapted in glycomics and glycoproteomics. These approaches can be grouped into two broad 
categories, relative quantitation and absolute quantitation.153, 155, 172 
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MS relative quantification approaches of glycoproteins are divided into label-free or label-
based strategies. Label-free is the easiest and most common strategy used in research that requires 
no expensive or exhausting steps. For instance, differentially expressed glycoproteins in the 
secretome of two human hepatocellular carcinoma (HCC) cell lines was easily quantified using 
MS intensity of N-glycopeptides.111 Simply, MS signals of glycopeptides were directly compared 
between HCC-derived peptides and controls without extra sample preparation or using expensive 
isotope labeling reagents. The accuracy of this approach, however, varies from run-to-run because 
of the instrument instability that leads to variations in ionization efficiencies of different analytes. 
Thus, in relative quantification, normalizing peak areas to internal standards is required to enhance 
the accuracy in glycomics and glycoproteomics analyses. 153, 155, 172 
In MS label-based approaches, on the other hand, heavy/light isotopes are introduced into 
proteins or peptides, and the area differences in protein/peptide peaks are measured to determine 
abundance alterations between two groups. For instance, abundance differences of serum 
glycoproteins derived from health and lung cancer individuals were quantitatively MS analyzed 
by introducing chemical-stable isotope to the proteolytically digested glycopeptides.  After LCAe-
based enrichment of α-(1-6)-fucosylated glycoproteins, the digested glycopeptides were 
chemically labeled with 12C- or 13C-2-nitrobenzenesulfenyl (NBS).173 In respect to glycomics, 
incorporation of stable isotopes to free glycans generate identifiable MS shits that allow 
simulations comparison of multiple samples in the same MS spectrum.153 The most common 
derivatization approaches, permethylation,150 and reductive amination,174 have been developed to 
introduce stable isotopes to free glycoforms for relatively quantifying multiple samples.175 
                                                 
e LCA: Lens culimaris agglutinin-A carbohydrate binding protein, used to in lectin affinity chromatography to enrich core 
fucosylated glycoproteins.  
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Although many types of labeling reagents are available, these substances are always expensive in 
addition to analytical problems generated from inefficient labeling or complicated MS spectra.172  
Regarding metabolic labeling, the surface glycoproteins are localized by functionalized sugars 
or amino acids that had previously nourished the targeted cells in-vivo. For example, abundance 
changes in cell surface glycosylation of T and B cells during neuronal activation were 
quantitatively compared by feeding the cells with light/heavy stable isotope labeling of amino 
acids in cell culture, so-called SILAC. The in-vivo pre-labeled glycoproteins were purified by 
streptavidin beads functionalized with hydrazide groups that chemically attached to surface 
glycans within the protein structure.176 Isotopic-labeling approaches are expensive and restricted 
to cell cultures although the loss of proteins during sample preparation is minimized.172 
Recently, the focus of proteomic quantification has been shifted from relatively quantifying 
proteins to absolute quantification, for assessing differential expression between two groups, 
characterizing biological models, understanding proteome dynamism, or validating protein 
biomarkers.177 Although immunoassay-based methods, such as immunosorbent assay (ELISA)178 
and the developed Western blotting179 are sensitive and excellent for throughput quantifying 
proteins, developed MS techniques might offer higher-quality quantitative information. That is, 
the sample with a targeted protein is mixed with synthetic isotopic-labeled peptide or synthetic 
protein standards177 to determine changes in total abundance of targeted peptide or protein by either 
selected reaction monitoring (SRM) or multiple reaction monitoring (MRM),172 depending on 
functions available on MS instruments. However, current absolute quantification in proteomics 
suffers from a critical hindrance regarding chemical changes of analyte in biological systems that 
requires accurately defining and synthesizing standards for the target analyte prior to MS 
26 
experiments, which is time-consuming180 and costly besides inaccuracy originated from protein 
degradation or incomplete enzymatic digestion if a bottom-up method is utilized.177 
Figure 1.4: General workflows for glycomic and glycoproteomic analysis. 
Both approaches include protein reduction, alkylation, and enzymatic digestion. Glycomics involves the enzymatic release of N-
glycans by PNGase F, while O-glycans are released by β-elimination before subsequent derivatization by either permethylation or 
reductive amination and then MS analysis. Glycoproteomics comprises the protein digestion by proteolytic enzymes than enrich 
intact glycopeptides prior to MS analysis. A complementary proteomic analysis accompanies glycomic analysis for protein 
identification N-glycan occupancy determination.   
In terms of glycomics and glycoproteomics, nevertheless, such absolute quantifying studies 
fall behind in all rate because PTMs introduce far more complexity to a protein structure. This 
approach, however, has been successfully employed to quantify GlcNAcylated tissue inhibitor of 
metalloproteinase 1 (TIMP 1) in colon cancer,181 plasma fucosylated proteins in HCC,182 sialylated 
proteins in prostate cancer (PSA),183 neutral and acidic human milk oligosaccharides (HMOs),184 
and Fc N-glycosylated peptides derived from immunoglobulins (subclasses IgG 1 and IgG2).185 
Although MS-based absolute quantification has been extensively employed to quantify glycoforms 
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for clinical purposes, relative quantification remains the most informative and decent strategy 
regarding time and cost.155 Figure 1.4 summarizes the simplify workflows for glycomic and 
glycoproteomic analyses of free N- and O-glycans and glycan conjugates derived from 
glycoproteins, respectively.  
1.11 The study objectives  
As one of the most complex and common co- and PTMs, glycosylation plays essential 
intrinsic and extrinsic recognition roles that affect numerous biological process, including cell 
signaling, communications, and adhesion.186 Considerable studies have demonstrated that aberrant 
glycosylation is somehow associated with countless diseases, including immune deficiencies,187 
various types of cancers,188 and inflammation diseases.189 Therefore, body health enormously 
depends on perfection in the glycosylation process. For comprehending the root of Carbohydrate-
mediated cell communications, protein bindings, or biological functions, it is essential to grasp 
extensive details of a glycoprotein structure. Because of the inevitable diversity of carbohydrate 
structures and other PTM processes taking place on protein, the task is discouraging. That is, a 
thorough analysis of glycoprotein structure must be able to identify peptide sequence, distinguish 
attached glycan sites, and elucidate glycan structures. 
Recently, mass spectrometry (MS) is a promising technique utilized for thoroughly 
analyzing intact carbohydrate moieties along with the covalently attached peptides. Recently 
developed tandem techniques are able to reveal the glycosylated amino acid along the protein 
backbone as well as informative fragments generated from the attached glycoforms 
(microheterogeneity) to that site. Glycoconjugates have attracted the most attention in the scientific 
community not only as potential disease biomarkers but also as a platform for developing 
therapeutic drugs. Tandem MS techniques, including single CID, HCD, ETD, or complementary 
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fragmentations, have been successfully employed in glycoproteomics and glycomics fields as that 
in proteomics. Each technique with its characteristically preferential cleavages17-20 provides 
distinct structural information, however, can be obtained from the same protein. Combined MS 
analysis of intact glycopeptides is an idealistic strategy that reveals correlative and simultaneous 
information about the portion identity, glycoform structures, and attachment sites.  
This work has been designed to recruit the MS power for analyzing carbohydrate moieties, 
specifically N- and O-glycans, derived from biological fluids or specimens. In combination with 
tandem MS techniques, such as CID and HCD interfaced to a UPLC LTQ-Orbitrap Elite system, 
MS analysis feasibly provides structural characterization and relative quantification of such 
complex carbohydrate conjugates. MS techniques have been adapted in pharmaceutical and 
clinical fields to control the product quality and explore early carbohydrate-based biomarkers, 
respectively. 
The production agents of pharmaceutical proteins are the fastest developing business in the 
therapeutic sectors. To be approved by the Food and Drug Administration (FDA) the therapeutic 
protein should have the minimum heterogeneity. Unlike small drugs, therapeutic proteins are 
susceptible to further enzymatic and chemical modification during generation, production, 
purification, as well as storage conditions, however. Alterations in the protein structure can, in 
principle, influence its safety, efficacy, and activity. Therefore, the first objective of this work is 
to thoroughly determine N- and O-glycosylation pattern of a therapeutic glycoprotein, plasma Von 
Willebrand Factor (VWF), an essential factor involved in primary hemostasis, by a combination 
of MS techniques. Deficiency or defects in VWF cause Von Willebrand Disease (VWD), a 
bleeding disorder treated with plasma concentrate VWF. The adapted MS techniques, CID and 
HCD, are practical for not only characterizing the glycan moieties linked to the protein backbone 
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but also for mapping glycosylation sites along the amino acid chain.  After all, cognitively precise 
estimation of the glycoprotein quality is indispensable to get into the core of protein 
pharmaceuticals. 
Besides the importance of determining glycosylation pattern for producing effective 
therapeutic proteins, evaluating glycosylation variations during a disease pathology and 
progression is essential for developing preventive treatments or discovering carbohydrate-based 
candidate biomarkers for early diagnosis. Due to the biological significance of glycosylation, we 
have focused this work for quantitatively profile changes in N-glycosylation affected during 
different diseases. Alzheimer’s disease (AD) is one of the neurodegenerative disorders (NDDs), 
accompanied by cognitive and functional deficits in patients’ brains that are commonly associated 
with behavioral changes. Clinical diagnosis of such disease depends on an assessment of patients’ 
cognitive abilities. Pathologically, Aβ imaging and genetics provide a great promise for early 
diagnosis and discrimination of AD from other NDDs. However, recent advances in carbohydrate-
based techniques have revealed a broad involvement of aberrant glycosylation in NDDs. Most of 
the AD-key proteins such as amyloid precursor protein (APP), Tau protein (T-tau), α-, β-, and γ- 
secretases are galactosylated. Up to date, no effective treatment has been developed yet because 
of our inadequate knowledge about pathology and prognosis of such a devastating disease. Thus, 
the second objective of this work is to determine glycosylation variations in frontal cortex region 
extracted from AD patients’ brains by MALDI-MS. We hypothesize that glycosylation is a delicate 
biological process that reflects changes in patients’ brains during AD pathogenesis and 
progression. The conclusion of this work might reveal early pathological glycan-based biomarkers 
for AD and further help to develop effective drugs for such devastating disease. 
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Nowadays, it is well-known that glycosylation changes accompany the development of 
malignant tumors. Our perception of colon cancer (CC) pathomechanisms is still inadequate. In 
particular, the pathological roles of PTMs, especially glycosylation, have remained poorly 
understood. Current advances in glycobiological technology have gradually revealed serious 
defects because of the altered glycosylation during CC growth, which is obviously tangled in the 
progressive disease onset. Further investigation is still in demand to reveal structural changes in 
respect to glycosylation. Thus, the standalone MALDI-MS robust technique is also adapted to 
discover early N-glycan-based biomarkers. The third objective of this work is to explore the 
quality of the N-glycosylation process by characterizing N-glycoforms covalently attached to 
soluble serum glycoproteins derived from CC patients. 
In comparison with healthy individuals, aberrant glycosylation might reveal the underneath 
etiology of CC and accelerate the discovery of glycan-based biomarkers. After all, the fruitful 
glycomics analysis requires an effective desalting/enrichment step for released glycoforms before 
MS analysis. Thus, a combination of filter-aided sample preparation (FASP), adequate enrichment, 
and appropriate derivatization is realistic for precisely characterizing and quantifying altered 
glycosylation for biomarkers discovery in various diseases. 
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2 CHAPTER 2.  GLYCO-MICROHETEROGENEITY OF PLASMA VON 
WILLEBRAND FACTOR (VWF) 
2.1 Introduction 
Among a wide range of post-translational modifications (PTMs), O- and most frequently N-
linked glycosylation have been attracting most of the researchers’ attention. 1 Proteins’ 
glycosylation is common in all eukaryotic living cells and plays essential roles covering the 
spectrum from those imperceptible to those critical for an organism to be survived. 2 For instance, 
von Willebrand factor (VWF), a large plasma glycoprotein, plays two essential roles in 
Hemostasis, 3 besides other coagulating factors, such as FV, FVII, FVIII, FIX, and FXI. That is, 
VWF mediates the platelet adhesion at the injured vascular area 4 and maintains the plasma FVIII 
level by preventing premature proteolytic degradation and clearance by active protein C.5  
Insufficiency in one or more of coagulating factors is correlated to many bleeding illnesses. 
6 The bleeding disorder, Von Willebrand Disease (VWD), commonly treated by plasma VWF 
concentrate, is caused by deficiency or defect in VWF. 7 Recombinant VWF (rVWF) has been, 
also, synthesized and developed for treating VWD. 8, 9 However, industrial production of this 
therapeutic protein is restrained by its large size and intrinsic complexity derived from extensive 
glycosylation and disulfide bond oligomerization. 10 One of the critical challenges of clotting 
factors expression includes addressing PTMs, e.g., glycosylation, and the choice of host cell lines. 
10 To meet the maximal fidelity, the quality of the glycosylation pattern of rVWF should be 
evaluated to the manifest glycosylation of the counterpart plasma-derived VWF. Thus, 
comprehensive glycoproteomic analysis of plasma concentrate VWF is indispensable. 
In vivo biosynthetic production, VWF is strictly expressed in megakaryocytes and 
endothelial cells (ECs). Plasma VWF, however, is entirely derived from ECs. 11 It is, then, either 
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directly secreted into the plasma or stored in organelles, so-called Weibel-Palade bodies (WPBs). 
11 Within ECs, VWF undergoes complex PTMs, including glycosylation with N- and O-linked 
oligosaccharides12. Briefly, VWF is initially synthesized in the endoplasmic reticulum (ER) as a 
pre-pro-polypeptide containing 2813 amino acids (AAs), organized into four homologous domains 
(D1-2-D’-D3-A1-3-D4-B1-3-C1-C2-CK). 12 Recently, all D domains have been re-annotated to 
VWD, cysteine 8 (C8), and trypsin-inhibitor-like (TIL) domains followed with an extra segment 
(E), except D4 uniquely preceded by a bridging region (D4N). The C-termini, further, is 
characterized to six homologous repeats (C1-C6) beside the dimerization domain, CTCK. 13 
Once the signaling peptide (22 AAs) is removed, and N-glycosites are occupied with high 
mannose oligosaccharides, the monomeric VWF-units dimerize by disulfide bond formation 
within CK-domains. In Golgi apparatus, the dimer undergoes further modification by a series of 
glycosidases and glycosyltransferases to produce complex N-glycans in addition to ten O-
glycosites. 11 Eventually, another round of PTMs, including disulfide bond formation and 
proteolytic cleavage to remove pro-peptide (741 AAs), occur in trans-Golgi to produce mature 
VWF multimers. 14 Carbohydrate moieties represent approximately 20% of the total molecular 
weight of the mature monomer VWF (2050 AAs). 15 
The influence of defect glycosylation in VWF life-cycle has attracted prolonged attention 
from searchers. 16 Alterations in the glycosylation pattern or absence of a glycosite might affect 
the protein multimerization, 17, 18 platelet adhesion, 19, 20 ADAMTS13 proteolysis, 21, 22 as well as 
biosynthesis and secretion of VWF. 23 Hence, well-known glycosylation positions, as well as 
glycoform structures, is critical for a plausible production of such therapeutic proteins. The initial 
studies performed on VWF glycome was conducted 20 years ago. 24-26 The main N-glycan 
structure was complex. Interestingly, some of characterized N-glycans terminated with H (Fuc 
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(α1-2) Gal (β1-4) GlcNAc β1), A (GalNAc (α1-3) [Fuc (α1-2)]C - Gal (β1-4) GlcNAc β1), 
and  B (Gal (α1-3) [Fuc (α1-2)] Gal (β1-4) GlcNAc β1) antigens. 26 These antigens may have 
significant effects on the level of plasma VWF and associated with different rates of the protein 
clearance in ABO individuals. 27  
The primary study on mature VWF sequence highlighted eleven consensus N-glycosites (N-
X-S/T, X is any AAs except P) and one infrequent sequon (N1147SC). The glycosites, N857, N1147, 
N1231, N1515, N1574, N2223, N2290, N2357, N2400, N2546, N2585, and N2790 were reported to be occupied, 
and the exception was (N2635). 15 However, a recent study has proved that N2635 is even heavily 
glycosylated. 28 The trypsin-digested VWF glycopeptides carrying consensus N-glycosites were 
off-line separated and mapped by LC-MALDI-TOF/TOF. The tryptic digest was affinity-enriched 
and treated with a series of glycosidases prior to MS analysis. Bi-, tri- and tetra-antennary complex 
glycans were observed besides high mannose glycans. Further modifications, such as antennae 
fucose, lactosaminic extension, sulfation, and ABH-antigen termination, were detected. 28 
On the other hand, initial characterization of VWF O-glycome showed that di-sialylated core 
1 (T antigen; Neu5Ac(α2-3)Gal(α1-3)-[Neu5Ac (α2-6)]GalNAc) was the dominant form. 29, 30  
Lately, the heterogeneity of VWF O-glycome was confirmed with di, tri- tetra-sialylated core 1 
and core 2 in addition to minor ABH-antigen carrying O-glycans. 31 Furthermore, a recent O-
glycoproteomic study of plasma VWF has exposed that all O-glycosites (T1248, T1255, T1256, S1263, 
T1468, T1477, S1486, T1487, T1679 and T2298) were occupied, and the predominant O-glycoform is T 
antigen. 32 The proteolytic digested O-glycopeptides were affinity-enriched and subjected to 
successive glycosidase-based digestions and offline separation before MALDI-TOF/TOF analysis.  
Although the glycosylation pattern of VWF has been extensively investigated for potential 
effects on the protein life-cycle, 17, 23 a full characterization of glycan microheterogeneity at all 
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possible VWF N-glycosites has yet been accomplished. Using modern analytical instruments 
reveals noteworthy structural information about the protein. 28, 32 Thus, further investigation of 
VWF microheterogeneity is crucial to lighten the glycosites that are shaded behind the instrument 
limitations. Moreover, the protein macro-heterogeneity (N-glycosite occupancy) is still unknown, 
either. Thus, full characterization of VWF mico- and macro-heterogeneity is vital for 
understanding the protein biosynthesis and functions, such as the effective interaction with the 
accompanied coagulating factor FVIII,33 besides evaluating the quality of the biopharmaceutical 
products.10 
For succeeded site-specific characterization, the digested glycopeptides are usually enriched 
before analysis because of the low abundance compared to nonglycosylated peptides. 34 Various 
types of lectin-based approaches are widely accepted for glycoprotein and glycopeptide 
enrichment. 35 However, these approaches are selective and often accompanied by successive 
enrichment steps as well as glycosidase digestions. 32, 36  
Unlike lectin affinity that targets specific glycan structures, HILIC is a promising enrichment 
approach attracting more attention in the past few years. In recent studies, HILIC-based 
enrichments have been employed for site-specific analysis of intact glycopeptides, such as those 
derived from erythropoietin (EPO)37 and alpha-1-antitrypsin (A1AT). 38 HILIC enrichment allows 
glycoprotein/glycopeptides isolation independently of the glycan structure. 35 Thus, we 
constructed a simple homemade HILIC SPE micro-tip column to effectively enrich and purify 
trypsin-digested VWF peptides carrying either a neutral or negatively charged glycan. 
Alongside effective enrichment approaches, sensitive structural characterization and glycan 
profiling have become attainable because of the major developments in mass spectrometry (MS) 
in the last decade. 39 Although glycoproteomic analysis can be performed on MALDI-TOF, prior 
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glycosidase-based treatments and off-line separation are required to obtain reliable results. 28, 32 In 
contrast, LC-MS, escorted with complementary or single MS/MS tandem mass, is widely 
acceptable because of the simplicity and high accuracy for characterizing carbohydrate moieties 
in conjunction with site specificity.39 For instance, α-1-acid glycoprotein (AGP)-derived N-
glycopeptides, separated on various revered phase (RP-C18) columns, from controls and human 
plasma hepatocellular carcinoma (HCC) were characterized by either collision-induced 
dissociation (CID), higher-energy collisional dissociations (HCD), or both.40  
Single tandem mass, CID, was used to label-free quantify low abundant site-specific N-
glycoforms derived from various types of immunoglobulin G (IgG1, IgG 2/3, and IgG4) in healthy 
plasma controls and patients with Cirrhosis (Liver).41 Also, the high accurate Orbitrap analyzer 
functionalized with HCD, so-called beam-type CID, with high energy and short activation time, 
allowed concurrent characterization of N- and O-glycopeptides in EPO.37 Electron-transfer 
dissociation (ETD) is preferable for characterizing small modifications, such as O-glycosylation 
and phosphorylation.42, 43 Up to date, a combination of state-of-the-art MS with an efficient 
enrichment approach is of the essence for successful microheterogeneity analysis. 
The central theme of this study is proteomic and glycoproteomic analyses of plasma VWF 
on a state-of-the-art RP-UPLC system interfaced with LTQ-Orbitrap Elite mass analyzer. 
Accompanied by on-line separation, the eluted O18-labelled N-deglycopeptides, and HILIC-
enriched glycopeptides were directly subjected to tandem mass to demonstrate VWF macro-
heterogeneity (N-glycosite occupancy) and heterogeneous population of N- and O-glycosites, 
respectively. In this work, we developed a systematic strategy for comprehensive and simultaneous 
characterization of N- and O-glycopeptides based on highly accurate and efficient resolution MS. 
Along with adequate enrichment on a home-made HILIC microcolumn, the sample complexity 
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was minimized by online RP separation on a nanoLC column. In silico deglycosylation of targeted 
peptides as well as the distinctive appearance of HCD spectra were used to confirm the peptide 
sequence and characterize the structure of the attached N- or O-glycoforms, respectively. Besides 
previously reported glycosylated sites, we have discovered and characterized glycoform 
microheterogeneity of formerly unconsidered N-glycosites with acceptable sequences. In view of 
this new detection, further research might reveal new insight into VWF biological roles and 
functions. 
2.1.1 Purpose of the study 
In the pharmaceutical field, the production of therapeutic proteins is the fastest developing 
business. Most of these proteins that are approved for treatment are glycosylated. The FDA criteria 
for a therapeutic protein being approved include the guarantee of minimum heterogeneity that 
reduces the potentiality of developing antibody inhibitors for such drug. Unlike small drugs, these 
proteins are susceptible to various enzymatic or chemical alterations during the processes of 
generation, production, purification, and storage.  These changes might include the protein 
structure, which influences the drug efficacy and activity. Thus, in this section of the study, we 
aim to thoroughly map all possible VWF N- and O-glycosites by using RP-LC-ESI-HCD/MS 
technique which allows simultaneous MS characterization of digested glycopeptides along with 
the covalently attached glycans. The second aim of this study is to identify the protein form in the 
bloodstream by Peptide Fragment Fingerprinting (PFF) by RP-LC-ESI-CID/MS and thus focus 
the glycoproteomic analysis on abundant glycosites. The third aim of this study is to determine the 
occupancy of isotopically labeled N-glycosites distributed along the amino acid chain after N-
glycan release. Accurate estimation of VWF glycosylation quality is indispensable for a conscious 
production of such a highly complex protein.  
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2.1.2 The experimental design  
Scheme 1 shows the overall workflow for the proteomic and glycoproteomic analysis of 
plasma VWF by RP-LC-ESI-MS/MS. The commercially available VWF drug was subjected to 
three parallel experiments. The sample was equally treated throughout the proteomic and 
glycoproteomic analyses. The entire protein, after purification from unwanted debris, was 
enzymatically digested via filter-aided sample preparation (FASP) as previously described with 
minor modifications.44 The digested protein was then divided into three portions, each was used 
for the different experiment. The first protein was subjected to identification of the protein form 
in the bloodstream after PNGase digestion (RP-LC-ESI-CID/MS). The second portion was 
isotopically labeled with 18O-water prior to LC-CID-MS analysis for site occupancy semi-
quantifications. The third part was subjected to glycoproteomic analysis (RP-LC-HCD/MS). 
 
Figure 2.1: Schematic depiction of overall workflow for the proteomic/glycoproteomic analysis of plasma VWF by RP-LC-ESI-
MS/MS. 
Y1n+ ([Peptide+GlcNAc]n+), Yon+([Peptide]n+). 
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2.2 Experimental  
2.2.1 Chemicals and Materials 
Human plasma VWF (HCVWF-0191 VWF-VIII “free”) was acquired from Haematologic 
Technologies Inc. (HTI, Essex, VT, USA). Fetuin from fetal bovine serum (Sigma-Aldrich) was 
used as a model glycoprotein. Sequencing grade modified porcine trypsin was purchased from 
Promega (Madison, WI, USA). Peptide-N-glycosidase F (PNGase F) was acquired from New 
England Biolabs (Ipswich, MA, USA). HILIC material (Click Mal, 5 µm, 100 Å) was obtained 
from ACCHROM (Beijing, China). Reduction and alkylation reagents, dithiothreitol (DTT) and 
iodoacetamide (IAM), respectively, were purchased from Acros Organics (Morris Plains, NJ, 
USA). Formic acid (FA) was obtained from Sigma-Aldrich (ST. Louis, MO, USA). Tris-HCl 
buffer was purchased from US Biological (Swampscott, MA, USA).  
HPLC grade acetonitrile (ACN) was purchased from J. T. Baker® Chemicals (Avantor 
Performance Materials, Inc. Center Valley, PA, USA). Water-18O, 97 atom % 18O was purchased 
from Sigma-Aldrich (ST. Louis, MO, USA), while deionized water was produced using a Milli-Q 
A 10 system from Millipore (Bedford, MA, USA). Microcon-30kDa Centrifugal Filter (YM-30, 
0.5 mL) with Ultracel® low-binding regenerated cellulose membrane was purchased from 
Millipore. 3M Empore C8 disk was bought from 3M Bioanalytical Technologies (St. Paul, MN, 
USA). Other materials, including urea, sodium dodecyl sulfate (SDS), and ammonium bicarbonate 
(ABC; NH4HCO3), were purchased from Sigma-Aldrich. 
2.2.2 Sample Preparation and Trypsin Digestion 
Approximately 100 µg of VWF concentrate, or 200 µg of the model glycoprotein, was 
subjected to filter-aided sample preparation (FASP) procedure as previously reported with minor 
51 
modifications.44 Briefly, the raw therapeutic protein was formerly subjected to ultrafiltration to 
remove accompanied contents including Na Citrate, NaCl, and Glycine. Then, the purified protein 
was thermally denatured and reduced by 50 μL of lysis buffer (20 mM Tris-HCl, 4% (v/v) SDS, 
10 mM DTT, pH 7.6) for 5 min at 95 °C. On the room-temperature chilled sample mixture, about 
200 μL of UA buffer (8 M urea in 0.1 M Tris/HCl, pH 8.5) was added, and the mixture was loaded 
into a 30 kDa Microcon filtration device.  
The sample was concentrated by a microcentrifuge at 13000 xg at 24 0C until the dead 
volume was ~ 10 μL. After washed twice with 200 μL UA buffer, the glycoprotein was alkylated 
by 100 μL of 50 mM IAM for 30 mins in the dark at room temperature. After centrifugation for 
20 min, the concentrate was rewashed with 200 μL of UA buffer twice. Afterward, the buffer was 
exchanged by 100 μL ABC buffer (40 mM, pH 8) before adding sequencing grade trypsin at an 
enzyme to protein ratio of 1:50 (w/w). The digestion was performed at 37 °C overnight. 
Subsequently, the proteolytically digested peptides were collected by centrifugation at 13,000 xg 
for 20 min and washed six times with 50 µL of 50 mM NH4HCO3. The collected peptide and 
glycopeptide digests were, then, subjected to protein identification (ID), N-glycosite occupancy, 
and intact glycopeptide analysis. 
2.2.3 Treatment with PNGase F for Protein ID 
For protein sequencing, a portion of the proteolytic digest (~10 μg) was subjected to in-
solution N-deglycosylation by Peptide-N-glycosidase F (PNGase F) after protease digestion45. 
Because the protease had been removed from the sample by ultrafiltration prior to adding PNGase 
F enzyme, the heating step was excluded. Briefly, the digest was dried and reconstituted in 100 µL 
ABC (pH ~8.0) to ensure the complete solubility of the peptide mixture. Then, 5 μL of PNGase F 
(2 U µL-1) was added to keep the ratio of enzyme: sample (1:1), and the sample was incubated 
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overnight at 37˚C. The sample, then, was dried and frozen at -20 ˚C for future use. Upon MS 
analysis, the peptide mixture was redissolved in 25 µL 2% ACN containing 0.1% FA and subjected 
to online purification and separation. 
2.2.4 N-glycosylation site analysis 
About 5 μg of the tryptic digest was subjected to glycosylation site-specific stable isotope 
tagging with H2
18O according to previously published protocol.46 In short, the digest was fully 
dried in a Vacufuge Concentrator and resuspended in 10 μL of 50 mM ammonium bicarbonate 
dissolved in H2
18O (97 atom % 18O, Sigma). Deglycosylation of intact N-glycans was performed 
with PNGase F at the ratio of 1:1 (enzyme: protein, w/w), and the mixture was incubated at 37 ºC 
for 12-14h. Afterward, the deglycosylated peptide mixture was dried and frozen at -20 °C, awaiting 
online purification and MS analysis. Upon analyzed, the mixture of peptides and 18O-labelled N-
deglycosylated peptides was redissolved in 5 µL of 2% ACN containing 0.1% FA before 
automatically injected into a nano-LC system. 
2.2.5 Enrichment and Desalting of Intact Glycopeptides 
The rest portion of the digest was desalted and enriched by HILIC media according to Ma’s 
procedure with minor modifications47. Concisely, a homemade SPE column was constituted by 
inserting a small piece of the C8 disk into a 200 µL tip. About 5 mg of HILIC media previously 
suspended in 100 µL ACN was transferred into the microcolumn and subsequently washed twice 
with 50 µL of the washing buffer (WB; 10% ACN containing 0.1% FA). The microcolumn was, 
next, twice washed and equilibrated with the binding buffer (BB; 80% ACN containing 1.0 % FA) 
for 10 min.  
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The proteolytically digested peptide mixture was dried and resuspended in 30 µL of BB 
before being loaded into the microcolumn. With a suitable syringe, the enriched glycopeptides 
were desalted and purified with 50 µL BB for five times. Later, the bounded glycopeptides were 
eluted with 100 µL of the elution buffer (EB; water contacting 1.0% FA) twice. The HILIC-
enriched glycopeptides were then dried and stored at – 20 ºC, pending for MS analysis. 
2.2.6 LC-MS/MS Analysis of N-deglycosylated/18O-labeled and intact glycopeptides 
The RP separation of the PNGase F deglycosylated, the isotopically labeled peptides or the 
intact glycopeptides was performed on Dionex Ultimate 3000 RSLCnano System (Thermo Fisher, 
Waltham, MA, USA). The system was interfaced with an LTQ-Orbitrap Elite mass spectrometer 
(Thermo Fisher) equipped with an EASY-spray source (1.6 kV). Both deglycosylated peptides and 
intact glycopeptides were resuspended in 2% ACN containing 0.1% FA, prepared for online 
separation and MS analysis. By a temperature-controlled autosampler, 5 µL of the deglycosylated 
peptide, 5 µL of the intact glycopeptides, or 3 µL of the 18O-labelled N-deglycosylated peptides 
were loaded into a Nano Trap column packed with Acclaim PepMap100 C18 (2 cm × 75 µm I.D., 
3 µm). The flow rate was adjusted to 5 μL/min for 10 min. Then, the sample was introduced onto 
the Easy-spray PepMap C18 Column (15 cm × 75 µm I.D., 3 µm, 100 Å) for separation. Briefly, 
the 10-min trapping/washing step was performed using Mobile Phase A (2% ACN, 0.1% FA), 
followed by a 30 min linear gradient from 3% to 40% Mobile Phase B (80% ACN, 0.1% FA) at a 
flow rate of 300 nL/min. Subsequently, the column was washed with 99% B for 10 min, followed 
with 5 min reconditioning to 1.0% B for the next run. 
The operation of the LTQ Orbitrap mass spectrometer was tuned in the data-dependent 
mode with an automatic switch between MS and MS2 acquisition. The survey of the full MS scan 
was performed in the Orbitrap mass analyzer with the following parameters: mass range, m/z 400 
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to 1,600 mass range; automatic gain control target (AGC), 106 ions, resolution at m/z 400, 6 × 
104; maximum ion accumulation time, 50 ms.  The ten most intense ions in MS1 were subjected 
to CID in the ion trap analyzer for deglycosylated peptide analysis or HCD in the Orbitrap analyzer 
for intact glycopeptide analysis. The MS/MS scan model was set as the centroid. For CID-MS, the 
default charge state was 3, the isolation width was m/z 3.0, normalized collision energy (NCE) 
was 35%, Activation Q was 0.25, and activation time was 5.0 ms.  For HCD, the resolution of the 
Orbitrap analyzer was 15,000 at m/z 400, AGC was 10,000 ions, and maximum ion accumulation 
time was 200 ms. All MS parameters were the same as CID, except the isolation width was m/z 
2.0 and the activation time was 0.5 ms. The precursor ions transferred to the HCD cell were 
exposed to fragmentation with 27 % NCE. 
2.2.7 MS/MS Data Interpretation 
2.2.7.1 LC-CID-MS data analysis of deglycosylated peptides 
In house pFind software 2.8 (http://pfind.ict.ac.cn)48 was used. FASTA sequence of human 
VWF (P04275-1) and Bovine Fetuin (P12763) were downloaded from UniProt 
(http://www.uniprot.org) and used for protein identification and sequencing with FDR 1%. The 
precursor peptide ion tolerance was 20 ppm, while the fragment ion tolerance was 0.5 Da. For 
human VWF, two FASTA databases were customized for sequencing. The first one included 2813 
AAs, representing the full pre-pro VWF protein (309 kDa), while the second represented the 
mature protein (~226 kDa), containing only 2050 residues (764-2813 AAs). The fixed 
modification was carbamidomethylation of cysteine (+57.021 Da), while the variable 
modifications were oxidation of methionine (+15.995 Da), and deamidation for N and Q (+0.984 
Da) (spontaneous deamidation in ordinary water). Two maximum missed cleavage sites were 
selected for trypsin (KR-C). 
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2.2.7.2 CID-MS/MS data analysis of 18O-labeled deglycosylated peptides 
The mass of the precursor ion was set between 350 and 6000 Da with S/N threshold peak 
filter at three. Trypsin full and two max missed cleavages were selected. The tolerance for the 
precursor ion was 20 ppm, while the fragment tolerance was 0.8 Da. Carbamidomethylated Cys 
(+57.021 Da) was chosen as a static modification, while oxidized Met (+15.995 Da), deamidated 
Asn and Gln (+0.984 Da), and O18-deamidated Asn (+2.988 Da) were specified as variable 
modifications, with FDR < 0.1. Peak intensities were obtained by extracted ion chromatogram 
(XIC). The intensities of equivalent peptides, non-glycosylated and deglycosylated, were manually 
extracted for occupancy estimation after matching the exact mass and the corresponding retention 
time. 
2.2.7.3 HCD-MS/MS data analysis of intact glycopeptides 
The MS2 spectra exhibiting diagnostic fragment ions (oxonium ions) at m/z 366 
(HexHexNAc1, 1
+), m/z 292 (Neu5Ac, 1+), m/z 204 (HexNAc, 1+), m/z 162 (Hex, 1+), and 
subfragment ions at m/z 186 (HexNAc-H2O, 1
+), m/z 168 (HexNAc-2H2O, 1
+), m/z 138 (HexNAc-
2H2O-CH3OH, 1
+), m/z 126 (HexNAc-2H2O-CH3COH, 1
+), and m/z 274 (Neu5Ac-H2O, 1
+) were 
selected for further investigation of candidate peptides and corresponding glycan structures. 
PEPTIDEMASS generated a list of theoretical masses of tryptically digested VWF peptides with 
a maximum of two trypsin missed cleavages.  
The online platform is freely accessible via the ExPASy World Wide server 
(http://web.expasy.org/peptide_mass)49. Moreover, an online accessible GlycoMod tool 
(http://web.expasy.org/glycomod) was also employed for intact N- and O-glycopeptide MS data 
interpretation. The last tool generated a list of potential peptides, containing asparagine residues 
with the consensus sequence (N-X-S/T/C, X is any AAs except Proline) besides possible glycan 
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compositions. Several glycan-peptide complements were proposed for even one input of the 
experimentally generated precursor ion [M+H]+. Unfortunately, O-glycosites lack the consensus 
sequence so that all serine and threonine residues are theoretically possible for O-glycosylation by 
GlycoMod, however. Further investigation and manual efforts, herein, were required on the picked 
HCD spectrum to confirm the glycopeptide identity. 
Interestingly, HCD-MS spectra of intact N- and O-glycopeptides were characterized with 
intense Y1
n+ ([Pep+GlcNAc]n+) and Y0
n+ (50n+) peaks, respectively, as well as a series of peaks 
representing the sequential fragmentation of glycosidic bonds. That is, Y1
n+ and Y0
n+ were 
employed for cross-referencing the selected spectra with peptide ID for unambiguous 
identification. Confirmation of O-glycan containing peptides was straightforward compared to N-
glycan containing peptides. The HCD-MS2 spectrum of an O-glycopeptide was uncomplicated as 
the attached glycan was small so that more energy was available for peptide backbone 
fragmentation.  
Hence, more b- and y-fragments were observed in O-glycopeptide HCD-MS2 spectra. In 
contrast to O-glycopeptides, the MS2 spectra of N-glycan containing peptides were predominated 
with glycosidic fragments.  Once the peptide ID was determined, the glycan mass was calculated 
from the difference between the precursor ion and the assigned peptide. The calculated mass was, 
then, searched against CarbBank51 using GlycoWorkbench software52. The search parameters were 
underivatized glycans with free reducing ends. The proposed structures were, then, specified by 
subsequent fragmentation of the oligosaccharide illustrated on the HCD spectrum. 
2.2.7.4 Semi-quantitation of the intact glycopeptide 
The peak area of each glycopeptide was extracted by XIC regarding the accurate mass and 
the corresponding retention time (RT) of the precursor ion. The extracted area was used for 
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calculating site-specific relative abundance (SRA) of N- and O-glycoforms detected on each site 
and total relative abundance (TRA) of all N-glycoforms derived from plasma VWF. For SRA, all 
glycan signal areas assigned (S:N>3) at each site were summed to generate a total signal area. 
Then, the peak area of each glycoform was normalized to the total signal at each specific site.  
A total of 173 N-glycoforms and 8 O-glycoforms were distributed among glycosites and 
quantified regarding the local glycan signals (for details see Appendices A.1-A.12). To simplify 
the representation of the microheterogeneity at each site, the glycoforms were categorized into 
closely related compositions, in which the N-glycan core and sialylated O-glycan core 1 
(Neu5Ac(α2-3)Gal(β1-3) GalNAc) are preserved. The microheterogeneity illustration was based 
on the SRA sum of closely related structures.  
For total quantification of VWF N-glycome, the categorized N-glycoforms, detected on all 
sites, were merged together to obtain a total of 61 N-glycan compositions as summarized in Table 
1. The TRA of each N-glycan composition was calculated by normalizing the summed peak areas 
of that particular composition observed on all sites to the total area of all compositions detected on 
VWF. 
2.3 Results and discussion 
2.3.1 Peptide Fragment Fingerprinting (PFF) and Protein Identification 
Plasma VWF glycoprotein was purified from excipients and subsequently tryptic digested 
by FASP. Then, a portion of the proteolytic digest was subjected to PNGase F treatment before 
bottom-up analysis. The deglycosylated peptides were online separated on an RP column to 
determine the peptide mass and the peptide fragment fingerprinting (PFF) by the Orbitrap and Ion 
Trap analyzers, respectively. All peptides were fully eluted within 40 minutes under RP conditions, 
and most of the abundant peptides showed mass to charge ratio lower than m/z 1,200 within a full 
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MS scan from m/z 400 to 1,600. Proteomic analysis of VWF tryptic digest confirmed the identity 
of plasma VWF. 
Table 1: Total putative N- and O-glycoforms derived from plasma VWF. 
No. Sites Glycan 
N
o. 
Site Glycan 
N
o. 
Sites Glycan 
N
o. 
Sites Glycan 
1 2290 
 
16 
820, 
2290 
 
31 1574 
 
46 2290 
 
2 
847, 1515, 
1574, 2290, 
2585, 2635  
17 
1574, 
2290 
 
32 
1574, 
2223 
 
47 
1515, 
1574, 
2585  
3 2223 
 
18 2290 
 
33 2290 
 
48 820 
 
4 820, 1515 
 
19 
820, 857, 
1515, 
1574, 
2223, 
2290, 
2546, 
2585, 
2635 
 
34 2290 
 
49 820 
 
5 2290 
 
20 820 
 
35 820 
 
50 2290 
 
6 2585 
 
21 
820, 
1574 
 
36 1515 
 
51 2290 
 
7 820, 1574 
 
22 2290 
 
37 2357 
 
52 
1515, 
1574, 
2290  
8 
1574, 2290, 
2585 
 
23 
820, 
1574 
 
38 
820, 847, 
857, 
1574, 
2223, 
2290, 
2357, 
2585, 
2635 
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2223, 
2290 
 
9 2585 
 
24 2585 
 
39 820, 2635 
 
54 1574 
 
10 1574, 2290 
 
25 
820, 
1574, 
2290 
 
40 820 
 
55 2290 
 
11 820 
 
26 2290 
 
41 820 
 
56 2357 
 
12 2290, 2585 
 
27 2290 
 
42 820 
 
57 2357 
 
13 
857, 1515, 
1574 
 
28 
820, 
1574, 
2290, 
2585 
 
43 2223 
 
58 2635 
 
14 2290, 2585 
 
29 
2223, 
1635 
 
44 2223 
 
59 2290 
 
15 820, 2635 
 
30 1574 
 
45 2290 
 
60 2290 
 
1 2298 
 
2 2298 
 
3 2298 
 
61 1574 
 
As shown in Figure 2.2 (A), the sequence coverage of the full glycoprotein (pre-pro VWF, 
2813 AAs, 309 kDa) is 63.06% with minimal protein impurities. A total of 17 N-glycosites and 10 
O-glycosites are involved in the full-length VWF. This form of the glycoprotein includes the 
signaling sequence (1-22 AAs), the propolypeptide sequence (23-763 AAs), and the mature 
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subunit with 2050 AAs. However, the detected peptides in the range 1-763 AAs, representing the 
signaling peptide as well as the propolypeptide, generated only one or two matched MS spectra 
with low scores. This result indicates that the protein is in its fully mature form as a result of the 
prior removal of 763 AAs.11 
 
Figure 2.2: Proteomic analysis of therapeutic VWF by RPLC-ESI-CID-MS. 
The upper depiction represents the full-length VWF including distinct domains, binding sites, and N- and O-glycosites. The lower 
part represents the coverage of (A) full-length VWF (2813 AAs) and (B) mature VWF (2050 AAs). 
Herein, we customized a FASTA sequence to include only the mature form of VWF. The 
input proteomic parameters were similar for both FASTA databases. As represented in Figure 2.2 
(B), proteomic analysis of the trypsin-digested VWF peptides shows coverage of 81.17%, and 
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most of the identified peptides have more than two matched MS/MS spectra with acceptable 
scores. Hence, the plasma VWF concentrate is most likely in its mature form (764-2813 AAs) in 
which thirteen N-glycosites and 10 O-glycosites are distributed over the functional domains. These 
sites were later screened for N-glycosite occupancy as well as N- and O-glycoform 
microheterogeneity. Although the proteolytically digested peptide, in advance treated with 
PNGase F, can be used for monitoring incomplete glycosylation at specific N-glycosites, the 
increment of + 1 Da, as a result of AsnAsp conversion, is indistinguishable. Indeed, spontaneous 
deamidation of unoccupied Asn in aqueous solution causes an increment of +0.984 Da.  
Therefore, we conducted a separate experiment for accurate determination of N-glycosite 
occupancy. Moreover, the peptide fragments including eight O-glycosites, flanking both sides of 
Domain A1 and modulate the interaction with the platelet receptors,
53 and two discrete O-
glycosites on Doman A3 and D4 were inaccessible for in-silico sequencing. Indeed, sequence 
matching of O-glycan containing peptides by proteomic software is still an algorithmic challenge. 
With various O-glycan structures, in-silico sequencing of O-glycan containing peptides is beyond 
the ability of most proteome software. Besides the absence of definable glycosite motifs, these O-
glycopeptides also lack a suitable deglycosylation approach that maintains the peptide integrity.54 
2.3.2 Occupancy of N-glycosites 
For determining glycosylation of all VWF asparagine residues involved in consensus 
sequence motifs, the tryptic digest derived from plasma VWF was isotopically labeled with 18O-
water. The canonical N-site motif is N-X-S/T/C, where X is any amino acids except proline. 
Generally speaking, PNGase F cleaves the amide linkage (-N-CO-) between the first N-
acetylglucosamine (GlcNAc) of N-glycan core, resulting in Asn residue conversion into aspartic 
acid (Asp).  
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The amide group (-CO-NH2) is replaced with a carboxyl group (-COOH). This replacement 
results in about +1 Da increment. However, in aqueous solutions, unoccupied Asn is spontaneously 
deamidated, which results in a mass change of 0.984 Da. Considering the deamidated Asn residues, 
the PNGase F-deglycosylated sites are indistinguishable from those naturally deamidated. Thus, 
estimation of the glycosylation occupancy is imprecise depending only on the regular conversion 
of AsnAsp. Thus, we performed PNGase F digestion in 18O-water, which leads to a mass 
increment of 2.988 Da at the deglycosylated site. Herein, N-glycosites can be readily and 
confidently differentiated from free deamidated Asn residues in ordinary aqueous solutions. 
Avoiding 18O-integration into C-terminus of the peptide, the proteolytic digestion was performed 
before N-glycan release in 18O-water. Also, the protease was excluded from the mixture by FASP, 
in advance. 
The intensity of 18O-labelled peptide (+2.988 Da mass shift) is compared with the counterpart 
that lacks glycosylation at the canonical N-sites.  To confirm the N-deglycosylated peptide 
identity, b- and y-ions generated by CID enable the glycosite recognition. The CID spectra confirm 
all expected glycosylation sites; N857CT, N1147SC, N1515RS, N1574RT, N2223VS, N2290CT, N2357FT, 
N2400ST, N2546VS, N2585GT, N2635NT, and N2970GS. However, one glycosite, N1231LT, is 
inaccessible for glycosite monitoring. This site is positioned on a long tryptic-digested peptide 
(R1204---R1274, 70 AAs), which carries multiple O-glycosites. As aforementioned, the O-glycan 
containing peptides are still problematic for most available proteomics software.54 Also, trypsin-
based digestion is unable to isolate the N1231-glycosite from the region containing the O-glycan 
clusters because of the absence of R or K residues. 
Noteworthy, we have detected an Asn residue with a canonical sequon that has been 
unreported as a glycosylated site, yet. The 18O-labelled peptide (IGCNDTCVCQDR) containing 
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an acceptable N-motif, N847TC on D’(E’) domain, shows approximately 13% glycosylation 
possibility, as illustrated in Figure 2.3 Also, relative quantification of 18O-labelled peptides and 
corresponding non-glycosylated peptides has indicated that N2290CT and N2357FT are highly 
occupied (>90%). Because the counterpart peptide of KVNDCTTQPCPTAK is absent, and the 
de-N-glycopeptide shows an increment of 2.988 Da, we have assumed N2290CT is completely 
glycosylated. Also, the results indicate that more than half of the monitored N-glycosites in our 
study, seven sites, are >50% pre-N-glycan occupied. 
 
Figure 2.3: N-glycosite occupancy of VWF analyzed by RP LC-ESI-CID-MS.  
The glycoprotein was tryptic digested and then treated with PNGase F in the presence of 18O-water. The asparagine residues were 
converted into aspartic acid with a mass increment of +2.988 Da, signaling pre-N-glycosylation.  N-glycosites,  non-screened 
sites, ⚫ occupied, ⚫ unoccupied. 
That is, the occupancy of N2223VS, N2290CT, N2357FT, N2400ST, N2546VS, N2585GT, and 
N2970GS are 67%, 100%, 94%, 64%, 57%, 76%, and 80%, respectively. However, N857CT, 
N1147SC, N1515RS, N1574RT, and N2635NT glycosites have less N-glycan inhabitation with 20%, 
25%, 49%, 45%, and 22%, respectively. Moreover, N-glycosylation occupancies are noticeably 
light towards N-terminus compared to the middle or C-terminus of mature VWF. The exception 
at the C-terminal side is N2635NT, which has only 22% occupancy. Regardless of the light 
occupancy, our glycoproteomic analysis has manifested slightly high microheterogeneity at this 
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site with various glycoform structures. Our results have confirmed the previously claimed glyco-
heterogeneity at this site.28 
 
Figure 2.4: CID fragmentation of VWF N-glycosite-containing 18O-peptides positioned on Domain D’(E’), D3 (TIL-3), D4 (TIL-
4), and C1-C2. 
Digestion, trypsin (two max missed cleavages); precursor ion tolerance, 20 ppm; fragment ion tolerance, 0.8 Da; fixed modification, 
Cys (+57.021 Da); variable modification, Met (+15.995 Da), Asn/Gln (+0.984 Da), and O18-Asn (+2.988 Da); FDR < 0.1. 
Unlike N- and C-termini, the midmost domain A2, carrying N
1515RS and N1574RT, have 
exhibited moderate glycan occupancy with 49% and 45%, respectively. Glycosylation at these two 
N-glycosites plays an essential and protective role in the protein life-cycle. 22 Glycosylation on 
domain A2 modulates the interaction of plasma VWF with ADAMTS13 protease and thus 
preserves the level of VWF in blood. 22, 55 According to McKinnon et al., mutations at N1574 
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increased the susceptibility of VWF to ADAMTS13 proteolysis because of the conformational 
changes in addition to steric hindrance ensued of glycan moieties.22 
 
Figure 2.5: CID fragmentation of VWF N-glycosite-containing 18O-peptides positioned on Domain A2, C2-C5, and CTCK. 
Digestion, trypsin (two max missed cleavages); precursor ion tolerance, 20 ppm; fragment ion tolerance, 0.8 Da; fixed modification, 
Cys (+57.021 Da); variable modification, Met (+15.995 Da), Asn/Gln (+0.984 Da), and O18-Asn (+2.988 Da); FDR < 0.1. 
All 18O-labelled deglycosylated peptides, sequenced in the ion trap analyzer with 35.0 
NCE, demonstrate predominant b- and y-ions in CID-MS/MS spectra of VWF. The peptide 
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carrying an acceptable sequon, IGCN847TCVCQDR, generates two distinct fragments, (y8
+1) at 
m/z 1055.49 and (b4
+1) at m/z 448.18 in the collision cell, as shown in Figure 2.4. Both fragments 
are representing an increment of 2.988 Da as a result of 18O incorporation at the pre-glycosylated 
site, compared to the unlabeled peptide. Up to our knowledge, this site has not been reported yet 
as a glycosylated site. The glycoproteomic analysis of the intact VWF-glycopeptides, meanwhile, 
has confirmed the glycosylation at this site with various glycoforms (Appendix A.2). CID 
sequencing of all de-N-glycosylated peptides subsequently 18O-labelled, indicating prior 
glycosylation at canonical sites, is represented in Figure 2.4 and Figure 2.5. 
2.3.3 Strategy for VWF Microheterogeneity Characterization 
Glycosylation is a highly complex modification that influences protein functions and hence 
is critical for adequate activities of the critical haemostatic proteins.16 Plasma VWF is a heavily 
glycosylated protein, and our SDS-PAGE experiment (data not shown) has implied that the 
glycosylation portion might represent about 20% of the whole protein molecular weight. The 
therapeutic VWF concentrate was purified from excipients and subjected to tryptic FASP-
digestion. Subsequently, the protein digest was desalted and enriched on a homemade HILIC SPE 
column before online RP separation.  
All eluted glycopeptides were directed into a high-precision Orbitrap Elite instrument in 
which the 10-most intense glycopeptide ions were oriented to the collision cell at the far side of 
the C-trap for HCD fragmentation. The fragments, then, were transferred back to the C-trap and 
analyzed by Orbitrap analyzer with high resolution and accuracy. HCD technique surmounts the 
problems of the low mass cutoff of ion trap fragmentation and dramatically improves the quality 
of MS/MS spectra because of the high accuracy at both the precursor mass and fragment levels.56 
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All HCD spectra with signature peaks were manually picked and cross-referenced with 
online available tools and databases to specify the peptide and glycan portions. Ultimately, Y0
n+ 
(Peptide) and Y1
n+ (peptideY0 + GlcNAc) were manually verified by sequential glycoside-bond 
cleavages to ensure accurate assignment of the glycopeptide ID. Also, [Y0-NH3]
n+ and [Y0-H2O]
n+ 
were also noticeable in O-glycopeptide HCD spectra. A total of 515 HCD spectra were diagnosed 
with oxonium ion fragments. However, only 257 spectra showed clear Y1
n+ and Y0
n+ ions with 
subsequent cleavages representing the glycosidic bonds within the carbohydrate portion. Out of 
257 HCD spectra, approximately 70% (181 spectra) were specified to either N- or O-glycosites, 
while ~ 30% (76 spectra) with acceptable glycosylation compositions were inaccessible for 
coordination to a certain VWF glycosite. The specified HCD spectra were categorized into 173 N-
glycopeptides and eight O-glycopeptides. Although some of the unspecified HCD spectra showed 
acceptable N- or O-glycan compositions, the unsynchronized Y1
n+ and Y0
n+ ions to a specific 
canonical VWF glycosite were excluded entirely from our results. 
Interestingly, Y1
n++Fuc (peptideY0+GlcNAc+Fuc) ion was also observed with high intensity 
compared to Y1
n+ in some core-fucosylated N-glycopeptides. HCD fragmentation of these core-
fucosylated glycopeptides most likely generates two synchronous peaks corresponding to the core-
fucosylated and the corresponded non-fucosylated glycopeptide. Figure 2.6 shows the 
phenomenon above for (KVN2290CTTQPCPTAK) peptide carrying a core-fucosylated biantennary 
glycan. As shown in HCD-MS2, the cluster of peaks at downstream m/z represent the diagnostic 
fragments: m/z 204 (HexNAc, 1+), m/z 162 (Hex, 1+), m/z 186 (HexNAc-H2O, 1
+), m/z 168 
(HexNAc-2H2O, 1
+), m/z 138 (HexNAc-2H2O-CH3OH, 1
+), m/z 366 (HexHexNAc1, 1
+), m/z 292 
(Neu5Ac, 1+), and m/z 274 (Neu5Ac-H2O, 1
+).  
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Figure 2.6: Extracted ion chromatogram (XIC), MS1 and HCD-MS2 spectra of (KVN2290CTTQPCPTAK) glycopeptide derived 
from VWF. 
Y1n+ ([Peptide+GlcNAc]n+), Yon+([Peptide]n+). ◼ N-acetylglucosamine (GlcNAc), ◼ N-acetylgalactosamine (GalNAc), ⚫ 
Mannose (Man), ⚫ Galactose (Gal), ◆ N-acetylneuraminic acid (Neu5Ac),  Fucose 
The daughter ions at m/z 854.91 and m/z 1708.83 represent Y1
2+ and Y1
1+, respectively. 
Although the intact glycopeptide (m/z 1189.50, MS1) is triply charged, the predominant fragments 
are either doubly or singly charged. The identity of the precursor ion is confirmed from its isotopic 
pattern together with Y1
n+ and Y0
n+, and available peptide-backbone fragments. The mass 
difference between the precursor ion and the corresponding peptide determines the glycan 
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composition, subsequently proposed by GlycoWorkbench. To stipulate the glycan structure, 
sequential fragmentation of the glycosidic bonds, as shown in Figure 2.6, affirms the glycan 
integrity. 
Noteworthy, N-acetylneuraminic acid residues (Neu5Ac) are imperceptible in the m/z range 
of sequential glycosidic bond cleavages, especially in HCD spectra of N-glycopeptides. The 
glycosidic bond of Neu5Ac is extremely vulnerable and susceptible to full pre-cleavage in the 
dissociation cell before detection by the Orbitrap analyzer. The existence of Neu5Ac is, however, 
endorsed by oxonium ion peaks at m/z 292 (Neu5Ac, 1+) and m/z 274 (Neu5Ac-H2O, 1+), as 
represented in Figure 2.6.  
Moreover, for further confirmation of the corresponding peptide, the peptide sequence is 
confirmed by pLabel (http://pfind.ict.ac.cn)48, a standalone software, once peptide backbone 
fragments are available. Peptide fragments, b- and y-ions, are assigned with the corresponding 
peaks, as shown in the HCD spectrum of (KVN2290CTTQPCPTAK). Unlike O-glycopeptides, 
the glycosidic bond cleavages are predominate in the N-glycopeptide HCD spectrum so that a few 
peaks are correlated to the peptide backbone fragments. Once the peptide portion and the 
carbohydrate moiety are characterized, the intact glycopeptide is semi-quantified via the 
normalized peak area obtained by XIC. 
2.3.4 N- and O-glycosite Microheterogeneity 
To attain site-specific characterization of plasma-derived VWF N- and O-glycosites, we 
performed trypsin-proteolysis, offline HILIC-enrichment, and RP-LC-MS/MS via HCD 
fragmentation. Manual characterization was simultaneously carried out on N- and O-glycopeptide 
69 
HCD spectra exhibiting signature fragments of oxonium ions. All observed N- and O-glycoform 
compositions are summarized in Table 1.  
To simplify the data display, we have categorized 181-detected glycoforms according to 
the glycan compositions in which N- and O-glycan cores are preserved. A total of 61 N-glycan 
compositions, representing 173 N-glycan structures, are assigned to 11 specific N-glycosites. That 
is, 32, 4, 3, 11, 32, 15, 44, 5, 2, 17, and 8 N-glycan structures have been assigned to 820NRC, 
847NTC, 857NCT, 1515NRS, 1574NRT, 2223NVS, 2290NCT, 2357NFT, 2546NVS, 2585NGT, 
and 2635NNT, respectively. Besides N-glycoforms, a total of 8 O-glycoforms is associated with 
2298T, all of which are classified into three O-glycan compositions. 
We have considered all glycopeptides carrying consensus sequences (N-X-S/T/C) for 
glycosylation investigation of HCD spectra. Once the identity of the glycopeptide ions (Y0
n+ and 
Y1
n+) are defined, the glycan composition is specified by glycosidic bond cleavages, and the 
precursor ion is confirmed by mass matching and peptide backbone fragments, the N-site is 
considered as glycosylated. Notably, 820NRC carried on HEN820RCVALER and 847NTC 
correlated to IGCN847TCVCQDRK or EYAPGETVKIGCN847TCVCQDR disclose various 
degrees of glycosylation, as shown in Table 1 and Figure 2.7.  
Our results indicate that 820NRC is even heavily glycosylated with 32 glycoforms, while 
847NTC shows less micro-heterogeneous peptides eluted at different RT. Similarly, Canis et al. 
have reported that 2635NNT was heavily glycosylated although this site had been reported as 
unoccupied.28 The employment of advanced MS increases the ability to uncover newly 
glycosylated sites even for well-known glycoproteins.  Hence, regarding the N-site occupancy, 
13% of 847NTC-carrying peptides are occupied with four different N-glycoforms compared to the 
70 
counterpart peptides. In contrast, the highly abundant non-glycosylated peptides might have 
suppressed the ionization efficiency of 820N-containing peptides. The glycoproteomic analysis, 
however, verifies high glycosylation at this site. Figure 2.7 shows in-depth sequencing of the 
detected glycopeptides containing either 820NRC or 847NTC. 
 
Figure 2.7: Characterized HCD spectra of intact VWF glycopeptides carrying 820NRC or 847NTC N-glycosites. 
Y1n+ ([Peptide+GlcNAc]n+), Yon+([Peptide]n+), y- and b-ions are peptide backbone fragments. ◼ N-acetylglucosamine (GlcNAc), 
◼ N-acetylgalactosamine (GalNAc), ⚫ Mannose (Man), ⚫ Galactose (Gal), ◆ N-acetylneuraminic acid (Neu5Ac),  Fucose. 
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Although glycosidic cleavages most likely predominate HCD spectra, Y1
n+ and Yo
n+ ions, 
as well as peptide backbone fragments, assist the confirmation of the glycopeptide identity. 
Similarly, other N- and O-glycopeptides are underlined by the presence of correlated fragment 
ions. 
The most likely detected N-glycoforms are biantennary glycans. Tri- and tetra-antennary, 
as well as those glycoforms including lactosaminic extension, ABH antigens, and sulfation, are 
also observed. Our results are harmonious with those previously published about Asn-attached 
carbohydrate moieties of VWF26, 28. However, HILIC-based enrichment is unbiased to specific 
glycan structures so that we have also detected hybrid glycans across multiple N-glycosites. Figure 
2.8 shows the relative abundance of these detected VWF N- and O-glycoforms. Detailed structures 
and site-specific relative abundance of detected glycoforms are summarized in the supplementary 
tables (S1-S12). Briefly, 820NRC, 1574NRT, 2290NCT, and 2585NGT represent the highest 
microheterogeneity in the level of glycan composition or structure. For instance, a total of 32 
glycan structures specified to 820NRC is categorized into 19 glycan compositions. These 
glycoforms mostly represent complex glycans with or without ABH antigens. Hybrid and sulfated 
glycans are also tangible. The highly abundant glycoforms are H5N5S1F1, H5N4S1F1, and 
H4N3S1F1 with 27%, 22%, and 18%, respectively. The lowest abundant glycan (< 1%) was the 
sulfated glycan (H3N4S1). The hybrid glycans represent <3% of the total identified glycans at his 
site. 
Moreover, the terminal 847NTC site displays two distinct compositions, high mannose and 
complex glycans, carried on two different peptides shown in Figure 2.7. Two glycoforms represent 
high mannose (H5N2) covalently linked to (EYAPGETVKIGCNTCVCQDR), while the other two 
complex glycans (H5N4S1F1) are covalently attached to (IGCNTCVCQDRK). The high mannose 
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carrying glycopeptides, eluted at 11.71 and 11.77 min, represent about 80% of the detected 
glycoforms on this site. The shorter glycopeptides, eluted at 9.77 (11%) and 10.42 (9%) min, carry 
either a core fucosylated biantennary glycans or the counterpart fucose-terminated glycoform, 
respectively.  The lowest number of detected glycoforms are observed on 857NCT (3 glycoforms) 
and 2546NVS (2 glycoforms).  
Both sites are modified with bi-antennary complex glycoforms, as illustrated in Figure 2.8. 
Glycosylation of 857NCT site is, in fact, essential for proper folding of the newborn protein and 
hence affects VWF expression.23 Less than ten glycoforms are detected on 2357NFT and 
2635NNT, most of which are bi-antennary complex glycoforms. Highly complex glycans, tri-
antennary, are also noticeable as well as blood group antigens (A and H). 
 
Figure 2.8: Microheterogeneity and relative abundances of N- and O-glycoforms attached to specific glycosites of VWF. 
◼ N-acetylglucosamine (GlcNAc), ◼ N-acetylgalactosamine (GalNAc), ⚫ Mannose (Man), ⚫ Galactose (Gal), ◆ N-
acetylneuraminic acid (Neu5Ac),  Fucose. 
The midmost glycosites, 1515NRS (11 glycoforms) and 2223NVS (15 glycoforms), as 
well as 2585NGT (17 glycoforms) on VWF C-terminus, reveal <20 glycoforms, most of which 
are bi-antennary glycans. On 1515NRS, the asialobiantennary H5N4 and core fucosylated 
H5N4F1 represent about 25% and 49% compared to the counterpart di-sialylated glycoforms, 
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2.5% and 15.4%, respectively. This site flanks the N-terminus side of the ADAMTS13 cleavage 
site (A2 domain). Sialylation pattern of the attached glycoforms might mediate VWF proteolysis 
by ADAMTS13 as well as clearance from the blood stream21. Noticeable, the bi-antennary core-
fucosylated glycan (H5N4S1F1) occupied ~78% of 2223NVS, while the same glycoform 
represented <3% of 2585NGT occupancy. The last mentioned site is mostly occupied with 
H4N4F1 (31.3%). 
Furthermore, two canonical N-glycosites, 1574NRT and 2290NCT, exhibit heavy 
glycosylation with 32 and 44 N-glycoforms, respectively. As shown in Figure 2.8, the highly 
abundant glycoforms on 1574NRT are H5N4S1 (22.6%) and H5N4S2 (17%). The fucosylated 
forms, H5N4S1F1 and H5N4S2F1, represent only (9.5%) and (<1%), respectively. Also, the 
highly complex glycan, H8N6S3F2 (<2%), with galactosaminic extension, is also observed. 
Several studies have claimed that sialylated glycans attached to 1574NRT might play an essential 
role in VWF proteolysis by ADAMTS13. 21, 22 That is, glycosylation at 1574NRT in conjunction 
with the Ca+2 binding site and the disulfide bond within domain A2 are necessary components for 
stable interaction with ADAMTS13.57 
Unsurprisingly, the second heavily glycosylated site, 2290NCT previously demonstrated 
as a fully occupied site, reveals the highly diverse microheterogeneity with 44 glycoforms 
characterized into 28 glycan structures. Most of the detected glycoforms are attached to 
(KVNCTTQPCPTAK, 0 or 1 missed cleavages), and only one glycoform (H5N5S2F3S2) is 
associated with a longer peptide (K2288---R2311, three missed cleavages). Briefly, bi-antennary core 
fucosylated glycoforms, H5N4S1F1(15.2%), H5N4S2F1 (12.2%), H4N4F1 (12.2%), and H5N4F1 
(11.2%) are representing the abundant glycoforms. 
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Figure 2.9: Characterized-HCD spectra of di- and tri-sialylated Core 1 and mono-sialylated Core 2 O-glycoforms attached to 
2298T O-glycosite of VWF.  
Y1n+ ([Peptide+GalNAc]n+), Yon+([Peptide]n+), y- and b-ions are peptide backbone fragments. ◼ N-acetylglucosamine (GlcNAc), 
◼ N-acetylgalactosamine (GalNAc), ⚫ Galactose (Gal), ◆ N-acetylneuraminic acid (Neu5Ac). 
Regarding tri-antennary glycans, only one core fucosylated glycan (H6N5S1F1) shows 
slightly high abundance (10.2%), while other tri-antennary glycans with or without H antigen are 
low abundance (<3.6%). Moreover, H and A antigens are observed on this site besides high 
mannose (4, 5, 6, and 7 <4%) and hybrid forms (<1%). 
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Regarding O-glycan microheterogeneity, a total of 8 HCD spectra is correlated to 2298T-
containing peptides. These HCD spectra are characterized to di-sialylated Core 1 (H1N1A2, 74%, 
five spectra), trisialylated Core 1 (H1N1A3, 19%, two spectra), and sialylated Core 2 (H2N2A1, 
7%, 1 spectrum). The primary structure of di-sialylated core 1 (T antigen) is (Neu5Ac(α2-
3)Gal(β1-3)-[Neu5Ac(α2-6)] GalNAc). Di- and trisialylated T antigens were previously reported 
on VWF 2298T-O-glycoforms32. Also, the mono-sialylated O-glycan core 2 (H2N2A1, <7%) is 
also common at this site. Figure 2.9 shows characterized-HCD spectra of di- and tri-sialylated Core 
1 as well as mono-sialylated Core 2, attached to 2298T. Of interest, the small the O-glycan 
structure is, the more fragments derived from the peptide backbone are observed in the HCD 
spectrum. On the other hand, other O-glycosites located on long trypsin-digested peptides are 
inaccessible for detection. It is reasonable that the effect of multiple hydrophobic amino acid 
residues might overwhelm the hydrophilic interaction with HILIC. These long O-glycopeptides 
can barely be enriched by HILIC interaction, especially when such small O-glycans attached to 
the peptide. However, this hydrophobic effect could be easily prevented by using multiple enzyme 
digestions so that an effective HILIC enrichment could be attainable. 
2.3.5 Characterization of VWF N-glycome 
All potential N-glycosites including Asn residues within consensus sequons (N-X-T/S/C) 
were monitored for glycan microheterogeneity. Eleven N-glycosites are identified with different 
glycoforms. Despite the structural details either at the core or the non-reducing terminus of the 
glycan, a total of 173 N-glycoforms are categorized into 61 N-glycan compositions, in which the 
N-glycan core is preserved. Figure 2.10 illustrates the general characterization and distribution of 
VWF N-glycome based on these sixty-one N-glycan compositions. 
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Figure 2.10: General characterization of plasma VWF N-glycome (61 compositions). 
(A) Total relative abundance (TRA) (bars; left side) and site-specific relative abundance (SRA (heat map; right side) of N-glycan 
compositions). (B) Distribution of N-glycan complexity (the outer circle represents the percentage of sulfated glycans of each 
type).◼ N-acetylglucosamine (GlcNAc, N); ◼ N-acetylgalactosamine (GalNAc, N); ⚫ Mannose (Man, H); ⚫ Galactose (Gal, H); 
◆ N-acetylneuraminic acid (Neu5Ac, S);  Fucose (Fuc, F); and sulfate groups (s). 
Depending on normalized areas, the relative abundance of all N-glycan compositions is 
determined for the total N-glycome and site-specific. Interestingly, the most abundant glycan is 
biantennary. As shown in Figure 2.10 (A), the most abundant glycoform is H5N4S1F1 (>26.2%). 
This N-glycan with either core- or terminal-fucose is defined on almost all monitored N-glycosites, 
except 1515NRS and 2546NVS. The second abundant glycoform is the asialo-form (H5N4F1, 
11.2%). The last glycoform is distributed among all N-glycosites except 847NRS and 2546NVS. 
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The abundance of bi-antennary glycoforms is unsurprising. Our result, indeed, is consistent 
with those characterized VWF N-glycan profile before decades26. Unlike bi-antennary glycoforms, 
most of the highly complex glycans (tri- and tetra-antennary) are represented in low abundance. 
The highest abundant triantennary glycan (H6N5S1F1, 2.5%) is covalently attached to Asn of 
2223NVS and 2290NCT. Also, a hybrid glycan, H6N3S1, is distributed among three glycosites, 
820NRC, 1574NRT, and 2290NCT with a total of 1.23% abundance. The counterpart core 
fucosylated hybrid glycan is even low abundant (<0.7%, 820NRC). Moreover, sulfated N-glycans 
represent only <1% of the total detected glycoforms as well as high mannose (4-9 Man, <1%). An 
exception is H5N2 (3.3%). As shown in Figure 2.10 (B), most of the detected N-glycans (~84%) 
are decorated with either fucose (28.9%), N-acetylneuraminic (17.92%) or both (37.57%), while 
the non-decorated forms represent only ~16%. The VWF N-glycome profile is highly fucosylated. 
Also, most sulfated glycans are accompanied with either fucosylation, sialylation, or both. Sulfated 
glycoforms, nevertheless, are infrequent. 
Furthermore, we have classified individual N-glycoform detected at each site based on the 
glycan type. A total of 173 glycoforms is categorized into complex, hybrid, or high mannose. As 
illustrated in Figure 2.11 (A), complex glycans represent ~79% of the total glycoforms, only ~1% 
of which are bisected. Unlike complex glycans, high mannose and hybrid glycans exist noticeably 
in lower abundance. Worth mentioning, the homemade HILIC column is efficient and unbiased 
for enriching all glycan structures, including those carrying ABH antigens. A total of 29 
glycoforms is characterized as A-, B- or H-antigen carrying glycans, as demonstrated in Figure 
2.11 (B). Approximately, ~17% of total N-glycoforms are carrying fucose residues on their non-
reducing termini. H antigen (13%) is highly abundant compared to A (3%) or B antigens (1%). 
Our result is predictable since it was estimated that 13% of N-glycans was terminated with H 
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antigens26. However, considering the unmonitored N-glycosites, the abundance of H-antigen 
carrying glycoforms might be underestimated. Hence, further analysis is required to determine 
blood group antigens at the unscreened sites. After all, rational understanding of glycoform 
microheterogeneity is, indeed, crucial for meaningful manufacturing and quality control in the 
biopharmaceutical industry. 
 
Figure 2.11: Classification of 173 N-glycoforms specified into VWF glycosites based on glycoform types and terminal epitopes. 
(A) Relative abundance of VWF N-glycoform types. (B) The number and relative abundance of ABH-antigens containing N-
glycoforms. ◼ N-acetylglucosamine (GlcNAc), ◼ N-acetylgalactosamine (GalNAc), ⚫ Mannose (Man), ⚫ Galactose (Gal), ◆ N-
acetylneuraminic acid (Neu5Ac),  Fucose. 
2.4 Conclusions 
In summary, the implementation of a state-of-the-art mass spectrometry system equipped 
with a sensitive tandem mass technique is an attractive method for glycoprotein detection and 
fragmentation. With high resolution and accuracy, the Orbitrap analyzer enabled us to 
simultaneously and elaborately determine structural diversities of even low abundant VWF N- and 
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O-glycoforms alongside with site localization. Conformational changes among the detected 
glycoforms were distinguishable via the sequential cleavages of glycosidic bonds. Also, for 
delicate assignment of the glycoform to a specific glycosite, Y1
n+ and Y0
n+ ions were verified on 
HCD spectra besides valuable b- and y-fragments derived from the peptide backbone.  
Together with N-occupancy estimation, the glycopeptide analysis revealed new N-
glycosites, one of which showed heavy glycosylation. The homemade SPE column packed with 
HILIC material endowed an efficient and equitable way to enrich short N- and O-glycopeptides, 
including those glycoforms terminated with ABH antigens, and sulfate groups as well as 
lactosaminic extension. Although the one-enzyme digestion system produced some peptide with 
insufficient hydrophilicity, essential for effective interaction with HILIC, the number of detected 
glycoforms was significant. A total of 257 HCD spectra were diagnosed with oxonium ions, 181 
of which were specified to VWF-glycosites.  
Multiple enzymatic digestions complemented with effective HILIC enrichment is an 
appropriate way that might reveal even more glycosite microheterogeneity unless very short 
peptides are produced. Furthermore, our findings on a real concentrate VWF, commonly used to 
treat bleeding disorders, have lightened the ambiguity shading glycosylation pattern of non-
reported canonical N-sites. Such explicit depiction of PTMs, e.g., glycosylation, is of great 
importance for the quality evaluation of rVWF to the maximal fidelity to the counterpart plasma-
derived VWF10. Characterization of N- and O-glycome heterogeneity might provide meaningful 
data that facilitates the complexity accompanied the industrial production of such a complex 
clotting factor, VWF. Moreover, given newly discovered N-glycosites, further studies are required 
to investigate probable effects on VWF properties and functions. 
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3 CHAPTER 3. GLYCOSYLATION QUALITY OF FRONTAL CORTEX IN 
ALZHEIMER’S DISEASE 
3.1 Introduction 
Protein glycosylation is an essential PTM that regulates various cellular functions, including 
cell-cell recognition, cell adhesion, cell growth, migration, differentiation, and immune 
surveillance.1-3 N-Glycosylation of a newly born protein is performed in both the Endoplasmic 
reticulum (ER) and Golgi apparatus by a series of specific glycosyltransferases (GTs) and 
glycosidases. N-glycosylation site is distinguished by the addition of β-GlcNAc residue to an 
asparagine residue (Asn, N) within a conserved sequence (N-X-S/T, X is any amino acid (AA) 
except P).4, 5 With overlapping specificities, GTs typically transfer a signal monosaccharide from 
nucleotide-monosaccharide donors to target AAs and sugar acceptors to produce final elongated 
glycans with various structures.4, 6 The produced glycans are typically categorized based on the 
attached AA residues (Asn or Ser/Thr) covalently attached to N-linked or O-linked glycans, 
respectively.7 For decades, variations in protein glycosylation are hallmarks associated with many 
human diseases8 such as cancer,9, 10 congenital disorders of glycosylation (CDG),11 diabetes,12 
inflammation,13 cardiovascular disorders,14 and neurodegenerative diseases.15-17 Thus, 
carbohydrate conjugates are considered undeniably potential tools not only for disease diagnosis 
and prognosis but also as anti-disease drug targets, cancer as an example.18-21  
Alzheimer’s disease (AD) is a common neurodegenerative disease featuring progressive 
deterioration in cognition and functions accompanied by behavioral changes.22-23 According to the 
World Alzheimer Report, up to 70% of dementia cases have been affected by AD and this number 
is anticipated to upsurge in the future due to lack of an adequate therapy24 in addition to the absence 
of reliable preclinical biomarkers.25, 26 This devastating disease causes more deaths in the US than 
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breast cancer and prostate cancer altogether.24 The AD brains undergo two pathological changes; 
the extracellular debris of amyloid precursor protein (APP), so-called amyloid-beta (Aβ) peptides 
(plaques), and intracellular accumulations of hyperphosphorylated tau protein (P-tau), so-called 
neurofibrillary tangles.23 According to the amyloid cascade hypothesis, irregular cleavage of the 
transmembrane APP by mutated secretase (BACE1) and γ-secretase contributes to the production 
of long hydrophobic fragments, Aβ-40 and Aβ-42, leaving an intercellular soluble fragment, 
sAPPβ.27, 28 However, the amyloid theory is immature for complete understanding pathological 
stages towards severely damaged brains.29 Hyperphosphorylation of soluble tau protein, stabilizing 
microtubules (MTs) inside neurons, leads to detachment of the protein from MTs and thus 
aggregation and fibrillization of itself. 28, 30 Up to date, cerebrospinal fluid (CSF), Aβ peptides, and 
P-tau levels are the acceptable biomarkers for AD.23,31 However, AD pathogenesis begins decades 
before the preclinically diagnostic phase of accumulations originated from Aβ peptides and 
neurofibrillary tangles in the brain.32 Also, these biomarkers are limited to the availability of 
postmortem brain tissues as well as the capability of spectroscopy instruments used for diagnoses. 
Thus, sensitive biomarkers detectable years before the disease diagnosis are yet to be defined. 
Thus, an increasing effort has been focused on studies investigating changes in AD 
glycosylation.33-36  
Several AD-related key proteins, such as APP, secretases and tau protein, have been 
explored for aberrant glycosylation and related roles during AD pathogenesis and progression.17, 
37, 38 For instance, altered glycosylation of APP, which has two N-glycosylation sites and modified 
with mucin-type O-glycans and O-GlcNAclylation, might play a regulating role of Aβ peptide 
production.37, 39-41 An increase of core-fucosylated and bisecting N-glycans was observed in the 
mutant human APP.42 The increment of total bisecting N-glycans was also observed in CSF 
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derived from AD and mild cognitive impairment (MCI) patients.43 An increase of altered O-
glycosylation was also observed in APP/Aβ peptides derived from CSF in AD patients.44 
Moreover, α-cleavage by α-secretase, cleaving APP to produce soluble APP (sAPPα) without 
generating any toxic Aβ peptides, is mediated by a disintegrin and metalloproteinase (ADAM) 
family proteins, among which, ADAM10 is characterized with four potential N-glycosites that 
regulate the enzyme activity.45 The mutated membrane-bound aspartic protease (BACE1, so-called 
β-secretase) is responsible for cleaving β-galactoside α2,6-sialyltransferase-1 (ST6Gal1) besides 
producing neurotoxic Aβ peptides.46 This observation might explain the overall reduction in the 
sialylation level in human CSF fluid in AD brains.47-43 However, hypersialylation of intracellular 
neurofibrillary tangles (NFTs) and granulovacuolar degenerations (GVDs) derived from P-tau was 
reported in AD brains, while the core of dystrophic neurites of senile plaques was utterly 
desialylated.48 Also, γ-secretase is another AD-key protein with multiple subunits; nicastrin is the 
only glycosylated subunit with sixteen potential N-glycosites and plays an indispensable role in 
the enzyme activity by interaction with the catalytic subunit, presenilin (PSEN-1/2).49 
Furthermore, under  AD conditions, the cytosolic tau protein undergoes increased occurrence of 
hyperphosphorylation and reduced production of GlcNAcylation that may as a result of regional 
glucose hypometabolism in AD brain.38, 50, 51 However, N-glycosylated tau protein was only 
observed in AD brains, suggesting the role of aberrant N-glycosylation of tau in AD pathology.52  
Recently, aberrant glycosylation in noninvasive human fluids, such as blood plasma, has 
been targeted for early AD candidate biomarkers. For instance, human plasma IgG-Fc N-glycome 
from thirty-one AD patients showed a significant decrease in complex galactosylation and 
sialylation.34 Also, plasma clusterin was suggested as a prognostic AD marker, particularly eight 
β64N-glycoforms significantly reduced in patients with high atrophy.53 Metal-carrying serum 
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protein, transferrin (Tf), had been characterized with altered glycosylation in patients with AD.54, 
55 However, CSF contains two Tf glycan-isoforms; serum-type Tf-2 appears to be produced from 
blood, while brain-type Tf-1 is produced from CSF-producing tissue, choroid plexus.56, 57 Unlike 
Tf-2, featured with α2,6-sialylated bi-antennary complex glycoform, the corresponding glycan 
linked to Tf-1 is asialylated, aglactosylated, bisected and core-fucosylated.58 The presence of Tf 
isoforms is because of the differential glycosylation in a protein expressed in the brain that plays 
notable roles from elsewhere in the body.59 That is, specific glycan structures on glycoproteins and 
glycolipids are key for normal neural development and play functional roles in the central nervous 
system (CNS), including myelination, migration, differentiation and synaptic plastic.60 Also, 
unique blood vessels termed the blood-brain barrier (BBB),  vascularizing the CNS regulates the 
movements of ions and molecules between the brain and the bloodstream and allow proper 
neuronal functions and protection of neural tissues from pathogens and toxins.61 In addition to the 
BBB, a protective barrier between brain and CSF, so-called the ependyma, with structural and 
enzymatic characteristics plays scavenging and detoxifying roles in CSF and thus forming a 
metabolic barrier in the interface between the brain and CSF. Thus, glycosylation patterns might 
differ among discrete brain regions. Our perception of AD pathomechanisms is still inadequate. 
Up to date, no informative study is available for the frontal cortex (FC) although aberrant 
glycosylation of CSF and plasma in AD patients have been extensively studied.  
In this study, we determined the N-glycosylation pattern in human FC and explored 
structural changes in N-glycoforms originated during AD pathological progression. In detailed 
structures and relative quantification of N-glycoforms derived from AD and normal FC tissues 
were performed by MALDI-MS. Besides the significantly differentiated species discovered in this 
study between the examined cohorts, several abnormal N-linked glycans were observed in brain 
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tissues. The examined groups showed differences in multiple levels of glycosylation, including the 
type of glycans and the degree of complexity besides changes in galactosylation, fucosylation, 
sialylation, and the presence of rare modifications. Exploration of altered glycosylation in FC 
might identify potential glycan-based biomarkers that are useful in terms of early diagnosis and 
effective intervention strategies for such devastating and irreversible disease. 
3.1.1 Purpose of the study 
  Our perception of AD pathomechanisms is not fully understood. In particular, the 
pathological roles of PTMs, specifical glycosylation, have remained poorly understood. Although 
current advances in glycobiology technology have gradually revealed that altered glycosylation of 
AD-related biomolecules is thoroughly tangled in the onset of the progressive disease, further 
investigation is still in demand to explore the quality of such natural biological processes during 
the disease promotion. Thus, in this work, the first aim of this study is to explore the overall 
changes in the N-glycosylation quality in the FC region caused during AD pathological 
progression. To achieve this goal, (A) we survey the overall N-glycoform profiles of FC obtained 
by MALDI-MS in order to differentiate the disease profile from the healthy one. (B) Second, the 
survey of profiles results in assigning unique N-glycoforms that are associated with AD brains and 
distinguishable from those assigned to normal FC brains. (C) Next, the overall changes in the 
glycosylation, including type and complexity, as well as the existence of rare modifications such 
as sulfation or phosphorylation, Hexosamine, LacNAc repeats, Neu5AcLac or Neu5Gc are 
monitored across FC samples. (D) this study also aims to distinguish N-glycoforms that are 
significantly differentiated in AD FC profiles and might work as early candidate biomarkers for 
AD. (E) The ultimate achievement of this study is thoroughly monitoring alterations in the 
glycosylation index of fucosylation, galactosylation, and sialylation. We have examined several 
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glycomic approaches to determine and optimize the best conditions for enrichment and 
derivatization of released N-glycans. 
3.1.2 The experimental design 
 
Figure 3.1: Workflow for profiling N-glycoforms derived from frontal cortex tissues extracted from AD patients’ and age-
matched controls’ brains. 
In purpose to survey variations of N-glycosylation pattern accrues in FC region of AD 
brains, the well-known fast technique, highly sensitive, and easy to use, MALDI-TOF-MS 
technique is adopted in this work. This technique has been utilized for free carbohydrates and 
glycoconjugates profiling not only to study neurodegenerative diseases but also other acute 
diseases, such as cancer. 62 In this work, the frontal cortex tissues extracted for human brains are 
subjected to glycomic analysis by MALDI-TOF-MS. These tissues are obtained from a total 
number of sixteen subjects; n=8 disease cases and controls for each. Separately treated, the isolated 
sample is subjected to ultrafiltration for buffer exchange before enzymatic digestion. This step of 
filtration is vital to remove residues that might affect the enzyme activity used in the next step for 
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releasing N-glycoforms from the protein backbone. The overall workflow is illustrated in Figure 
3.1. 
The protein concentration is detected by UV-absorption and bicinchoninic acid assay 
(BCA) before diving to the next step. Also, the protein profile is deliberated by gel electrophoresis 
to ensure the effectiveness of ultrafiltration. Once buffer conditioned, the protein extract is 
subjected to enzymatic release by PNGase F, which cleaves N-glycoforms for asparagine residues 
along the protein backbone. Next, the released N-glycoforms are subjected to purification, using 
graphite spin columns before derivatization. The approach selected for oligosaccharide 
derivatization is permethylation, the most effective derivatization method appropriate for 
quantification and glycosidic linkage characterization. Permethylation stabilizes all -OH and -NH 
groups along with other negatively charged groups, such as -COO- on sialic acid residues. Thus, 
the acidic glycoforms behave equally under MALDI conditions because of equalizing sialic acid 
MS signals with those obtained from neutral glycoforms. We have chosen this derivatization 
strategy because of its superiority for pinpointing the glycosidic linkages between monosaccharide 
residues in MS/MS by using an effective tandem fragmentation, CID. So, the glycoforms 
structures are easily revealed without further enzymatic digestion with glycosidases.63 
3.2 Experimental 
3.2.1 Chemical reagents 
Fetuin from fetal bovine serum (F2379) and Ribonuclease B from bovine pancreas 
(R1153), used as model glycoproteins, and β-cyclodextrin (molecular weight 1134.98 g/mol, 
C4767), used as an internal standard, were purchased from Sigma-Aldrich.  Peptide-N-glycosidase 
F (PNGase F, P0704S) was acquired from New England Biolabs (Ipswich, MA, USA). Reduction 
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and alkylation reagents, dithiothreitol (DTT) and iodoacetamide (IAM), respectively, were 
purchased from Acros Organics (Morris Plains, NJ, USA). Formic acid (FA), Trifluoracetic (TFA) 
(LC-MS grade) acid and super-DHB matrix for MALDI-MS (≥99.0%) were from Sigma-Aldrich 
(ST. Louis, MO, USA). Tris-HCl buffer was purchased from US Biological (Swampscott, MA, 
USA). HPLC grade acetonitrile (ACN) and methanol were purchased from J. T. Baker® 
Chemicals (Avantor Performance Materials, Inc. Center Valley, PA, USA). Deionized water was 
produced using a Milli-Q A 10 system from Millipore (Bedford, MA, USA). Microcon-10kDa 
Centrifugal Filter units (YM-30, 0.5 mL) with Ultracel® low-binding regenerated cellulose 
membrane was purchased from Millipore. Other materials, including sodium dodecyl sulfate 
(SDS), urea (UA), ammonium bicarbonate (ABC; NH4HCO3), sodium hydroxide beads (NaOH, 
20-40 mesh, 97%), iodomethane ICH3 (≥99.0%), dimethyl sulfoxide DMSO (anhydrous, ≥99.9%), 
Dichloromethane (DCM, HPLC grade), and ammonium hydroxide solution (NH4OH, 30%) were 
purchased from Sigma-Aldrich.  
3.2.2 Participants 
Individuals enrolled in the discovery set included Alzheimer’s Disease cases (AD, N=8) 
and age-matched controls (CT, N=8), pre-tested for cognitive concerns or symptoms by 
experienced clinical neurologists. The samples were obtained from the Emory Center for 
Neurodegenerative Disease Brain Bank.  The Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) protocol for neuritic plaque scoring was used to assess Amyloid plaque 
pathology.64 The Braak staging system was used to assess Neurofibrillary tangle pathology.65 
According to the National Institute on Aging-Alzheimer’s Association guidelines for the 
neuropathological assessment of Alzheimer’s disease; the AD cases met the criteria of high level 
based on ABC scores. 66 As previously described, the coexistence of Parkinson’s’ disease (PD) 
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neuropathology in AD cases was assessed by exploring the frequency of the apolipoprotein E 
(ApoE) genotype. 67  
All patients underwent a standardized protocol that included medical history, physical and 
neurological examinations, screening laboratory tests, and brain MRI. The probability of AD was 
diagnosed according to Diagnostic and Statistical Manual for Mental Diagnosis (4th ed) and the 
National Institute of Neurological, Communicative Disorders and Stroke-Alzheimer’s disease and 
Related Disorders Association criteria (NINCDS-ADRDA). All samples were obtained after a 
written informed contest in the context of the diagnostic routine. The human biological samples 
were sourced ethically, and their research use was in accord with the terms of the informed 
consents. The postmortem brain tissues exerted from the frontal context were collected in 
polypropylene tubes and stored at -80 oC, until thawing for lysis and subsequent glycomic analysis.    
3.2.3 Brain tissue preparation 
Approximately 25 mg of the postmortem brain tissue extracted from the frontal cortex (FC) 
of AD and age-matched control brains were homogenized for protein extraction as described 
previously.68 Briefly, the tissue pieces were lysed in 150 μL of lysis buffer (4% SDS, 100 mM 
DTT, 100 mM Tris/HCl, pH 7.6) and incubated at 95 0C for 5 min. No protease inhibitors were 
added because of the presence of SDS that effectively suppresses the protease activity. 68 After 
cooling down to room temperature, the lysate was clarified by centrifugation at 16,000 xg for 5 
min. The supernatant containing the extracted proteins were collected and stored at -80 0C for 
subsequent glycomic analyses. Before frozen, the brain protein concentration was measured by 
NanoDrop (ThermoFisher, Waltham, MA) spectrometer at 280 nm with an extinction coefficient 
of 1.1 for 0.1% (g/L) solution. 
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3.2.4 N-Glycan release 
Upon analysis, the clarified brain tissue supernatant collected after lysis was subjected to 
Filter-aided N-glycan Separation (FANG) as previously described with minor modifications.69 
About 50 μL of the supernatant was thawed to room temperature in a 1.5 microtube before adding 
Tris buffer (10 mM Tris/HCl, pH 8.0) in a ratio of 10:1 Tris buffer to sample solution to dilute 
SDS concentration to less than 1.0%. Then, the solution was transferred to an ultrafiltration device 
(Amicron Ultra-0.5, Ultracel-10 membrane, nominal mass cutoff 10 kDa, Millipore) and 
centrifuged at 14,000 xg for 10 min. The filtrate was washed with Tris buffer six times (400 
μL/each) to remove detergent for effective enzymatic N-glycan release in the subsequent step.70  
The filter unit was transferred into a new collection unit while the flow-through was 
discarded. The final dead volume (~ 30 μL) was diluted to ~50 μL with Tris buffer, and the 
concentration of the purified protein solution was measured with NanoDrop. Then, about 2 μL 
PNGase F (500 U/μL) was added to each unit, and the ultrafiltration unit was sealed with Parafilm 
and incubated at 37 °C overnight (~12 h). Next day, about 100 U of PNGase F, diluted in Tris 
buffer, was added to each unit and incubated for an additional 2 h to ensure complete N-glycan 
release. After incubation, each sample was spiked with 1 nmol of β-cyclodextrin as an internal 
standard and eluted six times with 100 μL of water (HPLC grade) by centrifugation for 10 min at 
14,000 xg. The released N-glycan solution was vacuum-dried in a tabletop centrifuge (Eppendorf 
5804 Benchtop Centrifuge) and further resuspended in 200 μL 1.0% TFA for subsequent 
purification. 
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3.2.5 Glycan enrichment and purification  
The enzymatically released N-glycans obtained from brain FC tissues were desalted on 
graphite spin-columns (Thermo-Scientific, Rockford, IL, USA) as described by the manufacturer 
with slight modifications.71 The N-glycan solution was loaded to a spin column, filled with ~ 20 
mg of graphite that was pre-washed with 200 μL of 1M NH4OH (twice), 200 μL of ACN, and 200 
μL of 1.0% TFA (twice), sequentially. After incubation with resin bed for 10 min with periodic 
vortex mixing, the enriched glycans were washed with 200 μL of 1.0% TFA three times and then 
eluted with 100 μL of 50% ACN containing 0.1% FA. The purified glycans were dried down and 
stored at -20 °C for the following derivatization.  
3.2.6 Glycan derivatization  
Permethylation is a valuable and widely used derivatization approach for carbohydrate 
analysis because of the enhanced sensitivity and the fruitful structural information obtained from 
MS/MS. Thus, for enhancing glycan analysis by MS, the native glycans were subjected to 
permethylation according to the procedure initially described by Ciucanu and Kerek 72 and 
modified by Morelle and Michalski.71 Among modified permethylation approaches, including in-
solution or solid phase permethylation developed to improve efficiency and qualitative 
applicability,73-77 the spin column-free (SCF) method has been recently developed to reduce 
laborious preparation steps with decent yields of small-size samples.78  
However, SCF introduces large amounts of salts to the sample during the neutralization 
step that might cause the glycoform loss, especially those low abundant species. Thus, the 
approach was modified to reduce salts and the reaction volume. Briefly, approximately 25 mg of 
NaOH beads were transferred into a screw-capped glass tube before quickly adding 60 μL DMSO 
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(~0.4g NaOH per mL of DMSO) to prevent absorption of moisture from the atmosphere. The 
freeze-dried glycans derived from the brain tissues were dissolved in 20 μL of DMSO and 
quantitatively transferred to the beads two times to ensure quantitative transferring so that the total 
volume of DMSO was 40 μL. To the reaction mixture, about 60 μL of ICH3 was added, and the 
tube was capped tightly and sonicated in an ultrasonic bath at room temperature for a total of 90 
min as previously described.71 After 45 min, another portion of ICH3 (60 μL) was added to ensure 
complete derivatization. The reaction was quenched by slowly adding 200 μL of 5% acetic acid 
solution. Then, the permethylated glycans were liquid/liquid (L/L) extracted twice with 200 μL 
DCM. The organic layers were pooled together before being washed five times with 400 μL water 
(HPLC grade) until neutralization (pH ~ 7.0). The aqueous layer was discarded while the organic 
layer was evaporated by heat in a rotary evaporator at 50 °C (Buchi Rotavapor R-100,). The 
glycans were quantitatively retrieved from glass tubes by re-dissolving in 200 μL of 50% methanol 
solution three times and then transferred into a sterilized microtube before vacuum-dried. 
3.2.7 N-glycan analysis by MALDI-TOF-MS.  
The dried permethylated glycans were resuspended in 10 μL of a 50% ACN. One microliter 
of the sample was mixed to an equal volume of super-DHB instead of bare DHB (10 mg/mL in 
50% ACN to generate homogenous crystals.79 The matrix contained 1mM sodium acetate 
(CH3COONa), essential to increase the chance of Na adduct formation. 
80 Then, 1 μL of the mixture 
was spotted on the target plate (Bruker Daltonics, MTP 384 polished steel) and left for dried-
droplet crystallization. Each sample was spotted in triplicate. The ionization was performed in the 
reflector positive-mode on an UltraFlextreme MALDI-TOF-MS (Bruker Daltonics, Bremen, 
Germany) equipped with 1 kHz Smartbeam-II laser operated by flexControl 3.4 software (Bruker 
Daltonics). Before glycan analysis, the instrument was externally calibrated using permethylated 
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dextran ladder from Leuconostoc mesenteroides (Analytical standard, molecular weight (MW) 
5000, Sigma-Aldrich) with accuracy up to 50 ppm. For each glycome spectrum, 20,000 laser shots 
were accumulated at a laser frequency of 1000 Hz, using a complete-sample random walk with 
500 shots per raster spot. High laser intensity was used for sample profiling to allow ionization of 
larger glycan species, while the monoisotopic peak was still clearly defined for all detectable 
glycan masses. The m/z range was monitored from 500 to 5000.  Tandem mass spectrometry 
(MALDI-MS/MS) was performed on twenty most abundant glycoforms to validate the glycoform 
structure via laser-induced disassociation (CID).  
3.2.8 MALDI-TOF-MS data processing. 
Using flexAnalysis v3.4 (Bruker Daltonics), the MALDI-MS spectra were smoothed and 
baselined across all the m/z range and internally recalibrated using a set of calibration masses 
(Appendix B.1). More specifically, masses were calculated as permethylated [M + Na]+ precursor 
ions. Carbohydrate compositions used to calibrate MS signals of FC N-glycome beside β-
cyclodextrin (m/z 1451.6876) were H5N2 (m/z 1579.7826), H3N4 (m/z 1661.8357), H6N2 (m/z 
1783.8824), H3N4F1 (m/z 1835.9249), and H3N5 (m/z 1906.9620) for small glycoforms. The 
following glycoforms; H4N4F1 (m/z 2040.0247), H3N5F1 (m/z 2081.0512), H4N5 (m/z 
2111.0618), H5N4F1 (m/z 2244.1245), and H4N5F2 (m/z 2459.2402), were used for calibrating 
large glycoforms with 50 ppm tolerance (H = Hexose, N =N-Acetylhexosamine, and F= Fucose, 
the number of residues given after the letter). Masses were picked in the spectra using 
monoisotopic heights as previously described. 81-83  
The recalibrated spectra were exported as an ‘xlsx’ format, and the average of three signals 
was searched against human glycome-DB that merges the carbohydrate structures with taxonomic 
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data from all main public databases (http://www.glycome-db.org/ ).84 The MS signals were 
assigned and annotated by freely available  GlycoWorkbech v.2 
(http://www.eurocarbdb.org/applications/ms-tools ) to find the glycoform compositions and 
associated structures.85 Representation of the glycoform structures and the corresponding 
compositions were according to the standardization of Symbol Nomenclature for Glycan 
(SNFG).86 For single letter representation of monosaccharide residues, the following letters were 
adopted; H=Hexose, N=N-acetylhexosamine, E=hexosamine F=Fucose, A=5-N-acetylneuraminic 
acid, ALac=5-N-acetylneuraminic acid lactone, and G=5-N-glycolylneuraminic acid. For 
modification groups, S=Sulfated group and P=Phosphorylated group were used. 
3.2.9 Statistical analyses 
Before performing statistics, the intensities across m/z range in individual MS spectrum 
were normalized to an internal standard to correct variabilities due to the analyte loss during the 
sample preparation, and chemical fluctuations cause instrumental errors.87, 88 Glycoform 
percentages were calculated with standardization to the overall signal intensity of each MADI-MS 
spectrum. From repeated experiments, the averages and standard error deviations were calculated 
across all sample groups to generate peak lists. The data were categorized into two subsets; Subset 
1 included glycoforms that were detected in at least 50% of either AD or CT tissues (n=104), while 
Subset 2 included those glycoforms detected in both cohorts across all examined samples (n=59).  
Student’s tests were performed on processed MALDI-MS data to determine the significant 
differences between AD and CT cases. Differentiations were evaluated across detected 
glycoforms, including glycoform type, complexity, fucosylation, galactosylation, and sialylation. 
The statistical analyses were performed using GraphPad Prism version for Windows (GraphPad 
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Software, La Jolla, California, USA). Corrections were applied to the statistical testing, in which 
a p-value of < 0.05 was considered significant. For heatmaps, the normalized intensities (‘xlsx’ 
format) were converted to ‘txt’ format and processed by freely available PermutMatrix 1.9.3 EN 
software (http://www.atgc-montpellier.fr/permutmatrix/).  The total normalized intensities were 
used to calculate relative intensity (RI) of each N-glycoform along with standard error mean 
(SEM).  
Calculation and graph visualization were performed by MATLAB and Statistics Toolbox 
Release 2018b, The MathWorks, Inc., Natick, Massachusetts, United States. Also, the calculation 
of glycosylation indices, based on normalized intensities, was conducted with MATLAB. 
Equations used to determine Galactosylation index (GI), Fucosylation index (FI), and Sialylation 
index (SI) of detected glycoforms were previously described and listed in (Appendix B.2).77, 89, 90 
Diagnostic evaluations of significant glycoforms were determined by Receiver Operating 
Characteristics (ROC), Area under ROC curve (AROC) and other related parameters performed 
by a MATLAB code previously published with a permission use.91 The self-developed MATLAB 
scripts for calculating glycosylation indices with the corresponding generated code used in this 
study was supplied in  Appendix B.3. 
3.3 Results 
In this study, the well-known fast technique, highly sensitive, and easy to use, MALDI-TOF-
MS was used to differentiate patients with AD from age-matched control subjects with no 
significant neurodegenerative variations. This technique has been adapted for carbohydrate and 
glycoconjugate analyses for decades. 62 Herein, brain FC N-glycome was profiled seeking 
discovery of early glycan-based biomarkers for AD pathology. The total six-teen FC brain tissues, 
including eight specimens extracted from AD brains and eight from healthy age-matched controls, 
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were subjected to glycomic analysis after extracting soluble proteins in lysis buffer. The protein 
concentration was measured in advance before and after ultrafiltration, and the protein profile was 
validated by SDS-PAGE (Appendix B.4).  
The extract was subjected to overnight PNGase F digestion, followed by centrifugation to 
separate released N-glycoforms from the retained proteins. Then, released glycoforms were 
subjected to derivatization, methylation, before glycomic analysis on MALDI-TOF instrument. 
Permethylation is critical to stabilize negatively charged neuraminic acid residues and thus 
enhance the efficiency of glycoform ionization in MS analyzer beside the privilege of linkage 
analysis under MS/MS condition.63 Subsequently, MALDI-MS spectra were thoroughly processed 
to evaluate aberrant glycosylation due to AD pathogenesis and progression. 
3.3.1 Identification of distinctive AD FC N-glycoforms  
Eight brain tissues derived from healthy CT subjects were examined by MALDI-TOF-MS 
in order to define the typical FC N-glycome pattern compared to that affected during AD 
pathological progression. A total of 122 N-glycoforms were derived from brain FC tissues, among 
which 104 N-glycoforms were observed in at least 50% of either AD or CT examined subjects 
(named Subset 1), while 60 N-glycoforms were detected across all cases (named Subset 2). 
Appendix B.5 represents putative N-glycoform structures observed in FC N-glycome. It shows the 
total characterized brain-FC N-glycoforms, including those categorized to each subset with the 
corresponding compositions and structures constructed according to SNFG.86 The MS profiles of 
FC N-glycome characterized in AD and healthy brains are depicted in Figure 3.2, presenting 
[M+Na]+ precursor ions observed from m/z 1100 to m/z 4100 (part of detected N-glycoforms are 
presented). FC glycoform pattern shows very similar profiling among examined cases, including 
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different families of N-linked glycans such as hybrid, high-mannose, and complex (bi-, tri-, and 
tetra-antennary) structures with or without fucose residues.  
Notably, most of the highly complex glycoforms are mostly fucosylated with core Fuc 
(1α6) linked to the first innermost GlcNAc residue besides those structures terminated with 
fucose-containing epitopes. Complex glycoforms capped with Neu5Ac, Neu5Gc or lactonized 
 
 
Figure 3. 2: MALDI-MS profile of FC N-glycoforms derived from (A) healthy age-matched controls’ and (B) AD patients’ 
brains. 
* internal standard β-cyclodextrin, ◼ N-acetylglucosamine (GlcNAc), ◼ N-acetylgalactosamine (GalNAc), ⚫ mannose 
(Man), ⚫ Galactose (Gal), and ◆ N-acetylneuraminic acid (Neu5Ac). 
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Neu5Ac are also observed in FC N-glycome. However, the number of sialylated N-glycoforms 
derived from FC is a way lower than that of asialylated glycoforms. Moreover, besides detecting 
a hexosamine-containing glycoform, those species terminated with LacNAc repeats or containing 
an additional Gal residue are detected in FC tissues. Further known modifications such as sulfation 
and phosphorylation were detected. However, these structures are low abundant compared to those 
free of these modifications. Thus, most of FC N-glycoforms are non-modified.   
Among 122 glycoforms derived from FC tissues, N-glycoforms that are considered unique 
for healthy FC brains are those absent in 50% or more of the examined AD cases. These unique 
CT N-glycoforms are H5N4A1F1 (m/z 2605.33±0.05), H4N5A1F2 (m/z 2820.32±0.06), H4N7A1 
(m/z 2962.04±0.11), H5N6F4 (m/z 3256.17±0.06), H6N6F5 (m/z 3634.66±0.09), H6N6A1F3 
(m/z 3647.97±0.09), H7N6F4 (m/z 3664.74±0.08), and H8N6A2(m/z 3894.47±0.10). Notable, 
these CT unique glycoforms were observed in all CT tissues, except H6N6F5, H6N6A1F3, and 
H7N6F4 which were absent in only one CT case (CT6). Details are shown in Table 2.  
Table 2: Unique N-glycoforms observed in FC N-glycome derived from CT brains 
Code 
 m/z signal  Accuracy  Intensity 
 Theoretical 
 
Experimental 
SEM 
± 
 
Da ppm 
 
NI 
SEM 
± 
Local 
RI 
SEM 
± 
H5N4A1F1  2605.2981  2605.3297 0.0525  0.04 13.86  0.0003 0.0001 25.16 1.99 
H4N5A1F2  2820.4139  2820.3166 0.0599  0.27 94.10  0.0002 0.0001 16.44 2.65 
H4N7A1  2962.4881  2962.0374 0.1127  0.43 146.83  0.0003 0.0001 19.00 1.70 
H5N6F4  3256.6447  3256.1663 0.0622  0.11 33.88  0.0002 0.0000 12.04 0.61 
H6N6F5  3634.8337  3634.6576 0.0928  0.28 75.72  0.0001 0.0000 7.22 1.15 
H6N6A1F3  3647.8290  3647.9723 0.0944  -0.23 -62.98  0.0001 0.0000 7.85 1.48 
H7N6F4  3664.8443  3664.7392 0.0779  0.08 22.31  0.0001 0.0000 7.44 1.10 
H8N6A2  3894.9345  3894.4726 0.0991  0.48 122.60  0.0001 0.0000 4.84 0.34 
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On the other hand, fifteen N-glycoforms were uniquely correlated to AD brains. 
Noteworthy, these N-glycoforms were completely absent in healthy FC controls characterized in 
this study; H4N3P1F1 (m/z 1890.16, ±0.14), H4N3G1(m/z 2012.22±0.15), H7N2P2F1(m/z 
2349.81±0.04), H6N4P1(m/z 2368.98±0.12), H3N6F2 (m/z 2500.66±0.14), H5N5P2 (m/z 
2503.12±0.09), H4N4A1ALac1 (m/z 2542.59±0.19), H5N6 (m/z 2559.95±0.18), H6N3A1F1(m/z 
2565.46±0.16), H6N4A1 (m/z 2635.05±0.17), H3N6F3 (m/z 2673.99±0.17), H6N6 (m/z 
2763.61±0.03), H6N4A1F1 (m/z 2809.26±0.16), H5N5A2 (m/z 3036.18±0.09), and H7N5F2 (m/z 
3071.534±0.14). These glycoforms are listed in Table 3. 
   Table 3: Unique N-glycoforms observed in FC N-glycome derived from AD brains. 
Code 
 m/z signal  Accuracy  Intensity 
 Theoretical 
 
Experimental 
SEM 
± 
 
Da ppm 
 
NI 
SEM 
± 
Local 
RI 
SEM 
± 
H4N3P1F1  1888.8803  1890.1640 0.1429  -1.28 -679.13  0.0010 0.0003 17.01 2.91 
H4N3G1  2011.9934  2012.2204 0.1458  -0.23 -112.82  0.0010 0.0002 23.25 5.92 
H7N2P2F1  2350.0353  2349.8069 0.0436  0.23 97.21  0.0002 0.0001 1.35 0.91 
H6N4P1  2368.1170  2368.9771 0.1216  -0.86 -363.07  0.0005 0.0003 6.57 2.58 
H3N6F2  2500.2668  2500.6565 0.1381  -0.39 -155.85  0.0003 0.0002 4.06 1.58 
H5N5P2  2503.1255  2503.1226 0.0863  0.00 1.17  0.0008 0.0003 11.87 2.66 
H4N4A1ALac1  2542.2409  2542.5868 0.1931  -0.35 -136.03  0.0001 0.0001 2.69 1.37 
H5N6  2560.2879  2559.9513 0.1803  0.34 131.48  0.0002 0.0001 5.65 1.91 
H6N3A1F1  2564.2716  2565.4650 0.1581  -1.19 -465.19  0.0004 0.0001 5.88 1.35 
H6N4A1  2635.3087  2635.0550 0.1711  0.25 96.27  0.0003 0.0001 7.75 2.61 
H3N6F3  2674.3560  2673.9935 0.1665  0.36 135.55  0.0002 0.0001 2.86 1.20 
H6N6  2764.3877  2763.6150 0.0328  0.77 279.58  0.0001 0.0001 1.57 1.10 
H6N4A1F1  2809.3979  2809.2574 0.1582  0.14 50.01  0.0003 0.0001 4.94 1.67 
H5N5A2  3037.5089  3036.1782 0.0899  1.33 438.28  0.0001 0.0001 1.43 0.59 
H7N5F2  3071.5395  3071.5365 0.1362  0.00 0.99  0.0002 0.0001 3.12 0.84 
 
For investigating these unique glycoforms, the local normal area (NI) and the 
corresponding local relative intensity (RI) are calculated. The latter is visualized in Figure 3.3  
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As illustrated in Figure 3.3 (A), 
healthy FC tissues show a high 
percentage of a mono-sialylated bi-
antennary complex glycoform 
(H5N4A1F1, 25.16±2.0%) compared to 
other N-glycoforms that are considered 
unique for healthy brains. This structure 
is absent in about 60% of AD cases 
subjected to glycomic analysis. Also, 
highly complex N-glycoforms (tri- and 
tetra-antennary) are featuring healthy FC 
brains. 
Notably, most of these N-
glycoforms are core fucosylated, in which 
fucose is linked to the innermost GlcNAc 
residue, with or without terminal 
fucosylated epitopes at the non-reducing 
end. The following glycoforms; H4N5A1F2 (16.44±2.7%), H4N7A1 (19.00±1.7%), H5N6F4 
(12.04±0.61%), H6N6A1F3 (7.85±1.48%), and H8N6A2 (4.84±0.34%) are observed in all CT 
tissues, except H6N6A1F3 missed in CT6, and absent in 50% of AD tissues. In addition to 
H5N4A1F1, which represented the highly abundant unique N-glycoform in normal FC, H6N6F5 
(7.22±1.15%) and H7N6F4 (7.44±1.10%), which are missed only in one CT tissue (CT6), are 
absent in more than 60% of examined AD tissues, especially the highly fucosylated glycoform, 
 
 
Figure 3.3: Unique N-glycoforms derived from frontal cortex 
tissues extracted from healthy subjects’ and AD patients’ brains. 
(A) Percentage of unique N-glycoforms derived from normal FC 
brains and (B) percentage of unique N-glycoforms derived from 
AD pathological FC brains, sorted based on m/z from small to 
large species.  
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H6N6F5 (missed in ~75% AD tissues). This observation is harmonious with our results when 
fucosylation is further investigated for differentiating diseased tissues in this study. In a few words, 
normal FC tissues are characterized with distinctive complex glycoforms including those mostly 
fucosylated either on the core or termini 
Unlike normal FC, AD tissues notably display uniqueness in terms of glycoform types and 
the presence of different forms of neuraminic acid residues. Unlike complex N-glycoforms 
observed on normal FC brains, AD brains show distinctive glycan families beside complex 
structures such as one high mannose H7N2P2F1 (1.35±0.91%) and two fucosylated hybrid 
structures (H6N3A1F1 (5.88±1.35%) and H6N4A1F1 (4.94±1.67%)). However, the MS 
intensities of these structures are lower than those observed from complex species (10 structures). 
Also, two truncated glycoforms represented the highly abundant glycoforms that are 
specified to FC in AD brains; H4N3P1F1 (17.01±2.90%) and H4N3G1 (23.25±5.92%). 
Conspicuously, the glycan structure terminated with Neu5Gc, H4N3G1, represented the highly 
plentiful glycoform in FC tissues characterized with AD compared to the accompanying AD 
structures. This structure is missed in healthy brains. This sialylated species is observed in almost 
all examined AD cases (~90%). In contrast, lactonized N-acetylneuraminic acid residue 
(Neu5AcLac, ALac) capping a bi-antennary complex glycoform (H4N4A1ALac1, 2.78±1.4%) is 
distinctively observed in AD tissues although the glycoform abundance is in totally low compared 
to other sialylated glycoforms because the observation is only <40% of examined AD cases. The 
exception is the di-sialylated bisecting glycoform (H5N5A2, 1.43±0.59%) which is detectable in 
50% of AD cases. One complex mono-sialylated glycoform (H6N4A1, 7.75±2.61%) is the highly 
abundant species among glycoforms capped with Neu5Ac residues and observed in 75% AD cases 
105 
although an additional Gal residue, without a GlcNAc branch, is presented to its non-reducing 
terminus. 
Phosphorylated bi-antennary glycoforms are also observed in AD brains with either an 
additional Hex residue H6N4P1 (6.57±2.58%) or HexNAc residue (H5N5P2, 11.87±2.66%). 
Moreover, five distinctive AD complex glycoforms derived from FC displayed highly branched 
structures, two of which without fucosylation (H5N6 (5.65±1.91%) and H6N6 (1.57±1.10), while 
three are highly fucosylated (H3N6F2 (4.06±1.58%), H3N6F3 (2.86±1.20%), and H7N5F2 
(3.12±0.84%)). Accordingly, AD tissues exclusively exhibit various glycoform types, among 
which complex glycoforms capped with different kind of sialic acid residues and or decorated with 
fucose residues and phosphate groups. These distinctive glycosylation traits are distinguishable in 
healthy FC tissues from that affected by neurodegenerative deformation during AD pathological 
development. This observation might reflect changes in glycosyltransferases that are essential 
during the disease progression. 
3.3.2 FC N-glycome profile in healthy and AD tissues  
Although MS profiles of FC N-glycome exhibit similarity between the examined groups, 
a close glance revealed disorderly differences concerning the glycoform manner or the type of 
modifications introduced as the result of consecutive biological processes. Moreover, in studies 
based on collecting samples from patients, the phenomenon of missing values is common 
regardless of the procedures used to achieve the highest degree of credibility.92 This limitation is 
also universal in the glycomic analysis to profile diagnostic biomarkers correlated to the stages of 
disease development.93 Therefore, N-glycoforms detected in fewer than 50% of cases are discarded 
from the downstream glycomic analysis to reduce the induced prejudice by attribution for missing 
values not at random as previously described.93 Thus, the quantitative analysis was restricted to 
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the glycoforms that are detectable in at least 50% of the examined cases in each group (Subset 1) 
and those perceptible across all cases (Subset 2) in order to differentiate FC N-glycome profiles 
and to determine significant variations in glycosylation. These glycoforms are listed in Appendix 
B.5, in which both subsets are represented. 
Subset 1, illustrated in Figure 3.4, represents the total N-glycoforms detected in at least 
50% of cases subjected to glycomic analysis. As shown in the heat map (Figure 3.4 (A), the overall 
FC N-glycome profile is featured with high abundant N-glycoforms at low m/z range compared to 
those at the high m/z range although some N-glycoforms are missing either in AD or CT cases. 
The highly abundant N-glycoform detectable across all examined tissues is H5N2 (9) followed by 
H3N3S1 (6) and H3N5F1(28). The other merit that characterizes the pattern of FC N-glycome 
profile is low abundances of large N-glycoforms. The highest intense peak is H4N5F2 (55) which 
is observed across all samples. Because of the apparent difference in the relative intensities, the 
range of small N-glycoforms, ordered from small to large species, is presented separately from 
large N-glycoforms as shown in Figure 3.4 (B) to clarify the pattern of FC N-glycome profile in 
AD and CT. In general, the pattern of AD N-glycome profile is comparable to that derived from 
CT frontal cortex tissues. That is, the abundance of individual N-glycoform derived from AD is 
analogous to the counterpart derived from CT in its relative intensity. Noteworthy, the most 
abundant N-glycoforms derived from either CT individuals’ and AD patients’ brains are H5N2 
(9), 47.40±5.60% and 70.32±3.16% respectively. 
The highly intense peak, representing a high mannose glycoform, masked the pattern of 
other N-glycoforms in FC N-glycome profile. The superior abundance of H5N2 derived from AD 
cases compared to CT cases might influence the overall variations in terms of glycoform types 
(high mannose glycoforms, p<0.008), as shown in this study later. 
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The next six abundant N-glycoforms are alike in the arrangement either in CT and AD 
cases with trivial exceptions; CT abundant N-glycoforms are (6) H3N3S1 (7.39±1.18%), (28) 
H3N5F1(6.40±1.03%), (14) H6N2 (4.01±0.71%), (12) H3N4 (3.11±0.88%), (3) H3N2F1 
(2.44±0.19%) and (4) H4N2 (2.20±0.24%), while AD abundant N-glycoforms are (28) H3N5F1 
(4.98±0.78%), (6) H3N3S1 (4.36±1.37%), (14) H6N2 (2.00±0.22%), (3) H3N2F1 (1.69±0.11%), 
(4) H4N2 (1.41±0.22%), and (12) H3N4 (1.13±0.31%). 
 
Figure 3.4: FC N-glycome profile of 104 N-glycoforms derived from healthy controls’ and AD patients’ brains, (Subset 1). 
A) Heat map of total N-glycoforms derived from FC of AD and CT brains, ranged from small (left) to large N-glycoforms (right) 
(green line divides the small glycoforms for large ones presented in the bar chart). The two bottom heat lines represent the 
average of each N-glycoform in CT and AD cases. B) Bar chart of FC N-glycome profile in which each bar represents the average 
of each glycoform relative intensity after being normalized to the internal standard. Because of the apparent difference in the 
relative intensities, the m/z range is divided into two m/z scopes. Small glycoforms are those with relative intensities ranged 
from m/z 1100 to 1145, 30 species, while large glycoforms are those with relative intensities ranged from m/z 2150 to 4100, 74 
species. (See Appendix B.6, Subset 1). *Star symbols represents N-glycoforms with significant variations (p<0.05). 
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Notable, the next abundant N-glycoform in AD CF N-glycome profile is the large 
glycoform (55) H4N5F2 (1.13±0.33%), while its intensity appears in CT profile lately with lower 
intensity (H4N5F2, 0.91±0.27%). However, significantly differentiated N-glycoforms (eight 
glycoforms) are included within the lower zone (m/z < 2145). Because the intensities of large N-
glycoforms (m/z > 2150, 31-104) are quite low compared to small glycoforms, these species are 
illustrated in a separate m/z zone, in which the relative intensity is < 1.2%. Again, (55) H4N5F2 
is the highly abundant N-glycoform in this range either in CT or AD profile. Apart from (55) 
H4N5F2, the next forth abundant N-glycoforms in this m/z scope are quietly similar in both groups 
with s slight difference in the order. That is, CT FC N-glycome profile includes (43) H4N5F1 
(0.55±0.12%), (36) H8N2 (0.51±0.13%), (52) H9N2 (0.43±0.15%), and (53) H5N4F2 
(0.39±0.09%), whereas AD profile comprises (52) H9N2 (0.42±0.14%), (43) H4N5F1 
(0.31±0.07%), (53) H5N4F2 (0.26±0.07%), and (36) H8N2 (0.25±0.05%). The complete statistical 
evaluations of N-glycoforms associated with Subset 1 are shown in Appendix B.6. 
  In Subset 2, total N-glycoforms detected across all cases are presented in Figure 3.5. The 
pattern of FC N-glycome profile is placidly comparable in both groups of subjects with a clear 
highly abundant (7) H5N2 among detected FC glycoforms. The relative abundance of N5N2 in 
Subset 2 is 49.20±5.44% and 71.94±3.00% in FC tissues derived from CT and AD cases, 
respectively. The relative intensity was calculated based on the total intensities of total N-
glycoforms detected across all cases. Therefore, the intensity of H5N2 in Subset 2 is higher than 
that in Subset 1. The abundance of this N-glycoform surpasses other glycoform abundances 
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determined in FC tissues. The next high abundant N-glycoforms detected in normal FC are (5) 
H3N3S1 (7.75±1.25%), (24) H3N5F1 (6.67±1.059%) and (12) H6N2 (4.19±0.74%).  
The counterpart N-glycoforms in AD are (24) H3N5F1 (5.10±0.79%), (5) H3N3S1 
(4.48±1.40%), and (12) H6N2 (2.04±0.22%), sorted based on their relative intensities. Away from 
H5N2, which is the only high intense glycoform in AD FC N-glycome profile in the range from 
m/z 1100 to m/z 2450, all other glycoforms in this range are low intense compared to CT 
counterparts. At the upstream m/z range of AD FC N-glycome profile, glycoforms with diverse 
intensities higher or lower than CT glycoforms with slight differences are observed. Beside 
 
Figure 3.5: FC N-glycome profile of 59 N-glycoforms derived from healthy controls’ and AD patients’ brains (Subset 2). 
A) Heat map of total N-glycoforms derived from FC of AD and CT brains, ranged from small (left) to large N-glycoforms (right). 
The two bottom heat lines represent the average of each N-glycoform in CT and AD cases. B) Bar chart of FC N-glycome profile 
in which each bar represents the average of each glycoform relative intensity after being normalized to the internal standard. 
Because of the apparent difference in the relative intensities, the m/z range is divided into two m/z scopes. Small glycoforms are 
those with relative intensities ranged from m/z 1100 to 2286, 30 species, while large glycoforms are those with relative intensities 
ranged from m/z 2300 to 4100, 74 species (See Appendix B.7, Subset 2). *Star symbols represents N-glycoforms with significant 
variations (p<0.05). 
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prominent (38) H4N5F2 (1.16±0.34%) detected in upstream m/z, (41) H4N3A2F1, (42) H4N6F1, 
(43) H9N2P2, (45) H6N4F2, (47) H4N6F2, (51) H5N4A2, (53) H5N5A1F1, (54) H5N6F2, (56) 
H6N5A1F1, (57) H6N6F2, (58) H6N5A1F3, and (59) H8N8A1 show slightly higher intensities 
compared to the counterparts assigned to normal FC N-glycome profile. Although more than third 
of N-glycoforms are excluded in Subset 2 from Subset 1 when considering detection across all 
cases, the significantly differentiated N-glycoforms (eight glycoforms) are still involved within 
FC N-glycome profile. This notice provides the confidence of considering missing values in Subset 
1 in which excluded values have a neglectable influence on the overall N-glycome profiling of FC. 
3.3.2.1  Statistical Analysis of FC N-glycome profile 
Altered glycosylation significantly affects cell functions and associated with various 
diseases,94-96 including neurodegenerative disorders.17, 97 Both CT and AD cases showed similar 
MS profile of FC N-glycome in terms of observed glycoform compositions. However, a thorough 
comparison of the average normalized intensity of the detected N-glycoforms derived from FC 
reveals significant differences between examined groups (p-value < 0.05). Eight N-glycoforms, 
including high mannose, hybrid and complex structures, are correlated to AD cases. These 
structures are, listed either in Subset 1 and Subset 2, are appreciably differentiated from the 
counterpart abundances in normal FC tissues according to the t-test. The AD/CT ratios of these N-
glycoforms are less than 0.31 with a p-value <0.05. Figure 3.6 displays the N-glycoforms 
mentioned above that are significantly differentiated in AD patients’ tissues compared to normal 
FC N-glycoforms derived from CT individuals.  
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Although Subset 2 includes approximately 56% of the total detected N-glycoforms listed 
in Subset1, both subsets have comprised these differentiable glycan compositions.  
 
Figure 3.6: Significantly differentiated FC N-glycoforms derived from FC tissues extracted from healthy individuals’ and AD 
patients’ brains. 
The left-side chart illustrates the scatter of normalized intensity ratios, while the right-side chart represents the boxplots of the 
relative intensities.  (A) Peak 5 and 4 (H3N3, m/z 1416.71),  (B) Peak 11 and 9 (H4N3, m/z 1620.81), (C) Peak 17 and 15 (H4N4, 
m/z 1865.94), (D) Peak 13 and 11 (H5N2F1, m/z 1753.87), (E) Peak 10 and 8 (H3N3F1, m/z 1590.80), (F) Peak 15 and 13 
(H4N3F1, m/z 1794.90), (G) Peak 24 and 20 (H5N3F1, m/z 1999.00), and (H) Peak 25 and 21 (H4N4F1, m/z 2040.02) ordered 
as appeared in Subset 1 and Subset 2, respectively. 
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FC N-glycome profile emerged from AD patients is indistinctive from normal. However, 
statistical analysis of MS spectra differentiates the average abundances of four truncated N-
glycoforms specified to FC tissues extracted from AD brains; A) Peak 5 and 4 (H3N3, m/z 
1416.71), (B) Peak 11 and 9 (H4N3, m/z 1620.81), (E) Peak 10 and 8 (H3N3F1, m/z 1590.80), 
and (F) Peak 15 and 13 (H4N3F1, m/z 1794.90) as listed in Subset 1 and Subset 2, respectively. 
These truncated glycoforms contain the N-glycan core ((Manα1,6) Manα1,3Manβ1,4-
GlcNAcβ1,4-GlcNAc) with or without a core Fuc (α1,6) residue linked to the innermost GlcNAc 
residue.98 However, because only one branch is presented on the core, these structures are 
classified as other structures rather than complex or hybrid species.  As illustrated in Figure 3.6 (A 
and B), the non-fucosylated glycoform, H3N3 (0.37±0.09%, p-value=0.03) and H4N3 
(0.25±0.05%, p-value=0.04), are significantly decreased in FC tissues diagnosed with AD 
compared to the normal counterparts (1.41±0.41% and 0.90±0.24%). It is also observed that the 
core-fucosylated truncated structures H3N3F1 (0.20±0.03%, p-value=0.03) and H4N3F1 
(0.14±0.03%, p-value=0.03) in FC categorized with AD are distinctively decreased relative to 
controls (0.66±0.13% and 0.58±0.14%, respectively) as shown in Figure 3.6 (E and F). 
Noteworthy, one oligomannosidic species, H5N2F1at m/z 1753.87 (Figure 3.6, D) is 
detected with a significant decrease in AD (0.13±0.02%, p-value=0.04) compared to the 
counterpart structure derived from normal FC tissues (0.43±0.095). This low abundant structure 
(AD/CT ratio<0.23) is core-fucosylated with a Fuc (α1,6) residue. Also, one structure, categorized 
as Hybrid, (H5N3F1 at m/z 1999.00, Figure 3.6, G) is distinctively reduced in AD FC N-glycome 
(0.15±0.03%, p-value=0.05), while the normal one’s abundance is 0.43±0.09%.  Regarding 
complex structures, two bi-antennary complex N-glycoforms, H4N4 at m/z 1865.94 and 4N4F1 at 
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m/z 2040.02 (Figure 3.6, C and H), are detected with a significant decrease in FC brains diagnosed 
with AD.  
Both structures are mono-galactosylated, one of which is core-fucosylated. The AD/CT 
ratio of the non-fucosylated species, H4N4, is 0.26 and the p-value=0.04. The relative abundance 
of H4N4 falls from 1.07±0.22% in normal FC to 0.35±0.08% in disease-related FC N-glycome. 
Similarly, the other fucosylated structure, H4N4F1, is highly abundant in healthy brains 
(1.38±0.26%) compared to the disease-related one (0.48±0.09%). The AD/CT ratio of the latter 
glycoform is approximately 0.31 with p-value close to 0.05. Thus, all significantly differentiated 
N-glycoforms derived from AD-related FC tissues show minimal abundances relative to control 
cases. This behavior is clearly illustrated in scatter charts (Figure 3.6, left side), in which the 
maximum intensity ratio of AD-correlated N-glycoforms is less than that of approximately a half 
of healthy cases examined in this study. However, large cohort samples might be necessary to 
reach a broad conclusion in this matter.  
3.3.2.2 Diagnostic evaluation of candidate biomarkers for AD 
For diagnosing the potentiality of these eight N-glycoforms for discriminating AD patients 
from healthy subjects, further ROC curve analysis was performed for evaluating the FC 
glycosylation pattern (Figure 3.7 and Table 4). The corresponding parameters, including 
sensitivity, specificity, and AROC for each N-glycoform are listed in Table 4. As mentioned 
before, four N-glycoforms are categorized as other structures, in which the N-glycan core is 
preserved but only one GlcNAc extension linked to either of the mannosyl residues. The small N-
glycoform, (A) H3N3 at m/z 1416.70, and the counterpart core-fucosylated form, (E) H3N3F1 at 
m/z 1590.80, gain the highest AROC scores close to 0.70, with high specificity scores of 87.50% 
and 100%, respectively, in the differentiation of AD cases from healthy subjects.  
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Although, the sensitivity scores 
are moderate (~60%), these two N-
glycoforms display high precision 
(PPV=0.82 and 1.00, respectively) that 
reflects the high probability to predict 
the true positive conditions if 
individuals diagnosed with AD. The 
negative predictive values (NPV) are 
close to 0.68 and 0.71 for both in 
respect, which means the probability to 
distinguish healthy individuals (true 
negative) from diseased cases. In 
support of the high AROC scores, 
these species generate positive 
Matthews correlation coefficient 
(MCC), representing a perfect 
prediction for disease cases.99, 100 
  Similarly, the mono-
galactosylated glycoform, (B) H4N3 at 
m/z 1620.81, and the counterpart core-
fucosylated form, (F) H4N3F1 at m/z 
1794.90, endue moderate sensitivity 
scores (~60%) with slightly high and 
 
Figure 3.7: ROC curve analysis of eight significantly differentiated N-
glycoforms derived from FC tissues for evaluating AD candidate 
biomarkers. 
(A) Peak 5 and 4 (H3N3, m/z 1416.71),  (B) Peak 11 and 9 (H4N3, m/z 1620.81), (C) 
Peak 17 and 15 (H4N4, m/z 1865.94), (D) Peak 13 and 11 (H5N2F1, m/z 1753.87), 
(E) Peak 10 and 8 (H3N3F1, m/z 1590.80), (F) Peak 15 and 13 (H4N3F1, m/z 
1794.90), (G) Peak 24 and 20 (H5N3F1, m/z 1999.00), and (H) Peak 25 and 21 
(H4N4F1, m/z 2040.02) ordered as appeared in Subset 1 and Subset 2, respectively. 
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close AROC values, 0.66 and 0.68 respectively. Alike H3N3 and H3N3F1, H4N3 and H4N3F1 
give high specificity scores at 95.83% and 87.50%, respectively, with minor changes compared to 
smaller structures. Also, H4N3 endues higher PPV (0.93) and NPV (0.70) compared to H3N3, 
while H4N3F1 show lower PPV (0.82) and NPV (0.68) compared to H3N3F1 although MCC 
values are positive for all structures. In any case, the sizeable non-fucosylated glycoform, H4N3, 
and the small fucosylated glycoform, H3N3F1, derived from FC N-glycome may be closely related 
to AD in terms of truncated N-glycoforms and should be gain more attention regarding their roles 
as a candidate for the disease.  
Table 4: Diagnostic evaluation of eight N-glycoforms significantly differentiated between AD patients’ and CT individuals’ cases. 
(ROC, Receiver Operating Characteristic curve test). AROC, area under ROC curve; PPV, positive predicted value (precision); 
NPV, negative predicted value; MCC, Matthews correlation coefficient. 
Candidate 
glycoform 
 
Theoretical 
m/z 
 Sensitivity %  Specificity%  AROC  Accuracy  PPV  NPV  MCC 
H3N3  1416.7094  58.33  87.50  0.69  0.73  0.8235  0.6774  0.4792 
H3N3F1  1590.7986  58.33  100.00  0.70  0.79  1.0000  0.7059  0.6417 
H4N3  1620.8091  58.33  95.83  0.66  0.77  0.9333  0.6970  0.5843 
H5N2F1  1753.8718  58.33  100.00  0.68  0.79  1.0000  0.7059  0.6417 
H4N3F1  1794.8984  58.33  87.50  0.68  0.73  0.8235  0.6774  0.4792 
H4N4  1865.9355  58.33  79.17  0.68  0.69  0.7368  0.6552  0.3834 
H5N3F1  1998.9981  54.17  83.33  0.65  0.69  0.7647  0.6452  0.3920 
H4N4F1  2040.0247  58.33  100.00  0.69  0.79  1.0000  0.7059  0.6417 
 
The oligomannosidic glycoform, (D) H5N2F1 at m/z 1753.87, which is the only 
significantly differentiated high mannose glycoform (p<0.05), give high specificity (100%) and 
precision (PPV=1.00) with slightly high NPV (0.71). Although this glycoform results in low 
AROC score but close to 0.70, it records high accuracy (~0.80), and MCC shows higher positive 
value among most candidate N-glycoforms. This observation promotes the suggestion to consider 
this glycoform for further investigation in large cohort samples. Likewise, one significantly 
differentiated hybrid glycoform, (G) (H5N3F1, m/z 1999.00, gives AROC value away outside the 
acceptable cutoff (<0.70) among candidate AD glycoforms, which is reflected in low positive 
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MCC. As expected, the sensitivity and specificity scores are low compared to other candidates 
although precision is close to 0.76 with slightly lower NPV among other species. This observation 
may be explained by the random error during sampling and processing data so that further 
investigation is necessary for large cohorts.  
The left two bi-antennary complex glycoforms, (C) H4N4 at m/z 1865.94) and (H) 
H4N4F1 at m/z 2040.02, show slightly different scores in ROC analysis with a preference for 
H4N4F1. Although both glycoforms give similar sensitivity, the specificity of H4N4F1 (100%) is 
better so that this glycoform is preferable to predict the probability of healthy individuals with a 
real negative test.  
Also, AROC (~0.70), PPV (1.00), and NPV (~0.71) scores of the core-fucosylated 
glycoform exceed that of H4N4. Therefore, H4N4F1 is far superior to H4N4 in terms of complex 
glycoforms as an indicator for AD pathological onset. In any case, these eight N-glycoforms 
particular to FC tissues may be probably considered as candidate biomarkers for AD for early 
diagnosis of the disease progression. Mainly, four N-glycoforms, including two truncated 
glycoforms H3N3F1 and H4N3, a high mannose glycan (H5N2F1) and a bi-antennary complex 
glycan (H4N4F1), may play an essential role during the disease progression and should gain more 
attention. 
3.3.3 General glycosylation deviations in FC N-glycome derived from AD brains   
As reported previously, aberrant N-glycosylation is observed in several AD-related proteins 
and evaluated in CSF during the disease pathogenesis and progression.17, 43  In this set of discovery, 
we have evaluated the glycosylation pattern in FC tissues for fingerprinting changes in FC N-
glycosylation process during the pathological disease development. For thorough exploration, the 
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total detected N-glycoforms in FC tissues are classified based on multiple criteria, including 
glycoform type and complexity based on branches emerged from the N-glycan core. Moreover, 
we have determined the general glycosylation pattern such as fucosylation, galactosylation, and 
sialylation as well as other modifications, including sulfation, phosphorylation or both and the 
presence of hexosamine, Neu5AcLac, Neu5Gc, and LacNAc repeats. In Subset 1, the total number 
of glycoforms (821 from CT cases and 759 from AD cases) derived from eight FC tissues in each 
group are classified into 104 N-glycoform structures listed in Subset 1. 
On the other hand, Subset 2, the total observed N-glycoforms observed across all examined 
samples are 472, classified into fifty-nine structures (See Appendix B.5). These individual 
glycoforms are grouped based on the examined trait to thoroughly explore and statistically evaluate 
changes in this level of glycosylation. Appendices B.8-B.13 summarize calculations for 
glycosylation variations in terms of glycoform type, complexity, fucosylation, galactosylation, and 
sialylation as well as other modifications observed in FC N-glycome in purpose to differentiate 
AD from CT cases.  
3.3.3.1 Changes of FC N-glycoform type in AD 
For assessing the changes in the glycosylation type as a result of AD pathological 
progression, the total detected N-glycoforms are categorized into four groups: high mannose, 
hybrid, complex and other. The ‘other’ class glycoform preserves the N-glycan core while the non-
reducing end is either truncated or featured with only one GlcNAc branch. In Subset 1(Figure 3.8, 
A), a total of 79 high mannose glycoforms are detected in either CT or AD cases. However, this 
number represents only 9.63±0.15% or 10.44±0.19% of the total number of glycoforms detected 
in a CT (821) or AD (759) cases, respectively. This change is significantly increased in AD 
compared to CT cases (p-value<0.005). Close observation reveals that the abundance of high 
118 
mannose type glycoforms derived for AD cases is also significantly high (p-value=0.0076) in AD 
cases (75.56±2.88%) compared to the one derived from CT subjects (57.15±5.16%). For hybrid 
glycoforms, Although the number of hybrid glycoforms detected in CT (70, representing 
8.52±0.13%) and AD (66, representing 8.70±0.23%) are relatively equal and close to the number 
of High mannose glycoforms (79), the abundances are notably low either in CT (1.49±0.30%) or 
AD (0.71±0.15%). Moreover, the abundance difference is significant (p-value<0.033) between the 
examined cohorts, while the difference in the hybrid glycoform number is trivial.  
 
Figure 3.8: Changes of FC N-glycome in terms of glycosylation type in the differentiation of AD patients from normal 
individuals.  
A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with a 
total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-glycoforms 
derived from either CT or AD (See Appendices B.8 and B.11).  The left-side graph represents the relative intensity of the summed 
average intensities of each glycoform class to the total glycoform intensity. The right-side graph represents the average percentage 
of the summed numbers of each glycoform class to the total number of detected glycoforms in each group. 
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Unlike hybrid species, complex glycoforms show a significant difference in both criteria, 
the number of detected glycoforms and the corresponding total abundance (p-value<0.022). 
Noteworthy, the total number of detected complex glycans derived from CT cases is 547, 
representing the majority of detected glycoforms (66.63±0.31% of glycoforms), while the 
corresponding average abundance is 23.90±3.01%. Likewise, a smaller number of complex 
glycoforms are derived from AD FC N-glycome (492, representing 64.73±0.63% of total 
glycoforms), but the corresponding average abundance is considerable low (14.72±1.90%) in AD 
cases. All remain glycoforms classified as Other, 125 from CT cases (15.21±0.28% and 122 from 
AD cases (16.14±0.45%), are inconsiderable in terms of number, whereas the corresponding 
abundance is significantly differentiated (p-value<0.015) between normal FC N-glycome and the 
diseased one. In total, all glycoforms types are significantly differentiated in terms of the overall 
abundance among the examined cohorts (p-value<0.05). However, the premature glycoforms, high 
mannose type, and complex glycoforms are the only considerable species in terms of the number 
of detected glycoforms derived from FC tissues. 
Similarly, in Subset 2 (Figure 3.8, B), a total of 64 high mannose glycoforms, representing 
13.56% of the total 472 glycoforms detected in FC tissues, are significantly elevated in AD 
(76.72±2.75) compared to CT (58.43±5.03) (p-value=0.0066). Although the number of this 
glycoform type is slight and comes after hybrid species, it represents the dominantly abundant 
species generated by the glycosylation process in the FC region of the brain. On the contrary, the 
abundance of hybrid glycoforms is considerable in CT (0.68±0.13%) compared to disease cohorts 
(0.31±0.07%), while only three structures are classified from a total of 24 hybrid glycoforms 
detected from all cases, representing 5.08% of the total detected glycoforms. Still, the complex 
type glycoforms are the major detected structures with a total of 304, representing approximately 
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64% out of 472 species derived from each group. The complex glycoform abundance, at any rate, 
is less than that of high mannose species either in CT (23.55±2.99%) or AD (14.13±1.79%). The 
abundance of this complex type is significantly decreased in abnormal FC tissues (p-value<0.018) 
but not as significant as high mannose. Another equally important observation is the decreased 
glycoform type assigned to AD FC N-glycome (8.83±1.85%, p-value<0.015) compared to those 
derived from the normal, which shows a moderate abundance of this glycoform type 
(17.33±2.41%). After all, Subset 2 shows similar behavior as that displayed in Subset 1, in which 
AD FC N-glycome is significantly distinguishable from normal FC N-glycan profile regarding the 
glycoform types, despite the glycoform numbers detected in each cohort. 
3.3.3.2   Changes of FC N-glycoform complexity in AD 
For considering the complexity style, the total listed complex N-glycoforms in Subset 1 
and Subset 2 are classified based on the number of branches that are emerged from the non-
reducing end into bi-, tri- and tetra-antennary complex glycoforms. In this manner, all N-
glycoforms inconvenient for this category are labeled as ‘other’ in this section. As mentioned 
previously, the complex glycoforms represent the vast majority of the total number of glycoforms 
observed in each cohort either in Subset 1 or Subset 2. A close glance to Subset 1 (Figure 3.9, A), 
A total of 152 (18.52±0.14%), 245 (29.84±0.19% and 150 (18.27±0.07%) bi-, tri- and tetra-
antennary complex glycoforms are derived from the eight examined CT tissues verses 148 
(19.57±0.46%), 213 (27.97±0.61%) and 131 (17.19±0.54%) detected in AD cases, respectively. 
Although the number of detected complex glycoforms is quietly relative among the monitored 
complexity classes, tri-antennary complex glycoforms show a considerable difference (p-
value=0.01) and even more significant than that of bi-antennary class glycoforms (p-value=0.01) 
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for differentiating disordered FC N-glycome from the regular profile though tri-class species are 
the most common glycoforms.  
However, in respect to abundance, the bi-antennary complex glycoforms are the only 
pointedly decreased species in AD FC tissues (4.92±0.78%, p-value<0.01) among other complex 
glycoforms compared to the one derived from normal FC (10.84±1.83%). The abundance of tri-
antennary complex glycans is 9.13±1.40% in AD cases compared to 12.28±1.72% in CT subjects 
with no significance. Noticeably, tetra-antennary glycoforms are the lowest abundant class that is 
 
Figure 3.9: Changes of FC N-glycome in terms of glycosylation complexity in the differentiation of AD patients from normal 
individuals.  
A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with a 
total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-glycoforms 
derived from either CT or AD (See Appendices B.8 and B.11).  The left-side graph represents the relative intensity of the summed 
average intensities of each glycoform class to the total glycoform intensity. The right-side graph represents the average percentage 
of the summed numbers of each glycoform class to the total number of detected glycoforms in each group. 
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indistinguishable between the examined cohorts (AD, 0.67±0.18%; CT, 0.78±0.13%, p-
value>0.05). In general, AD FC N-glycome shows fewer numbers and low abundance in overall 
complex glycoforms in all rate with a significant decrease in the abundance of bi-antennary 
glycoforms and the number of bi- and tri-antennary glycoforms. Concerning other structures, 
including high mannose, hybrid and non-specified structures altogether, AD FC N-glycome 
demonstrates a significant increase in the overall number of detected glycoforms (267 out of 759 
glycoforms, 35.27±0.63%, p-value<0.016) compared to CT (274 out of 821 glycoforms, 
33.37±0.31%). The overall increment in the other-class glycoforms results in a considerable 
increase in the overall abundance of these species in AD FC N-glycome (85.28±1.90%, p-
value=0.02). This observation is plausible since the vast majority of glycoforms observed in AD 
FC tissues are high mannose species and moderately non-specified species next after complex 
structures.  
In respect to N-glycoforms detected across all cases (Subset 2), the glycosylation traits that 
are considered significant in differentiation neurodegenerative disordered FC N-glycome from 
normal profile are similar to the observations when considering species detected in at least 50% of 
examined cases (Subset1) (See Figure 3.9, B). Similarly, most of the detected glycoforms are 
complex species in total; 128 bi-, 112 tri- and 64 tetra- out of 472 antennary complex glycoforms, 
grouped into 16 bi-, 14 tri- and eight tetra-antennary glycoform structures. The major detected 
glycoforms are bi-antennary (~27%), followed by tri- (~24%) and tetra-antennary glycans (~14). 
In compression to Subset 1, the only difference is the change in the relative ratio of bi- and tri-
antennary glycoform numbers. However, similarly to Subset1, the total abundance of bi-antennary 
glycoforms is still considerably reduced in AD FC N-glycome (4.74±0.74%, p-value<0.0088) 
compared to that determined in normal FC profile (10.87±1.87%).   
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Also, the total relative abundance of tri-antennary glycoforms (AD,8.92±1.37%; CT, 
12.16±1.70%) and tetra-antennary glycoforms (AD, 0.48±0.13%; CT, 0.53±0.10%, p-value>0.05) 
are still undistinguishable for differentiating the examined groups. The non-specified glycoforms 
(other) are the most detected glycoforms with a total of 168 species representing ~36% of the total 
detected glycoforms. Other-class glycoforms are still the major species detected either in AD 
(85.87±1.79%) or CT (76.45±2.99%) and perceptibly close to those observed in Subset 1. The 
other-class glycoforms, the sum of high mannose and non-specified species, can be used to 
distinguish AD cases for CT cases (p-value<0.02). After all, changes in glycosylation behavior 
during AD progression is reflected not only on the glycoform type but also the number of branches 
that are emerged from the glycan core. Also, observing all glycoforms across all cases or those 
detected in at least 50% of the ceases is acceptable and results in a similar conclusion of aberrant 
glycosylation process during AD pathogenesis and progression.  
3.3.3.3 Changes of FC N-glycoform fucosylation in AD  
For evaluating disorders occur in the fucosylation process as a consequence of AD 
pathological progression, the total glycoforms derived from FC tissues across all cases are 
categorized into four subgroups based on the degree of fucosylation. In this level of investigation 
core- or terminal-fucosylated glycoforms are generally considered regardless of the glycoform 
type. Thus, high mannose and hybrid type glycoforms, as well as non-specified species, are 
counted for assessing the fucosylation quality. In general, a total of 104 glycoform structures 
includes 41 non-, 27 mono-, 22 di-, and 14 multi-fucosylated glycans. In Subset 1 (Figure 3.10, 
A), the distribution of the total 759 detected glycoforms from AD FC tissues includes 304 non-
fucosylation, 208 mono-fucosylated, 158 di-fucosylated, and 89 multi-fucosylated glycoforms, 
representing 40.08±0.27%, 27.48±0.46%, 20.79± 0.38%, 11.66± 0.53% out of the total 
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glycoforms, respectively. The total number of CT counterparts are 323 (39.34±0.29%), 213 
(25.95±0.13%), 176 (21.45±0.16%), and 109 (13.27±0.20%), in respect to the increment of the 
fucosylation degree.  
Noteworthy, as illustrated in Figure 3.10, A-right side, Non-fucosylated glycoforms 
represent the dominant species among detected glycoforms either in CT or AD. Equally pattern in 
CT and AD cases, the glycoform populations decrease by the increase in the number of fucose 
residues covalently linked to core GlcNAc residues or on terminal residues. Nevertheless, mono-
fucosylated glycoforms are significantly differentiated between the examined cohorts (p-
 
Figure 3.10: Changes of FC N-glycome in terms of glycosylation fucosylation in the differentiation of AD patients from normal 
individuals. 
 A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with a 
total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-glycoforms 
derived from either CT or AD (See Appendices B.9 and B.12).  The left-side graph represents the relative intensity of the 
summed average intensities of each glycoform class to the total glycoform intensity. The right-side graph represents the average 
percentage of the summed numbers of each glycoform class to the total number of detected glycoforms in each group. 
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value<0.007) with a far great difference (~1.53%). Also, the number of multi-fucosylated species 
are considerably less in AD compared to those determined in CT (p-value<0.013). Other non-
fucosylated and di-fucosylated glycoforms show no significance between investigated groups.  
On the other hand, the abundance of these glycoforms somewhat reflects the observation 
in the glycoform numbers (Figure 3.10, A-left side). That is, mono-fucosylated glycoforms display 
a significant change between the cohorts, but low abundance is characterizing AD FC N-glycome 
(10.78±0.95%, p-value<0.0024) in comparison to CT FC N-glycome (17.65±1.59%). No 
significant changes are observed between the examined cohorts when two or more fucose residues 
are linked to the glycoform (p-value>0.05). Moreover, though the difference in the total number 
of non-fucosylated glycoforms is not significant between the two groups, the relative abundances 
of such species are considerably elevated in AD (86.44±1.54%, p-value<0.014) relatively to CT 
group (78.84±2.18%). In brief, the overall mono-fucosylation process is defective FC N-glycome 
in the level of glycoform numbers and abundance compared to normal tissues. Also, non-
fucosylated species represent the major glycoforms that notably characterize FC tissues undergone 
neurodegenerative defects. 
Glycoform fucosylation in Subset 2 demonstrates a similar pattern of glycosylation as that 
discussed in Subset 1. A total of 472 glycoforms derived from FC tissues are distributed among 
208 (~44%) non-, 152 (~32%) mono-, 88 (~19%) di- and 24 (~5%) multi-fucosylated glycoforms, 
which are classified into 26 non-, 19 mono-, 11 di- and 3 multi-fucosylated structures. Similar to 
the Subset 1 fucosylation pattern, the number of detected glycoforms is gradually decreased by the 
increase in the fucose residues added to the glycan (Figure 3.10, B-right side). This decrease is 
manifested when more than two fucose residues are added to the glycan. In particular, only 24 
multi-fucosylated glycoforms are observed across all cases. In respect to the abundance, the 
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fucosylation pattern is still similar to that observed in Subset 1 with a slight decrease in multi-
fucosylated species (AD, 0.11±0.04%; CT, 0.13±0.02%) because of eliminating most of these 
fucosylated glycoforms that are undetectable across all samples. The difference between groups is 
still insignificant along with di-fucosylated species (p-value>0.05). However, non- and mono-
fucosylated glycoforms preserves significant changes between the characterized groups (p-
value<0.013 and <0.003, respectively) (See Appendices B.9 and B.12 for details). Again, 
considering glycoforms detectable in at least 50% of the examined cases demonstrates a 
comparable glycosylation behavior as those observed across all cases. 
3.3.3.4 Changes of FC N-glycoform galactosylation in AD  
For evaluating the overall proportion of galactosylated glycoforms, the detected species 
are classified based on the appearance of terminal galactose residues linked to the non-reducing 
end. Thus, glycoforms are grouped to non-(aglactosylated), mono-, di-, tri-, and multi-
galactosylated structures. In Subset 1 (Figure 3.11, A-right side), from the total detected 
glycoforms, non- and mono-galactosylated forms are the major populations either in AD FC 
tissues (203 and 264 out of 759 glycans) or CT FC tissues (205 and 290 out of 821 glycans). The 
accordingly proportions are 26.85±0.59% and 34.73±0.55% in AD cases besides 24.97±0.16% 
and 35.32±0.17% in CT cases, respectively. Other glycoforms characterized by a high degree of 
galactosylation are less observed across the two examined groups. The lowest population is the 
multi-galactosylated species; 18 glycoforms in AD tissues (2.37±0.25%) 24 glycoforms in CT 
tissues (2.92±0.02%). The number of multi-galactosylated glycans is significantly differentiated 
between tested cohorts (p-value<0.05). The differentiation of non-galactosylated and tri-
galactosylated form is the most significant between AD FC N-glycome and CT FC N-glycome 
profiles with p-values <0.0075 and <0.0055, respectively. Mono- and di-galactosylated species are 
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inconsiderable for differentiating the disease group from the normal one in terms of the detected 
numbers. On the other hand, FC N-glycome pattern in AD brains (5.31±0.97%) is significantly 
differentiated from the normal profile (10.12±1.71%) specifically for mono-galactosylated 
glycoforms with p-value<0.03 (Figure 3.11, A-left side). Other galactosylated species, as well as 
aglactosylated forms, show no significant changes regarding relative abundances between tested 
cohorts. 
 
Figure 3.11: Changes of FC N-glycome in terms of glycosylation galactosylation in the differentiation of AD patients from 
normal individuals. 
A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with 
a total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-
glycoforms derived from either CT or AD (See Appendices B.9 and B.12).  The left-side graph represents the relative 
intensity of the summed average intensities of each glycoform class to the total glycoform intensity. The right-side graph 
represents the average percentage of the summed numbers of each glycoform class to the total number of detected glycoforms 
in each group. 
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In Subset 2 (Figure 3.11, B-right side), the total number of detected glycoforms (472) is 
divided into 168 (~36%) non-, 136 (~29%) mono-, 120 (~25%) di-, 40 (~8%) tri-, and 8 (~2%) 
multi-galactosylated species. The number of glycoforms decreases gradually by the addition of 
galactose residues during the glycosylation process. Comparably to Subset 1 (Figure 3.11, B-left 
side), aglactosylated glycoforms are the major abundant populations in both groups (AD, 
93.16±1.31%; CT, 87.96±2.04%) with no significance (p-value>0.05). This observation is 
originated from the fact that high mannose glycoforms, which are the major glycan type, are 
considered non-galactosylated in this section. Later in this set of discovery, the galactosylation 
pattern is investigated thoroughly with consideration of the glycoform type.  
All galactosylated classes display insignificant differences between the examined groups, 
except mono-galactosylated forms (p-value<0.03). The latter galactosylated glycans present 
4.50±0.82% of the total glycoforms relative intensities assigned to AD FC N-glycome profile 
compared to 8.59±1.45% characterized for normal FC N-glycome. In short, the abundance 
distribution of aglactosylated and galactosylated forms in AD FC N-glycome is analogous to 
normal FC profile even if N-glycoforms observable across all cases are considered for calculation. 
In both Subsets, the mono-galactosylated glycans are the most distinctively deceased form in AD 
patients compared to normal. Thus, further investigation may reveal the role played in the disease 
pathogenesis.  
3.3.3.5  Changes of FC N-glycoform sialylation in AD  
Similarly, the total observed FC N-glycoforms are classified based on the presence of sialic 
acid residues capping the reducing end, regardless of the glycoform type. Later in this discovery 
set, only glycoforms eligible for sialylation are considered for further investigation to determine 
the glycosylation changes in the matter of sialylation. In this section, the overall sialylation pattern 
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of detected glycoforms is monitored for significant differentiation in FC N-glycome profiles 
between AD and CT cases.  
Figure 3.12 (A-right side) visualizes the sialylation pattern generated from N-glycoforms 
listed in Subset 1. A total of 759 AD N-glycoforms are distributed into 543 (71.75±1.21%), 181 
(23.63±1.22%), and 35 (4.62±0.17%) classified to non- (asialo), mono-, and di-sialylated 
glycoforms. At all rates, the number of glycoforms and the corresponding proportions exhibit less 
representation in disturbed tissues compared to the counterparts in CT, except non-sialylated 
forms. That is, normal FC N-glycome generates less proportion of asialo-glycoforms 
 
Figure 3.12: Changes of FC N-glycome in terms of glycosylation sialylation in the differentiation of AD patients from 
normal individuals. 
A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with 
a total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-
glycoforms derived from either CT or AD (See Appendices B.9 and B.12).  The left-side graph represents the relative 
intensity of the summed average intensities of each glycoform class to the total glycoform intensity. The right-side graph 
represents the average percentage of the summed numbers of each glycoform class to the total number of detected glycoforms 
in each group. 
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(69.43±0.17%) compared to AD cases although more numbers detected from the normal tissues. 
This remark may indicate to the fact that these species are less abundant in normal FC, which is 
confirmed when the corresponding relative intensities are quantitively contemplated, as shown in 
Figure 3.12 (A-left side). Non-sialylated glycoforms represent the major population of the detected 
N-glycans at any rate in both groups, while sialylated species are far low abundant (<2%). The 
abundance of mono-sialylated forms derived from normal FC tissues (1.39±0.27%) is higher than 
that obtained from the same region in AD brains (0.92±0.23%). The di-sialylated species are the 
lowest abundant species among demonstrated classes with a slight increase in favor of AD cases 
(AD, 0.20± 0.06%; CT, 0.19±0.04%). However, at this level of investigation, no evidence of 
significant differences is revealed among all classes (p-value>0.05).  
Figure 3.12 (B), illustrates the distribution of sialylation classes categorized from the total 
472 N-glycoforms derived from FC tissues across all cases (Subset 2). The right-side graph shows 
that non-sialylated glycoforms represent the major population (400 out of 742 glycoforms, ~85%), 
while sialylated species are minor. The number of sialylated glycans detected in FC tissues is far 
low (<50, <11%) in comparison to non-sialylated. Moreover, the abundance of such species is 
quietly equal in both groups with no significance (p-value>0.05). In respect to abundance, AD FC 
N-glycome contains 99.69±0.09% non-, 0.14±0.04% mono-, and 0.17±0.05% di-sialylated forms, 
while the normal generates 99.70±0.05%, 0.14±0.02%, and 0.16±0.03%, respectively. As 
perceived from the sialylation pattern either in Subset 1 or 2, the patterns are similar in both sets, 
indicating no effects of excluding glycoforms that are missing in less than 50% of cases. 
3.3.3.6 Changes of FC N-glycoform modifications in AD  
The final trait evaluated in FC N-glycome is the presence of rare modifications decorating the 
glycoform structure, including sulfation, phosphorylation, sulfation-phosphoprotein, HexN 
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(Hexosamine), Neu5Gc (N-glycolylneuraminic acid), Neu5AcLac (lactonized Neu5Ac), and 
LacNAc repeats. These alterations may play an essential role during disease pathogenesis and 
progression. Figure 3.13 demonstrates the relative quantification of screened features in Subset 1 
(A) and Subset 2 (B). 
Apart from insignificant non-modified species, which represent the dominant population 
in either AD or CT cases in both subsets, sulfated glycoforms are the second most present species 
in AD cases (51 glycoforms, 6.73±0.24%) and CT cases (56 glycoforms, 6.82±0.05%), as shown 
in Figure 3.13 (A-right side). The followed are phosphorylated (24 AD glycoforms (3.18±0.09%) 
and 23 CT glycoforms (2.80±0.11%)) and then Neu5Gc-containing glycoforms (16 AD 
 
Figure 3.13: Changes of FC N-glycome in terms of glycosylation modification in the differentiation of AD patients from normal 
individuals. 
A) Subset 1 with a total of 104 N-glycan structures detected in at least 50% of the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from CT tissues and 759 N-glycoforms derived from AD tissues. B) Subset 2 with a 
total of 59 N-glycan structures detected across all examined cases in each group and classified from a total of 472 N-glycoforms 
derived from either CT or AD (See Appendices B.10 and B.13).  The left-side graph represents the relative intensity of the 
summed average intensities of each glycoform class to the total glycoform intensity. The right-side graph represents the average 
percentage of the summed numbers of each glycoform class to the total number of detected glycoforms in each group. 
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glycoforms (2.12±0.06%) and 16 CT glycoforms (1.95±0.01%)). The two late mentioned species 
are significantly differentiated between the examined cohorts (p-value<0.02) regarding the number 
of glycoforms obtained from FC tissues. Other modified glycoforms are present in fewer numbers 
(<10 glycoforms) either in AD or CT FC tissues and demonstrating low proportion (<1.1%) among 
other species. However, the proportion of HexN-containing and LacNAc-carrying glycoforms is 
considerable different (p-value,0.02) in AD FC N-glycome (1.06±0.03%) than that in normal FC 
profile (0.97±0.01%) although an equal number of glycoforms is observed in both cohorts (8 
glycoforms). However, when the glycoform abundance is considered for relative quantitation, only 
phosphorylated glycoforms are significantly differentiated (p-value<0.05) as its intensity is visibly 
low in disordered FC (0.50±0.10%) compared to that in normal (1.44±0.40%), Figure 3.13, A-left 
side. 
Similar glycosylation pattern is observed in Subset 2. However, modifications such as 
sulfated/phosphorylated glycoforms as well as Neu5AcLac-capped glycoforms are missing in 
some cases so that these species are excluded in Subset 1. Out of 742 glycoforms, 32 sulfated 
species derived from FC tissues, representing ~7% as a second class in FC N-glycome as illustrated 
in Figure 3.13, B-right side. Comparable to Subset, one phosphorylated and Neu5Gc-containing 
species are the following proportion (16 glycoforms representing ~3.4%) out of the overall 
population derived from FC tissues. Since this subset comprises the glycoforms detected across all 
cases without missing data, no significance outcomes are expected. Therefore, evaluating the total 
abundance of each class of glycoforms is crucial to differentiate the disease cohort from normal. 
As shown in Figure 3.13 (B-left side), FC glycoforms with moderate abundance such as sulfated 
species (AD, 4.82±1.42%; CT, 8.42±1.33%) or those species with very low abundance (<0.4%) 
are irrelevant for differentiating examined groups (p-value>0.05). The exception is phosphorylated 
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species (p-value<0.05). In this case, the relative abundance of phosphorylated glycoforms is 
meaningfully elevated in normal FC (1.18±0.34%) in comparison to that obtained from FC 
affected by AD progression (0.38±0.10%). After all, in this layer of exploration, both subsets (1 
and 2) show a comparable behavior in relevant to the abundance of glycoform classes, regardless 
of the number of glycoforms classified to each class. That is, the ignorance of glycoforms missed 
in less than 50% of cases is acceptable and obtains valuable results comparable to outcomes 
obtained from glycoforms detectable across all cases.  
3.3.4 Glycosylation indices for differentiating AD FC N-glycome from normal 
For thoroughly investigating the quality of the glycosylation process in the FC region of 
AD brains, the glycosylation indices of fucosylation, galactosylation, and sialylation have been 
calculated according to previously reported equations.77, 90 However, minor modifications have 
been introduced to some equations. The performance of these equations to differentiate the 
glycosylation traits between the examined cohorts is statistically evaluated by t-test and ROC 
analysis. Index equations that provide the best AROC values are illustrated in this manuscript. All 
calculations and the corresponding figures representing these equations are summarized in 
Appendix B.2, Appendix B.14-19.  
3.3.4.1 Diagnostic evaluation of fucosylation index 
For calculating fucosylation indices, three equations have been tested, FI-1, FI-2, and FI-3 
(see Appendix B.2 and Appendix B.17). The modified equations, FI-2 and FI-3, showed better 
performance than that obtained by FI-1 equation for differentiating the examined cohorts in both 
categories (Subset 1 and Subset 2). Mostly, FI-2 showed the best performance for all determined 
glycan types, including complex, high mannose, hybrid, other, and total glycoforms. Furthermore, 
AROC scores obtained from FI-2 are quietly similar in both categories, Subset 1 and Subset2. That 
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means the effect of missing values in less than 50% of cases is negligible. Therefore, the 
performance of Subset 1 (FI-2) mostly reflects the overall changes in FC fucosylation and thus 
thoroughly explained in this manuscript. Figure 3.14 illustrated the fucosylation indices (FI) 
calculated by FI-2 for all glycoforms listed in Subset 1. 
The interpretation of fucosylation index means the highest FI value is, the more 
fucosylation occurrence the FC glycoforms have. As shown in Figure 3.14, the AD cohort shows 
the lowest FI values across all glycoform types. The median values of N-glycoforms derived from 
 
Figure 3. 14: Fucosylation indices calculated for total N-glycoforms detected in at least 50% of AD patients’ and healthy 
individuals’ FC tissues. 
Subset 1 consists of 104 N-glycan structures detected in at least 50% across the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from normal FC tissues and 759 N-glycoforms derived from AD FC tissues. (a) 
total complex, (b) bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) high mannose, (f) 
hybrid, (g) other, and (h) total N-glycoforms.  
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AD FC N-glycome are always less than that obtained from normal tissues. Among complex 
glycoforms, bi-antennary complex glycoforms exhibit a significant FI decrease in AD cases 
compared to other branched structures, tri- and tetra-antennary glycoforms. This observation is 
confirmed by ROC analysis (Appendix B.17). That is, the AROC value of bi-antennary complex 
glycoforms is >0.84, while the corresponding values of tri- and tetra-antennary complex 
glycoforms are 0.61 and 0.55. Regarding the total complex N-glycoforms, the AROC value is 
higher than 0.73. Although fucosylation index of the total complex N-glycoforms shows a fair 
value of AROC with 75% sensitivity and 60% specificity, FI of bi-antennary complex glycoforms 
is the best indication for fucosylation quality in FC tissues affected by inflammation during the 
disease progression.  
Moreover, core-fucosylated high mannose glycoforms were detected in FC tissues. This 
type of glycosylation displays a decent AROC score (>0.70). Fucosylated hybrid glycoforms and 
those truncated structures (other) exhibit high AROC values (>0.81 and >0.90, respectively) and 
highly recommended for discriminating the examined cohorts in terms of fucosylation. Both 
structures have preferable sensitivity (75% both) and specificity (87% hybrid and 100% other). 
Bi-antennary complex, high mannose, hybrid, and other N-glycoforms are significantly 
differentiated between the examined cohorts in terms of fucosylation (p-value <0.05). However, 
fucosylated truncated glycoforms are the most significantly differentiated species in FC tissues (p-
value <0.003) followed by bi-antennary complex species (p-value <0.005). The overall FI 
considered for all N-glycoform types (Figure 3.14 (h) is also low in AD FC N-glycome with 
agreeable AROC score (>0.85) and superior sensitivity (75%) and specificity (100%). The overall 
changes in fucosylation are significantly decreased in FC tissues derived from individuals’ brains 
suffered AD (p-value <0.02). Similarly, fucosylation in Subset 2 is significantly decreased in AD 
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FC N-glycome (see Appendix B.14). The most significant decrease is observed in truncated 
glycoforms (p-value <0.003) followed by bi-antennary complex species (p-value <0.005). 
3.3.4.2 Diagnostic evaluation of galactosylation indices  
For calculating galactosylation indices, four equations have been tested, GI-1, GI-2, GI-3, 
and GI-4 (see Appendix B.2 and Appendix B.18). The modified equations, GI-2, GI-3, and GI-4, 
show better performance than the reported equation (GI-1). More weight is considered for di-
galactosylated glycoforms in both GI-2 and GI-3 equations. However, the performance of GI-2, 
GI-3, and GI-4 equations are similar, and no considerable changes are shown when both mono- 
and di-galactosylated forms are equally considered in calculations, as represented in GI-4. Also, 
among the used equations, equally weighting mono- and di-galactosylated glycoforms, as 
represented in GI-4, shows better discrimination between the examined groups. Thus, we have 
chosen GI-4 equation to investigate changes in the galactosylation quality of FC N-glycome during 
the disease progression. Only Subset 1 is thoroughly represented here since both categories show 
similar statistics and no effect is observed when considering glycoforms detected across all cases. 
Galactosylation index (GI) calculated by GI-4 is illustrated in Figure 3.15. 
The interpretation of galactosylation index means the highest GI value is, the more 
galactosylation occurrence the FC glycoforms have. As shown in Figure 3.15, the AD cohort 
shows the lowest GI values across all glycoform types. The median values of N-glycoforms 
derived from AD FC N-glycome are always less than that obtained from normal tissues. Among 
complex N-glycoforms detected from FC tissues, bi-antennary complex glycoforms exhibit a 
significant GI decrease in AD cases compared to other branched structures, tri- and tetra-antennary 
glycoforms. The p values are <0.03 for bi-antennary species, while tri- and tetra-antennary 
glycoforms are insignificantly differentiated between the tested groups. Statistically, bi-antennary 
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glycoforms show the best AROC value among branched species (AROC >0.76) with moderate 
sensitivity (62%) and high specificity (100%).  
The GI performance of total complex glycoforms shows fair AROC score (>0.71) that is 
enough for discriminating the examined groups. On the other hand, truncated species are the most 
significantly differentiated among FC N-glycoforms in terms of galactosylation (p-value <0.018), 
followed by bi-branching glycans (p-value <0.027) and hybrid glycans (p-value <0.032). Thus, 
truncated glycoforms show the highest AROC value (>0.79) with the same sensitivity and 
 
Figure 3. 15: Galactosylation indices calculated for total N-glycoforms detected in at least 50% of AD patients’ and healthy 
individuals’ FC tissues. 
Subset 1 consists of 104 N-glycan structures detected in at least 50% across the examined cases in each cohort and classified 
from a total of 821 N-glycoforms derived from normal FC tissues and 759 N-glycoforms derived from AD FC tissues. (a) total 
complex, (b) bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) hybrid, (f) other, and (g) total 
N-glycoforms.  
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specificity (75%) as that also shown for the hybrid. GI values of truncated glycoforms and then bi-
antennary complex species and hybrid are the best choice for discriminating FC AD N-glycome 
from normal cases. The total galactosylation is represented by calculating GI for total glycoforms 
(Figure 3.15 (g)). Although the population is distributed over a wide GI range (p-value =0.053), 
AROC score is fair (>0.76) and can still be discriminated between the examined groups. However, 
Subset 2 show a decreased GI value for total glycoforms that is significant (p-value <0.05, 
AROC>0.76), as shown in Appendix B.15. 
3.3.4.3 Diagnostic evaluation of sialylation indices  
Sialylation indices have also been calculated for N-glycoforms derived from FC tissues 
extracted from AD patients’ and healthy individuals’ brains. The calculation was performed based 
on the previously published equation without modification (see Appendix B.2 and Appendix 
B.19).90 Figure 3.16 shows SI indices calculated for N-glycoforms (listed in Subset 1) derived 
from FC tissues in order to differentiate the examined groups. The indices are calculated based on 
the glycan type and degree of complexity. As described previously, non-sialylated (asialylated) 
glycoforms represent the dominant population of total species detected in FC tissues. According 
to the total detected glycoforms, high mannose species represent the majority in FC tissues either 
from AD or normal brains. These species are inconsiderable for SI calculation. Thus, only 
sialylated glycoforms are counted for indices. As shown in Figure 3.16 (a-h), the glycan 
populations representing AD are always distributed over a narrow range of SI compared to that 
obtained for normal. However, the decrease is insignificant since SI medians are slightly close (p-
value >0.05). ROC analysis of SI values has confirmed this observation (Appendix B.19). For 
example, SI values of complex glycoforms, including bi-, tri-, and tetra-antennary complex 
glycans show unacceptable AROC values (close to 0.50) for all species although the specificity 
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values are 75%, 87%, and 75%, respectively. Similar observations are noticed when considering 
other glycan types, such as hybrid and truncated glycoforms. No significant decreases are shown 
among the investigated species, and AROC is still unacceptable. The sensitivity values are 
unpreferable (~50%) so that these species cannot be used to discriminate the disease from normal 
although the specificity values are 87% and 62%, respectively. 
Moreover, considering more than one glycan type in SI calculation does not show any 
enhancement in differentiating the examined cohorts in terms of sialylation. Thus, AROC value of 
SI calculated for the summed complex and hybrid glycoforms or the summed sialylated glycans is 
still inadmissible along with reduced sensitivity, while a slight enhancement is perceived in 
 
Figure 3. 16: Sialylation indices calculated for total N-glycoforms detected in at least 50% of AD patients’ and healthy 
individuals’ FC tissues. 
Subset 1 consists of 104 N-glycan structures detected in at least 50% across the examined cases in each cohort and 
classified from a total of 821 N-glycoforms derived from normal FC tissues and 759 N-glycoforms derived from AD FC 
tissues. (a) total complex, (b) bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) hybrid, 
(f) other, (g) complex hybrid, and (f) total glycoforms (complex + hybrid + other).  
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specificity (>87%). Similar behavior of SI is notable in Subset 2 (AppendixB.16). More samples 
might reveal critical changes in FC sialylation that are induced by associated inflammations. 
3.4 Discussion  
Glycosylation variations significantly affect various biological processes and associated with 
many diseases.94-96 Numerous indications have pointed to the possible links between aberrant 
glycosylation and imperfect metabolism of β amyloid in AD,37,101, 102  a prevalent and debilitating 
neurodegenerative disorder in the elderly and the most common form of dementia associated with 
cognitive impairment and deteriorated memory functions.23 Most of the dementia patients are 
affected by AD, and the cases are expected to rise in future due to inadequate therapy103 aside from 
lacking reliable biomarkers sensitive to pathological changes years before clinical diagnosis.25, 26 
The AD brains undergo two pathological changes; the extracellular deposition of amyloid-beta 
(Aβ) peptides (plaques) and intracellular neurofibrillary tangles derived from hyperphosphorylated 
tau protein (P-tau).23  
According to the amyloid cascade hypothesis, the transmembrane APP is irregularly cleaved 
by mutated secretase (BACE1) and γ-secretase to produce long hydrophobic Aβ-40 and Aβ-42 
instead of protein 3 (p3).27, 28 On the other hand, the soluble Tau protein, stabilizing microtubules 
inside neurons, raises a secondary pathogenic event, in which the protein is hyperphosphorylated 
and thus detached from the microtubule to form aggregation and fibrillization of itself.28, 30 
However, this recognized background exemplifies how the pathological mechanisms of AD are 
not fully understood yet, indicating to the need for further novel approaches in AD research to 
discover target biomarkers sensitive for the disease early stage so that focused diagnoses and 
effective treatments will be reachable so far. 
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In this set of discovery, we have determined glycosylation changes in FC tissues affected by 
AD pathogenesis. A total of 122 N-glycoforms were derived from FC brains, among which 104 
structures were detectable in at least 50% of the examined cohorts, either AD or CT. The FC N-
glycome profiles of both groups were similar and exhibited various glycan types, including hybrid, 
high mannose, and complex glycans besides truncated glycans. N-glycoforms detected in fewer 
than 50% of either case were discarded from subsequent statistical analysis to reduce disparity 
attributed to missing values.93 Missing values is a common phenomenon despite the analytical 
procedures used to achieve the highest credibility.92 This deficiency is universal 
notwithstanding the glycomic strategy used, such as MS, to profile diagnostic biomarkers 
correlated to disease stages.93  
A total of eight complex N-glycoforms were detected in all normal FC tissues, except 
H6N6F5, H6N6A1F3, and H7N6F4 absent in CT6, but absent in at least half of AD FC tissues. 
The most abundant form that is unique for healthy brains was H5N4A1F1 but missed in ~60% 
of AD cases. Noteworthy, all unique FC N-glycoforms derived from normal cases were 
complex-type glycans, most of which are core-fucosylated. Complex glycoforms, bi- and tri-
antennary species with or without fucose residues, covalently linked to Asn467 and Asn496 
are essential for proper secretion and localization of APP.104 Also, unlike serum glycoproteins, 
brain-localized proteins, such as Tf, are mostly modified with core-fucosylated N-
glycoforms.56, 57 Under inflammatory conditions, as occurs in AD, the protein undergoes 
glycosylation changes, 54, 55 Abundant core-fucosylated glycoforms in healthy brains are the results 
of the highly expressed α1,6-fucosyltransferase (FUT8) in brain tissue.105 FUT8 plays a regulating 
role in neurite formation.106 On the other hand, fifteen N-glycoforms were exclusively 
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correlated to AD brains, the dominant three species among which are either phosphorylated or 
capped with Neu5Gc. N-glycan metabolic pathway involves a unique phosphorylase, a so-
called β-1,4-D-mannosyl-N-acetyl-D-glucosamine phosphorylase, which phosphorylates the 
D-mannose of β-1,4-D-mannosyl-N-acetyl-D-glucosamine.107  
The overall glycosylation variations in FC of AD brains are a result of local changes 
presenting on AD-key proteins. Most of the critical AD proteins as glycosylated. For example, 
APP undergoes several PTMs including N- and O-glycosylation. 39-41 AD N-glycans derived from 
APP showed higher contents of bisecting GlcNAc residues because of the high expression of N-
acetylglucosaminyltransferase III (Gn-T-III) in AD brains. Upregulation of GnT-III in AD brains 
is an adaptive response to protect the brain from additional Aβ production. 37 A recent study has 
confirmed that CSF N-glycome profiling in AD is associated with an increase in bisecting GlcNAc 
and a decrease in the overall sialylation degree.43 Although our results of sialylated FC glycoforms 
showed insignificant changes, more samples might be necessary to differentiate this trait. Also, 
APP/Aβ glycopeptides released in CSF showed modification with sialylated core 1 O-glycans 
linked to multiple Thr or Tyr residues. The common O-glycan structures, (Neu5Ac)1-
2Hex(Neu5Ac)HexNAc-O-, are occasionally modified with O-acetylation or lactonization on 
terminal Neu5Ac residues. This glycosylation on Tyr10 glycosylated Aβ peptides was 2.5 times 
higher in AD patients compared to non-AD individuals. 44 Thus, the overall changes in FC 
glycosylation quality is a result of local variations occurs on crucial proteins. 
3.5 Conclusions 
In this study, we have explored the quality of N-glycosylation in the FC region of human 
brains in purpose to discover AD candidate biomarkers for AD onset. Based on the present 
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specimens, we have defined fifteen unique glycoforms for AD FC specimens, which were 
completely absent in normal FC tissues. On the other hand, eight unique glycoforms have been 
assigned to the normal FC profile and were undetectable in more than 50% of AD cases.  
Unique AD glycoforms represent various glycoform types among which complex 
glycoforms capped with different kind of sialic acid residues and or decorated with fucosylation 
and phosphorylation. Also, AD FC glycosylation is featured with eight glycoforms that are 
significantly differentiated from normal tissues. Noteworthy, these eight glycoforms present across 
all samples and thus are represented in Subset 1 and Subset 2. Bases on diagnostic evolution, four 
of these N-glycoforms, including two truncated glycoforms H3N3F1 and H4N3, a high mannose 
glycan (H5N2F1) and a bi-antennary complex glycan (H4N4F1), show the highest AROC and thus 
more attention is necessary to explore their roles during the disease progression. Moreover, AD 
FC N-glycome showed significant changes in terms of glycoform type.  
That is, AD glycome exhibited increased mannosylation, while hybrid, complex and other 
type glycoforms were significantly lower than that of normal. Although both FC cohorts showed 
a quietly close number of complex glycoforms, the abundance of bi-antennary complex 
glycoforms was significantly low in AD FC N-glycome. In terms of fucosylation, mono-
fucosylated glycoforms were low abundant in AD although more glycoforms were released from 
disordered tissues. Similarly, in galactosylation, mono-galactosylated glycoforms were low 
abundant, while aglactosylated glycoforms represented the most abundant species in AD FC 
tissues. Although sialylation was not significantly differentiated between the examined groups, a 
slight reduction was observed on diseased tissues. These distinctive glycosylation traits 
distinguished healthy FC tissue from that affected by neurodegenerative deformation during AD 
pathology might play an essential role during the disease progression. Thus, further attention is 
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necessary to grasp the changes in underneath enzymes controlling the glycosylation process during 
the disease progression. 
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4 CHAPTER 4. GLYCOSYLATION QUALITY OF COLON CANCER REVEALS 
POTENTIAL EARLY N-GLYCAN BIOMARKERS 
4.1 Introduction 
Colon cancer (CC) is one of the leading causes of cancer-related deaths in developed 
countries. The disease onset is initiated from a small polyp that is developed to unusual infections 
invading various organs at metastatic stages.1 Until nowadays, most of the cancer cases, mainly 
CC, are diagnosed at metastatic stages. At this stage, cancer patients barely recovered; the 
endurance rate within five years is less than ten percent.2 Currently used screening techniques, 
such as colonoscopy, barium enema, or sigmoidoscopy, are insufficient in terms of sensitivity and 
specificity besides the fact that current therapeutic approaches are invasive and costly. Biological 
specimens such as blood or urine fluids, nevertheless, are not only noninvasive and unexpansive 
compared to traditional approaches but also sensitive and specific.3 More attention has been 
focused on discovering promising early biomarkers for cancer diseases based on glycobiology, 
which is possible by noticeable developments in MS techniques.4-6  
Most of the human proteins are glycosylated and play critical roles in various biological 
processes, including cell signaling, adhesion, proliferation or immune responses.7 Glycosylation 
is one among PTMs that regulate protein functionalities and prevalent in all eukaryotic living 
cells.8 The most attracting field in glycobiology is  O- and N-glycosylation.9 In terms of N-linked 
glycans, an asparagine residue within a conserved sequence along the protein backbone (N-X-S/T, 
X is any AAs except P) is covalently linked to at least five monosaccharides residues (two GlcNAc 
and three mannose, so-called N-glycan core stating with β-GlcNAc). This modification decorates 
most of the membrane, lysosomal and secreted proteins. Assembly of an N-glycan starts at the 
cytosolic side of the ER and further modified in the Golgi apparatus by numerous GTs and 
153 
glycosidases.10 Unlike N-glycans, the first building block in O-glycan type is GalNAc residue that 
is post transferred to either Ser or Thr AAs within the newborn protein proceeded to the Golgi 
apparatus. O-glycosylation lacks a clear motif within the protein AA chain but similarly modified 
with a series of GTs and glycosidases, as N-glycans, to produce a final structure that affects the 
protein folding, trafficking, secretion and interactions with other macromolecules.11,12  
Alterations in the protein glycosylation unsurprisingly accompany tumor development and 
malignancies. Several studies have reported changes in N-glycosylation, including a decrease in 
bisecting GlcNAc and an increase in sulfated, paucimannose and sialylated Lewis epitopes 
terminated glycans in primary colorectal carcinoma (CRC) tissues.13 In a recent study, plasma 
CRC showed a decrease in core fucosylated bi-antennary N-glycans.14 Also, a decrease in 
galactosylation, sialylation and an increase in core-fucosylation of neutral glycans have been 
reported in plasma Immunoglobulin (IgG). Core-fucosylated sialylated glycans, on the other hand, 
showed reduction across examined CRC cases.15 Li and his co-workers found that among 72 MS-
based identified proteins, pre-enriched by Solanum tuberosum lectin (STL), 17 glycoproteins 
containing GlcNAc residues were exclusively detected in CC tissues, fourteen of which were 
significantly upregulated in tumor tissues.5  A study from Australia on CRC cell lines (SW1116, 
SW480, SW620, SW837, and LS174T) showed five abundant O-glycans in tumor cells, including 
an increase in the well-known cancer marker (sialyl-Tn) and a decrease in Core 1 O-glycans.4 
Moreover, Haptoglobin, with four N-glycosylation sites, showed significant increases in core-
fucosylated and Lewis epitope-containing N-glycans at all sites in various types of cancer, 
including CRC.6  
Aforementioned glycoproteomic studies of CC have revealed associated changes in the 
glycosylation process. However, our perception of CC pathomechanisms is still inadequate. In 
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particular, the pathological roles of PTMs, specifical glycosylation, have remained poorly 
understood. Although current advances in glycobiology-based studies have gradually revealed that 
altered glycosylation in CC-related biomolecules is thoroughly tangled in the disease onset, further 
investigation is still in demand to explore the quality of such biological process during the disease 
promotion. Thus, in this work, we have explored variations in CC glycosylation pattern and 
accurately assessed the quality of N-glycosylation in soluble serum glycoproteins. 
4.1.1 Purpose of the study 
Recent studies have confirmed that the development of malignant tumors is accompanied by 
glycosylation changes. Although cancer is the extensively studied disease, our insight into colon 
cancer (CC) pathomechanisms is still inadequate. There is ample evidence that aberrant N-
glycosylation is associated with malignant stages in CRC.14-18 However, the conclusions are 
contradictory not only in among CRC tissues but also incomprehensive for complete N-glycome 
profile.16, 17  This inconsistency may have originated due to differently used procedures and 
inconsiderable association of TNM, which depends on patients’ age and tumor localization.19 In 
this set of study, N-glycosylation has gained the most attention since it remains poorly understood 
in CC regardless of the tumor position. In this study, we aim to thoroughly explore the quality of 
N-glycosylation pattern of soluble glycoproteins derived from blood sera collected from CC 
patients in comparison with healthy individuals. The robust technique, MALDI-MS, has been 
adopted in this section of the study to discover early N-glycan-based biomarkers for CC. This 
method is noninvasive since human fluids are easily collected from human subjects after consents 
for analysis use. The technique is fast so that glycomic analysis requires about a week for the entire 
procedure to be completed, in case of small sample cohorts.   
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4.1.2 The experimental design 
 
Figure 4.1: Overall workflow for MALDI-MS profiling of PNGase F-released N-glycoforms covalently attached to soluble 
glycoproteins derived from human blood sera of CC patients and healthy controls. 
The overall workflow is depicted in Figure 4.1. Briefly, the concentration of soluble proteins 
is measured by UV-absorption and BCA before glycomic analysis. The soluble proteins are 
reduced and alkylated before being subjected to ultrafiltration to remove salts and unwanted small 
chemical and biological molecules. The filter cut-off is ten kDa, which is enough to exclude 
genetic and other fragments accompanied soluble proteins while retaining large biomolecules for 
subsequent enzymatic digestion. The soluble protein profile is deliberated by gel electrophoresis 
before and after ultrafiltration to ensure enough amount of proteins for the subsequent glycomic 
analysis. In an appropriate buffer for PNGase F, N-glycoforms are cleaved from the protein 
backbone after overnight incubation at 37 °C. Then, released N-glycoforms are subjected to 
purification on home-made HILIC microcolumns before derivatization. Because of the advantages 
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as mentioned earlier, permethylation has been chosen to stabilize all hydroxyl groups along with 
other negatively charged sialic acid residues.20 Thus, all N-glycoforms, neutral and sialylated 
species, behave equally in MS analyzer regardless of the original structures carrying different 
charges. The obtained MALDI-MS spectra are, then, subjected to further data processing and 
statistical analysis.  
4.2 Experimental 
4.2.1 Chemical and materials: 
Standard proteins, such as Fetuin from fetal bovine serum (F2379) and Ribonuclease B from 
bovine pancreas (R1153) and standard polysaccharides, such as β-Cyclodextrin (MW 1134.98 
g/mol, C4767, Sigma-Aldrich) were purchased from Sigma-Aldrich. Maltopentaose, DP5 (MW 
828.72 g/mol, CAS No. 34620-76-3) was obtained from Carbosynth (Carbosynth USA, Canda & 
South America). The standards, model glycoproteins, and oligosaccharides were used for 
experimental optimization and internal calibrants, respectively. Peptide-N-glycosidase F (PNGase 
F, P0704S) was acquired from New England Biolabs (Ipswich, MA, USA). Super-DHB matrix for 
MALDI-MS (≥99.0%, Sigma-Aldrich). HILIC material (Click Mal, 5 µm, 100 Å) was obtained 
from ACCHROM (Beijing, China). Reduction and alkylation reagents, dithiothreitol (DTT) and 
iodoacetamide (IAM), respectively, were purchased from Acros Organics (Morris Plains, NJ, 
USA).  
Formic acid (FA) and Trifluoracetic (LC-MS grade) acid were from Sigma-Aldrich (ST. 
Louis, MO, USA). Tris-HCl buffer was purchased from US Biological (Swampscott, MA, USA). 
HPLC grade acetonitrile (ACN) was purchased from J. T. Baker® Chemicals (Avantor 
Performance Materials, Inc. Center Valley, PA, USA). Deionized water was produced using a 
157 
Milli-Q A 10 system from Millipore (Bedford, MA, USA). Microcon-10kDa Centrifugal Filter 
units (YM-30, 0.5 mL) with Ultracel® low-binding regenerated cellulose membrane was purchased 
from Millipore. 3M Empore C8 disk was bought from 3M Bioanalytical Technologies (St. Paul, 
MN, USA). Other materials, including sodium dodecyl sulfate (SDS), urea (UA), ammonium 
bicarbonate (ABC; NH4HCO3), NaOH, ICH3 and DMSO were purchased from Sigma-Aldrich. 
4.2.2 Participants and sample information  
Patients’ blood sera diagnosed with colon cancer (CC) were obtained from Northeast Georgia 
Cancer Care (NGCC). The healthy human serum (P2918 from platelet poor, sterile-filtered, 
(mycoplasma tested, virus tested, Lot# SLBQ1606V) were purchased from Sigma-Aldrich and 
used as controls. All patient samples are age-matched with the absence of other health concerns or 
symptoms that are pre-examined by experienced clinical physicians. All patients underwent a 
standardized protocol that included medical history, physical examinations, and screening 
laboratory tests. The probability of colon cancer was diagnosed according to Diagnostic and 
Statistical Manual standards. All samples were subjected to protein SDS-PAGE profiling followed, 
protein concentration detection by BCA, and subsequently glycomic analyses by MALDI-MS. 
4.2.3 Protein reduction and alkylation 
The CC patients’ and health pooled sera were subjected to protein reduction and alkylation. 
Briefly, a total of 50 μL of each sample premixed with 100 μl of the lysis buffer (4% SDS in 100 
mM Tris/HCl, pH 8.0) and an adequate amount of 1 M DTT was added to a final concentration 10 
mM. Proteins were denatured, and disulfide bonds were reduced by boiling the sample in a water 
bath at 95 ˚C for 10 min. After cooling down, the buffer was diluted with freshly prepared UA 
buffer (UA: 8 M urea in 50 mM Tris/HCl, pH ~ 8.5) to minimize SDS concentration to less than 
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0.5%. The denatured proteins were then subjected to Filter-aided sample preparation (FASP) for 
in-filter alkylation, subsequently followed with enzymatic digestion. 
4.2.4 Glycan release from biological samples 
The blood soluble proteins in diluted buffer were then subjected to alkylation before enzymatic 
release with Filter-aided N-glycan Separation (FANG) as previously described with minor 
modifications. 21 Briefly, the purified proteins derived from blood sera transferred into a 10 kDa 
filter (Amicron Ultra-0.5, Ultracel-10 membrane, nominal cutoff 10 kDa, Millipore) and washed 
four times with UA buffer before the subsequent step. The filter membrane was pre-washed with 
water followed with the used buffer (UA buffer) and centrifuged at 14,000 xg for 10 min in a fixed 
angle rotor.  
After removing SDS traces, the left volume dead (~50 μL) containing soluble serum proteins 
were subjected to alkylation with 50 mM IAM (prepared in UA buffer) and incubation in the dark 
for 30 min. After incubation, the excess reagents were removed by a cycle of centrifugation with 
UA (100 μL, twice), and the denaturing buffer was exchanged with 50 mM ABC (100 μL, three 
times). The flow-through was discarded. The filter unit with a final volume of ~50 μL was 
transferred into a new collecting tube. To a total volume, 80 μL, of the protein mixture (MW >10 
kDa) in ABC, about two μL of PNGase F (250 U/μL) was added to each filter with ratio 1:1 
(enzyme: protein) and incubated overnight at 37 0C. The protein profile and concentration were 
measured by SDS-PAGE and BCA assay, respectively. Next day, the released N-glycans were 
collected by washing filters with 200 μL purified water, twice. The flow-through was collected 
and dried in a tabletop centrifuge (Eppendorf 5804 Benchtop Centrifuge). Then, released N-
glycans were stored at -20 0C in sterilized microtubes, waiting for the subsequent enrichment step. 
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4.2.5 Glycan clean up and derivatization  
The released N-glycans were subjected to desalting and enrichment on HILIC as previously 
published.22 Concisely, a homemade micro-SPE column was constituted by inserting a small piece 
of the C8 disk into a 200 µL tip. About 5 mg of HILIC media previously suspended in 100 µL 
ACN was transferred into the microcolumn and subsequently washed twice with 50 µL of the 
washing buffer (WB; 10% ACN containing 0.1% FA). The microcolumn was, next, twice washed 
and equilibrated with the binding buffer (BB; 80% ACN containing 1.0 % FA) for 10 min. The 
PNGase released N-glycans were resuspended in 30 µL of BB before being loaded into the 
microcolumn. With a suitable syringe, the enriched N-glycans were desalted and purified with 50 
µL BB for five times. Later, the bounded native glycans, neutral and sialylated, were eluted with 
100 µL of the elution buffer (EB; HPLC grade water containing 1.0% FA), twice. The HILIC-
enriched N-glycans were then dried and stored at – 20 ºC, pending for consequent permethylation. 
To enhance glycan analysis by MS techniques, the highly hydrophilic N-glycoforms released 
from human serum glycoproteins were subjected to in-solution permethylation as previously 
reported, 23, 24 with minor modifications.25 Briefly, the released N-glycans were completely 
dissolved in 40 μL of dry DMSO and slightly vortexed to ensure solubility prior to quantitative 
transference into a screw-capped glass tube containing 50 mg NaOH beads suspended in 60 μL 
DMSO (to guarantee optimal NaOH/DMSO ratio).26 Each sample was spiked with 1 nmol DP5 as 
an internal standard. The permethylation reaction started by adding 60 μL of ICH3 and sonicated 
in a water bath for 90 min. An equal amount of ICH3 was added after 45 min of the reaction start. 
The reaction was quenched by adding 200 μL 5.0% acetic acid solution before extracted twice 
with 200 μL of dichloromethane (DCM). The organic layer was washed with 500 μL water five 
times or until neutralization (pH ~ 7.0). The organic layer was evaporated in a rotavapor (Buchi 
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R-100), and the remain derivatives were collected into a clean sterilized microtube by three-time 
washing with 200 μL of 50% methanol. The derivatized N-glycoforms were then thoroughly dried 
under vacuum and then stored at -20 0C. However, native or derivatized N-glycoforms were stable 
for MALDI-MS analysis for 48 hours at 4˚C.27 Upon analysis, the dried N-glycoforms were 
dissolved in an appropriate buffer compatible with MS.  
4.2.6 MALDI-TOF and MS/MS analysis 
The permethylated glycans were fully redissolved in 20 μL of 50% ACN, and about one μL 
of the solution was mixed with one μL of sDHB (20 mg/mL) prepared in 50% ACN containing 
0.1% TFA). One μL of each sample was deposited on a polished steel target (Bruker Daltonics, 
MTP 384) and left for slow crystallization and full dryness at room temperature. Two spots were 
performed for each sample for MS data acquisition. The mass spectra were acquired in positive 
reflectron mode on an UltraflexXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, 
Bremen, Germany). The instrument is equipped with 1 kHz Smartbeam-II laser, operated by an 
autoXecute method in flexControl (v3.4, Bruker Daltonics). The mass spectrum of permethylated 
glycan was externally calibrated by permethylated dextran and internally by a set of 
oligosaccharides, including DP5 and human N-glycoforms such as H3N4F1 (m/z 1835.9249), 
H4N4F1 (m/z 2040.0247), H5N4F1 (m/z 2244.1245), H5N4A1 (m/z 2431.2089), H5N4A2 (m/z 
2792.3826), H5N5F1A1 (m/z 2850.4244), H6N5A3 (m/z 3602.7823), H6N5F1A3 (m/z 
3776.8716) and H7N6A4 (m/z 4413.1821). All calibrants were considered as permethylated Na 
adducts. The other MALDI parameters in the positive mode were: ion source 1, 25.15 kV; ion 
source 2, 22.75 kV; reflectron 1, 26.66 kV; reflectron 2, 13.48 kV; lens, 8.32 kV; detector gain, 
x4.0. For each MS spectrum, 2000 shots were accumulated with 500 Hz/shot and further baselined 
and smoothed by flexAnalysis (3.4, Bruker Daltonics). 
161 
4.2.7 Data evaluation and statistical analysis 
All MS profiles acquired from CC patients’ and controls’ blood sera were compared in 
order to define apparent changes in N-glycosylation profiles that might reflect associating N-
glycome modifications in CC individuals. GlycoWorkbench software v2.1 manually interpreted 
all processed data, 28 searched against CarbBank29 using derivatized glycans with a free end. 
Considering all adducts of singly charged precursor ions with 2.0 Da accuracy, the identified 
glycans were structurally specified by the human-like glycan structures corresponding to MS/MS 
fragmentation. Peak lists were extracted to Excel 2016 for further processing and statistically 
evaluation. 
The calculation and graph visualization were performed by MATLAB and Statistics 
Toolbox Release 2018b, The MathWorks, Inc., Natick, Massachusetts, United States. All 
calculations of glycosylation indices, including fucosylation, galactosylation, and sialylation, were 
based on normalized intensities, as previously described.24, 30, 31 The self-developed software 
allows direct comparison of relative intensities (RI) so that differentiation among tested cases are 
applicable. Data were expressed as mean values (±SD) of four MS data acquisitions for each case.  
4.3 Results 
4.3.1 The primary assessment of blood soluble proteins before glycomic analysis 
4.3.1.1 Protein Profiling by SDS-PAGE 
The raw blood sera were subjected to protein profiling using 8% SDS-PAGE gel 
electrophoresis. About 1 μL of each sample was mixed with 10 μL of SDS buffer (4X, containing 
100 mM DTT) before denaturing in a water bath at 95 °C for 5 min. The gel was loaded with a 
standard ladder (10-170 kDa) into gel walls and run at 90 V for about 1 h. Staining/de-staining 
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was performed in a microwave for 5 min, twice. The protein profile from one health serum and 
five CC are shown in Figure 4.2. As illustrated in SDS-gel, total serum proteins derived from 
human blood are abundant and ranged from 15 kDa to 178 kDa. However, glycosylation affects 
the protein migration during SDS-PAGE electrophoresis,32 which means the represented profile 
does not precisely reflect the actual size of protein MWs. 
 
At this point, large proteins (MW >180 kDa) and small proteins (MW < 15 kDa) were 
excluded since all samples were processed in 10 kDa filters, which retain all proteins larger than 
~10 kDa. Some loss is predicted but retaining soluble proteins with MW >30 kDa are guaranteed 
since the filter membrane fully retain proteins with 2x kDa assigned for the membrane.  The raw 
protein profile shows a smear around 65 kDa, which represents Human serum albumin (HSA). 
 
Figure 4.2: SDS-PAGE profile of soluble proteins derived from CC patients’ and healthy individuals’ blood sera. 
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This protein is highly abundant in human sera.33 In terms of glycosylation, HSA is principally non-
enzymatic glycosylated at multiple sites.34 However, the protein level in the blood is sensitive to 
aberrant N-glycosylation of other serum glycoproteins in multiple myeloma.35 In terms of N-
glycosylation, the influence of this protein is negligible in the subsequent glycomic analysis step 
since used filters retained the intact portions and no further proteolytic digestion was performed as 
well as serum N-glycoforms were enriched before MS analysis. The protein profiling was also 
performed on purified proteins after ultrafiltration to ensure enough soluble serum proteins for 
subsequent glycomics analysis.  
4.3.1.2 Measurement of protein concentration by BCA  
The colorimetric detection by BCA was performed according to the microplate procedure 
designed by the manufacturer. From SDS-PAGE profiling, serum proteins are highly abundant. 
Thus, about 2 μL of the raw serum was diluted to 75 uL in Working Buffer for subsequent chemical 
determination. The diluted sample was used for triple measurements for each case (25 uL/ each). 
The dilution factor was considered in calculation later for calculating the total protein 
concentration in either raw blood sera and purified soluble proteins, as shown in Table 5 and Figure 
4.3. BCA assay is a detergent-compatible formulation that depends on the reduction of copper ions 
by proteins in alkaline medium. The method is highly sensitive and selective colorimetric 
detection, by which cuprous cation (Cu+) is representing the total amount of proteins that are 
oxidized during the colorimetric reaction. The produced purple-color is the indication of forming 
chelation of two molecules of bicinchoninic acid with the cuprous ion in the presence of proteins. 
The complex absorbance was measured at 562 nm, which shows a linear correlation with the 
concentration range of the standard protein (Albumin). The protein concentration was expressed 
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as μg/mL in the calibration curve. The total protein concentration of soluble proteins derived from 
CC cases is ranged from 33 to 52 mg/mL  
Table 5: BCA assay for calculating the concentration of total soluble proteins derived from CC patients’ sera.  
Replicate CC1 CC2 CC3 CC4 CC5 
1 1.007 1.125 0.806 0.785 0.717 
2 1.019 1.139 1.055 0.683 0.988 
3 0.918 0.994 0.995 0.783 1.050 
Mean 0.981 1.086 0.952 0.750 0.918 
SEM 0.032 0.046 0.075 0.033 0.102 
RSD% 3.26 4.24 7.88 4.40 11.11 
Practical Conc. 
(diluted) 
1218.19 1367.51 1176.68 888.69 1128.09 
Conc. in 2 μl (μg/mL) 45682.28 51281.54 44125.59 33325.85 42303.33 
Conc. (mg/mL) 45.68 51.28 44.13 33.33 42.30 
 
Figure 4.3: Calibration curve for calculating the absolute concentration of total soluble proteins derived from CC 
patients’ and healthy individuals’ blood sera.   
Thus, in a total of 50 μL volume used in the experiment contains 1.65 to 2.6 mg of soluble 
serum proteins, which is enough start for subsequent glycomics analysis. It is well-known that 
more than 50% of human proteins are glycosylated.36  Since carbohydrate moiety contents can 
contribute to more than 20% to the total MW of a glycoprotein, especially heavily glycosylated,32 
165 
we have assumed that microheterogeneity originated from glycosylation is ranged from 330 to 520 
ug in the examined samples, which is enough for subsequent glycomic analyses. 
4.3.2 Total detected N-Glycoforms derived from blood soluble glycoproteins 
A total of 133 MS signals were determined in permethylated N-glycome profile. 
Approximately, a total of 120 peaks were successfully assigned to N-glycosylation, in which 
glycoforms preserved N-glycan core with five principle monosaccharides; Two GlcNAc and three 
Mannose residues. The MS signals, as m/z of Na adducts, were manually searched against human 
carbohydrate database via GlycoWorkbench. Peaks representing fragmented N-glycoforms were 
excluded from the table and calculations. Although the solution containing derivatized N-
glycoforms was flavored with 1 mM sodium acetate to ensure generation of the sodiated adduct, 
other adducts such as H+ and K+ precursor ions were observed in MS spectra. The total list of 
experimental m/z signals and the corresponding compositions of monosaccharides are summarized 
in Appendix C.1. Each glycoform composition is illustrated as a putative structure according to 
Human database search with accuracy up to 2.0 Da. However, most of MS peaks are assigned to 
specific N-glycoforms with higher accuracy (<1 ppm). All determined N-glycoforms are reported 
with theoretical and experimental m/z values and the corresponding accuracy. The structures of 
most abundant glycoforms were confirmed with MS/MS in positive mode. Permethylation 
facilitates the structure determination by unique fragmentation of linkage cleavages. 
As expected, the observed N-glycoforms derived from human serum showed various types 
of N-glycans, including high mannose, hybrid and complex species. Interestingly, we have 
reported more N-glycoforms derived from soluble glycoproteins in human sera than those 
previously reported.27 The explanation of such observation may be originated from experimental 
differences that affect the sample handling and thus the final data. That is, native glycans are highly 
166 
hydrophilic because of the existence of multiple -OH groups besides the probable presence of 
negative charges carried by acidic glycoforms. Such hydrophilic molecules exhibit inadequate 
ionization in MS analyzes, especially in positive mode. Thus, permethylation neutralizes acidic 
glycoforms and allows simultaneous detection with neutral glycoforms in positive mode.37,38 
Therefore, we have detected more glycoforms from soluble glycoproteins in human sera, as 
enhanced by derivatization allowing sensitive detection for glycan-related biomarkers.39, 40  
Various types of glycoforms have been detected from soluble serum glycoproteins. At 
downstream m/z, we have observed multiple high mannose species, some of which are core-
fucosylated. The largest high mannose species is Hex9HexNAc2 (m/z 2396.1753), representing a 
premature glycoform that undergoes slight processing at the Golgi apparatus. Hybridization is 
considered for those glycoforms containing at least two branches, one of which is mannosylated 
while the other has at least the first GlcNAc (β22 or 6) residue. Truncated N-glycoforms with 
unclear branches and those fragments derived from an intact glycoform have been disregarded in 
type-based categorization.  
Five hybrid species are observed in serum glycoproteins, m/z 1825.0582 (Hex5HexNAc3), 
m/z 2186.1502 (Hex5HexNAc3Neu5Ac1), m/z 2274.2584 (Hex6HexNAc4), m/z 2739.7490 
(Hex6HexNAc3Neu5Ac1dHex2) and m/z 2925.8219 (Hex6HexNAc3Neu5Ac2dHex1), some of 
which are sialylated and/or fucosylated. Complex glycoforms represent the major population of 
N-glycoforms derived from serum glycoprotein N-glycome profile. Various type of branches, 
including bi-, tri, tetra-antennary species with or without core or terminal fucose residues have 
been detected, agreeable with well-known N-glycan species derived from human blood serum.27,41  
Four complex N-glycoforms are decorated with sulphate groups, m/z 1973.26 (Hex3HexNAc5S1), 
m/z 2689.55 (Hex4HexNAc5Neu5Ac1S1dHex1), m/z 2711.64 
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(Hex4HexNAc5Neu5Ac1S1dHex1) and m/z 2875.50 (Hex6HexNAc4Neu5Ac1S1dHex1). The 
last species carries terminal α-Gal on one of its branches, while the other branch is capped with 
Neu5Ac residue. As expected, Hex5HexNAc4Neu5Ac2 (m/z 2792.3668, 6 ppm) is the most 
abundant biantennary glycans, followed by mono-sialyat4ee4d species, Hex5HexNAc4Neu5Ac1 
(m/z 2431.1978, 5 ppm). This observation is predictable since Hex5HexNAc4Neu5Ac2 is derived 
from high abundant glycosylated proteins, such as Alpha-2-HS-glycoprotein, Hemopexin, and 
Alpha-1-antitrypsin, while most of the hydrolyzed species are contributed to Alpha-1B-
glycoprotein and Alpha-2-macroglobulin.42 Human serum glycoforms detected in this set of 
discovery is reasonable and harmonious with previously published research on serum 
glycoproteins.  
4.3.3 The relative intensity of specific glycoforms 
 
Figure 4.4: Abundance distribution of N-glycoforms enzymatically released from soluble glycoproteins purified from CC patients’ 
and normal individuals’ blood sera. 
The putative N-glycoform structures detected across all samples are considered for further statistical assessment. 
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The intensities of H+ and K+ ions were added to Na+ ions, which are >80% highly abundant 
compared to non-sodiated adducts. Thus, all sodiated N-glycoforms have been considered for 
further processing. A total of 60 glycoforms are detected across all cases, and their relative 
intensities are considered for differentiating disease cases from normal. As shown in Figure 4.4, 
the sixty N-glycoforms are sequentially organized according to the appearance in MS spectrum 
from N-glycoforms observed in m/z range 1000 to 3000 represent the most abundant species, while 
those species detected at m/z >3000 show low abundance. However, four sialylated tri-antennary 
complex species show high abundance at m/z > 3000, two of which are core fucosylated.  That is, 
two are di-sialylated glycoforms, Hex6HexNAc5Neu5Ac2 at m/z 3241.66 and 
Hex6HexNAc5Neu5Ac2dHex1 at m/z 3415.85, while the tri-sialylated species are 
Hex6HexNAc5Neu5Ac3 at m/z 3602.87 and Hex6HexNAc5Neu5Ac3dHex1 at m/z 3777.02.  
Also, at this high m/z range, two sialylated tetra-antennary species, 
Hex7HexNAc6Neu5Ac3 and Hex7HexNAc6Neu5Ac4, are abundant in comparison to other non-
sialylated species at this range. As shown in the MS spectra profile (Appendix C.2), most of the 
highly abundant species are complex N-glycoforms, sialylated and sialylated/fucosylated species 
represent the most abundant among detected complex structures. These results are harmonious 
with those published for human plasma N-glycosylation.42 Most of the highly glycosylated 
proteins in plasma are heavily decorated with such glycoforms capped with sialic acid residues. 
Statistically, most of the sixty N-glycoforms considered in both cohorts show significant 
differences (p-value < 0.05); the dominant population has moderate MWs. This observation 
suggests further investigation on such species that are masked as highly abundant glycoforms. So, 
we assume that glycoforms derived from low abundant glycoproteins might also reveal significant 
biomarkers for early detection of CC. 
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4.3.4 Glycosylation quality of soluble serum glycoproteins in colon cancer 
4.3.4.1 Changes in relative intensity of biantennary complex glycoforms  
The total sixty N-glycoforms (Na adducts) that are detectable across all CC patients’ and 
healthy subjects’ sera are considered for statistically calculating the pattern of glycosylation to 
differentiate disease from normal cases. Since most of the detected glycoforms are bi-antennary 
complex glycoforms, these species have been undergone further investigation for initial estimation 
of the relative intensity distribution. In this stage, all N-glycoforms with at least two branches are 
considered for intensity distribution, regardless of the presence of core-fucosylation, sialylation or 
rare modifications such as sulfation. Thus, all bi-antennary glycoforms, without Gal residues as 
H3N4 (G0), glycoforms with one branch as H4N4 (G1) and glycoforms with two branches as 
H5N4 (G2) are represented, while fucosylation or sialylation are involved in the calculation under 
this category. Figure 4.5 shows the scattering distribution of the examined glycoforms among CC 
and CT cases. 
 
Figure 4.5: Scattering of relative intensities correlated to summed bi-antennary complex glycoforms derived from soluble 
glycoproteins purified from CC patients’ and health individuals’ blood sera. 
Plotting RI of H3N4 (G0) against H4N4 (G1) or H3N4 (G0) against H5N4 (G2) show 
noticeably distinction among examined cohorts. Scattered RI of CT exhibit high values (>3.5) for 
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all cases when considering H3N4 against H4N4 or H5N4. Although some CC cases show high 
scattered RI, most of the cases fall below 3.5, the minimum scattered RI of CT. Thus, box plotting 
RI of these species exhibit distinct mean values (Figure 4.6). Control cohort show slightly low 
mean values (<1.8) in terms of non-extended N-glycoforms (H3N4) compared to CC patients. 
Thus, truncated glycoforms with at least two branches are less abundant in healthy individuals. On 
the other hand, complex bi-antennary glycoforms with one or two extended arms show significant 
differentiation between the examined cohorts. Always, healthy individuals have serum 
glycoproteins that are heavily glycosylated with bi-antennary species that carry at least one 
extended arm, despite the presence of core fucose or capping sialic acid residues. These 
observations induce a precise calculation of glycosylation indices that might reveal changes in GTs 
activity during tumor development. 
  
Figure 4.6: Differentiation of bi-antennary N-glycoforms (H3N4, H4N4, and H5N4) released from soluble glycoproteins purified 
from CC patients’ and healthy controls’ blood sera. 
4.3.4.2 Galactosylation index in CC serum glycoproteins 
The galactosylation index has been calculated according to the following equation: 30 
𝐺𝐼 =
𝐺0
(𝐺1 + 2 × 𝐺2))
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In which GI is galactosylation index, G0 represents non-galactosylated glycoforms, G1 
represents mono-galactosylated glycoforms, and G2 represents di-galactosylated glycoforms. 
Initially, all complex bi- or tri-antennary complex glycoforms are considered for calculating 
galactosylation indices before application on all complex glycans. Figure 4.7 represents the 
calculations mentioned above, in which scatted RI of aglactosylated and galactosylated forms as 
well as GI are illustrated by scattering and box plot graphs, respectively. 
 
Figure 4.7: Correlation of galactosylation versus aglactosylation and galactosylation Indices (GI) of bi-antennary, tri-antennary, 
and complex N-glycoforms derived from soluble glycoproteins purified from CC patients’ and health individuals’ blood sera 
The equation is interpreted as the higher GI value is, the lowest galactosylation is in the N-
glycome. For bi-antennary complex N-glycoforms, the scattered RI is distinguishable among 
tested cohorts. Healthy CT cases show more dots at RI (>10) for the ratio 
galactosylation/galactosylation. Thus, CT glycoproteins carry more galactosylated glycoforms 
compared to CC serum proteins. This conclusion is clearly illustrated in box plots, which shows a 
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significant decrease in GI values regarding CT cases. AROC score of GI of biantennary 
glycoforms is higher than 0.94 with acceptable sensitivity (80%) and specificity (90%) (see 
Appendix C.3 (A). On the other hand, scattered RI of tri-antennary glycoforms is indistinguishable. 
That is, some of galactosylation/galactosylation ratio values of CT fall below the cut off mean 
(<6.0). In the descriptive boxplot graph, the median value of CC is slightly higher than that of CT 
cases. However, GI of tri-antennary glycoforms exhibits high AROC score (>0.81) with adequate 
sensitivity (85%) and acceptable specificity (65%). 
The overall galactosylation of serum N-glycoforms has also been evaluated by calculating 
GI. Most of the N-glycoforms derived from CC cases have low galactosylation (RI<15). Although 
some CC dots are distributed between RI=14 and RI=19, ROC analysis of complex glycan GI 
showed distinguishable values with AROC (0.97), sensitivity (90%) and specificity (100%) that 
confirmed differentiated median values examined cohorts. After all, both bi- and tri-antennary 
glycoforms show the same pattern in terms of galactosylation. However, considering the whole 
population of complex glycans reveals a significant difference between the tested groups. This 
difference distinction is visualized in Figure 4.7 either for galactosylation/galactosylation ratio or 
GI values. Also, bi-antennary complex species might serve as a valid indication for aberrant 
galactosylation in CC. 
4.3.4.3 Fucosylation index in CC serum glycoproteins  
For the fucosylation index (FI) calculation, all glycoforms have been considered in the 
following equation:24 
𝐹𝐼 =
(1 × 𝑔𝑙𝑦𝑐𝑎𝑛 𝐹1 + 2 × 𝑔𝑙𝑦𝑐𝑎𝑛 𝐹2)
∑ 𝐺𝑙𝑦𝑐𝑎𝑛𝑠
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  In the equation, fucosylated glycoforms with one fucose residue are represented as F1, 
while fucosylated glycoforms with two fucose residues are represented as F2, including those core 
and terminal fucosylated species. Unlike GI, the FI equation is interpreted as the high FI value is, 
the more glycoforms carry fucose residues. Core-fucosylated glycoforms are those with fucose 
(α1-6) residue covalently linked to the first innermost GlcNAc monosaccharide within N-glycan 
core, while terminal fucosylation includes all glycoforms exhibit fucose residues covalently 
attached to either sugar residue on the non-reducing end. Figure 4.8 shows the correlation between 
fucosylation degrees and FI of various categories of fucosylated glycans. The total identified N-
glycoforms have been categorized based on the position of fucose residues and the presence of 
sialic acid residues on the non-reducing termini.  
 
Figure 4.8: Correlation among fucosylation degrees and fucosylation indices (FI) of N-glycoforms derived from 
soluble glycoproteins purified from CC patients’ and health individuals’ blood sera. 
Noteworthy, soluble serum glycoproteins are heavily fucosylation. Most of the detected N-
glycoforms derived from the examined cohorts are fucosylated. However, the degree of 
fucosylation significantly differs among the cases. Most of CC- and CT- derived glycoforms carry 
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at least one fucose residue. However, CC cases show outlier RI dots representing non-fucosylated 
glycans as shown in Figure 4.8 (a). Regarding di-fucosylated species, CC glycoproteins are heavily 
decorated with two fucose residues compared to normal, and again outlier dots are shown in Figure 
4.8 (b) representing high RI of non-fucosylated structures. Scattering RI of total F1 versus F2 
calculated from all N-glycoforms derived from controls is displayed in a distinct region from that 
presenting dots of disease as shown in Figure 4.8 (c).  Most normal N-glycoforms are most likely 
core-fucosylated, while the major population in CC proteins are fucosylated glycoforms with at 
least two residues. When considering the total fucosylation of all detected glycoforms, a linear 
correlation is represented as shown in Figure 4.8 (d). Interestingly, most detected N-glycans from 
CT cases are represented within a  moderate range of RI, while CC cases show outlier dots 
representing the most non-fucosylated and the most multi-fucosylated glycoforms. 
 Regarding FI, CC glycoproteins exhibit a slight increase in fucosylation compared to 
normal cases, as shown in Figure 4.8 (e). Changes in total fucosylation is insignificant; AROC 
=0.55 with 45% sensitivity and 90% specificity. Thus, core-fucosylated glycoforms show 
considerable differences between the examined cohorts. The total core-fucosylated glycoforms 
derived from CC soluble glycoproteins, including neutral and acidic species, show FI difference 
compared to normal. The moderate AROC score (>0.64) reflects the possibility to differentiate CC 
cases from normal with high sensitivity (95%) and accuracy (0.77), see Appendix C.3 (B). The 
further significance is observed when considering either neutral or acidic core-fucosylated 
glycoforms. Tumor-derived N-glycoforms show a significant decrease in neutral core-fucosylated 
species in comparison to controls (Figure 4.8 (g)). AROC score is >0.70, the acceptable 
differentiation value, while sensitivity and specificity are 90% and 65%, respectively.  
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Unlike neutral core-fucosylated N-glycoforms, the corresponding acidic species show a 
considerable increase in CC-derived glycoproteins in differentiation to normal cases, as illustrated 
in Figure 4.8 (h). The value of AROC is >0.96, even much higher than that of neutral species. 
Acidic core-fucosylated N-glycoforms can be detected in tumor cases (100% sensitivity) and 
differentiated from normal cases (85% specificity). Such core-fucosylated glycoforms have 
acquired most of the attention in previously published studies about serum IgG N-glycome. 15, 16, 
18 Afterall, tumor-derived serum glycoproteins carry more fucosylated glycoforms either with core 
or terminal fucose residues. However, normal serum glycoproteins are more likely fucosylated 
with a fucose residue (α1,6) covalently linked to the innermost GlcNAc residue. Moreover, core-
fucosylated glycoforms exhibit a significant increase in CC glycoproteins with acceptable 
sensitivity and specificity when one or more sialic acid residues are capping non-reducing ends. 
4.3.4.4 Sialylation index in CC serum glycoproteins  
Correlation between scattered RI of different sialylation degrees is illustrated in Figure 4.9. 
The correlation between asialylated N-glycoforms and mono-sialylated glycoforms show a similar 
pattern between tumor and control cases (Figure 4.9 (a)). However, N-glycoforms derived from 
tumor show a slight increase in mono-sialylation compared to CT cases. This increase in sialylation 
is noticeable when considering di-sialylated glycoforms as shown in Figure 4.9 (b) with outlier 
dots that refer to a high di-sialylation degree versus asialylation. Most of the normal N-glycoforms 
exhibit a noticeable decrease in di-sialylation and tri-sialylation versus asialylated N-glycoforms 
compared to tumor N-glycoforms (Figure 4.9 (b and c). Distinguishable regions are also shown 
when considering scattered RI of mono-sialylated N-glycoforms against di- and tri-sialylated 
species as illustrated in Figure 4.9 (d and e). Also, scattered RI of N-glycoforms derived from 
healthy serum glycoproteins remarkably gathers within a close distance (Figure 4.9 (f)), indicating 
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to the significantly low abundance of di- and tri-sialylation compared to tumor-derived species. 
From this observation, we have expected a significant variation in the overall sialylation of all rate. 
 
Figure 4.9: Correlation among sialylation degrees of total N-glycoforms derived from soluble glycoproteins purified 
from CC patients’ and health individuals’ blood sera 
Consequently, the sialylation index (SI) has been calculated according to the following 
equation, in which the total sialylated glycoforms are considered against total glycoforms. 
𝑆𝐼 =
∑ 𝑠𝑖𝑎𝑙𝑦𝑙𝑎𝑡𝑒𝑑 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑ 𝑎𝑙𝑙 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
 
Thus, the higher the SI value is, the more glycoforms carry N-acetylneuraminic acid 
residues, Neu5Ac, capping the non-reducing ends. In this set of discovery, rare sialic acid residues, 
such as 5-N-acetylneuraminic acid lactone (Neu5AcLac) or 5-N-glycolylneuraminic acid 
(Neu5Gc), are undetectable under experimental conditions. Conditionally, glycoforms capped 
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with Neu5Ac residues are galactosylated with at least one Gal residue. Sialylation is represented 
as Hex5HexNAc4Neu5Ac2, as shown in Figure 4.10 but not limited to such structure. 
Glycosylation, in terms of sialylation, is significantly differentiated between the examined 
cohorts. Scattered RI for N-glycoforms derived from normal serum glycoproteins is limited up to 
21 on the y-axis as shown in Figure 4.10 (a), which represents the degree of sialylation versus total 
asialylation. Most of the tumor-derived N-glycoforms, on the contrary, exhibit more sialylation of 
N-glycoforms that exceed 20 along the y-axis. Hence, we have expected a significant increase in 
sialylation of those species derived from the tumor. 
  
Figure 4.10: Correlation of sialylated and asialylated glycoforms and sialylation index (SI) of total N-glycoforms 
derived from soluble glycoproteins purified from CC patients’ and health individuals’ blood sera 
Our expectation is confirmed by calculating the sialylation index of total N-glycoforms 
derived from serum glycoproteins. The median values of the tumor and normal serum N-
glycoforms are significantly differentiated as shown in Figure 4.10 (b). The median value of SI in 
CC patients’ sera is >0.2, while in healthy individuals’ sera is <0.1. Calculated SI is considered 
for all N-glycoforms structures despite the complexity degree, di-, tri- or tetra-antennary. ROC 
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analysis of SI values has confirmed the significant variation between the examined cohorts. The 
very high and acceptable AROC score (>0.96) with superior sensitivity (100%) and specificity 
(85%) indicate to undeniable variation regarding sialylation in tumor cases. The complete ROC 
analysis of sialylation is summarized in Appendix C.3 (C). Changes in sialic acid levels are 
governed by various sialidases and GTs, particularly sialyltransferase (STs), involved in the 
generation of different sialylation types. Thus, more specification of the glycoform structure might 
reveal more information that enhances our understanding of such changes in the glycosylation 
biosynthesis during tumor development. 
4.4 Discussion 
In this study, we have investigated the changes in the glycosylation quality of soluble 
glycoproteins derived from CC patients’ and healthy subjects’ blood sera using MALDI-MS. 
Approximately 90% of MS signals originated from serum glycoproteins have been assigned to 
human-like N-glycoform structures. The search was performed against free-available carbohydrate 
databases, using GlycoWorkbench software. All reported glycoforms, preserved N-glycan core, 
were detected as permethylated adducts with acceptable accuracy. To simplify the calculations and 
data processing, we only considered sodiated N-glycoforms detectable across all samples for 
further processing. The intensity of metal adduct (K+) and protonated adduct (H+) was added to 
the highly intense MS signal that represents the sodiated glycoform. Missing glycoforms across 
MS spectra were excluded to ensure the data consistency besides those previously unreported. 
Therefore, a total of sixty N-glycoforms have been considered for assessing the glycosylation 
quality of N-glycome in blood sera in order to differentiate CC patients from healthy cases. 
N-glycome of serum glycoproteins exhibits insignificant changes among small and large 
glycoforms. Most changes in abundance levels are observed among species with moderate MWs.  
179 
However, slight changes are noticeable among truncated N-glycoforms. This observation may 
indicate to increased activities of some cytosolic, lysosomal or Golgi located glycosidases during 
tumor development.43-45 For instance, neuraminidase 1, NEU1, suppressed metastasis in human 
CC by playing an essential role during regulation of integrin β-mediated signaling.46 Also, the 
impairment of NEU4 sialidases, some localized on the cell surface, in CC plays an essential role 
in controlling sialyl Lewis antigen.47 Up-regulation of some sialidases, such as plasma membrane 
NEU3, are involved in apoptosis suppression of CC cells.48 Takahashi et al. (2015) reported that 
NEU3 sialidase contributes to tumorigenic potential in CC as a critical modulator of gangliosides 
and regulates phosphorylation of ERK and Akt by Ras cascades initiated on EGF receptor.49 
Alterations in phosphorylation pathways including a series of enzymes, such as Tyrosine kinase, 
Cadherin-catenin complex, and MAP kinase, results in serious outcomes in cancer.50 Enzymatic 
changes in human colonic adenocarcinoma cells are also reflected in degradation of ABO-
antigens;43 the main carbohydrate moieties carried on blood glycoproteins.51, 52  
Altered glycosylation, including truncated high mannose, have been reported with an 
increased level in CRC tumor cases.17 Although CRC tissues expressed a significant decrease of 
paucimannosidic glycans,13 a truncated glycoform containing 1 to 3 mannose residues and 2 
GlcNAc residues with the option of core fucosylation, 53 this truncated glycoform have been 
detected in this set of discovery but not screened for further investigation of glycosylation quality. 
Glycosylation is a non-driven template process that is entirely controlled by a series of 
glycosidases and GTs to produce adequate glycoforms covalently linked to specific AAs on the 
protein backbone.10 Abnormal glycosylation shown in cancer is governed by changes in activities 
of multiple glycosidases and GTs.54 That is, changes in glycoform abundance indicate to defects 
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in the biosynthesis/trimming of N-glycans in the ER and Golgi apparatus, resulting in vital 
consequences in disease. 
 Moreover, aberrant galactosylation is observed in inflammatory diseases, such as ovarian 
cancer,30 In this study, we have found an overall decrease in galactosylation of complex 
glycoforms derived from CC tumor glycoproteins. This decrease is significantly clear when 
considering bi-antennary complex N-glycoforms relative to non-tumorigenic cases. In details, di-
sialylated N-glycoform, Hex5HexNAc4Neu5Ac2, is most likely generated from high abundant 
glycosylated proteins, such as Alpha-2-HS-glycoprotein, Hemopexin or Alpha-1-antitrypsin, 
while the hydrolyzed form, Hex5HexNAc4Neu5Ac1, is contributed to Alpha-1B-glycoprotein and 
Alpha-2-macroglobulin, equally.42 Although IgG is not the highest source for these particular bi-
antennary glycoforms,42 our result show consistency with reported observations of plasma IgG N-
glycome derived from CRC patients. In an extensive study of plasma IgG derived from 1229 CRC 
patients, IgG N-glycome showed a decrease in galactosylated glycans.18 Also, in another search of 
N-glycome, protein-G isolated IgG of human plasma collected from CRC patients exhibited a 
decrease in IgG galactosylation.15 Defects in glycosidases and GTs expression under tumorigenic 
conditions mostly contribute to aberrant galactosylation of serum glycoproteins, That is, 
significant mutations have been reported for glycosylation-associated genes that may contribute to 
the pathogenesis of gastrointestinal malignancies, particularly CRC.55 For instance, beta-1,4-
galactosyltransferase 2 (B4GALT2), responsible for the synthesis of complex glycans by 
transferring a Gal residue to terminal GlcNAc arms, displayed a mutation in colon cancer..55    
In respect to fucosylation, our result shows a slight increase in total fucosylation in CC cases 
regarding the total core- and termini-fucosylated species. This observation is consistent with well-
known altered N-glycosylation in tumors, such as pancreatic cancer.24 Colon cancer is featured 
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with an increase in the level of core-fucosylated species.17 However, our results show an opposite 
trend between neutral and acidic species. The level of neutral core-fucosylated N-glycoforms is 
significantly decreased in CC glycoproteins, while the level of the corresponding acidic species is 
considerably increased in CC cases compared to the normal cohort. Similar trends, but oppositely, 
have been reported for IgG-derived core-fucosylated glycoforms. In an extensive study of plasma 
IgG, N-glycome showed a decrease in sialylation of fucosylated glycoforms despite the 
fucosylation position.18 In another study, plasma IgG N-glycome exhibited an increase in core-
fucosylation of neutral glycoforms, while the corresponding sialylated core-fucosylated species 
showed a decrease across CRC disease cases.15 Despite the experimental difference, the variations 
among core-fucosylated glycoforms derived from total serum glycoproteins and those reported for 
IgG N-glycome may refer to a change in GTs activities and preferences during malignancy and 
tumor development. Furthermore, although IgG is a highly abundant plasma protein, the majority 
of core-fucosylated species can be also derived from various abundant glycoproteins rather than 
IgG, such as IgM, Alpha-2macrogobulin, Apolipoprotein D, Alpha-2-HS-glycoprotein, 
Vitronectin, etc.42 Thus, further investigation of each protein might be necessary to reveal the root 
of variations in terms of fucosylation. On the other hand, up-regulation of fucosyltransferase 8, an 
enzyme responsible for core fucosylation and encoded by FUT8, may contribute to the high level 
of fucosylation in CC cases, particularly sialylated core-fucosylated N-glycoforms. This enzyme 
was reported with high expression in numerous solid cancers.56 
Most of the detected serum N-glycoforms are complex glycans that are either neutral or 
sialylated with or without fucose residues. Detected species from sera are comparable with those 
reported for human plasma N-glycosylation.42 In this study, we have found that normal serum N-
glycoforms show a less degree of sialylation compared to tumor-related species. At all rate, N-
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glycoforms derived from CC cohort have higher mono-, di- and tri-sialyation levels across all cases 
compared to those originated from normal sera. This observation is unsurprising. Various 
malignancies are associated with an increase in the total serum sialyation levels that show a 
potentiality for clinical applications.57 Sialylation index of total serum glycoforms shows a 
significant increase in CC sera that is confirmed by ROC analysis. Increased sialylation includes 
all sialic acid linkages (α2,3 and α2,6) despite the presence of sialyl Lewis epitopes, known in 
CRC.17  
In a glycomics study of CRC tissues, sialylated glycoforms, especially α2,6-Neu5Ac, were 
considered high in tumor tissues, while α2,3-Neu5Ac carrying glycans were under-represented. 
However, an increase in α2,3-Neu5Ac and Lewis-type fucosylation were observed in tissues with 
mild-stage CRC relative to EGFR-negative CRC tissues.58 Also, CRC tissues expressed a low level 
of sialyl Lewis epitope-containing glycans.13 Compared to plasma IgG, N-glycome showed a 
decrease in sialylation of fucosylated glycoforms in CRC.18 However, in another study, core-
fucosylated species carrying sialic acids were up-expressed on IgG glycoproteins purified from 
CRC plasma.15 These changes might be originated from destruction in glycosylation-related 
enzymes. That is, mutations in genes, such as B3GNT2, B4GALT2, and ST6GALNAC2 involved 
in the biosynthesis of N- and Cores 1–3 O-glycans, have been observed in CRC cell lines.55 
However, close attention to changes in enzyme activities and preferences under tumor conditions 
may reveal details in individual key proteins that contribute to pathogenesis and CC malignancy. 
4.5 Conclusion 
In this study, we demonstrate the quality of soluble serum glycoproteins as a source for 
prognostic glycan-related biomarkers for CC. We analyzed the N-glycome profile derived from a 
set of five CC patients’ sera in comparison with matched healthy controls by MALDI-MS. 
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Truncated glycoforms were observed across CC cases with considerable changes. Also, our 
finding demonstrated a significant decrease in galactosylation across all complex N-glycan types. 
The overall fucosylation was slightly higher in CC compared to controls, but core fucosylation 
showed an observable decrease in tumor sera. However, the level of core-fucosylation of sialylated 
glycoforms was decreased in tumor cases, while the corresponding neural species were increased 
in tumorigenic conditions. The quality of sialylation, on the other hand, was significantly higher 
in tumor cases across all sialylation degrees than those observed in normal sera. Our findings are 
compatible with some glycosylation variations known in cancers. Nevertheless, differentially 
expression levels of N-glycosylation in particular proteins may contribute to comprehensive 
profiling and detailed understanding of the biological relevance of altered glycosylation in CC 
prognosis.  More samples are crucial for the discovery of promising biomarkers or development 
of clinical therapy. 
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5 CHAPTER 5. THE OVERALL CONCLUSIONS OF GLCOMICS AND 
GLYCOPROTEOMICS ANALYSES 
5.1 Project 1: Glycoproteomics analysis of VWF therapeutic protein  
In this set of glycoproteomic study, human plasma von Willebrand Factor (VWF), which 
plays essential roles in primary hemostasis in cooperation with other coagulation factors, is 
comprehensively investigated in the macro- and micro-heterogeneity levels. There is ample 
indication that glycosylation affects many biological phases during the protein life-cycle. 
However, a comprehensive characterization of all probable N-glycosites in simultaneous with O-
glycosites is still not fully revealed. Thus, this exploration intended to estimate the occupancy of 
all canonical N-glycosites besides simultaneous characterization of N- and O-glycoforms. An RP-
LC-MS/MS system functionalized with CID and HCD tandem mass was utilized to analyze VWF. 
N-glycosite occupancy varied along the protein backbone chain. 
 Out of 257 HCD spectra, 181-characterized glycoforms were specified into either N- or O-
glycosites. Sequential cleavage of glycosidic bonds besides Human Database mass matching have 
confirmed the glycoform structures. A total of 173 glycoforms represented most commonly 
biantennary and infrequently tri- and tetra-antennary N-glycans beside high mannose, hybrid, 
ABH-antigen terminated, and sulfated N-glycans. Many glycoforms were common across all N-
sites. Noteworthy, previously unreported N-glycosites within domain D’(TIL’-E’) showed 
glycosylation. Moreover, sialylated core 1 and core 2 O-glycans were detected on 2298T. Given 
the subtle characterization of site-specific glycoforms, we can attain a profound understanding of 
VWF-biological roles as well as facilitate the production of VWF-based therapeutics. 
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5.2 Project 2: Glycomics analysis of AD for early biomarker candidates   
The first part of glycomics sets of analyses includes a thorough exploration of the quality of 
N-glycosylation in FC tissues derived from human brains. The primary purpose of this study is to 
discover early glycan-based biomarkers that may differentiate AD candidates ate the disease onset. 
The primary outcomes include the identification of fifteen unique N-glycoforms derived from FC 
tissues diagnosed with AD. These glycoforms are utterly absent in normal FC tissues. Although 
these N-glycoforms have been excluded from further statistical assessment, serious attention to 
such glycoforms might increase our knowledge of the disease pathogenesis and progression.   On 
the other hand, eight unique glycoforms have been assigned to normal FC and were undetectable 
in more than 50% of AD cases. N-glycoforms assigned to AD tissues involve various types of 
glycoforms, including complex glycoforms that are capped with different kind of sialic acid 
residues and or decorated with fucosylation and phosphorylation.  
Statistical evaluation of FC N-glycome reveals eight N-glycoforms that are significantly 
differentiated from healthy tissues. Noteworthy, although more than 50% of Subset 1 glycoforms 
are excluded from Subset 2, these eight glycoforms present across all samples. From ROC curve 
analysis, we suggest paying more attention to four of these N-glycoforms, including two truncated 
glycoforms H3N3F1 and H4N3, a high mannose glycan (H5N2F1) and a bi-antennary complex 
glycan (H4N4F1). These significantly differentiated structures show the highest AROC, and thus 
they might play essential roles during the disease progression.  
Moreover, AD FC N-glycome showed significant changes in terms of glycoform type, 
including increased mannosylation, whereas hybrid, complex and other type glycoforms are 
significantly lower than that of normal N-glycome. Also, regardless of the number of detected N-
glycoforms, a close glance to the glycosylation pattern reveals considerable changes in terms of 
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type, complexity, fucosylation, galactosylation, sialylation and the presence of rare modifications.  
Glycosylation pattern in AD FC tissues shows a decrease in mono-fucosylated glycoforms 
compared to healthy cohort. However, a high number of core-fucosylated glycoforms were 
released from disordered tissues. Also, mono-galactosylated glycoforms were low abundant, while 
aglactosylated glycoforms represented the most abundant species in AD FC tissues.  
Sialylation, on the other hand, showed insignificant differentiation between the examined 
cohort. However, a slight reduction was observed in AD FC cases. These aberrant glycosylation 
changes in AD brains might reflect the neurodegenerative deformation during AD pathology and 
progression. Thus, additional attention is essential to explore distortion in the overall glycosylation 
process and the associated GTs.  
5.3 Project 3: Glycomics analysis of CC for biomarker discovery   
Glycosylation variations are the most commonly observed PTMs in cancers and have 
significant structural and functional consequences on the protein and thus the disease surveillance 
and therapy. Colon cancer is a major type of malignancies leading worldwide deaths. Until now, 
most of the used procedures for screening colorectal cancer, such as colonoscopy, sigmoidoscopy 
or fecal occult blood testing, are invasive and uncomfortable and almost reasonable for diagnosing 
the disease at metastatic stages. Thus, most of the cancer patients barely survive with a survival 
rate of <10% within five years. Our accumulated knowledge of altered glycosylation associated 
with CC is still contradictory. Thus, further investigation is necessary for better understanding the 
disease prognosis and could accelerate enhanced methods that are noninvasive for early revelation 
and characterization of the tumor. Herein, in this project, we have examined five CC patients’ and 
healthy subjects’ blood sera for discovering the glycosylation quality under tumorigenic status. N-
glycosylation of soluble serum glycoproteins was explored by MALDI-TOF for PNGase F-
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released and enriched glycoforms subsequently subjected to permethylation. Approximately 90% 
of MS signals were assigned to human-like glycoforms. However, N-glycoforms detected across 
all cases and previously reported have been considered for further descriptive and quantitative 
analyses. Among sixty N-glycoforms derived from human sera, most of these structures showed 
significant changes between the examined cohorts. 
Truncated structures were found to be increased in the tumor, while soluble serum proteins 
from healthy individuals were heavily glycosylation with complex N-glycoform, especially bi-
antennary forms. The overall galactosylation showed a considerable decrease in tumor cases. This 
reduction was even noticeable with bi-antennary species. The increment of the overall fucosylation 
quality in tumor sera is consistent with previously known changes in CRC. However, serum core-
fucosylated N-glycoforms showed a contrary difference to those reported from serum IgG N-
glycome. Tumor-derived N-glycoforms showed a significant decrease in neutral core-fucosylated 
species, while the corresponding acidic species were considerably increased in CC serum 
glycoproteins. 
Moreover, the level of sialylation in tumor glycoproteins was, in all rate, higher than that of 
normal. The increment involved all sialylation degrees, mono-, di-, and tri-sialylation. This study 
is a primary exploration that might be used for further identifying candidate glycan-related 
biomarkers directly from the human serum. N-glycan biomarkers affected by the pathogenic 
progress of a particular disease would be a useful assessment for clinical diagnosis and conscious 
development for effective therapeutics. 
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APPENDICES 
Appendix A 
Appendix A.1 Detected N-glycoforms correlated to 820NRC-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 7.10 
 
1396.4938 
 
1396.4433 
 
H3N4s1 
 
 
 
Complex 
 
0.56 
2 7.54 
 
1786.6750 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex, H/O 
 
1.60 
3 7.90 
 
1843.7247 
 
1843.6715 
 
H5N5 
 
 
 
Complex 
 
1.34 
4 8.02 
 
1827.6896 
 
1827.6766 
 
H4N5F1 
 
 
 
Complex, H/O 
 
2.62 
5 8.20 
 
1890.6686 
 
1890.6610 
 
H6N3S1 
 
 
 
Hybrid 
 
2.26 
6 8.20 
 
1728.6236 
 
1728.6082 
 
H5N3S1 
 
 
 
Hybrid 
 
0.82 
7 8.25 
 
2223.8318 
 
2223.8034 
 
H5N4S1F2 
 
 
 
Complex, H/O 
 
0.75 
8 8.25 
 
1566.5759 
 
1566.5554 
 
H4N3S1 
 
 
 
Hybrid 
 
0.59 
9 8.32 
 
1931.6937 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
4.76 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
10 8.32 
 
1931.6895 
 
1931.6876 
 
H5N4S1 
 
 
 Complex 
 
1.53 
11 8.32 
 
2036.7422 
 
2036.7189 
 
H6N3S1F1 
 
 
 Hybrid 
 
1.15 
12 8.37 
 
2077.7568 
 
2077.7455 
 
H5N4S1F1 
 
 
 Complex 
 
2.67 
13 8.37 
 
1874.6701 
 
1874.6661 
 
H5N3S1F1 
 
 
 Hybrid 
 
2.14 
14 8.43 
 
2077.7547 
 
2077.7455 
 
H5N4S1F1 
 
 
 Complex 
 
14.46 
15 8.43 
 
2115.7198 
 
2116.6758 
 
H6N3S1F1s1 
 
 
 Hybrid 
 
0.56 
16 8.49 
 
1712.6226 
 
1712.6133 
 
H4N3S1F1 
 
 
 Hybrid 
 
15.96 
17 8.49 
 
2036.7392 
 
2036.7189 
 
H6N3S1F1 
 
 
 Hybrid 
 
1.44 
18 8.49 
 
1421.5443 
 
1421.5179 
 
H4N3F1 
 
 
 Hybrid 
 
1.56 
19 8.49 
 
2099.7203 
 
2100.7374 
 
H5N4S1F1 
 
 
 Complex 
 
0.43 
20 8.54 
 
2115.7070 
 
2116.6758 
 
H6N3S1F1s1 
 
 
 Hybrid 
 
0.76 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
21 8.60 
 
2134.7786 
 
2134.7670 
 
H5N5S1  
 
 
Bisected 
 
5.00 
22 8.65 
 
2280.8453 
 
2280.8249 
 
H5N5S1F1  
 
 
Bisected, 
H/O 
 
9.09 
23 8.65 
 
2077.7490 
 
2077.7455 
 
H5N4S1F1  
 
 
Complex 
 
2.77 
24 8.65 
 
1712.6065 
 
1712.6133 
 
H4N3S1F1  
 
 
Hybrid 
 
1.68 
25 8.71 
 
2116.7731 
 
2117.7500 
 
H6N4F2  
 
 
Complex, B 
 
1.83 
26 8.71 
 
2118.7738 
 
2118.7720 
 
H4N5S1F1  
 
 
Complex 
 
1.31 
27 8.83 
 
2280.8720 
 
2280.8249 
 
H5N5S1F1  
 
 
Complex 
 
10.24 
28 8.83 
 
2280.8293 
 
2280.8249 
 
H5N5S1F1  
 
 
complex 
 
7.05 
29 8.94 
 
2280.8398 
 
2280.8249 
 
H5N5S1F1  
 
 
Complex 
 
0.63 
30 9.18 
 
2279.8777 
 
2280.8249 
 
H5N5S1F1  
 
 
complex, A 
 
0.18 
31 9.24 
 
2077.7629 
 
2077.7455 
 
H5N4S1F1  
 
 
Complex, 
H/O 
 
1.66 
32 9.30 
 
1712.6351 
 
1712.6133 
 
H4N3S1F1  
 
 
Complex, 
H/O 
 
0.61 
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Appendix A.2 Detected N-glycoforms correlated to 847NTC-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 9.77  2077.7523  2077.7455  H5N4S1F1  
 
 Complex  11.46 
2 10.42  2077.7207  2077.7455  H5N4S1F1  
 
 
Complex, 
H/O 
 8.19 
3 11.71  1234.4209  1234.4334  H5N2  
 
 HighMan  60.86 
4 11.77  1234.4358  1234.4334  H5N2  
 
 HighMan  19.49 
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Appendix A.3 Detected N-glycoforms correlated to 857NCT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance  
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 21.84  2076.8400  2077.7455  H5N4S1F1  
 
 Complex  57.17 
2 22.18  1785.7472  1786.6501  H5N4F1  
 
 Complex  16.87 
3 22.24  1639.6824  1640.5922  H5N4  
 
 Complex  25.95 
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Appendix A.4 Detected N-glycoforms correlated to 1513NRC-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 7.72 
 
2046.6838 
 
2046.7509 
 
H5N6 
 
 
 
Complex 
 
1.70 
2 9.53 
 
1396.4921 
 
1396.4433 
 
H3N4s1 
 
 
 
Complex 
 
1.11 
3 9.53 
 
1234.4430 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
1.26 
4 9.82 
 
1234.4355 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
3.69 
5 12.35 
 
1640.6264 
 
1640.5922 
 
H5N4 
 
 
 
Complex 
 
7.23 
6 12.41 
 
1786.6610 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
36.50 
7 12.41 
 
1640.5909 
 
1640.5922 
 
H5N4 
 
 
 
Complex 
 
17.75 
8 12.41 
 
1786.6528 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
12.79 
9 15.92 
 
2368.8841 
 
2368.8409 
 
H5N4S2F1 
 
 
 
Complex 
 
4.21 
10 16.04 
 
2368.8392 
 
2368.8409 
 
H5N4S2F1 
 
 
 
Complex 
 
11.22 
11 18.26 
 
2222.7864 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
2.54 
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Appendix A.5 Detected N-glycoforms correlated to 1574NRT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
o. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 
Experimental  Theoretical 
    
1 6.73 
 
3698.5414 
 
3698.3115 
 
H8N6S3F2 
 
 
 
Complex, B 
 
0.39 
2 7.23 
 
3699.4988 
 
3698.3115 
 
H8N6S3F2 
 
 
 
Complex, B 
 
0.82 
3 8.49 
 
2222.8323 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
14.84 
4 8.65 
 
1914.7214 
 
1913.6503 
 
H6N3S1 
 
 
 
Hybrid 
 
3.61 
5 8.76 
 
1786.6584 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
2.56 
6 8.83 
 
1421.5057 
 
1421.5179 
 
H4N3F1 
 
 
 
Hybrid 
 
0.94 
7 9.65 
 
1640.5920 
 
1640.5922 
 
H5N4 
 
 
 
Complex 
 
4.46 
8 9.65 
 
1786.6595 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex, 
H/O 
 
0.57 
9 9.82 
 
1843.6694 
 
1843.6715 
 
H5N5 
 
 
 
Complex 
 
4.77 
10 9.82 
 
1989.7341 
 
1989.7295 
 
H5N5F1 
 
 
 
Complex, 
H/O 
 
1.61 
11 9.88 
 
1462.5453 
 
1462.5444 
 
H3N4F1 
 
 
 
Complex 
 
3.46 
12 10.24 
 
2222.8032 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
1.65 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 
Experimental  Theoretical 
    
13 10.24 
 
1234.4415 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
1.20 
14 10.72 
 
1931.6959 
 
1931.6875 
 
H5N4S1 
 
 
 
Complex 
 
7.18 
15 10.83 
 
2077.7477 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex, 
H/O 
 
8.30 
16 10.78 
 
1946.7142 
 
1946.5637 
 
H5N4F1s2 
 
 
 
Complex, 
H/O 
 
1.63 
17 10.89 
 
1931.6898 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
15.05 
18 10.95 
 
1769.6275 
 
1769.6348 
 
H4N4S1 
 
 
 
Complex 
 
3.95 
19 10.95 
 
2536.8677 
 
2536.8676 
 
H5N4S3 
 
 
 
Complex 
 
1.66 
20 11.01 
 
1945.7390 
 
1946.5637 
 
H5N4F1s2 
 
 
 
Complex, 
H/O 
 
0.88 
21 11.07 
 
2536.9072 
 
2536.8676 
 
H5N4S3 
 
 
 
Complex 
 
3.99 
22 11.07 
 
1972.7107 
 
1972.7141 
 
H4N5S1 
 
 
 
Complex 
 
1.69 
23 12.35 
 
1234.4305 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
3.13 
24 12.41 
 
2222.7915 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
0.46 
25 14.14 
 
1785.6403 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
6.23 
26 15.09 
 
2077.7392 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
1.11 
27 15.09 
 
2221.9033 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
0.06 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 
Experimental  Theoretical 
    
28 15.22 
 
1930.7514 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
0.32 
29 15.34 
 
2078.7856 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
0.05 
30 16.30 
 
2368.8329 
 
2368.8409 
 
H5N4S2F1 
 
 
 
Complex 
 
0.18 
31 19.07 
 
1558.5446 
 
1558.5391 
 
H7N2 
 
 
 
HighMan 
 
0.45 
32 21.39 
 
1874.5464 
 
1874.6661 
 
H5N3S1F1 
 
 
 
Hybird 
 
2.82 
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Appendix A.6 Detected N-glycoforms correlated to 2223NVS-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass    
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 11.71  1785.7001  1786.6501  H5N4F1  
 
 Complex  7.78 
2 11.77  2150.8128  2151.7823  H6N5F1  
 
 Complex  6.35 
3 11.77  1931.7840  1932.7080  H5N4F2  
 
 
Complex, 
H/O 
 1.03 
4 11.77  1786.7164  1786.6501  H5N4F1  
 
 Complex  0.80 
5 11.77  1988.7485  1989.7295  H5N5F1  
 
 Complex  0.46 
6 11.82  2134.8950  2135.7874  H5N5F2  
 
 
Complex, 
A 
 1.56 
7 12.41  2077.7787  2077.7455  H5N4S1F1  
 
 Complex  6.89 
8 12.46  2077.7905  2077.7455  H5N4S1F1  
 
 Complex  1.96 
9 12.62  2077.7813  2077.7455  H5N4S1F1  
 
 Complex  4.06 
10 12.73  2441.8895  2442.8777  H6N5S1F1  
 
 
Complex, 
H/O 
 3.34 
11 12.84  2077.7809  2077.7455  H5N4S1F1  
 
 Complex  1.55 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 
Experimental  Theoretical 
    
12 12.90  2077.8222  2077.7455  H5N4S1F1  
 
 Complex  54.21 
13 13.13  2077.8166  2077.7455  H5N4S1F1  
 
 Complex  7.53 
14 13.70  2077.8181  2077.7455  H5N4S1F1  
 
 
Complex, 
H/O 
 1.78 
15 13.81  1258.5996  1259.4651  H3N3F1  
 
 Complex  0.71 
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Appendix A.7 Detected N-glycoforms correlated to 2290NCT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
1 7.10 
 
1769.6816 
 
1769.6348 
 
H4N4S1 
 
 
 
Complex 
 
0.31 
2 7.48 
 
2004.7961 
 
2005.7244 
 
H6N5 
 
 
 
Complex 
 
0.66 
3 7.66 
 
1786.6699 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
2.02 
4 8.14 
 
1770.5673 
 
1770.6552 
 
H4N4F2 
 
 
 
Complex, 
H/O 
 
0.95 
5 8.32 
 
2295.8480 
 
2296.8198 
 
H6N5S1 
 
 
 
Complex 
 
1.03 
6 8.43 
 
2442.8961 
 
2442.8777 
 
H6N5S1F1 
 
 
 
Complex 
 
10.16 
7 8.49 
 
1931.6894 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
1.24 
8 8.49 
 
2296.8262 
 
2295.7010 
 
H5N5F2s2 
 
 
 
Complex, 
A 
 
1.49 
9 8.54 
 
2077.7535 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
10.46 
10 8.65 
 
2222.8052 
 
2222.7385 
 
H4N5F3s1 
 
 
 
Complex, 
A 
 
0.87 
11 8.71 
 
1558.5456 
 
1558.5391 
 
H7N2 
 
 
 
HighMan 
 
2.64 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
12 8.71 
 
1915.7497 
 
1915.6927 
 
H4N4S1F1 
 
 
 
Complex 
 
1.30 
13 8.76 
 
2221.7570 
 
2221.7181 
 
H4N5S1F1s1 
 
 
 
Complex 
 
1.06 
14 8.76 
 
1234.4409 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
0.76 
15 8.83 
 
1396.4959 
 
1396.4863 
 
H6N2 
 
 
 
HighMan 
 
3.94 
16 8.83 
 
1234.4392 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
1.66 
17 8.83 
 
1858.5356 
 
1858.6712 
 
H4N3S1F2 
 
 
 
Hybrid 
 
0.67 
18 8.88 
 
1072.3836 
 
1072.3806 
 
H4N2 
 
 
 
HighMan 
 
2.63 
19 9.30 
 
1234.4399 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
1.36 
20 9.36 
 
2587.9494 
 
2587.9152 
 
H6N5S2 
 
 
 
Complex 
 
2.29 
21 9.48 
 
2953.0839 
 
2954.0678 
 
H7N6S1F2 
 
 
 
Complex, 
H/O 
 
2.14 
22 9.65 
 
2587.9048 
 
2587.9152 
 
H6N5S2 
 
 
 
Complex 
 
1.24 
23 10.12 
 
1890.6877 
 
1890.6610 
 
H6N3S1 
 
 
 
Hybrid 
 
0.46 
24 10.18 
 
1728.6139 
 
1728.6082 
 
H5N3S1 
 
 
 
Hybrid 
 
0.91 
25 10.66 
 
1786.6954 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
3.66 
26 10.66 
 
1624.6073 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
10.11 
27 10.72 
 
1462.5568 
 
1462.5444 
 
H3N4F1 
 
 
 
Complex 
 
1.67 
28 10.72 
 
1624.6134 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
1.01 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
29 10.78 
 
1786.6875 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
4.00 
30 10.83 
 
1461.5626 
 
1462.5440 
 
H3N4F1 
 
 
 
Complex 
 
0.67 
31 11.01 
 
1665.6284 
 
1665.6238 
 
H3N5F1 
 
 
 
Complex 
 
2.46 
32 11.71 
 
2077.7600 
 
2077.7455 
 
 
H5N4S1F1 
 
 
 
Complex 
 
1.02 
33 11.88 
 
2077.7500 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
1.51 
34 11.94 
 
1915.7192 
 
1915.6927 
 
H4N4S1F1 
 
 
 
Complex 
 
1.52 
35 12.00 
 
1930.7549 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
0.94 
36 12.00 
 
2077.7961 
 
2077.7455 
 
H5N4S1F1 
 
 
 Complex, 
H/O 
 
0.99 
37 12.17 
 
1786.5316 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
1.56 
38 12.23 
 
1623.5361 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex, 
H/O 
 
1.10 
39 12.41 
 
2077.6091 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
1.20 
40 13.13 
 
1891.6791 
 
1891.6814 
 
H6N3F2 
 
 
 
Hybrid 
 
0.58 
41 14.65 
 
2368.7535 
 
2368.8409 
 
H5N4S2F1 
 
 
 
Complex 
 
5.65 
42 14.76 
 
2020.7276 
 
2020.7240 
 
H5N3S1F2 
 
 
 
Complex 
 
1.09 
43 14.82 
 
2368.7829 
 
2368.8409 
 
H5N4S2F1 
 
 
 
Complex 
 
6.52 
44 15.82 
 
3022.1434 
 
3023.9497 
 
H5N5S2F3s2 
 
 
 
Complex, 
H/O 
 
0.49 
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Appendix A.8 Detected N-glycoforms correlated to 2298T-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 8.88  1039.3942  1039.3704  H2N2S1  
 
 Core2  6.94 
2 10.12  965.3369  965.3336  H1N1S2  
 
 
Core 1  28.33 
3 10.18  965.3548  965.3336  H1N1S2  
 
 
Core 1  6.85 
4 10.72  966.3249  965.3336  H1N1S2  
 
 
Core 1  16.59 
5 10.83  966.3375  965.3336  H1N1S2  
 
 
Core 1  14.49 
6 10.89  1256.4298  1256.4290  H1N1S3  
 
 
Core 1  6.93 
7 15.41  965.3172  965.3336  H1N1S2  
 
 
Core 1  7.74 
8 16.14  1254.5063  1256.4290  H1N1S3  
 
 
Core 1  12.13 
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Appendix A.9 Detected N-glycoforms correlated to 2357NFT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 12.46 
 
2077.7677 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
18.71 
2 12.51 
 
2897.0673 
 
2898.0667 
 
H7N5F5 
 
 
 
Complex, 
H/O 
 
8.70 
3 12.57 
 
2815.0781 
 
2815.0042 
 
H6N6S1F2 
 
 
 
Complex, A 
 
34.72 
4 12.68 
 
2074.8658 
 
2075.6602 
 
H4N5S1s1 
 
 
 
Complex 
 
27.63 
5 12.68 
 
2077.7987 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
10.24 
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Appendix A.10 Detected N-glycoforms correlated to 2546NVS-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA 
 Experimental  Theoretical     
1 15.52  1785.6827  1786.6501  H5N4F1  
 
 Complex  35.48 
2 18.38  2368.9606  2368.8409  H5N4S2F1  
 
 Complex  64.52 
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Appendix A.11 Detected N-glycoforms correlated to 2585NGT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
1 8.02 
 
1404.5312 
 
1405.5230 
 
H3N3F2 
 
 
 
Complex 
 
15.24 
2 8.20 
 
1624.6046 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
26.92 
3 8.20 
 
1786.6827 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
14.29 
4 8.20 
 
1462.5475 
 
1462.5444 
 
H3N4F1 
 
 
 
Complex 
 
5.58 
5 8.20 
 
1624.5959 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
1.59 
6 8.25 
 
1478.5638 
 
1478.5393 
 
H4N4 
 
 
 
Complex 
 
1.31 
7 8.25 
 
1786.5393 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
1.70 
8 8.32 
 
1462.4123 
 
1462.5444 
 
H3N4F1 
 
 
 
Complex 
 
2.16 
9 8.32 
 
1624.4767 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
1.61 
10 8.43 
 
2077.7968 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
2.72 
11 8.49 
 
1665.5143 
 
1665.6238 
 
H3N5F1 
 
 
 
Complex 
 
3.67 
12 9.48 
 
1624.5004 
 
1624.5973 
 
H4N4F1 
 
 
 
Complex 
 
1.18 
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Continued 
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
13 12.06 
 
1931.6949 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
4.89 
14 12.17 
 
1931.7358 
 
1931.6876 
 
H5N4S1 
 
 
 
Complex 
 
2.49 
15 13.30 
 
2222.8264 
 
2222.7830 
 
H5N4S2 
 
 
 
Complex 
 
3.58 
16 13.87 
 
1882.6535 
 
1882.6447 
 
H9N2 
 
 
 
HighMan 
 
6.99 
17 16.58 
 
1234.5230 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
4.08 
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Appendix A.12 Detected N-glycoforms correlated to 2635NNT-containing VWF peptides 
analyzed by RPLC-ESI-MS/MS. Rt, retention time; SRA, site-specific relative abundance   
No. Rt 
 Glycan Mass  
Composition 
 
Structure 
 
Type/Antigen 
 
SRA  
Experimental  Theoretical 
    
1 8.88 
 
1234.4243 
 
1234.4334 
 
H5N2 
 
 
 
HighMan 
 
16.11 
2 9.88 
 
1787.7528 
 
1786.6501 
 
H5N4F1 
 
 
 
Complex 
 
10.43 
3 10.00 
 
1932.7130 
 
1932.7080 
 
H5N4F2 
 
 
 
Complex, 
H/O 
 
11.02 
4 11.01 
 
2077.7384 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
11.94 
5 11.07 
 
2961.1208 
 
2960.0417 
 
H6N6S2F1 
 
 
 
Complex 
 
9.01 
6 11.24 
 
1712.6260 
 
1712.6133 
 
H4N3S1F1 
 
 
 
Hybrid 
 
10.76 
7 11.30 
 
2115.7899 
 
2116.6758 
 
H6N3S1F1s
1 
 
 
 
Hybrid 
 
17.38 
8 23.40 
 
2078.8083 
 
2077.7455 
 
H5N4S1F1 
 
 
 
Complex 
 
13.36 
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Appendix B 
Appendix B.1 List of calibrants that were used to calibrate MALDI-MS spectra. 
No. 
 
Peak  
 Mass signal 
(m/z) 
 Tolerance 
(ppm) 
 
calibrant 
1  β-Cyclodextrin (Na+)  1451.6876  50   
2  H5N2 (Na+)  1579.7826  50   
3  H3N4 (Na+)  1661.8357  50   
4  H6N2 (Na+)  1783.8824  50   
5  H3N4F1 (Na+)  1835.9249  50   
6  H3N5 (Na+)  1906.9620  50   
7  H4N4F1 (Na+)  2040.0247  50   
8  H3N5F1 (Na+)  2081.0512  50   
9  H4N5 (Na+)  2111.0618  50   
10  H5N4F1 (Na+)  2244.1245  50   
11  H4N5F2 (Na+)  2459.2402  50   
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Appendix B.2 List of equations, definitions and corresponding descriptions that were used 
for calculating glycosylation indices.  
Index Symbol Equation Abbreviation 
Fucosylation FI 
𝐹𝐼 = ∑(𝐹1 + 𝐹2 + 𝐹𝑝)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠 … (𝐹𝐼 − 1) 𝑎 
F0=non-fucosylated glycoforms 
F1=mono-fucosylated glycoforms 
F2=di-fucosylated glycoforms 
Fp=multi-fucosylated glycoforms 
*Modified equation for this study 
∗ 𝐹𝐼 =
∑(𝐹1 + 𝐹2 + 𝐹𝑝)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑(𝐹0 + 𝐹1 + 𝐹2 + 𝐹𝑝) 𝑡𝑜𝑡𝑎𝑙 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
… (𝐹𝐼 − 2) 
𝐹𝐼 =
(1 × 𝐹1 + 2 × 𝐹2)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑(𝐹0 + 𝐹1 + 𝐹2 + 𝐹𝑝)𝑡𝑜𝑡𝑎𝑙 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
… (𝐹𝐼 − 3)𝑏 
Galactosylation GI 
 
𝐺𝐼 = 0.5(𝐺0) + 𝐺2)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠 … (𝐺𝐼 − 1)𝑎 
 
G0=Non-galactosylated glycoform 
(aglactosylated) 
G1=mono-galactosylated glycoform 
G2=di-galactosylated glycoforms 
G3=tri-galactosylated glycoforms 
G>3=multi-galactosylated glycoforms 
*Modified equation for this study 
∗ 𝐺𝐼 =
0.5(𝐺0) + 𝐺2)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑ 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
… (𝐺𝐼 − 2) 
∗ 𝐺𝐼 =
∑(𝐺 1 + 2 × 𝐺2) 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑ 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
… (𝐺𝐼 − 3) 
∗ 𝐺𝐼 =
∑(𝐺 1 + 𝐺2 + 𝐺3 + 𝐺 > 3)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
∑(𝐺0 + 𝐺1 + 𝐺2 + 𝐺3 + 𝐺 > 3) 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠
… (𝐺𝐼
− 4) 
Sialylation SI 𝑆𝐼 = ((0.5 × 𝐴1) + 𝐴2)𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠) … (𝑆𝐼 − 1)𝑎 
A0=non-sialylated glycoforms (asialo 
glycoforms) 
A1=mono-sialylated glycoforms 
A2=di-sialylated glycoforms 
Ap=multi-sialylated glycoforms 
a) Kemna, M. J.;  Plomp, R.;  van Paassen, P.;  Koeleman, C. A. M.;  Jansen, B. C.;  Damoiseaux, J.;  Cohen Tervaert, 
J. W.; Wuhrer, M., Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA 
Associated Vasculitis. EBioMedicine 2017, 17, 108-118. 
b) Lin, Z.; Lubman, D. M., Permethylated N-glycan analysis with mass spectrometry. Methods in molecular biology 
(Clifton, N.J.) 2013, 1007, 289-300. 
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Appendix B.3 MATLAB codes that were used for glycosylation indices and ROC 
analysis calculations.  
The following codes are for Subset 1 (n=104), as an example.  
A-Calculate Total Glycoforms intensity 
Total_intens=ds.H3N4+ds.H3N4F1+ds.H3N5+ds.H3N5S1+ds.H3E1N4F1+ds.H3N5F1+ds.H3N4S2F2+ds.H3N6+ds.
H3N6F1+ds.H4N4+ds.H4N4F1+ds.H4N5+ds.H4N5S1+ds.H4N4F2+ds.H4N4A1+ds.H4N4G1+ds.H4N5F1+ds.H4N4S2F2+ds.
H4N6+ds.H4N5F2+ds.H4N5A1+ds.H4N6F1+ds.H4N5F3+ds.H4N5A1F1+ds.H4N6F2+ds.H4N6A1+ds.H4N5A1F2+ds.H4N6A
1F1+ds.H4N7A1+ds.H5N4+ds.H5N4F1+ds.H5N5+ds.H5N5S1+ds.H5N4F2+ds.H5N4A1+ds.H5N5F1+ds.H5N4F3+ds.H5N5F2
+ds.H5N6F1+ds.H5N4A1F2+ds.H5N4A2+ds.H5N4A1G1+ds.H5N5F3+ds.H5N5A1F1+ds.H5N6F2+ds.H5N5A1F2+ds.H5N6F
3+ds.H5N6A1F1+ds.H5N6F4+ds.H5N6A1F2+ds.H6N4F2+ds.H6N5F2+ds.H6N5A1+ds.H6N5P1S1F2+ds.H6N5F3+ds.H6N5A
1F1+ds.H6N6F2+ds.H6N5F4+ds.H6N5A1F2+ds.H6N6F3+ds.H6N5A1F3+ds.H6N6F4+ds.H6N6A1F2+ds.H6N7F3+ds.H6N6A
1F3+ds.H6N7F4+ds.H7N6F5+ds.H8N6A2+ds.H8N8A1+ds.H4N2+ds.H4N2F1+ds.H5N2+ds.H5N2F1+ds.H6N2+ds.H7N2+ds.
H8N2+ds.H9N2+ds.H9N2P2+ds.H10N2+ds.H5N3F1+ds.H5N3F2+ds.H5N3A1+ds.H6N3F1+ds.H5N3A1F1+ds.H6N3F2+ds.H6
N3A1+ds.H5N3A2F1+ds.H7N4+ds.H3N2+ds.H3N2P1+ds.H3N2F1+ds.H3N3+ds.H3N3S1+ds.H3N3P1+ds.H3N3F1+ds.H4N3
ALac1+ds.H4N3+ds.H4N3F1+ds.H4N3F2+ds.H4N3A1+ds.H4N3A1F1+ds.H4N3A1S1F1+ds.H4N3A2F1+ds.H4N3A2F2; 
B-Fucosylation Indices 
Extract Vectors for Fucosylation of Total Complex Glycoforms (n=69) 
F0_C=ds.H3N4+ds.H4N4+ds.H3N5+ds.H3N5S1+ds.H5N4+ds.H4N5+ds.H3N6+ds.H4N5S1+ds.H4N4A1+ds.H4N4G
1+ds.H5N5+ds.H4N6+ds.H5N5S1+ds.H5N4A1+ds.H4N5A1+ds.H4N6A1+ds.H5N4A2+ds.H5N4A1G1+ds.H6N5A1+ds.H4N7
A1+ds.H8N6A2+ds.H8N8A1; 
F1_C=ds.H3N4F1+ds.H4N4F1+ds.H3E1N4F1+ds.H3N5F1+ds.H5N4F1+ds.H4N5F1+ds.H3N6F1+ds.H5N5F1+ds.H4
N6F1+ds.H4N5A1F1+ds.H5N6F1+ds.H5N5A1F1+ds.H4N6A1F1+ds.H6N5A1F1+ds.H5N6A1F1; 
F2_C=ds.H3N4S2F2+ds.H4N4F2+ds.H4N4S2F2+ds.H5N4F2+ds.H4N5F2+ds.H6N4F2+ds.H5N5F2+ds.H4N6F2+ds.
H5N4A1F2+ds.H4N5A1F2+ds.H6N5F2+ds.H5N6F2+ds.H5N5A1F2+ds.H6N5P1S1F2+ds.H6N6F2+ds.H6N5A1F2+ds.H5N6A
1F2+ds.H6N6A1F2; 
Fp_C=ds.H5N4F3+ds.H4N5F3+ds.H5N5F3+ds.H6N5F3+ds.H5N6F3+ds.H6N5F4+ds.H5N6F4+ds.H6N6F3+ds.H6N5
A1F3+ds.H6N6F4+ds.H6N7F3+ds.H6N6A1F3+ds.H6N7F4+ds.H7N6F5; 
Equation 1: Calculate Fucosylation Index based on Kemna's equation (FI_Kenma=sum all fucosylated glycoforms)  
FI_C_Kemna=F1_C+F2_C+Fp_C; 
Equation 2: Calculate Fucosylation Index based on Modified Kemna's equation (FI_MKenma=sum fucosylated 
glycoforms/sum glycoforms or sum complex glycoforms ) 
FI_C_MKemna_1=FI_C_Kemna./Total_intens; 
FI_C_MKemna_2=FI_C_Kemna./(F0_C+F1_C+F2_C+Fp_C); 
Equation 3: Calculate Fucosylation Index based fucosylation index (FI=(1*F1+2*F2)/sum glycoforms 
FI_C_1=((1*F1_C)+(2*F2_C))./Total_intens; 
Equation 4: Calculate Fucosylation Index based fucosylation index (FI=(1*F1+2*F2)/sum complex glycoforms 
FI_C_2=((1*F1_C)+(2*F2_C))./(F0_C+F1_C+F2_C+Fp_C); 
Plot Data of Fucosylation Based on Total glycoforms 
boxplot(FI_C_Kemna,ds.Group) 
title({'FI of Complex Glycoforms';'(FI=Total fucosylated complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_C_MKemna_1,ds.Group) 
title({'FI of Complex Glycoforms';'(FI=Fucosylated complex glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_C_MKemna_2,ds.Group) 
title({'FI of Complex Glycoforms';'(FI=Fucosylated complex glycoforms/Total complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_C_1,ds.Group) 
title({'FI of Complex Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_C_2,ds.Group) 
title({'FI of Complex Glycoforms';'(FI=(1*F1+2*F2)/Total complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Biantennary Glycans (n=19) 
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Extract Vectors for Fucosylation of Biantennary Glycans 
F0_CA2=ds.H3N4+ds.H4N4+ds.H4N4A1+ds.H4N4G1+ds.H5N4+ds.H5N5+ds.H5N4A1+ds.H5N4A2+ds.H5N4A1G
1; 
F1_CA2=ds.H3N4F1+ds.H4N4F1+ds.H5N4F1; 
F2_CA2=ds.H3N4S2F2+ds.H4N4F2+ds.H4N4S2F2+ds.H5N4F2+ds.H5N4A1F2+ds.H6N4F2; 
Fp_CA2=ds.H5N4F3; 
Calculate FI of Biantennary glycans 
FI_CA2_Kemna=F1_CA2+F2_CA2+Fp_CA2; 
FI_CA2_MKemna_1=FI_CA2_Kemna./Total_intens; 
FI_CA2_MKemna_2=FI_CA2_Kemna./(F0_CA2+F1_CA2+F2_CA2+Fp_CA2); 
FI_CA2_1=((1*F1_CA2)+(2*F2_CA2))./Total_intens; 
FI_CA2_2=((1*F1_CA2)+(2*F2_CA2))./(F0_CA2+F1_CA2+F2_CA2+Fp_CA2); 
Plot GI index of Biantennary glycans 
boxplot(FI_CA2_Kemna,ds.Group) 
title({'FI of Bi-antennary Glycoforms';'(FI=Total fucosylated bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA2_MKemna_1,ds.Group) 
title({'FI of Bi-antennary Glycoforms';'(FI=Fucosylated bi-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA2_MKemna_2,ds.Group) 
title({'FI of Bi-antennary Glycoforms';'(FI=Fucosylated bi-antennary glycoforms/Total bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA2_1,ds.Group) 
title({'FI of Bi-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA2_2,ds.Group) 
title({'FI of Bi-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Triantennary Glycans (n=31) 
Extract Vectors for Triantennary glycans  
F0_CA3=ds.H3N5+ds.H3N5S1+ds.H4N5+ds.H4N5S1+ds.H4N5A1+ds.H5N5S1+ds.H6N5A1; 
F1_CA3=ds.H3E1N4F1+ds.H3N5F1+ds.H4N5F1+ds.H4N5A1F1+ds.H5N5F1+ds.H5N5A1F1+ds.H6N5A1F1; 
F2_CA3=ds.H4N5F2+ds.H4N5A1F2+ds.H5N5F2+ds.H5N5A1F2+ds.H5N6A1F2+ds.H6N5F2+ds.H6N5P1S1F2+ds.
H6N5A1F2+ds.H6N6A1F2; 
Fp_CA3=ds.H4N5F3+ds.H5N5F3+ds.H5N6F4+ds.H6N5F3+ds.H6N5F4+ds.H6N5A1F3+ds.H6N6F4+ds.H6N6A1F3; 
Calculate GI of Triantennary glycans 
FI_CA3_Kemna=F1_CA3+F2_CA3+Fp_CA3; 
FI_CA3_MKemna_1=FI_CA3_Kemna./Total_intens; 
FI_CA3_MKemna_2=FI_CA3_Kemna./(F0_CA3+F1_CA3+F2_CA3+Fp_CA3); 
FI_CA3_1=((1*F1_CA3)+(2*F2_CA3))./Total_intens; 
FI_CA3_2=((1*F1_CA3)+(2*F2_CA3))./(F0_CA3+F1_CA3+F2_CA3+Fp_CA3); 
Plot GI of Triantennary glycans 
boxplot(FI_CA3_Kemna,ds.Group) 
title({'FI of Tri-antennary Glycoforms';'(FI=Total fucosylated tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA3_MKemna_1,ds.Group) 
title({'FI of Tri-antennary Glycoforms';'(FI=Fucosylated tri-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA3_MKemna_2,ds.Group) 
title({'FI of Tri-antennary Glycoforms';'(FI=Fucosylated tri-antennary glycoforms/Total tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA3_1,ds.Group) 
title({'FI of Tri-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
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ylabel('Fucosylation index') 
boxplot(FI_CA3_2,ds.Group) 
title({'FI of Tri-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Tetra-antennary Glycans (n=18) 
Extract Vectors For Tetra-antennary glycans 
F0_CA4=ds.H3N6+ds.H4N6+ds.H4N6A1+ds.H4N7A1+ds.H8N6A2+ds.H8N8A1; 
F1_CA4=ds.H3N6F1+ds.H4N6F1+ds.H4N6A1F1+ds.H5N6F1+ds.H5N6A1F1; 
F2_CA4=ds.H4N6F2+ds.H5N6F2+ds.H6N6F2; 
Fp_CA4=ds.H5N6F3+ds.H6N6F3+ds.H6N7F3+ds.H6N7F4+ds.H7N6F5; 
Calculate FI of Tetra-antennary glycans 
FI_CA4_Kemna=F1_CA4+F2_CA4+Fp_CA4; 
FI_CA4_MKemna_1=FI_CA4_Kemna./Total_intens; 
FI_CA4_MKemna_2=FI_CA4_Kemna./(F0_CA4+F1_CA4+F2_CA4+Fp_CA4); 
FI_CA4_1=((1*F1_CA4)+(2*F2_CA4))./Total_intens; 
FI_CA4_2=((1*F1_CA4)+(2*F2_CA4))./(F0_CA4+F1_CA4+F2_CA4+Fp_CA4); 
Plot FI of Tetra-antennary glycans 
boxplot(FI_CA4_Kemna,ds.Group) 
title({'FI of Tetra-antennary Glycoforms';'(FI=Total fucosylated tetra-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA4_MKemna_1,ds.Group) 
title({'FI of Tetra-antennary Glycoforms';'(FI=Fucosylated tetra-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA4_MKemna_2,ds.Group) 
title({'FI of Tetra-antennary Glycoforms';'(FI=Fucosylated tetra-antennary glycoforms/Total tetra-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA4_1,ds.Group) 
title({'FI of Tetra-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CA4_2,ds.Group) 
title({'FI of Tetra-antennary Glycoforms';'(FI=(1*F1+2*F2)/Total tetra-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of High mannose Glycoforms) (n=10) 
Extract Vectors of High mannose glycoforms 
F0_HM=ds.H4N2+ds.H5N2+ds.H6N2+ds.H7N2+ds.H8N2+ds.H9N2+ds.H9N2P2+ds.H10N2; 
F1_HM=ds.H4N2F1+ds.H5N2F1; 
Calculate FI of High mannose glycoforms 
FI_HM_Kemna=F1_HM; 
FI_HM_MKemna_1=FI_HM_Kemna./Total_intens; 
FI_HM_MKemna_2=FI_HM_Kemna./(F0_HM+F1_HM); 
FI_HM_1=((1*F1_HM))./Total_intens; 
FI_HM_2=((1*F1_HM))./(F0_HM+F1_HM); 
Plot FI of High mannose glycoforms  
boxplot(FI_HM_Kemna,ds.Group) 
title({'FI of High mannose Glycoforms';'(FI=Total fucosylated high mannose glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_HM_MKemna_1,ds.Group) 
title({'FI of High mannose Glycoforms';'(FI=Fucosylated high mannsoe glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_HM_MKemna_2,ds.Group) 
title({'FI of High mannsoe Glycoforms';'(FI=Fucosylated high mannsoe glycoforms/Total high mannsoe glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
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boxplot(FI_HM_1,ds.Group) 
title({'FI of High mannsoe Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_HM_2,ds.Group) 
title({'FI of High mannsoe Glycoforms';'(FI=(1*F1+2*F2)/Total high mannsoe glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Hybrid Glycoforms) (n=9) 
Extract Vectors of Hybrid glycoforms 
F0_Hy=ds.H5N3A1+ds.H6N3A1+ds.H7N4; 
F1_Hy=ds.H5N3F1+ds.H6N3F1+ds.H5N3A1F1+ds.H5N3A2F1; 
F2_Hy=ds.H5N3F2+ds.H6N3F2; 
Calculate FI of Hybrid glycoforms  
FI_Hy_Kemna=F1_Hy+F2_Hy; 
FI_Hy_MKemna_1=FI_Hy_Kemna./Total_intens; 
FI_Hy_MKemna_2=FI_Hy_Kemna./(F0_Hy+F1_Hy+F2_Hy); 
FI_Hy_1=((1*F1_Hy)+(2*F2_Hy))./Total_intens; 
FI_Hy_2=((1*F1_Hy)+(2*F2_Hy))./(F0_Hy+F1_Hy+F2_Hy); 
Plot FI of Hybrid glycoforms  
boxplot(FI_Hy_Kemna,ds.Group) 
title({'FI of Hybrid Glycoforms';'(FI=Total fucosylated hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_Hy_MKemna_1,ds.Group) 
title({'FI of Hybrid Glycoforms';'(FI=Fucosylated hybrid glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_Hy_MKemna_2,ds.Group) 
title({'FI of Hybrid Glycoforms';'(FI=Fucosylated hybrid glycoforms/Total hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_Hy_1,ds.Group) 
title({'FI of Hybrid Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_Hy_2,ds.Group) 
title({'FI of Hybrid Glycoforms';'(FI=(1*F1+2*F2)/Total hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Other Glycoforms) (n=16) 
Extract Vectors of Other glycoforms 
F0_R=ds.H3N2+ds.H3N2P1+ds.H3N3+ds.H3N3S1+ds.H3N3P1+ds.H4N3+ds.H4N3ALac1+ds.H4N3A1; 
F1_R=ds.H3N2F1+ds.H3N3F1+ds.H4N3F1+ds.H4N3A1F1+ds.H4N3A1S1F1+ds.H4N3A2F1; 
F2_R=ds.H4N3F2+ds.H4N3A2F2; 
Calculate FI of Other glycoforms  
FI_R_Kemna=F1_R+F2_R; 
FI_R_MKemna_1=FI_R_Kemna./Total_intens; 
FI_R_MKemna_2=FI_R_Kemna./(F0_R+F1_R+F2_R); 
FI_R_1=((1*F1_R)+(2*F2_R))./Total_intens; 
FI_R_2=((1*F1_R)+(2*F2_R))./(F0_R+F1_R+F2_R); 
Plot FI of Other glycoforms  
boxplot(FI_R_Kemna,ds.Group) 
title({'FI of Other Glycoforms';'(FI=Total fucosylated other glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_R_MKemna_1,ds.Group) 
title({'FI of Other Glycoforms';'(FI=Fucosylated other glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_R_MKemna_2,ds.Group) 
title({'FI of Other Glycoforms';'(FI=Fucosylated other glycoforms/Total other glycoforms)'}) 
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xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_R_1,ds.Group) 
title({'FI of Other Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_R_2,ds.Group) 
title({'FI of Other Glycoforms';'(FI=(1*F1+2*F2)/Total other glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
Fucosylation of Complex, High mannose, Hybrid, and Other (Total glycoforms) (n=104) 
Extract Vectors of Complex, High mannose, Hybrid, and Other 
F0_CHMHyR=F0_C+ds.H4N2+ds.H5N2+ds.H6N2+ds.H7N2+ds.H8N2+ds.H9N2+ds.H9N2P2+ds.H10N2+ds.H5N3
A1+ds.H6N3A1+ds.H7N4+ds.H3N2+ds.H3N2P1+ds.H3N3+ds.H3N3S1+ds.H3N3P1+ds.H4N3+ds.H4N3ALac1+ds.H4N3A1; 
F1_CHMHyR=F1_C+ds.H4N2F1+ds.H5N2F1+ds.H5N3F1+ds.H6N3F1+ds.H5N3A1F1+ds.H5N3A2F1+ds.H3N2F1+
ds.H3N3F1+ds.H4N3F1+ds.H4N3A1F1+ds.H4N3A1S1F1+ds.H4N3A2F1; 
F2_CHMHyR=F2_C+ds.H5N3F2+ds.H6N3F2+ds.H4N3F2+ds.H4N3A2F2; 
Fp_CHMHyR=Fp_C; 
Calculate FI of Complex, High mannose, Hybrid, and Other 
Note: becuase in this stage all glycoforms are considered, only one modified Kemna's equation is considered.  
FI_CHMHyR_Kemna=F1_CHMHyR+F2_CHMHyR+Fp_CHMHyR; 
FI_CHMHyR_MKemna=FI_CHMHyR_Kemna./Total_intens; 
FI_CHMHyR=((1*F1_CHMHyR)+(2*F2_CHMHyR))./Total_intens; 
Plot FI of Complex, Hybrid, and Other 
boxplot(FI_CHMHyR_Kemna,ds.Group) 
title({'FI of Total Glycoforms';'(FI=Total fucosylated glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CHMHyR_MKemna,ds.Group) 
title({'FI of Total Glycoforms';'(FI=Fucosylated glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
boxplot(FI_CHMHyR,ds.Group) 
title({'FI of Total Glycoforms';'(FI=(1*F1+2*F2)/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Fucosylation index') 
ROC Curve Analysis of FI 
ROC Curve for Total Complex Glycoforms 
ROC_FI_C_Kemna=roc_curve(FI_C_Kemna(1:8,1),FI_C_Kemna(9:16,1),1,1) 
title('Total Complex Glycoforms_Kemna') 
ROC_FI_C_MKemna_1=roc_curve(FI_C_MKemna_1(1:8,1),FI_C_MKemna_1(9:16,1),1,1) 
title('Total Complex Glycoforms_MKemna_1') 
ROC_FI_C_MKemna_2=roc_curve(FI_C_MKemna_2(1:8,1),FI_C_MKemna_2(9:16,1),1,1) 
title('Total Complex Glycoforms_MKemna_2') 
ROC_FI_C_1=roc_curve(FI_C_1(1:8,1),FI_C_1(9:16,1),1,1) 
title('Total Complex Glycoforms_FI_C_1') 
ROC_FI_C_2=roc_curve(FI_C_2(1:8,1),FI_C_2(9:16,1),1,1) 
title('Total Complex Glycoforms_FI_C_2') 
ROC Curve for Bi-antennary Glycoforms 
ROC_FI_CA2_Kemna=roc_curve(FI_CA2_Kemna(1:8,1),FI_CA2_Kemna(9:16,1),1,1) 
title('Bi-antennary Glycoforms_Kemna') 
ROC_FI_CA2_MKemna_1=roc_curve(FI_CA2_MKemna_1(1:8,1),FI_CA2_MKemna_1(9:16,1),1,1) 
title('Bi-antennary Glycoforms_MKemna_1') 
ROC_FI_CA2_MKemna_2=roc_curve(FI_CA2_MKemna_2(1:8,1),FI_CA2_MKemna_2(9:16,1),1,1) 
title('Bi-antennary Glycoforms_MKemna_2') 
ROC_FI_CA2_1=roc_curve(FI_CA2_1(1:8,1),FI_CA2_1(9:16,1),1,1) 
title('Bi-antennary Glycoforms_FI_CA2_1') 
ROC_FI_CA2_2=roc_curve(FI_CA2_2(1:8,1),FI_CA2_2(9:16,1),1,1) 
title('Bi-antennary Glycoforms_FI_CA2_2') 
ROC Curve for Tri-antennary Glycoforms 
ROC_FI_CA3_Kemna=roc_curve(FI_CA3_Kemna(1:8,1),FI_CA3_Kemna(9:16,1),1,1) 
title('Tri-antennary Glycoforms_Kemna') 
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ROC_FI_CA3_MKemna_1=roc_curve(FI_CA3_MKemna_1(1:8,1),FI_CA3_MKemna_1(9:16,1),1,1) 
title('Tri-antennary Glycoforms_MKemna_1') 
ROC_FI_CA3_MKemna_2=roc_curve(FI_CA3_MKemna_2(1:8,1),FI_CA3_MKemna_2(9:16,1),1,1) 
title('Tri-antennary Glycoforms_MKemna_2') 
ROC_FI_CA3_1=roc_curve(FI_CA3_1(1:8,1),FI_CA3_1(9:16,1),1,1) 
title('Tri-antennary Glycoforms_FI_CA3_1') 
ROC_FI_CA3_2=roc_curve(FI_CA3_2(1:8,1),FI_CA3_2(9:16,1),1,1) 
title('Tri-antennary Glycoforms_FI_CA3_2') 
ROC Curve for Tetra-antennary Glycoforms 
ROC_FI_CA4_Kemna=roc_curve(FI_CA4_Kemna(1:8,1),FI_CA4_Kemna(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_Kemna') 
ROC_FI_CA4_MKemna_1=roc_curve(FI_CA4_MKemna_1(1:8,1),FI_CA4_MKemna_1(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_MKemna_1') 
ROC_FI_CA4_MKemna_2=roc_curve(FI_CA4_MKemna_2(1:8,1),FI_CA4_MKemna_2(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_MKemna_2') 
ROC_FI_CA4_1=roc_curve(FI_CA4_1(1:8,1),FI_CA4_1(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_FI_CA4_1') 
ROC_FI_CA4_2=roc_curve(FI_CA4_2(1:8,1),FI_CA4_2(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_FI_CA4_2') 
ROC Curve for High Mannose Glycoforms 
ROC_FI_HM_Kemna=roc_curve(FI_HM_Kemna(1:8,1),FI_HM_Kemna(9:16,1),1,1) 
title('High Mannose Glycoforms_Kemna') 
ROC_FI_HM_MKemna_1=roc_curve(FI_HM_MKemna_1(1:8,1),FI_HM_MKemna_1(9:16,1),1,1) 
title('High Mannose Glycoforms_MKemna_1') 
ROC_FI_HM_MKemna_2=roc_curve(FI_HM_MKemna_2(1:8,1),FI_HM_MKemna_2(9:16,1),1,1) 
title('High Mannose Glycoforms_MKemna_2') 
ROC_FI_HM_1=roc_curve(FI_HM_1(1:8,1),FI_HM_1(9:16,1),1,1) 
title('High Mannose Glycoforms_FI_HM_1') 
ROC_FI_HM_2=roc_curve(FI_HM_2(1:8,1),FI_HM_2(9:16,1),1,1) 
title('High Mannose Glycoforms_FI_HM_2') 
ROC Curve for Hybrid Glycoforms 
ROC_FI_Hy_Kemna=roc_curve(FI_Hy_Kemna(1:8,1),FI_Hy_Kemna(9:16,1),1,1) 
title('Hybrid Glycoforms_Kemna') 
ROC_FI_Hy_MKemna_1=roc_curve(FI_Hy_MKemna_1(1:8,1),FI_Hy_MKemna_1(9:16,1),1,1) 
title('Hybrid Glycoforms_MKemna_1') 
ROC_FI_Hy_MKemna_2=roc_curve(FI_Hy_MKemna_2(1:8,1),FI_Hy_MKemna_2(9:16,1),1,1) 
title('Hybrid Glycoforms_MKemna_2') 
ROC_FI_Hy_1=roc_curve(FI_Hy_1(1:8,1),FI_Hy_1(9:16,1),1,1) 
title('Hybrid Glycoforms_FI_Hy_1') 
ROC_FI_Hy_2=roc_curve(FI_Hy_2(1:8,1),FI_Hy_2(9:16,1),1,1) 
title('Hybrid Glycoforms_FI_Hy_2') 
ROC Curve for Other Glycoforms 
ROC_FI_R_Kemna=roc_curve(FI_R_Kemna(1:8,1),FI_R_Kemna(9:16,1),1,1) 
title('Other Glycoforms_Kemna') 
ROC_FI_R_MKemna_1=roc_curve(FI_R_MKemna_1(1:8,1),FI_R_MKemna_1(9:16,1),1,1) 
title('Other Glycoforms_MKemna_1') 
ROC_FI_R_MKemna_2=roc_curve(FI_R_MKemna_2(1:8,1),FI_R_MKemna_2(9:16,1),1,1) 
title('Other Glycoforms_MKemna_2') 
ROC_FI_R_1=roc_curve(FI_R_1(1:8,1),FI_R_1(9:16,1),1,1) 
title('Other Glycoforms_FI_R_1') 
ROC_FI_R_2=roc_curve(FI_R_2(1:8,1),FI_R_2(9:16,1),1,1) 
title('Other Glycoforms_FI_R_2') 
ROC Curve for Total Glycoforms (Complex/HighMannose/Hybrid/Other) 
ROC_FI_CHMHyR_Kemna=roc_curve(FI_CHMHyR_Kemna(1:8,1),FI_CHMHyR_Kemna(9:16,1),1,1) 
title('Total Glycoforms_Kemna') 
ROC_FI_CHMHyR_MKemna=roc_curve(FI_CHMHyR_MKemna(1:8,1),FI_CHMHyR_MKemna(9:16,1),1,1) 
title('Total Glycoforms_MKemna_1') 
ROC_FI_CHMHyR=roc_curve(FI_CHMHyR(1:8,1),FI_CHMHyR(9:16,1),1,1) 
title('Total Glycoforms_FI_CHMHyR_1') 
C-Galactosylation indices 
Extract Vectors for Galactosylation of Total Glycoforms 
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G0_C=ds.H3N4+ds.H3N4F1+ds.H3N5+ds.H3N5S1+ds.H3E1N4F1+ds.H3N5F1+ds.H3N4S2F2+ds.H3N6+ds.H3N6F
1; 
G1_C=ds.H4N4+ds.H4N4F1+ds.H4N5+ds.H4N5S1+ds.H4N4F2+ds.H4N4A1+ds.H4N4G1+ds.H4N5F1+ds.H4N4S2F
2+ds.H4N6+ds.H4N5F2+ds.H4N5A1+ds.H4N6F1+ds.H4N5F3+ds.H4N5A1F1+ds.H4N6F2+ds.H4N6A1+ds.H4N5A1F2+ds.H4
N6A1F1+ds.H4N7A1; 
G2_C=ds.H5N4+ds.H5N4F1+ds.H5N5+ds.H5N5S1+ds.H5N4F2+ds.H5N4A1+ds.H5N5F1+ds.H5N4F3+ds.H5N5F2+
ds.H5N6F1+ds.H5N4A1F2+ds.H5N4A2+ds.H5N4A1G1+ds.H5N5F3+ds.H5N5A1F1+ds.H5N6F2+ds.H5N5A1F2+ds.H5N6F3
+ds.H5N6A1F1+ds.H5N6F4+ds.H5N6A1F2; 
G3_C=ds.H6N4F2+ds.H6N5F2+ds.H6N5A1+ds.H6N5P1S1F2+ds.H6N5F3+ds.H6N5A1F1+ds.H6N6F2+ds.H6N5F4
+ds.H6N5A1F2+ds.H6N6F3+ds.H6N5A1F3+ds.H6N6F4+ds.H6N6A1F2+ds.H6N7F3+ds.H6N6A1F3+ds.H6N7F4; 
G4_C=ds.H7N6F5; 
G5_C=ds.H8N6A2+ds.H8N8A1; 
G1_Hy=ds.H5N3F1+ds.H5N3F2+ds.H5N3A1+ds.H6N3F1+ds.H5N3A1F1+ds.H6N3F2+ds.H6N3A1+ds.H5N3A2F1; 
G2_Hy=ds.H7N4; 
G0_R=ds.H3N2+ds.H3N2P1+ds.H3N2F1+ds.H3N3+ds.H3N3S1+ds.H3N3P1+ds.H3N3F1; 
G1_R=ds.H4N3ALac1+ds.H4N3+ds.H4N3F1+ds.H4N3F2+ds.H4N3A1+ds.H4N3A1F1+ds.H4N3A1S1F1+ds.H4N3A
2F1+ds.H4N3A2F2; 
Galactosylation of Total Complex Glycans (n=69) 
Calculate Galactosylation Index of Total Complex Glycoforms (Based on Kemna's equation (GI=(0.5*G1)+G2) 
GI_C_Kemna=(0.5*G1_C)+G2_C; 
GI_C_MKemna_1=((0.5*G1_C)+G2_C)./Total_intens; 
GI_C_MKemna_2=((0.5*G1_C)+G2_C)./(G0_C+G1_C+G2_C+G3_C+G4_C+G5_C); 
Calculate Galactosylation Index of Total Complex Glycoforms (Based on equation GI=(1*G1+2*G2)complex/Total 
glycoforms 
GI_C_1=((1*G1_C)+(2*G2_C))./Total_intens; 
GI_C_2=((1*G1_C)+(2*G2_C))./(G0_C+G1_C+G2_C+G3_C+G4_C+G5_C); 
GI_C_3=(G1_C+G2_C+G3_C+G4_C+G5_C)./Total_intens; 
GI_C_4=(G1_C+G2_C+G3_C+G4_C+G5_C)./(G0_C+G1_C+G2_C+G3_C+G4_C+G5_C); 
Plot GI of Total Complex glycoforms 
boxplot(GI_C_Qian_1,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=G0 Complex glycoforms/(G1+2*G2) Complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_Qian_2,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=G0 Complex glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_Qian_3,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=G0 Complex glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_Kemna,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=(0.5*G1+G2) Complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_MKemna_1,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=(0.5*G1+G2) Complex glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_MKemna_2,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=(0.5*G1+G2) Complex glycoforms/Total complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_1,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=(G1+2*G2) Complex glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_2,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=(G1+2*G2) Complex glycoforms/Total complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_3,ds.Group) 
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title({'GI of Complex Glycoforms';'(GI=Total galactosylated complex glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_C_4,ds.Group) 
title({'GI of Complex Glycoforms';'(GI=Total galactosylated complex glycoforms/Total complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Bi-antennary Glycans (n=19) 
Extract Vectors for Galactosylation of Bi-antennary Glycans 
G0_CA2=ds.H3N4+ds.H3N4F1+ds.H3N4S2F2; 
G1_CA2=ds.H4N4+ds.H4N4F1+ds.H4N4F2+ds.H4N4A1+ds.H4N4G1+ds.H4N4S2F2; 
G2_CA2=ds.H5N4+ds.H5N4F1+ds.H5N5+ds.H5N4F2+ds.H5N4A1+ds.H5N4F3+ds.H5N4A1F2+ds.H5N4A2+ds.H5
N4A1G1; 
G3_CA2=ds.H6N4F2; 
Calculate GI of Bi-antennary glycans 
GI_CA2_Qian_1=G0_CA2./(G1_C+(2*G2_C)); 
GI_CA2_Qian_11=G0_CA2./(G1_CA2+(2*G2_CA2)); 
GI_CA2_Qian_2=G0_CA2./((G1_C+G1_Hy+G1_R)+(2*(G2_C+G2_Hy))); 
GI_CA2_Qian_3=G0_CA2./Total_intens; 
GI_CA2_Kemna=(0.5*G1_CA2)+G2_CA2; 
GI_CA2_MKemna_1=((0.5*G1_CA2)+G2_CA2)./Total_intens; 
GI_CA2_MKemna_2=((0.5*G1_CA2)+G2_CA2)./(G0_CA2+G1_CA2+G2_CA2+G3_CA2); 
GI_CA2_1=((1*G1_CA2)+(2*G2_CA2))./Total_intens; 
GI_CA2_2=((1*G1_CA2)+(2*G2_CA2))./(G0_CA2+G1_CA2+G2_CA2+G3_CA2); 
GI_CA2_3=(G1_CA2+G2_CA2+G3_CA2)./Total_intens; 
GI_CA2_4=(G1_CA2+G2_CA2+G3_CA2)./(G0_CA2+G1_CA2+G2_CA2+G3_CA2); 
Plot GI index of Bi-antennary glycans 
boxplot(GI_CA2_Qian_1,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=G0 Bi-antennary glycoforms/(G1+2*G2) Complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_Qian_11,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=G0 Bi-antennary glycoforms/(G1+2*G2) Bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_Qian_2,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=G0 Bi-antennary glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_Qian_3,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(G0 Bi-antennary glycoforms+/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_Kemna,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(0.5*G1+G2) Bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_MKemna_1,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(0.5*G1+G2) Bi-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_MKemna_2,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(0.5*G1+G2) Bi-antennary glycoforms/Total bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_1,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(G1+2*G2) Bi-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_2,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=(G1+2*G2) Bi-antennary glycoforms/Total bi-antennary glycoforms)'}) 
xlabel('Samples') 
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ylabel('Galactosylation index') 
boxplot(GI_CA2_3,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=Total galactosylated Bi-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA2_4,ds.Group) 
title({'GI of Bi-antennary Glycoforms';'(GI=Total galactosylated Bi-antennary glycoforms/Total bi-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Tri-antennary Glycans (n=31) 
Extract Vectors for Galactosylation of Tri-antennary glycans  
G0_CA3=ds.H3N5+ds.H3N5S1+ds.H3E1N4F1+ds.H3N5F1; 
G1_CA3=ds.H4N5+ds.H4N5S1+ds.H4N5F1+ds.H4N5F2+ds.H4N5A1+ds.H4N5F3+ds.H4N5A1F1+ds.H4N5A1F2; 
G2_CA3=ds.H5N5S1+ds.H5N5F1+ds.H5N5F2+ds.H5N5F3+ds.H5N5A1F1+ds.H5N5A1F2+ds.H5N6F4+ds.H5N6A1
F2; 
G3_CA3=ds.H6N5F2+ds.H6N5A1+ds.H6N5P1S1F2+ds.H6N5F3+ds.H6N5A1F1+ds.H6N5F4+ds.H6N5A1F2+ds.H6
N5A1F3+ds.H6N6F4+ds.H6N6A1F2+ds.H6N6A1F3; 
Calculate GI of Tri-antennary glycans 
GI_CA3_Qian_1=G0_CA3./(G1_C+(2*G2_C)); 
GI_CA3_Qian_11=G0_CA3./(G1_CA3+(2*G2_CA3)); 
GI_CA3_Qian_2=G0_CA3./((G1_C+G1_Hy+G1_R)+(2*(G2_C+G2_Hy))); 
GI_CA3_Qian_3=G0_CA3./Total_intens; 
GI_CA3_Kemna=(0.5*G1_CA3)+G2_CA3; 
GI_CA3_MKemna_1=((0.5*G1_CA3)+G2_CA3)./Total_intens; 
GI_CA3_MKemna_2=((0.5*G1_CA3)+G2_CA3)./(G0_CA3+G1_CA3+G2_CA3+G3_CA3); 
GI_CA3_1=((1*G1_CA3)+(2*G2_CA3))./Total_intens; 
GI_CA3_2=((1*G1_CA3)+(2*G2_CA3))./(G0_CA3+G1_CA3+G2_CA3+G3_CA3); 
GI_CA3_3=(G1_CA3+G2_CA3+G3_CA3)./Total_intens; 
GI_CA3_4=(G1_CA3+G2_CA3+G3_CA3)./(G0_CA3+G1_CA3+G2_CA3+G3_CA3); 
Plot GI of Tri-antennary glycans 
boxplot(GI_CA3_Qian_1,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=G0 Ti-antennary glycoforms/(G1+2*G2) Complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_Qian_11,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=G0 Tri-antennary glycoforms/(G1+2*G2) Tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_Qian_2,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=G0 Tri-antennary glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_Qian_3,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=G0 Tri-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_Kemna,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=(0.5*G1+G2) Tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_MKemna_1,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=(0.5*G1+G2) Tri-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_MKemna_2,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=(0.5*G1+G2) Tri-antennary glycoforms/Total tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_1,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=(G1+2*G2) Tri-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
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ylabel('Galactosylation index') 
boxplot(GI_CA3_2,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=(G1+2*G2) Tri-antennary glycoforms/Total tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_3,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=Total galactosylated Tri-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA3_4,ds.Group) 
title({'GI of Tri-antennary Glycoforms';'(GI=Total galactosylated Tri-antennary glycoforms/Total tri-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Tetra-antennary Glycans (n=18) 
Extract Vectors For Galactosylation of Tetra-antennary glycans 
G0_CA4=ds.H3N6+ds.H3N6F1; 
G1_CA4=ds.H4N6+ds.H4N6F1+ds.H4N6F2+ds.H4N6A1+ds.H4N6A1F1+ds.H4N7A1; 
G2_CA4=ds.H5N6F1+ds.H5N6F2+ds.H5N6F3+ds.H5N6A1F1; 
G3_CA4=ds.H6N6F2+ds.H6N6F3+ds.H6N7F3+ds.H6N7F4; 
G4_CA4=ds.H7N6F5; 
G5_CA4=ds.H8N6A2+ds.H8N8A1; 
Calculate GI of Tetra-antennary glycans 
GI_CA4_Qian_1=G0_CA4./(G1_C+(2*G2_C)); 
GI_CA4_Qian_11=G0_CA4./(G1_CA4+(2*G2_CA4)); 
GI_CA4_Qian_2=G0_CA4./((G1_C+G1_Hy+G1_R)+(2*(G2_C+G2_Hy))); 
GI_CA4_Qian_3=G0_CA4./Total_intens; 
GI_CA4_Kemna=(0.5*G1_CA4)+G2_CA4; 
GI_CA4_MKemna_1=((0.5*G1_CA4)+G2_CA4)./Total_intens; 
GI_CA4_MKemna_2=((0.5*G1_CA4)+G2_CA4)./(G0_CA4+G1_CA4+G2_CA4+G3_CA4+G4_CA4+G5_CA4); 
GI_CA4_1=((1*G1_CA4)+(2*G2_CA4))./Total_intens; 
GI_CA4_2=((1*G1_CA4)+(2*G2_CA4))./(G0_CA4+G1_CA4+G2_CA4+G3_CA4+G4_CA4+G5_CA4); 
GI_CA4_3=(G1_CA4+G2_CA4+G3_CA4+G4_CA4+G5_CA4)./Total_intens; 
GI_CA4_4=(G1_CA4+G2_CA4+G3_CA4+G4_CA4+G5_CA4)./(G0_CA4+G1_CA4+G2_CA4+G3_CA4+G4_CA4+
G5_CA4); 
Plot GI of Tetra-antennary glycans 
boxplot(GI_CA4_Qian_1,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=G0 Tetra-antennary glycoforms/(G1+2*G2) Complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_Qian_11,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=G0 Tetra-antennary glycoforms/(G1+2*G2) Tetra-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_Qian_2,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=G0 Tetra-antennary glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_Qian_3,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=G0 Tetra-antennary glycoforms+/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_Kemna,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=(0.5*G1+G2) Tetra-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_MKemna_1,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=(0.5*G1+G2) Tetra-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_MKemna_2,ds.Group) 
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title({'GI of Tetra-antennary Glycoforms';'(GI=(0.5*G1+G2) Tetra-antennary glycoforms/Total tetra-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_1,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=(G1+2*G2) Tetra-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_2,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=(G1+2*G2) Tetra-antennary glycoforms/Total tetra-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_3,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=Total galactosylated Tetra-antennary glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CA4_4,ds.Group) 
title({'GI of Tetra-antennary Glycoforms';'(GI=Total galactosylated Tetra-antennary glycoforms/Total bi-antennary 
glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Hybrid (n=9) 
Extract Vectors of Hybrid  
G1_Hy and G2_Hy were extracted previously. However, there is no G0_Hy. There for Qian's equation can not be used. 
Calculate GI of Hybrid glycoforms  
GI_Hy_Kemna=(0.5*G1_Hy)+G2_Hy; 
GI_Hy_MKemna_1=((0.5*G1_Hy)+G2_Hy)./Total_intens; 
GI_Hy_MKemna_2=((0.5*G1_Hy)+G2_Hy)./(G1_Hy+G2_Hy); 
GI_Hy_1=((1*G1_Hy)+(2*G2_Hy))./Total_intens; 
GI_Hy_2=((1*G1_Hy)+(2*G2_Hy))./(G1_Hy+G2_Hy); 
GI_Hy_3=(G1_Hy+G2_Hy)./Total_intens; 
Plot GI of Hybrid glycforms 
boxplot(GI_Hy_Kemna,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=(0.5*G1+G2) Hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_Hy_MKemna_1,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=(0.5*G1+G2) Hybrid glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_Hy_MKemna_2,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=(0.5*G1+G2) Hybrid glycoforms/Total hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_Hy_1,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=(G1+2*G2) Hybrid glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_Hy_2,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=(G1+2*G2) Hybrid glycoforms/Total hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_Hy_3,ds.Group) 
title({'GI of Hybrid Glycoforms';'(GI=Total galactosylated Hybrid glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Other (n=16) 
Calculate GI Other glycoforms  
GI_R_Qian_1=G0_R./(G1_R); 
GI_R_Qian_2=G0_R./((G1_C+G1_Hy+G1_R)+(2*(G2_C+G2_Hy))); 
GI_R_Qian_3=G0_R./Total_intens; 
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GI_R_Kemna=(0.5*G1_R); 
GI_R_MKemna_1=(0.5*G1_R)./Total_intens; 
GI_R_MKemna_2=(0.5*G1_R)./(G0_R+G1_R); 
GI_R_1=(G1_R)./Total_intens; 
GI_R_2=(G1_R)./(G0_R+G1_R); 
Plot GI of Other glycoforms 
boxplot(GI_R_Qian_1,ds.Group) 
title({'GI of Other Glycoforms';'(GI=G0 Other glycoforms/(G1) other glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_Qian_2,ds.Group) 
title({'GI of Other Glycoforms';'(GI=G0 Other glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_Qian_3,ds.Group) 
title({'GI of Other Glycoforms';'(GI=G0 Other glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_Kemna,ds.Group) 
title({'GI of Other Glycoforms';'(GI=(0.5*G1) Other glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_MKemna_1,ds.Group) 
title({'GI of Other Glycoforms';'(GI=(0.5*G1) Other glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_MKemna_2,ds.Group) 
title({'GI of Other Glycoforms';'(GI=(0.5*G1) Other glycoforms/Total other glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_1,ds.Group) 
title({'GI of Other Glycoforms';'(GI=Total galactosylated other glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_R_2,ds.Group) 
title({'GI of Other Glycoforms';'(GI=Total galactosylated other glycoforms/Total other glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
Galactosylation of Complex, Hybrid, and Other (n=94) 
Extract Vectors of Complex, Hybrid, and Other 
G0_CHyR=G0_C+G0_R; 
G1_CHyR=G1_C+G1_Hy+G1_R; 
G2_CHyR=G2_C+G2_Hy; 
Calculate GI of Complex, Hybrid, and Other  
GI_CHyR_Qian_1=G0_CHyR./(G1_CHyR+(2*G2_CHyR)); 
GI_CHyR_Qian_2=G0_CHyR./Total_intens; 
GI_CHyR_Kemna=(0.5*G1_CHyR)+G2_CHyR; 
GI_CHyR_MKemna_1=((0.5*G1_CHyR)+G2_CHyR)./Total_intens; 
GI_CHyR_MKemna_2=((0.5*G1_CHyR)+G2_CHyR)./(G0_CHyR+G1_CHyR+G2_CHyR+G3_C+G4_C+G5_C); 
GI_CHyR_1=((1*G1_CHyR)+(2*G2_CHyR))./Total_intens; 
GI_CHyR_2=((1*G1_CHyR)+(2*G2_CHyR))./(G0_CHyR+G1_CHyR+G2_CHyR+G3_C+G4_C+G5_C); 
GI_CHyR_3=(G1_CHyR+G2_CHyR+G3_C+G4_C+G5_C)./Total_intens; 
GI_CHyR_4=(G1_CHyR+G2_CHyR+G3_C+G4_C+G5_C)./(G0_CHyR+G1_C+G2_C+G3_C+G4_C+G5_C); 
Plot GI of Complex, Hybrid, and Other 
boxplot(GI_CHyR_Qian_1,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=G0 CHyR glycoforms/(G1+2*G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_Qian_2,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=G0 CHyR glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
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boxplot(GI_CHyR_Kemna,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=(0.5*G1+G2) CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_MKemna_1,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=(0.5*G1+G2) CHyR glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_MKemna_2,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=(0.5*G1+G2) CHyR glycoforms/Total CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_1,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=(G1+2*G2) CHyR glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_2,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=(G1+2*G2) CHyR glycoforms/Total CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_3,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=Total galactosylated CHyR glycoforms/Total glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
boxplot(GI_CHyR_4,ds.Group) 
title({'GI of CHyR Glycoforms';'(GI=Total galactosylated CHyR glycoforms/Total CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Galactosylation index') 
ROC Curve Analysis of GI 
Note: the following ROC curve analysis is performed on specific equations. 
ROC Curve for Total Complex Glycoforms 
ROC_GI_C_Kemna=roc_curve(GI_C_Kemna(1:8,1),GI_C_Kemna(9:16,1),1,1) 
title('Total Complex Glycoforms_Kemna') 
ROC_GI_C_MKemna_1=roc_curve(GI_C_MKemna_1(1:8,1),GI_C_MKemna_1(9:16,1),1,1) 
title('Total Complex Glycoforms_MKemna_1') 
ROC_GI_C_MKemna_2=roc_curve(GI_C_MKemna_2(1:8,1),GI_C_MKemna_2(9:16,1),1,1) 
title('Total Complex Glycoforms_MKemna_2') 
ROC_GI_C_1=roc_curve(GI_C_1(1:8,1),GI_C_1(9:16,1),1,1) 
title('Total Complex Glycoforms_C_1') 
ROC_GI_C_3=roc_curve(GI_C_3(1:8,1),GI_C_3(9:16,1),1,1) 
title('Total Complex Glycoforms_C_3') 
ROC Curve for Bi-antennary Glycoforms 
ROC_GI_CA2_Kemna=roc_curve(GI_CA2_Kemna(1:8,1),GI_CA2_Kemna(9:16,1),1,1) 
title('Bi-antennary Glycoforms_Kemna') 
ROC_GI_CA2_MKemna_1=roc_curve(GI_CA2_MKemna_1(1:8,1),GI_CA2_MKemna_1(9:16,1),1,1) 
title('Bi-antennary Glycoforms_MKemna_1') 
ROC_GI_CA2_MKemna_2=roc_curve(GI_CA2_MKemna_2(1:8,1),GI_CA2_MKemna_2(9:16,1),1,1) 
title('Bi-antennary Glycoforms_MKemna_2') 
ROC_GI_CA2_1=roc_curve(GI_CA2_1(1:8,1),GI_CA2_1(9:16,1),1,1) 
title('Bi-antennary Glycoforms_GI_CA2_1') 
ROC_GI_CA2_3=roc_curve(GI_CA2_3(1:8,1),GI_CA2_3(9:16,1),1,1) 
title('Bi-antennary Glycoforms_GI_CA2_3') 
ROC Curve for Tri-antennary Glycoforms 
ROC_GI_CA3_Kemna=roc_curve(GI_CA3_Kemna(1:8,1),GI_CA3_Kemna(9:16,1),1,1) 
title('Tri-antennary Glycoforms_Kemna') 
ROC_GI_CA3_MKemna_1=roc_curve(GI_CA3_MKemna_1(1:8,1),GI_CA3_MKemna_1(9:16,1),1,1) 
title('Tri-antennary Glycoforms_MKemna_1') 
ROC_GI_CA3_MKemna_2=roc_curve(GI_CA3_MKemna_2(1:8,1),GI_CA3_MKemna_2(9:16,1),1,1) 
title('Tri-antennary Glycoforms_MKemna_2') 
ROC_GI_CA3_1=roc_curve(GI_CA3_1(1:8,1),GI_CA3_1(9:16,1),1,1) 
title('Tri-antennary Glycoforms_GI_CA3_1') 
ROC_GI_CA3_3=roc_curve(GI_CA3_3(1:8,1),GI_CA3_3(9:16,1),1,1) 
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title('Tri-antennary Glycoforms_GI_CA3_3') 
ROC Curve for Tetra-antennary Glycoforms 
ROC_GI_CA4_Kemna=roc_curve(GI_CA4_Kemna(1:8,1),GI_CA4_Kemna(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_Kemna') 
ROC_GI_CA4_MKemna_1=roc_curve(GI_CA4_MKemna_1(1:8,1),GI_CA4_MKemna_1(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_MKemna_1') 
ROC_GI_CA4_MKemna_2=roc_curve(GI_CA4_MKemna_2(1:8,1),GI_CA4_MKemna_2(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_MKemna_2') 
ROC_GI_CA4_1=roc_curve(GI_CA4_1(1:8,1),GI_CA4_1(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_GI_CA4_1') 
ROC_GI_CA4_3=roc_curve(GI_CA4_3(1:8,1),GI_CA4_3(9:16,1),1,1) 
title('Tetra-antennary Glycoforms_GI_CA4_3') 
ROC Curve for Hybrid Glycoforms 
ROC_GI_Hy_Kemna=roc_curve(GI_Hy_Kemna(1:8,1),GI_Hy_Kemna(9:16,1),1,1) 
title('Hybrid Glycoforms_Kemna') 
ROC_GI_Hy_MKemna_1=roc_curve(GI_Hy_MKemna_1(1:8,1),GI_Hy_MKemna_1(9:16,1),1,1) 
title('Hybrid Glycoforms_MKemna_1') 
ROC_GI_Hy_MKemna_2=roc_curve(GI_Hy_MKemna_2(1:8,1),GI_Hy_MKemna_2(9:16,1),1,1) 
title('Hybrid Glycoforms_MKemna_2') 
ROC_GI_Hy_1=roc_curve(GI_Hy_1(1:8,1),GI_Hy_1(9:16,1),1,1) 
title('Hybrid Glycoforms_GI_Hy_1') 
ROC_GI_Hy_3=roc_curve(GI_Hy_3(1:8,1),GI_Hy_3(9:16,1),1,1) 
title('Hybrid Glycoforms_GI_Hy_3') 
ROC Curve for Other Glycoforms 
ROC_GI_R_Kemna=roc_curve(GI_R_Kemna(1:8,1),GI_R_Kemna(9:16,1),1,1) 
title('Other Glycoforms_Kemna') 
ROC_GI_R_MKemna_1=roc_curve(GI_R_MKemna_1(1:8,1),GI_R_MKemna_1(9:16,1),1,1) 
title('Other Glycoforms_MKemna_1') 
ROC_GI_R_MKemna_2=roc_curve(GI_R_MKemna_2(1:8,1),GI_R_MKemna_2(9:16,1),1,1) 
title('Other Glycoforms_MKemna_2') 
ROC_GI_R_1=roc_curve(GI_R_1(1:8,1),GI_R_1(9:16,1),1,1) 
title('Other Glycoforms_GI_R_1') 
ROC_GI_R_2=roc_curve(GI_R_2(1:8,1),GI_R_2(9:16,1),1,1) 
title('Other Glycoforms_GI_R_2') 
ROC Curve for Total Glycoforms (Complex/Hybrid/Other) 
ROC_GI_CHyR_Kemna=roc_curve(GI_CHyR_Kemna(1:8,1),GI_CHyR_Kemna(9:16,1),1,1) 
title('Total Glycoforms_Kemna') 
ROC_GI_CHyR_MKemna_1=roc_curve(GI_CHyR_MKemna_1(1:8,1),GI_CHyR_MKemna_1(9:16,1),1,1) 
title('Total Glycoforms_MKemna_1') 
ROC_GI_CHyR_MKemna_2=roc_curve(GI_CHyR_MKemna_2(1:8,1),GI_CHyR_MKemna_2(9:16,1),1,1) 
title('Total Glycoforms_MKemna_2') 
ROC_GI_CHyR_1=roc_curve(GI_CHyR_1(1:8,1),GI_CHyR_1(9:16,1),1,1) 
title('Total Glycoforms_GI_CHyR_1') 
ROC_GI_CHyR_3=roc_curve(GI_CHyR_3(1:8,1),GI_CHyR_3(9:16,1),1,1) 
title('Total Glycoforms_GI_CHyR_3') 
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C-Sialylation indices 
Extract Vectors for Sialylation Index Calculation 
A0_CA2=ds.H3N4+ds.H3N4F1+ds.H4N4+ds.H4N4F1+ds.H5N4+ds.H3N4S2F2+ds.H4N4F2+ds.H5N4F1+ds.H4N4G
1+ds.H5N5+ds.H4N4S2F2+ds.H5N4F2+ds.H5N4F3+ds.H6N4F2; 
A1_CA2=ds.H4N4A1+ds.H5N4A1+ds.H5N4A1F2+ds.H5N4A1G1; 
A2_CA2=ds.H5N4A2; 
A0_CA3=ds.H3N5+ds.H3N5S1+ds.H3E1N4F1+ds.H3N5F1+ds.H4N5+ds.H4N5S1+ds.H4N5F1+ds.H5N5S1+ds.H4N
5F2+ds.H5N5F1+ds.H4N5F3+ds.H5N5F2+ds.H5N5F3+ds.H6N5F2+ds.H6N5P1S1F2+ds.H6N5F3+ds.H6N5F4+ds.H5N6F4+ds
.H6N6F; 
A1_CA3=ds.H4N5A1+ds.H4N5A1F1+ds.H4N5A1F2+ds.H5N5A1F1+ds.H6N5A1+ds.H5N5A1F2+ds.H6N5A1F1+ds
.H6N5A1F2+ds.H5N6A1F2+ds.H6N5A1F3+ds.H6N6A1F2+ds.H6N6A1F3; 
A0_CA4=ds.H3N6+ds.H3N6F1+ds.H4N6+ds.H4N6F1+ds.H4N6F2+ds.H5N6F1+ds.H5N6F2+ds.H5N6F3+ds.H6N6F
2+ds.H6N6F3+ds.H6N7F3+ds.H6N7F4+ds.H7N6F5; 
A1_CA4=ds.H8N8A1+ds.H4N6A1+ds.H4N6A1F1+ds.H4N7A1+ds.H5N6A1F1; 
A2_CA4=ds.H8N6A2; 
A0_C=A0_CA2+A0_CA3+A0_CA4; 
A1_C=A1_CA2+A1_CA3+A1_CA4; 
A2_C=A2_CA2+A2_CA4; 
A0_Hy=ds.H5N3F1+ds.H5N3F2+ds.H6N3F1+ds.H6N3F2+ds.H7N4; 
A1_Hy=ds.H5N3A1+ds.H5N3A1F1+ds.H6N3A1; 
A2_Hy=ds.H5N3A2F1; 
A0_R=ds.H3N2+ds.H3N2P1+ds.H3N2F1+ds.H3N3+ds.H3N3S1+ds.H3N3P1+ds.H3N3F1+ds.H4N3+ds.H4N3F1+ds.
H4N3ALac1+ds.H4N3F2; 
A1_R=ds.H4N3A1+ds.H4N3A1F1+ds.H4N3A1S1F1; 
A2_R=ds.H4N3A2F1+ds.H4N3A2F2; 
A0_CHyR=A0_C+A0_Hy+A0_R; 
A1_CHyR=A1_C+A1_Hy+A1_R; 
A2_CHyR=A2_C+A2_Hy+A2_R; 
Sialylation indices for Complex Glycans (n=69) 
Calculate Sialylation Index based on (SI=0.5*A1+A2)  
SI_C=(0.5*A1_C)+A2_C; 
SI_CA2=(0.5*A1_CA2)+A2_CA2; 
SI_CA3=(0.5*A1_CA3); 
SI_CA4=(0.5*A1_CA4)+A2_CA4; 
Plot Sialylation Indices (SI of total complex glycoforms (n=69)) 
boxplot(SI_C,ds.Group) 
title({'SI of Complex Glycoforms';'(SI=(0.5*A1)+A2 complex glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
Plote Sialylation Indexes (SI of biantinnary glycoforms (n=19)) 
boxplot(SI_CA2,ds.Group) 
title({'SI of Bi-antennary Glycoforms';'(SI=(0.5*A1)+A2 bi-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
Plote Sialylation Indices (SI of Triantinnary glycoforms (n=31)) 
boxplot(SI_CA3,ds.Group) 
title({'SI of Tri-antennary Glycoforms';'(SI=(0.5*A1)+A2 tri-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
Plote Sialylation Indices (SI of Tetra-antinnary glycoforms (n=18)) 
boxplot(SI_CA4,ds.Group) 
title({'SI of Tetra-antennary Glycoforms';'(SI=(0.5*A1)+A2 tetra-antennary glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
Sialylation of Total Hybrid Glycoforms (n=9) 
Calculate SI of Hybrid  
SI_Hy=(0.5*A1_Hy)+A2_Hy; 
Plot SI of Hybrid 
boxplot(SI_Hy,ds.Group) 
title({'SI of Total Hybrid Glycoforms';'(SI=(0.5*A1)+A2 hybrid glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
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Sialylation of Total Other Glycoforms (n=16) 
Calculate SI of Other Glycoforms 
SI_R=(0.5*A1_R)+A2_R; 
Plot SI of Other Glycoforms 
boxplot(SI_R,ds.Group) 
title({'SI of Total Other Glycoforms';'(SI=(0.5*A1)+A2 other glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
Sialylation of Total glycoforms (Complex, Hybrid, and Other (n=94) 
Calculate SI of Complex, High mannose, Hybrid, and Other  
SI_CHyR=(0.5*A1_CHyR)+A2_CHyR; 
SI_CHy=(0.5*(A1_C+A1_Hy))+A2_C+A2_Hy; 
Plot SI of Complex, Hybrid, and Other 
boxplot(SI_CHyR,ds.Group) 
title({'SI of Total Glycoforms';'(SI=(0.5*A1)+A2 CHyR glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
boxplot(SI_CHy,ds.Group) 
title({'SI of Total Glycoforms';'(SI=(0.5*A1)+A2 CHy glycoforms)'}) 
xlabel('Samples') 
ylabel('Sialylation index') 
ROC Curve Analysis of SI 
Note: the following ROC curve analysis is performed on specific equations. 
ROC Curve for Glycoforms based on equation (SI=0.5*A1+A2) 
ROC_SI_C=roc_curve(SI_C(1:8,1),SI_C(9:16,1),1,1) 
title('Total Complex Glycoforms') 
ROC_SI_CA2=roc_curve(SI_CA2(1:8,1),SI_CA2(9:16,1),1,1) 
title('Bi-antennary Complex Glycoforms') 
ROC_SI_CA3=roc_curve(SI_CA3(1:8,1),SI_CA3(9:16,1),1,1) 
title('Tri-antennary Complex Glycoforms') 
ROC_SI_CA4=roc_curve(SI_CA4(1:8,1),SI_CA4(9:16,1),1,1) 
title('Tetra-antennary Complex Glycoforms') 
ROC_SI_Hy=roc_curve(SI_Hy(1:8,1),SI_Hy(9:16,1),1,1) 
title('Hybrid Glycoforms') 
ROC_SI_R=roc_curve(SI_R(1:8,1),SI_R(9:16,1),1,1) 
title('Other Glycoforms') 
ROC_SI_CHyR=roc_curve(SI_CHyR(1:8,1),SI_CHyR(9:16,1),1,1) 
title('Total Glycoforms') 
ROC_SI_CHy=roc_curve(SI_CHy(1:8,1),SI_CHy(9:16,1),1,1) 
title('Complex and Hybrid Glycoforms') 
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Appendix B.4 SDS-PAGE Profile of soluble proteins that were extracted from the FC 
region of AD and healthy age-matched brains.  
 
SDS-PAGE elucidation of FC protein profile is ranged from 10 to 180 kDa after ultrafiltration (the filter nominal mass cutoff is 10 
kDa). The SDS concentration was 12%, and the gel was dyed with Coomassie brilliant blue.  
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 Appendix B.5 Putative N-glycoforms of FC N-glycome that was derived from AD and 
healthy brains.  
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
1 1171.7307 1171.5831 -0.1476 Hex3HexNAc2 Na Y Y Y 
 
2 1266.3833 1265.5650 -0.8183 Hex3HexNAc2P1 Na Y Y N 
 
3 1345.7540 1345.6723 -0.0817 Hex3HexNAc2dHex1 Na Y Y Y 
 
4 1375.7464 1375.6828 -0.0636 Hex4HexNAc2 Na Y Y Y 
 
5 1416.7676 1416.7094 -0.0582 Hex3HexNAc3 Na Y Y Y 
 
6 1481.7422 1482.6505 0.9083 Hex3HexNAc3S1 Na Y Y Y 
 
7 1511.7614 1510.6914 -1.0700 Hex3HexNAc3P1 Na N Y Y 
 
8 1551.7469 1549.7720 -1.9749 Hex4HexNAc2dHex1 Na Y Y N 
 
9 1579.7661 1579.7826 0.0165 Hex5HexNAc2 Na Y Y Y 
 
10 1590.8100 1590.7986 -0.0114 Hex3HexNAc3dHex1 Na Y Y Y 
 
11 1620.8759 1620.8091 -0.0668 Hex4HexNAc3 Na Y Y Y 
 
12 1661.8082 1661.8357 0.0275 Hex3HexNAc4 Na Y Y Y 
 
13 1753.8704 1753.8718 0.0014 Hex5HexNAc2dHex1 Na Y Y Y 
 
14 1783.8370 1783.8824 0.0454 Hex6HexNAc2 Na Y Y Y 
 
15 1794.8538 1794.8984 0.0446 Hex4HexNAc3dHex1 Na Y Y Y 
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Continued  
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
16 1835.8937 1835.9249 0.0312 Hex3HexNAc4dHex1 Na Y Y Y 
 
17 1865.9961 1865.9355 -0.0606 Hex4HexNAc4 Na Y Y Y 
 
18 1890.1640 1888.8803 -1.2837 Hex4HexNAc3P1dHex1 Na N N N 
 
19 1907.0347 1906.9620 -0.0727 Hex3HexNAc5 Na Y Y Y 
 
20 1934.5085 1935.9410 1.4325 Hex4HexNAc3Neu5AcLac1 Na N Y N 
 
21 1968.9515 1968.9876 0.0361 Hex4HexNAc3dHex2 Na Y Y Y 
 
22 1973.9504 1972.9032 -1.0472 Hex3HexNAc5S1 Na Y Y Y 
 
23 1981.9580 1981.9828 0.0248 Hex4HexNAc3Neu5Ac1 Na Y Y N 
 
24 1988.0247 1987.9821 -0.0426 Hex7HexNAc2 Na Y Y Y 
 
25 1998.9134 1998.9981 0.0847 Hex5HexNAc3dHex1 Na Y Y Y 
 
26 2012.2204 2011.9934 -0.2270 Hex4HexNAc3Neu5Gc1 Na Y N N 
 
27 2040.0651 2040.0247 -0.0404 Hex4HexNAc4dHex1 Na Y Y Y 
 
28 2053.0411 2053.0563 0.0152 Hex3HexN1HexNAc4dHex1 Na N Y Y 
 
29 2070.0084 2070.0352 0.0268 Hex5HexNAc4 Na Y Y Y  
30 2081.0757 2081.0512 -0.0245 Hex3HexNAc5dHex1 Na Y Y Y 
 
31 2111.2424 2111.0618 -0.1806 Hex4HexNAc5 Na Y Y Y 
 
32 2141.7501 2141.8964 0.1463 Hex3HexNAc4S2dHex2 Na N Y N 
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Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
33 2151.1645 2152.0883 0.9238 Hex3HexNAc6 Na Y Y N 
 
34 2156.1008 2156.0720 -0.0288 Hex4HexNAc3Neu5Ac1dHex1 Na Y Y N 
 
35 2173.0388 2173.0873 0.0485 Hex5HexNAc3dHex2 Na Y Y N 
 
36 2178.1002 2177.0030 -1.0972 Hex4HexNAc5S1 Na Y Y N 
 
37 2186.2335 2186.0826 -0.1509 Hex5HexNAc3Neu5Ac1 Na Y Y N 
 
38 2192.1708 2192.0819 -0.0889 Hex8HexNAc2 Na Y Y Y 
 
39 2203.0787 2203.0979 0.0192 Hex6HexNAc3dHex1 Na Y Y N 
 
40 2214.2282 2214.1139 -0.1143 Hex4HexNAc4dHex2 Na Y Y Y 
 
41 2222.1854 2222.0132 -0.1722 Hex4HexNAc3Neu5Ac1S1dHex1 Na Y Y N 
 
42 2227.1167 2227.1091 -0.0076 Hex4HexNAc4Neu5Ac1 Na Y Y N 
 
43 2244.2866 2244.1245 -0.1621 Hex5HexNAc4dHex1 Na Y Y Y 
 
44 2257.3351 2257.1197 -0.2154 Hex4HexNAc4Neu5Gc1 Na Y Y Y 
 
45 2285.2323 2285.1510 -0.0813 Hex4HexNAc5dHex1 Na Y Y Y 
 
46 2315.2925 2315.1616 -0.1309 Hex5HexNAc5 Na Y Y Y 
 
47 2326.2450 2326.1776 -0.0674 Hex3HexNAc6dHex1 Na Y Y Y 
 
48 2346.2122 2345.9962 -0.2160 Hex4HexNAc4S2dHex2 Na N Y Y 
 
49 2349.8069 2350.0353 0.2284 Hex7HexNAc2P2dHex1 Na N N N 
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Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
50 2356.2857 2356.1881 -0.0976 Hex4HexNAc6 Na Y Y Y 
 
51 2360.2536 2360.1718 -0.0818 Hex5HexNAc3Neu5Ac1dHex1 Na Y Y N 
 
52 2368.9771 2368.1170 -0.8601 Hex6HexNAc4P1 Na N N N 
 
53 2377.1166 2377.1871 0.0705 Hex6HexNAc3dHex2 Na Y Y N 
 
54 2382.2339 2381.1027 -1.1312 Hex5HexNAc5S1 Na N Y Y 
 
55 2390.1164 2390.1824 0.0660 Hex6HexNAc3Neu5Ac1 Na Y Y N 
 
56 2396.3995 2396.1817 -0.2178 Hex9HexNAc2 Na Y Y Y 
 
57 2418.2673 2418.2137 -0.0536 Hex5HexNAc4dHex2 Na Y Y Y 
 
58 2431.3654 2431.2089 -0.1565 Hex5HexNAc4Neu5Ac1 Na Y Y N 
 
59 2459.4446 2459.2402 -0.2044 Hex4HexNAc5dHex2 Na Y Y Y 
 
60 2472.2787 2472.2355 -0.0432 Hex4HexNAc5Neu5Ac1 Na Y Y N 
 
61 2478.2859 2478.2348 -0.0511 Hex7HexNAc4 Na Y Y Y 
 
62 2489.4150 2489.2508 -0.1642 Hex5HexNAc5dHex1 Na Y Y Y 
 
63 2500.6565 2500.2668 -0.3897 Hex3HexNAc6dHex2 Na Y N N 
 
64 2503.1226 2503.1255 0.0029 Hex5HexNAc5P2 Na N N N 
 
65 2516.6330 2517.2457 0.6127 Hex4HexNAc3Neu5Ac2dHex1 Na Y Y Y 
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Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
66 2530.5613 2530.2773 -0.2840 Hex4HexNAc6dHex1 Na Y Y Y 
 
67 2542.5868 2542.2409 -0.3459 
Hex4HexNAc4Neu5Ac1Neu5AcL
ac1 
Na N N N 
 
68 2559.9513 2560.2879 0.3366 Hex5HexNAc6 Na Y N N 
 
69 2565.4650 2564.2716 -1.1934 Hex6HexNAc3Neu5Ac1dHex1 Na Y N N 
 
70 2584.6240 2584.1457 -0.4783 Hex9HexNAc2P2 Na Y Y Y 
 
71 2592.5640 2592.3029 -0.2611 Hex5HexNAc4dHex3 Na Y Y Y 
 
72 2600.3365 2600.2815 -0.0550 Hex10HexNAc2 Na Y Y N 
 
73 2605.2620 2605.2981 0.0361 Hex5HexNAc4Neu5Ac1dHex1 Na Y N N 
 
74 2622.5062 2622.3134 -0.1928 Hex6HexNAc4dHex2 Na Y Y Y 
 
75 2633.1332 2633.3294 0.1962 Hex4HexNAc5dHex3 Na Y Y N 
 
76 2635.0550 2635.3087 0.2537 Hex6HexNAc4Neu5Ac1 Na Y N N 
 
77 2646.5020 2646.3247 -0.1773 Hex4HexNAc5Neu5Ac1dHex1 Na Y Y N 
 
78 2663.3413 2663.3400 -0.0013 Hex5HexNAc5dHex2 Na Y Y Y 
 
79 2673.9935 2674.3560 0.3625 Hex3HexNAc6dHex3 Na Y N N 
 
80 2690.3603 2691.3349 0.9746 Hex4HexNAc3Neu5Ac2dHex2 Na Y Y N 
 
 
236 
Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
81 2704.4218 2704.3665 -0.0553 Hex4HexNAc6dHex2 Na Y Y Y 
 
82 2717.1943 2717.3618 0.1675 Hex4HexNAc6Neu5Ac1 Na Y Y N 
 
83 2721.4449 2721.3455 -0.0994 Hex5HexNAc3Neu5Ac2dHex1 Na Y Y Y 
 
84 2734.4391 2734.3771 -0.0620 Hex5HexNAc6dHex1 Na Y Y Y 
 
85 2763.6150 2764.3877 0.7727 Hex6HexNAc6 Na Y N N 
 
86 2779.3503 2779.3873 0.0370 Hex5HexNAc4Neu5Ac1dHex2 Na Y Y Y 
 
87 2792.2829 2792.3826 0.0997 Hex5HexNAc4Neu5Ac2 Na Y Y Y 
 
88 2809.2574 2809.3979 0.1405 Hex6HexNAc4Neu5Ac1dHex1 Na Y N N 
 
89 2820.1485 2820.4139 0.2654 Hex4HexNAc5Neu5Ac1dHex2 Na Y Y N 
 
90 2823.4923 2822.3931 -1.0992 Hex5HexNAc4Neu5Ac1Neu5Gc1 Na Y Y Y 
 
91 2837.4701 2837.4292 -0.0409 Hex5HexNAc5dHex3 Na Y Y N 
 
92 2850.4983 2850.4244 -0.0739 Hex5HexNAc5Neu5Ac1dHex1 Na Y Y Y 
 
93 2867.3848 2867.4398 0.0550 Hex6HexNAc5dHex2 Na Y Y N 
 
94 2880.4800 2880.4350 -0.0450 Hex6HexNAc5Neu5Ac1 Na Y Y N 
 
95 2891.3562 2891.4510 0.0948 Hex4HexNAc6Neu5Ac1dHex1 Na Y Y N 
 
 
237 
Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
96 2908.4718 2908.4663 -0.0055 Hex5HexNAc6dHex2 Na Y Y Y 
 
97 2962.0532 2962.4881 0.4349 Hex4HexNAc7Neu5Ac1 Na Y Y N 
 
98 3024.0257 3024.5137 0.4880 Hex5HexNAc5Neu5Ac1dHex2 Na Y Y N 
 
99 3027.3599 3027.3629 0.0030 Hex6HexNAc5P1S1dHex2 Na N Y N 
 
100 3036.1782 3037.5089 1.3307 Hex5HexNAc5Neu5Ac2 Na Y N N 
 
101 3041.1848 3041.5290 0.3442 Hex6HexNAc5dHex3 Na Y Y Y 
 
102 3054.2873 3054.5242 0.2369 Hex6HexNAc5Neu5Ac1dHex1 Na Y Y Y 
 
103 3071.5365 3071.5395 0.0030 Hex7HexNAc5dHex2 Na Y N N 
 
104 3082.4860 3082.5555 0.0695 Hex5HexNAc6dHex3 Na Y Y N 
 
105 3094.8649 3095.5508 0.6859 Hex5HexNAc6Neu5Ac1dHex1 Na Y Y N 
 
106 3112.1659 3112.5661 0.4002 Hex6HexNAc6dHex2 Na Y Y Y 
 
107 3215.1062 3215.6182 0.5120 Hex6HexNAc5dHex4 Na Y Y N 
 
108 3228.2922 3228.6134 0.3212 Hex6HexNAc5Neu5Ac1dHex2 Na Y Y N 
 
109 3256.5344 3256.6447 0.1103 Hex5HexNAc6dHex4 Na Y Y N 
 
 
238 
Continued 
# 
Experimental 
m/z 
Theoretical 
m/z 
Accuracy 
(Da) 
Composition Charges GlycomeDB* 
Subset 
1 
Subset 
2 
Structure 
110 3270.1556 3269.6400 -0.5156 Hex5HexNAc6Neu5Ac1dHex2 Na Y Y N  
111 3285.9221 3286.6553 0.7332 Hex6HexNAc6dHex3 Na Y Y N 
 
112 3402.8905 3402.7026 -0.1879 Hex6HexNAc5Neu5Ac1dHex3 Na Y Y Y 
 
113 3461.1039 3460.7445 -0.3594 Hex6HexNAc6dHex4 Na Y Y N 
 
114 3472.7209 3473.7397 1.0188 Hex6HexNAc6Neu5Ac1dHex2 Na Y Y N 
 
115 3531.7938 3531.7816 -0.0122 Hex6HexNAc7dHex3 Na Y Y N 
 
116 3634.5586 3634.8337 0.2752 Hex6HexNAc6dHex5 Na Y N N 
 
117 3648.0587 3647.8290 -0.2297 Hex6HexNAc6Neu5Ac1dHex3 Na Y Y N 
 
118 3664.7625 3664.8443 0.0818 Hex7HexNAc6dHex4 Na Y N N 
 
119 3705.9636 3705.8708 -0.0928 Hex6HexNAc7dHex4 Na Y Y N 
 
120 3838.1678 3838.9335 0.7657 Hex7HexNAc6dHex5 Na Y Y N 
 
121 3894.4571 3894.9345 0.4774 Hex8HexNAc6Neu5Ac2 Na Y Y N 
 
122 4025.1659 4024.0135 -1.0924 Hex8HexNAc8Neu5Ac1 Na Y Y Y 
 
*Glycoform m/z signals, as [M+Na] adducts, were searched against GlycomeDB database, (Y) represented in the database, (N) 
predicted by peak finder.   
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Appendix B.6 Statistical analysis of N-glycoforms that were derived from FC tissues 
extracted from AD patients’ and healthy individuals’ brains (Subset 1).  
# Code 
Average m/z CT AD 
AD/CT T-test 
AD CT Theoretical NI RI 
± 
SEM 
NI RI 
± 
SEM 
1 H3N2 1171.7403 1171.7210 1171.5831 0.0214 1.7069 0.2835 0.0130 1.0808 0.1007 0.606201 0.197624 
2 H3N2P1 1266.3696 1266.3970 1265.5650 0.0054 0.3291 0.0961 0.0012 0.1294 0.0300 0.21972 0.053628 
3 H3N2F1 1345.7814 1345.7265 1345.6723 0.0295 2.4367 0.1852 0.0223 1.6917 0.1106 0.754817 0.415021 
4 H4N2 1375.7546 1375.7382 1375.6828 0.0277 2.2048 0.2414 0.0146 1.4060 0.2200 0.526431 0.093171 
5 H3N3 1416.7631 1416.7720 1416.7094 0.0191 1.4057 0.4095 0.0037 0.3679 0.0932 0.192023 0.031878 
6 H3N3S1 1481.7698 1481.7146 1482.6505 0.0768 7.3903 1.1788 0.0375 4.3625 1.3687 0.488652 0.13021 
7 H3N3P1 1511.7670 1511.7557 1510.6914 0.0152 1.0838 0.3089 0.0030 0.3382 0.0922 0.199183 0.065788 
8 H4N2F1 1551.7434 1551.7505 1549.7720 0.0141 0.8883 0.2131 0.0061 0.5363 0.0670 0.434821 0.100732 
9 H5N2 1579.7581 1579.7741 1579.7826 0.5095 47.3982 5.6050 1.0132 70.3181 3.1603 1.988857 0.130853 
10 H3N3F1 1590.8067 1590.8134 1590.7986 0.0086 0.6583 0.1330 0.0020 0.1962 0.0333 0.236559 0.032026 
11 H4N3 1620.9347 1620.8172 1620.8091 0.0127 0.9032 0.2431 0.0026 0.2531 0.0540 0.203487 0.037264 
12 H3N4 1661.7712 1661.8453 1661.8357 0.0396 3.1132 0.8847 0.0132 1.1312 0.3072 0.334378 0.073221 
13 H5N2F1 1753.8771 1753.8637 1753.8718 0.0058 0.4328 0.0919 0.0013 0.1299 0.0223 0.229572 0.040609 
14 H6N2 1783.8012 1783.8728 1783.8824 0.0429 4.0106 0.7138 0.0288 2.0007 0.2226 0.672032 0.292082 
15 H4N3F1 1794.8379 1794.8697 1794.8984 0.0078 0.5760 0.1377 0.0014 0.1397 0.0302 0.182301 0.034658 
16 H3N4F1 1835.8342 1835.9531 1835.9249 0.0202 1.7294 0.2185 0.0089 0.7191 0.1136 0.44178 0.081389 
17 H4N4 1865.9814 1866.0107 1865.9355 0.0139 1.0702 0.2194 0.0036 0.3487 0.0843 0.262767 0.041982 
18 H3N5 1907.0412 1907.0283 1906.9620 0.0155 1.3631 0.1611 0.0067 0.6593 0.1240 0.435107 0.084685 
19 H4N3ALac1 1934.3477 1934.6693 1935.9410 0.0027 0.1708 0.0590 0.0007 0.0457 0.0190 0.245138 0.121842 
20 H4N3F2 1968.9203 1968.9827 1968.9876 0.0034 0.2631 0.0518 0.0008 0.0924 0.0222 0.248974 0.052705 
21 H3N5S1 1973.9706 1973.9303 1972.9032 0.0051 0.3875 0.0716 0.0017 0.1572 0.0270 0.338045 0.082144 
22 H4N3A1 1981.9387 1981.9774 1981.9828 0.0018 0.1271 0.0331 0.0004 0.0497 0.0133 0.236739 0.081696 
23 H7N2 1988.0904 1987.9591 1987.9821 0.0122 1.2135 0.2892 0.0062 0.4278 0.0497 0.512762 0.148712 
24 H5N3F1 1998.8582 1998.9687 1998.9981 0.0057 0.4346 0.0888 0.0013 0.1499 0.0335 0.23634 0.047787 
25 H4N4F1 2040.0593 2040.0709 2040.0247 0.0159 1.3758 0.2589 0.0049 0.4832 0.0856 0.306413 0.048385 
26 H3E1N4F1 2053.0962 2052.9860 2053.0563 0.0044 0.3392 0.0673 0.0023 0.2232 0.0519 0.515873 0.233036 
27 H5N4 2069.9641 2070.0528 2070.0352 0.0135 1.1374 0.2044 0.0090 0.7274 0.1171 0.667933 0.390418 
28 H3N5F1 2081.0534 2081.0980 2081.0512 0.0586 6.4017 1.0326 0.0774 4.9788 0.7786 1.321481 0.58925 
29 H4N5 2111.3788 2111.1059 2111.0618 0.0131 1.0963 0.2224 0.0064 0.7633 0.2144 0.486652 0.149446 
30 H3N4S2F2 2141.9580 2141.5423 2141.8964 0.0038 0.2858 0.0681 0.0015 0.1506 0.0456 0.404419 0.197498 
31 H3N6 2151.2001 2151.1289 2152.0883 0.0018 0.1125 0.0319 0.0007 0.0569 0.0219 0.394019 0.145858 
32 H4N3A1F1 2156.0969 2156.1047 2156.0720 0.0025 0.1534 0.0423 0.0008 0.0680 0.0217 0.325148 0.081081 
33 H5N3F2 2172.9701 2173.1075 2173.0873 0.0028 0.2329 0.0436 0.0012 0.0909 0.0197 0.409103 0.145699 
34 H4N5S1 2178.1346 2178.0659 2177.0030 0.0021 0.1726 0.0296 0.0010 0.0534 0.0159 0.48745 0.265327 
35 H5N3A1 2186.3756 2186.0913 2186.0826 0.0022 0.1060 0.0362 0.0009 0.0804 0.0185 0.407999 0.125535 
36 H8N2 2192.2242 2192.1175 2192.0819 0.0048 0.5127 0.1301 0.0032 0.2518 0.0493 0.675558 0.421594 
37 H6N3F1 2202.9852 2203.1722 2203.0979 0.0028 0.2157 0.0433 0.0011 0.0854 0.0304 0.390154 0.148183 
240 
38 H4N4F2 2214.3069 2214.1495 2214.1139 0.0036 0.3253 0.0584 0.0013 0.1375 0.0323 0.365439 0.082443 
39 H4N3A1S1F1 2222.2753 2222.0956 2222.0132 0.0018 0.1379 0.0336 0.0006 0.0712 0.0201 0.331334 0.111769 
40 H4N4A1 2227.0818 2227.1516 2227.1091 0.0008 0.0639 0.0130 0.0004 0.0377 0.0091 0.447292 0.177896 
41 H5N4F1 2244.4153 2244.1579 2244.1245 0.0044 0.3769 0.0686 0.0020 0.2033 0.0410 0.464975 0.147606 
42 H4N4G1 2257.4044 2257.2658 2257.1197 0.0021 0.1724 0.0351 0.0012 0.1166 0.0230 0.560732 0.247766 
43 H4N5F1 2285.1981 2285.2665 2285.1510 0.0053 0.5458 0.1228 0.0035 0.3138 0.0679 0.660726 0.343115 
44 H5N5 2315.4120 2315.1730 2315.1616 0.0031 0.2445 0.0583 0.0013 0.1597 0.0468 0.414519 0.149089 
45 H3N6F1 2326.2012 2326.2887 2326.1776 0.0016 0.1512 0.0302 0.0013 0.1266 0.0316 0.810011 0.62585 
46 H4N4S2F2 2346.1968 2346.2277 2345.9962 0.0016 0.1282 0.0272 0.0007 0.0777 0.0190 0.420768 0.10877 
47 H4N6 2356.2960 2356.2755 2356.1881 0.0010 0.0775 0.0164 0.0005 0.0512 0.0095 0.537845 0.203965 
48 H5N3A1F1 2360.4161 2360.0910 2360.1718 0.0013 0.1053 0.0210 0.0007 0.0497 0.0144 0.53163 0.269799 
49 H6N3F2 2377.0667 2377.1666 2377.1871 0.0011 0.0861 0.0173 0.0005 0.0414 0.0136 0.481872 0.212589 
50 H5N5S1 2382.3265 2382.1414 2381.1027 0.0014 0.1188 0.0228 0.0011 0.0971 0.0214 0.810123 0.685216 
51 H6N3A1 2390.0404 2390.1924 2390.1824 0.0013 0.1023 0.0230 0.0005 0.0541 0.0205 0.369842 0.169304 
52 H9N2 2396.4708 2396.3281 2396.1817 0.0035 0.4347 0.1523 0.0069 0.4212 0.1396 1.983784 0.455777 
53 H5N4F2 2418.2730 2418.2616 2418.2137 0.0037 0.3926 0.0924 0.0028 0.2579 0.0687 0.742122 0.53758 
54 H5N4A1 2431.5211 2431.2097 2431.2089 0.0017 0.1498 0.0333 0.0014 0.1213 0.0383 0.816155 0.691197 
55 H4N5F2 2459.5150 2459.3742 2459.2402 0.0074 0.9099 0.2673 0.0163 1.1280 0.3300 2.189545 0.349805 
56 H4N5A1 2472.3334 2472.2240 2472.2355 0.0009 0.0835 0.0177 0.0005 0.0526 0.0146 0.494637 0.164224 
57 H7N4 2478.3396 2478.2322 2478.2348 0.0019 0.1604 0.0344 0.0011 0.1083 0.0220 0.598732 0.299839 
58 H5N5F1 2489.4784 2489.3517 2489.2508 0.0032 0.3195 0.1074 0.0021 0.2258 0.0576 0.654276 0.336612 
59 H4N3A2F1 2516.8957 2516.3703 2517.2457 0.0008 0.0762 0.0163 0.0009 0.0925 0.0259 1.078965 0.857601 
60 H4N6F1 2530.7493 2530.3733 2530.2773 0.0010 0.0923 0.0192 0.0009 0.0958 0.0331 0.931967 0.875845 
61 H9N2P2 2584.4775 2584.7704 2584.1457 0.0003 0.0287 0.0048 0.0004 0.0356 0.0070 1.125437 0.737623 
62 H5N4F3 2592.6810 2592.4470 2592.3029 0.0010 0.0891 0.0169 0.0007 0.0745 0.0230 0.716018 0.47053 
63 H10N2 2600.4975 2600.1756 2600.2815 0.0003 0.0263 0.0046 0.0004 0.0311 0.0096 1.168322 0.740795 
64 H6N4F2 2622.7635 2622.2488 2622.3134 0.0009 0.0786 0.0163 0.0007 0.0819 0.0295 0.75232 0.557024 
65 H4N5F3 2633.0395 2633.2268 2633.3294 0.0005 0.0366 0.0078 0.0003 0.0354 0.0164 0.654423 0.38838 
66 H4N5A1F1 2646.6207 2646.3834 2646.3247 0.0004 0.0328 0.0066 0.0003 0.0329 0.0150 0.601933 0.252886 
67 H5N5F2 2663.2465 2663.4360 2663.3400 0.0009 0.0807 0.0147 0.0005 0.0528 0.0143 0.583986 0.220336 
68 H4N3A2F2 2690.2785 2690.4420 2691.3349 0.0004 0.0380 0.0077 0.0005 0.0365 0.0120 1.202046 0.758185 
69 H4N6F2 2704.4788 2704.3648 2704.3665 0.0007 0.0725 0.0168 0.0011 0.0802 0.0248 1.569749 0.540778 
70 H4N6A1 2717.0579 2717.3306 2717.3618 0.0003 0.0240 0.0038 0.0003 0.0177 0.0053 1.171937 0.707772 
71 H5N3A2F1 2721.5204 2721.3694 2721.3455 0.0006 0.0490 0.0094 0.0004 0.0454 0.0128 0.710547 0.414676 
72 H5N6F1 2734.4986 2734.3796 2734.3771 0.0005 0.0452 0.0087 0.0004 0.0406 0.0117 0.710956 0.433583 
73 H5N4A1F2 2779.2603 2779.4402 2779.3873 0.0004 0.0326 0.0056 0.0002 0.0285 0.0091 0.629089 0.27362 
74 H5N4A2 2792.1326 2792.4332 2792.3826 0.0003 0.0253 0.0044 0.0002 0.0258 0.0087 0.856916 0.678828 
75 H4N5A1F2 2819.9804 2820.3166 2820.4139 0.0002 0.0188 0.0043 0.0003 0.0103 0.0057 1.273973 0.592072 
76 H5N4A1G1 2823.4898 2823.4948 2822.3931 0.0005 0.0480 0.0083 0.0005 0.0411 0.0120 0.840058 0.741108 
77 H5N5F3 2837.4769 2837.4633 2837.4292 0.0009 0.0948 0.0235 0.0011 0.0786 0.0261 1.336427 0.634622 
78 H5N5A1F1 2850.6580 2850.3386 2850.4244 0.0002 0.0216 0.0053 0.0002 0.0252 0.0097 0.844015 0.672301 
79 H6N5F2 2867.3731 2867.3966 2867.4398 0.0005 0.0434 0.0093 0.0003 0.0358 0.0122 0.555072 0.254775 
80 H6N5A1 2880.4488 2880.5111 2880.4350 0.0004 0.0321 0.0064 0.0004 0.0360 0.0118 1.087688 0.844619 
241 
81 H4N6A1F1 2891.4240 2891.2884 2891.4510 0.0002 0.0191 0.0037 0.0002 0.0206 0.0070 1.026471 0.951272 
82 H5N6F2 2908.4757 2908.4678 2908.4663 0.0004 0.0388 0.0069 0.0004 0.0402 0.0122 0.950217 0.905821 
83 H4N7A1 2962.0691 2962.0374 2962.4881 0.0003 0.0226 0.0039 0.0002 0.0086 0.0034 0.910024 0.868626 
84 H5N5A1F2 3023.8654 3024.1859 3024.5137 0.0002 0.0150 0.0027 0.0001 0.0171 0.0052 0.987054 0.963972 
85 H6N5P1S1F2 3027.3704 3027.3494 3027.3629 0.0003 0.0244 0.0042 0.0002 0.0229 0.0083 0.785012 0.614685 
86 H6N5F3 3041.0049 3041.3646 3041.5290 0.0003 0.0226 0.0040 0.0002 0.0229 0.0084 0.676115 0.349224 
87 H6N5A1F1 3054.3090 3054.2655 3054.5242 0.0002 0.0173 0.0030 0.0002 0.0207 0.0042 1.036845 0.9261 
88 H5N6F3 3082.5511 3082.4208 3082.5555 0.0004 0.0373 0.0081 0.0006 0.0391 0.0118 1.492232 0.483863 
89 H5N6A1F1 3094.8838 3094.8461 3095.5508 0.0002 0.0154 0.0031 0.0002 0.0192 0.0077 0.985664 0.967352 
90 H6N6F2 3112.0641 3112.2676 3112.5661 0.0002 0.0191 0.0035 0.0002 0.0209 0.0055 0.850355 0.673542 
91 H6N5F4 3215.0366 3215.1757 3215.6182 0.0002 0.0199 0.0030 0.0002 0.0154 0.0042 0.920807 0.84114 
92 H6N5A1F2 3228.2818 3228.3026 3228.6134 0.0001 0.0104 0.0016 0.0001 0.0082 0.0029 0.975542 0.948644 
93 H5N6F4 3256.9024 3256.1663 3256.6447 0.0002 0.0145 0.0024 0.0001 0.0098 0.0050 0.787668 0.643086 
94 H5N6A1F2 3270.3303 3269.9808 3269.6400 0.0002 0.0194 0.0049 0.0002 0.0197 0.0066 1.197803 0.6386 
95 H6N6F3 3285.7817 3286.0626 3286.6553 0.0002 0.0155 0.0025 0.0002 0.0162 0.0050 0.987721 0.973735 
96 H6N5A1F3 3402.7860 3402.9950 3402.7026 0.0001 0.0095 0.0015 0.0001 0.0124 0.0034 1.160242 0.701115 
97 H6N6F4 3461.5001 3460.7076 3460.7445 0.0001 0.0152 0.0038 0.0002 0.0114 0.0048 1.310697 0.531831 
98 H6N6A1F2 3472.4130 3473.0288 3473.7397 0.0001 0.0064 0.0009 0.0001 0.0051 0.0021 1.246536 0.572134 
99 H6N7F3 3531.8469 3531.7407 3531.7816 0.0001 0.0083 0.0012 0.0001 0.0061 0.0027 0.764657 0.534746 
100 H6N6A1F3 3648.1451 3647.9723 3647.8290 0.0001 0.0094 0.0028 0.0001 0.0050 0.0031 0.53584 0.298463 
101 H6N7F4 3706.1292 3705.7980 3705.8708 0.0001 0.0060 0.0015 0.0001 0.0083 0.0024 0.932567 0.847643 
102 H7N6F5 3837.9119 3838.4237 3838.9335 0.0001 0.0104 0.0036 0.0001 0.0081 0.0031 1.216504 0.624767 
103 H8N6A2 3894.4417 3894.4726 3894.9345 0.0001 0.0057 0.0011 0.0001 0.0036 0.0016 0.940197 0.904693 
104 H8N8A1 4025.3456 4024.9861 4024.0135 0.0001 0.0055 0.0013 0.0000 0.0069 0.0028 0.89027 0.76865 
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Appendix B.7 Statistical analysis of N-glycoforms that were derived from FC tissues 
extracted from AD patients’ and healthy individuals’ brains (Subset 2). 
# Code 
Average m/z CT AD 
AD/CT T-test 
AD CT Theoretical NI RI 
± 
SEM 
NI RI 
± 
SEM 
1 H3N2 1171.7403 1171.7210 1171.5831 0.0214 1.7906 0.3069 0.0130 1.1075 0.1034 0.606201 0.197624 
2 H3N2F1 1345.7814 1345.7265 1345.6723 0.0295 2.5476 0.2020 0.0223 1.7313 0.1109 0.754817 0.415021 
3 H4N2 1375.7546 1375.7382 1375.6828 0.0277 2.3113 0.2665 0.0146 1.4418 0.2255 0.526431 0.093171 
4 H3N3 1416.7631 1416.7720 1416.7094 0.0191 1.4831 0.4333 0.0037 0.3771 0.0953 0.192023 0.031878 
5 H3N3S1 1481.7698 1481.7146 1482.6505 0.0768 7.7495 1.2545 0.0375 4.4751 1.3953 0.488652 0.13021 
6 H3N3P1 1511.7670 1511.7557 1510.6914 0.0152 1.1485 0.3344 0.0030 0.3471 0.0942 0.199183 0.065788 
7 H5N2 1579.7581 1579.7741 1579.7826 0.5095 49.1932 5.4418 1.0132 71.9363 2.9986 1.988857 0.130853 
8 H3N3F1 1590.8067 1590.8134 1590.7986 0.0086 0.6939 0.1436 0.0020 0.2014 0.0344 0.236559 0.032026 
9 H4N3 1620.9347 1620.8172 1620.8091 0.0127 0.9543 0.2596 0.0026 0.2596 0.0554 0.203487 0.037264 
10 H3N4 1661.7712 1661.8453 1661.8357 0.0396 3.2742 0.9317 0.0132 1.1576 0.3139 0.334378 0.073221 
11 H5N2F1 1753.8771 1753.8637 1753.8718 0.0058 0.4567 0.0995 0.0013 0.1333 0.0229 0.229572 0.040609 
12 H6N2 1783.8012 1783.8728 1783.8824 0.0429 4.1856 0.7357 0.0288 2.0443 0.2230 0.672032 0.292082 
13 H4N3F1 1794.8379 1794.8697 1794.8984 0.0078 0.6083 0.1478 0.0014 0.1434 0.0312 0.182301 0.034658 
14 H3N4F1 1835.8342 1835.9531 1835.9249 0.0202 1.8140 0.2360 0.0089 0.7360 0.1161 0.44178 0.081389 
15 H4N4 1865.9814 1866.0107 1865.9355 0.0139 1.1287 0.2361 0.0036 0.3580 0.0870 0.262767 0.041982 
16 H3N5 1907.0412 1907.0283 1906.9620 0.0155 1.4300 0.1757 0.0067 0.6788 0.1306 0.435107 0.084685 
17 H4N3F2 1968.9203 1968.9827 1968.9876 0.0034 0.2776 0.0563 0.0008 0.0952 0.0231 0.248974 0.052705 
18 H3N5S1 1973.9706 1973.9303 1972.9032 0.0051 0.4087 0.0784 0.0017 0.1616 0.0282 0.338045 0.082144 
19 H7N2 1988.0904 1987.9591 1987.9821 0.0122 1.2680 0.2979 0.0062 0.4382 0.0506 0.512762 0.148712 
20 H5N3F1 1998.8582 1998.9687 1998.9981 0.0057 0.4586 0.0960 0.0013 0.1544 0.0350 0.23634 0.047787 
21 H4N4F1 2040.0593 2040.0709 2040.0247 0.0159 1.4459 0.2750 0.0049 0.4970 0.0894 0.306413 0.048385 
22 H3E1N4F1 2053.0962 2052.9860 2053.0563 0.0044 0.3577 0.0734 0.0023 0.2302 0.0546 0.515873 0.233036 
23 H5N4 2069.9641 2070.0528 2070.0352 0.0135 1.1963 0.2204 0.0090 0.7469 0.1217 0.667933 0.390418 
24 H3N5F1 2081.0534 2081.0980 2081.0512 0.0586 6.6658 1.0588 0.0774 5.1020 0.7943 1.321481 0.58925 
25 H4N5 2111.3788 2111.1059 2111.0618 0.0131 1.1537 0.2372 0.0064 0.7875 0.2231 0.486652 0.149446 
26 H8N2 2192.2242 2192.1175 2192.0819 0.0048 0.5356 0.1337 0.0032 0.2590 0.0513 0.675558 0.421594 
27 H4N4F2 2214.3069 2214.1495 2214.1139 0.0036 0.3419 0.0622 0.0013 0.1419 0.0338 0.365439 0.082443 
28 H5N4F1 2244.4153 2244.1579 2244.1245 0.0044 0.3967 0.0736 0.0020 0.2095 0.0431 0.464975 0.147606 
29 H4N4G1 2257.4044 2257.2658 2257.1197 0.0021 0.1817 0.0378 0.0012 0.1201 0.0242 0.560732 0.247766 
30 H4N5F1 2285.1981 2285.2665 2285.1510 0.0053 0.5718 0.1278 0.0035 0.3234 0.0713 0.660726 0.343115 
31 H5N5 2315.4120 2315.1730 2315.1616 0.0031 0.2581 0.0625 0.0013 0.1651 0.0491 0.414519 0.149089 
32 H3N6F1 2326.2012 2326.2887 2326.1776 0.0016 0.1588 0.0317 0.0013 0.1306 0.0332 0.810011 0.62585 
33 H4N4S2F2 2346.1968 2346.2277 2345.9962 0.0016 0.1352 0.0291 0.0007 0.0802 0.0199 0.420768 0.10877 
34 H4N6 2356.2960 2356.2755 2356.1881 0.0010 0.0818 0.0177 0.0005 0.0528 0.0101 0.537845 0.203965 
35 H5N5S1 2382.3265 2382.1414 2381.1027 0.0014 0.1249 0.0243 0.0011 0.1000 0.0224 0.810123 0.685216 
36 H9N2 2396.4708 2396.3281 2396.1817 0.0035 0.4527 0.1560 0.0069 0.4327 0.1427 1.983784 0.455777 
37 H5N4F2 2418.2730 2418.2616 2418.2137 0.0037 0.4110 0.0959 0.0028 0.2662 0.0718 0.742122 0.53758 
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38 H4N5F2 2459.5150 2459.3742 2459.2402 0.0074 0.9480 0.2743 0.0163 1.1607 0.3403 2.189545 0.349805 
39 H7N4 2478.3396 2478.2322 2478.2348 0.0019 0.1690 0.0367 0.0011 0.1115 0.0230 0.598732 0.299839 
40 H5N5F1 2489.4784 2489.3517 2489.2508 0.0032 0.3356 0.1119 0.0021 0.2331 0.0604 0.654276 0.336612 
41 H4N3A2F1 2516.8957 2516.3703 2517.2457 0.0008 0.0801 0.0173 0.0009 0.0955 0.0272 1.078965 0.857601 
42 H4N6F1 2530.7493 2530.3733 2530.2773 0.0010 0.0969 0.0202 0.0009 0.0991 0.0346 0.931967 0.875845 
43 H9N2P2 2584.4775 2584.7704 2584.1457 0.0003 0.0302 0.0052 0.0004 0.0367 0.0074 1.125437 0.737623 
44 H5N4F3 2592.6810 2592.4470 2592.3029 0.0010 0.0935 0.0179 0.0007 0.0770 0.0241 0.716018 0.47053 
45 H6N4F2 2622.7635 2622.2488 2622.3134 0.0009 0.0828 0.0174 0.0007 0.0848 0.0308 0.75232 0.557024 
46 H5N5F2 2663.2465 2663.4360 2663.3400 0.0009 0.0847 0.0154 0.0005 0.0545 0.0150 0.583986 0.220336 
47 H4N6F2 2704.4788 2704.3648 2704.3665 0.0007 0.0759 0.0174 0.0011 0.0826 0.0257 1.569749 0.540778 
48 H5N3A2F1 2721.5204 2721.3694 2721.3455 0.0006 0.0515 0.0101 0.0004 0.0469 0.0135 0.710547 0.414676 
49 H5N6F1 2734.4986 2734.3796 2734.3771 0.0005 0.0476 0.0093 0.0004 0.0420 0.0122 0.710956 0.433583 
50 H5N4A1F2 2779.2603 2779.4402 2779.3873 0.0004 0.0343 0.0060 0.0002 0.0295 0.0095 0.629089 0.27362 
51 H5N4A2 2792.1326 2792.4332 2792.3826 0.0003 0.0265 0.0047 0.0002 0.0266 0.0091 0.856916 0.678828 
52 H5N4A1G1 2823.4898 2823.4948 2822.3931 0.0005 0.0504 0.0088 0.0005 0.0424 0.0125 0.840058 0.741108 
53 H5N5A1F1 2850.6580 2850.3386 2850.4244 0.0002 0.0227 0.0056 0.0002 0.0261 0.0101 0.844015 0.672301 
54 H5N6F2 2908.4757 2908.4678 2908.4663 0.0004 0.0407 0.0072 0.0004 0.0415 0.0128 0.950217 0.905821 
55 H6N5F3 3041.0049 3041.3646 3041.5290 0.0003 0.0238 0.0043 0.0002 0.0237 0.0088 0.676115 0.349224 
56 H6N5A1F1 3054.3090 3054.2655 3054.5242 0.0002 0.0183 0.0033 0.0002 0.0214 0.0044 1.036845 0.9261 
57 H6N6F2 3112.0641 3112.2676 3112.5661 0.0002 0.0201 0.0038 0.0002 0.0216 0.0058 0.850355 0.673542 
58 H6N5A1F3 3402.7860 3402.9950 3402.7026 0.0001 0.0100 0.0016 0.0001 0.0128 0.0036 1.160242 0.701115 
59 H8N8A1 4025.3456 4024.9861 4024.0135 0.0001 0.0058 0.0014 0.0000 0.0071 0.0030 0.89027 0.76865 
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Appendix B.8 General glycosylation deviations in terms of type and complexity that were observed in FC N-glycome in the 
differentiation of AD cases from normal cases (Subset 1).  
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total.  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Glycoform Type ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Other 16 0.0910 9.02 1.84 0.2086 17.46 2.39 0.014 2.80 122 16.14 0.45 125 15.21 0.28 0.106 1.73 
High mannose 10 1.0811 75.56 2.88 0.6192 57.15 5.16 0.008 3.12 79 10.44 0.19 79 9.63 0.15 0.005 3.35 
Hybrid 9 0.0071 0.71 0.15 0.0190 1.49 0.30 0.033 2.37 66 8.70 0.23 70 8.52 0.13 0.526 0.65 
Complex 69 0.1839 14.72 1.90 0.2625 23.90 3.01 0.022 2.58 492 64.73 0.63 547 66.63 0.31 0.016 2.74 
Total 104 1.3631 100.00  1.1093 100.00    759 100.00  821 100.00    
                  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Complexity ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Other 35 1.1792 85.28 1.90 0.8468 76.10 3.01 0.022 2.58 267 35.27 0.63 274 33.37 0.31 0.016 2.74 
Bi-antennary 19 0.0539 4.92 0.78 0.1309 10.84 1.83 0.010 2.98 148 19.57 0.46 152 18.52 0.14 0.045 2.20 
Tri-antennary 31 0.1230 9.13 1.40 0.1228 12.28 1.72 0.177 1.42 213 27.97 0.61 245 29.84 0.19 0.011 2.93 
Tetra-antennary 19 0.0069 0.67 0.18 0.0088 0.78 0.13 0.622 0.50 131 17.19 0.54 150 18.27 0.07 0.068 1.98 
Total 104 1.3631 100.00  1.1093 100.00    759 100.00  821 100.00    
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Appendix B.9 General glycosylation deviations in terms of fucosylation, galactosylation, and sialylation that were observed in 
FC N-glycome in the differentiation of AD cases from normal cases (Subset 1). 
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total.  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Fucosylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Nonfucosylated (F=0) 41 1.1874 86.44 1.54 0.8771 78.84 2.18 0.013 2.84 304 40.08 0.27 323 39.34 0.29 0.080 1.89 
Mono-fucosylated 
(F=1) 
27 0.1432 10.78 0.95 0.1953 17.65 1.59 0.002 3.71 208 27.48 0.46 213 25.95 0.13 0.006 3.23 
Di-fucosylated(F=2) 22 0.0291 2.44 0.58 0.0329 3.12 0.57 0.411 0.85 158 20.79 0.38 176 21.45 0.16 0.136 1.58 
Multi-
fucosylated(F>2) 
14 0.0034 0.34 0.11 0.0041 0.39 0.07 0.743 0.33 89 11.66 0.53 109 13.27 0.20 0.013 2.85 
Total 104 1.3631 100.00  1.1093 100.00    759 100.00  821 100.00    
                  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Galactosylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Aglactosylated (G=0) 26 1.2770 91.93 1.55 0.9448 86.05 2.33 0.054 2.10 203 26.85 0.59 205 24.97 0.16 0.008 3.10 
Mono-galactosylated 
(G=1) 
37 0.0572 5.31 0.97 0.1216 10.12 1.71 0.028 2.44 264 34.73 0.55 290 35.32 0.17 0.323 1.02 
Di-galactosylated 
(G=2) 
22 0.0257 2.41 0.50 0.0389 3.48 0.65 0.212 1.31 166 21.87 0.26 176 21.45 0.16 0.188 1.38 
Tri-galactosylated 16 0.0029 0.33 0.10 0.0039 0.34 0.06 0.949 0.07 108 14.18 0.35 126 15.35 0.08 0.005 3.28 
Multi-galactosylated 3 0.0002 0.02 0.01 0.0002 0.02 0.01 0.548 0.62 18 2.37 0.25 24 2.92 0.02 0.045 2.20 
Total 104 1.3631 100.00  1.1093 100.00    759 100.00  821 100.00    
                  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Sialylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Asialylated 72 1.3525 98.88 0.28 1.0897 98.42 0.30 0.287 1.11 543 71.75 1.21 570 69.43 0.17 0.077 1.91 
Mono-sialylated (A=0) 27 0.0086 0.92 0.23 0.0175 1.39 0.27 0.206 1.33 181 23.63 1.22 211 25.69 0.20 0.118 1.67 
Di-sialylated  
(A=2) 
5 0.0020 0.20 0.06 0.0022 0.19 0.04 0.886 0.15 35 4.62 0.17 40 4.87 0.04 0.173 1.44 
Multi-sialylated (A>2) 0 0.0000 0.00 0.00 0.0000 0.00 0.00 N/A N/A 0 0.00 0.00 0 0.00 0.00 N/A N/A 
Total 104 1.3631 100.00  1.1093 100.00    759 100.00  821 100.00    
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Appendix B.10 General glycosylation deviations in terms of modifications that were observed in FC N-glycome in the 
differentiation of AD cases from normal cases (Subset 1). 
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total.  
Trait 
Total 
structure 
AD CT t-test AD CT t-test 
Modification ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value t ratio # % 
± 
SEM 
# % 
± 
SEM 
P value t ratio 
Sulfated (S) 7 0.0434 4.97 1.42 0.0925 8.62 1.33 0.082 1.87 51 6.73 0.24 56 6.82 0.05 0.695 0.40 
Phosphorylated (P) 3 0.0046 0.50 0.10 0.0203 1.44 0.40 0.040 2.26 24 3.18 0.09 23 2.80 0.11 0.017 2.70 
S+P 1 0.0002 0.02 0.01 0.0003 0.02 0.00 0.781 0.28 7 0.93 0.14 8 0.97 0.01 0.775 0.29 
LacNAc repeats 1 0.0000 0.01 0.00 0.0001 0.01 0.00 >0.999 0.00 8 1.06 0.03 8 0.97 0.01 0.019 2.66 
Hexosamine 1 0.0023 0.22 0.05 0.0044 0.34 0.07 0.199 1.35 8 1.06 0.03 8 0.97 0.01 0.019 2.66 
Neu5AcLac 1 0.0005 0.05 0.02 0.0024 0.17 0.06 0.066 1.99 6 0.81 0.18 7 0.85 0.12 0.855 0.19 
Nonmodified 88 1.3104 94.07 1.55 0.9869 89.18 1.69 0.051 2.13 639 84.12 0.49 695 84.66 0.16 0.305 1.07 
Neu5Gc 2 0.0016 0.16 0.03 0.0026 0.22 0.04 0.266 1.16 16 2.12 0.06 16 1.95 0.01 0.019 2.66 
Total 104 1.3631 100.00  1.1093 89.91    759 100.00  821 100.00    
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Appendix B.11 General glycosylation deviations in terms of type and complexity that were observed in FC N-glycome in the 
differentiation of AD cases from normal cases (Subset 2).  
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total. 
 
Trait AD CT t-test AD or CT 
Glycoform Type ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Other 0.0873 8.83 1.85 0.1954 17.33 2.41 0.014 8.499 2.8 80 16.95 0.00 
High mannose 1.0747 76.72 2.75 0.6066 58.43 5.03 0.006 -18.29 3.19 64 13.56 0.00 
Hybrid 0.0029 0.31 0.07 0.0081 0.68 0.13 0.029 0.365 2.436 24 5.08 0.00 
Complex 0.1747 14.13 1.79 0.2456 23.55 2.99 0.017 9.424 2.702 304 64.41 0.00 
Total 1.3395 100.00  1.0557 100.00     472 100.00  
             
Trait AD CT t-test AD or CT 
Complexity ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Other 1.1648 85.87 1.79 0.8101 76.45 2.99 0.017189 -9.424 2.702 168 35.59 0.00 
Bi-antennary 0.0512 4.74 0.74 0.1246 10.87 1.87 0.00873 6.133 3.045 128 27.12 0.00 
Tri-antennary 0.1187 8.92 1.37 0.1156 12.16 1.70 0.160495 3.236 1.482 112 23.73 0.00 
Tetra-antennary 0.0048 0.48 0.13 0.0054 0.53 0.10 0.75827 0.05125 0.3138 64 13.56 0.00 
Total 1.3395 100.00  1.0557 100.00     472 100.00  
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Appendix B.12 General glycosylation deviations in terms of fucosylation, galactosylation, and sialylation that were observed 
in FC N-glycome in the differentiation of AD cases from normal cases (Subset 2).  
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total 
Trait AD CT t-test AD or CT 
Fucosylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Non-fucosylated (F=0) 1.1798 87.67 1.41 0.8568 80.59 2.04 0.012744 -7.078 2.854 208 44.07 0.00 
Mono-fucosylated (F=1) 0.1338 10.16 0.91 0.1742 16.83 1.58 0.002591 6.673 3.657 152 32.20 0.00 
Di-fucosylated(F=2) 0.0250 2.06 0.52 0.0233 2.45 0.49 0.593607 0.39 0.5461 88 18.64 0.00 
Multi-fucosylated(F>2) 0.0010 0.11 0.04 0.0013 0.13 0.02 0.748656 0.01375 0.3268 24 5.08 0.00 
Total 1.3395 100.00  1.0557 100.00     472 100.00  
             
Trait AD CT t-test AD or CT 
Galactosylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Aglactosylated (G=0) 1.2677 93.16 1.31 0.9221 87.96 2.04 0.050175 -5.199 2.143 168 35.59 0.00 
Mono-galactosylated (G=1) 0.0479 4.50 0.82 0.0965 8.59 1.45 0.02766 4.098 2.457 136 28.81 0.00 
Di-galactosylated (G=2) 0.0225 2.17 0.44 0.0352 3.29 0.63 0.165921 1.12 1.462 120 25.42 0.00 
Tri-galactosylated 0.0014 0.16 0.05 0.0017 0.15 0.03 0.870515 -0.01 0.166 40 8.47 0.00 
Multi-galactosylated 0.0000 0.01 0.00 0.0000 0.00 0.00 0.148904 -0.005 1.528 8 1.69 0.00 
Total 1.3395 100.00  1.0556 100.00     472 100.00  
             
Trait AD CT t-test AD or CT 
Sialylation ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Non-sialylated 1.3367 99.69 0.09 1.0525 99.70 0.05 0.916813 0.01125 0.1064 400 84.75 0.00 
Mono-sialylated 0.0013 0.14 0.04 0.0015 0.14 0.02 0.979628 0.00125 0.026 48 10.17 0.00 
Di-sialylated 0.0015 0.17 0.05 0.0017 0.16 0.03 0.833808 -0.0125 0.2138 24 5.08 0.00 
Multi-sialylated 0.0000 0.00 0.00 0.0000 0.00 0.00 N/A N/A N/A 0 0.00 0.00 
Total 1.3395 100.00  1.0557 100.00     472 100.00  
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Appendix B.13 General glycosylation deviations in terms of modifications that were observed in FC N-glycome in the 
differentiation of AD cases from normal cases (Subset 2).  
Note: ∑NI, sum averages of normalized intensities; ∑RI, sum averages of relative intensities, SEM, standard error of mean; #, number of detected glycoforms; % the percentage 
number of glycoforms to the total 
Trait AD CT t-test AD or CT 
Modification ∑ NI ∑ RI 
± 
SEM 
∑ NI ∑ RI 
± 
SEM 
P value Difference t ratio # % 
± 
SEM 
Sulfated 0.0410 4.82 1.42 0.0848 8.42 1.33 0.08483 3.603 1.855 32 6.78 0.00 
Phosphorylated 0.0034 0.38 0.10 0.0156 1.18 0.34 0.040315 0.795 2.26 16 3.39 0.00 
Sulfated/Phosphorylated 0.0000 0.00 0.00 0.0000 0.00 0.00 N/A N/A N/A 0 0.00 0.00 
LacNAc repeats 0.0000 0.01 0.00 0.0001 0.01 0.00 >0.999 0 0 8 1.69 0.00 
HexN 0.0023 0.23 0.05 0.0044 0.36 0.07 0.18769 0.1263 1.385 8 1.69 0.00 
Neu5AcLac 0.0000 0.00 0.00 0.0000 0.00 0.00 N/A N/A N/A 0 0.00 0.00 
Nonmodified 1.2911 94.40 1.52 0.9482 89.81 1.64 0.059636 -4.589 2.049 392 83.05 0.00 
Neu5Gc 0.0016 0.16 0.03 0.0026 0.23 0.05 0.265707 0.0625 1.159 16 3.39 0.00 
Total 1.3395 100.00  1.0557 100.00     472 100.00  
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Appendix B.14 Fucosylation indices calculated for N-glycoforms that were detected 
across all AD patients’ and healthy individuals’ FC tissues. 
Subset 2 consists of 59 N-glycan structures detected across all examined cases in each group and 
classified from a total of 472 N-glycoforms derived from either CT or AD. (a) total complex, (b) 
bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) high mannose, 
(f) hybrid, (g) other, and (h) total N-glycoforms 
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Appendix B.15 Galactosylation indices calculated for N-glycoforms that were detected 
across all AD patients’ and healthy individuals’ FC tissues. 
Subset 2 consists of 59 N-glycan structures detected across all examined cases in each group and 
classified from a total of 472 N-glycoforms derived from either CT or AD. (a) total complex, (b) 
bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) hybrid, (f) other, 
and (g) total N-glycoforms.  
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Appendix B.16 Sialylation indices calculated for N-glycoforms that were detected across 
all AD patients’ and healthy individuals’ FC tissues. 
Subset 2 consists of 59 N-glycan structures detected across all examined cases in each group and 
classified from a total of 472 N-glycoforms derived from either CT or AD. (a) total complex, (b) 
bi-antennary complex, (c) tri-antennary complex, (d) tetra-antennary complex, (e) hybrid, (f) 
other, (g) complex + hybrid, and (h) total N-glycoforms (complex + hybrid + other). 
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Appendix B.17 ROC curve analysis of fucosylation indices (Subset 1) 
Subset 1 Complex CA2 CA3 CA4 HM Hy R Total 
Group FI-2 FI-2 FI-2 FI-2 FI-2 FI-2 FI-2 FI-2 
AD 0.070231784 0.021478946 0.046495264 0.002257575 0.006713084 0.003777685 0.028511639 0.109234193 
AD 0.102702016 0.036305166 0.062133912 0.004262938 0.007890064 0.009372273 0.030041201 0.150005554 
AD 0.099600648 0.013937662 0.083332643 0.002330343 0.005268161 0.001942214 0.017438873 0.124249895 
AD 0.137322837 0.011267661 0.120156868 0.005898307 0.003685086 0.002834901 0.018030313 0.161873137 
AD 0.07099272 0.021762493 0.047228665 0.002001562 0.009502931 0.003437154 0.029626679 0.113559483 
AD 0.032327919 0.011081793 0.019537023 0.001709103 0.003339178 0.002337424 0.019112086 0.057116607 
AD 0.154760191 0.031703106 0.110710703 0.012346381 0.008955111 0.007201414 0.023183161 0.194099877 
AD 0.135852573 0.029599229 0.095304802 0.010948542 0.007937494 0.006112884 0.025114391 0.175017343 
CT 0.190038343 0.049427148 0.133992835 0.00661836 0.002867391 0.00883192 0.032408507 0.234146161 
CT 0.150740702 0.065567314 0.079043331 0.006130057 0.015759449 0.016875874 0.052228683 0.235604708 
CT 0.156075464 0.065454101 0.084384044 0.006237319 0.025336124 0.018845244 0.05923754 0.259494372 
CT 0.132999668 0.055387099 0.070995729 0.00661684 0.022172803 0.016239473 0.060331321 0.231743264 
CT 0.119990494 0.052819596 0.061851625 0.005319274 0.016295944 0.011545951 0.053633197 0.201465585 
CT 0.244687112 0.061718159 0.173994642 0.00897431 0.006524338 0.011696512 0.02661478 0.289522741 
CT 0.071569408 0.016530666 0.05358572 0.001453022 0.004881843 0.002722748 0.035286776 0.114460774 
CT 0.08382715 0.018238288 0.064451612 0.00113725 0.011847986 0.003128025 0.027436088 0.126239249 
p-value: 0.100950198 0.004953596 0.388638952 0.959521383 0.046660469 0.013711792 0.002840455 0.013091655 
 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.6250 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.7500 
 
  - Specificity:  
0.6250 
  - Specificity:  
1.0000 
  - Specificity:  
0.5000 
  - Specificity:  
0.6250 
  - Specificity:  
1.0000 
  - Specificity:  
0.8750 
  - Specificity:  
1.0000 
  - Specificity:  
1.0000 
 
  - AROC:         
0.7344 
  - AROC:         
0.8438 
  - AROC:         
0.6094 
  - AROC:         
0.5469 
  - AROC:         
0.7031 
  - AROC:         
0.8125 
  - AROC:         
0.9063 
  - AROC:         
0.8594 
 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.8750 
  - Accuracy:     
0.6250 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.8125 
  - Accuracy:     
0.8125 
  - Accuracy:     
0.8750 
  - Accuracy:     
0.8750 
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Appendix B.18 ROC curve analysis of galactosylation indices (Subset 1) 
Subset 1 Complex CA2 CA3 CA4 Hy R Total 
Group GI-4 GI-4 GI-4 GI-4 GI-4 GI-4 GI-4 
AD 0.043733485 0.025404887 0.016616484 0.002400611 0.002805734 0.009903458 0.062176668 
AD 0.088246986 0.048217279 0.037475653 0.003894523 0.005463507 0.014026167 0.122620785 
AD 0.027868404 0.013261396 0.013158382 0.002353908 0.00095397 0.0029951 0.037101334 
AD 0.060323894 0.021199495 0.035110735 0.005368475 0.001710355 0.003720486 0.073862654 
AD 0.04183396 0.026216575 0.013996627 0.001728104 0.002712911 0.010500078 0.05772037 
AD 0.013707448 0.007915721 0.004855803 0.001868057 0.001011021 0.004090538 0.02440248 
AD 0.104011662 0.043601555 0.05260575 0.010985489 0.005376884 0.010344441 0.137972395 
AD 0.095069373 0.041796323 0.045635376 0.010071495 0.004991778 0.012331102 0.129904301 
CT 0.081722927 0.03862173 0.039460249 0.005999498 0.004415335 0.01273169 0.114827595 
CT 0.119020005 0.078065979 0.036325141 0.00623287 0.010003336 0.037980037 0.185333399 
CT 0.133478864 0.087703822 0.041278457 0.006019332 0.011483405 0.043017348 0.206549482 
CT 0.114392117 0.073875116 0.035246935 0.007269476 0.009677722 0.036337476 0.179556115 
CT 0.090054283 0.060897098 0.025489576 0.005373354 0.007826222 0.040492748 0.150135437 
CT 0.156984442 0.085908298 0.064976552 0.007596199 0.007549774 0.011835784 0.193874603 
CT 0.026333307 0.01576614 0.009557158 0.001628011 0.001550355 0.006719625 0.03969887 
CT 0.033630217 0.021803418 0.011137122 0.001088308 0.001819498 0.006551719 0.046398805 
p-value 0.103065311 0.022185817 0.543338904 0.8434249 0.028298765 0.017861891 0.05435773 
 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.6250 
  - Sensitivity:  
0.6250 
  - Sensitivity:  
0.7500 
  - Sensitivity:  
0.6250 
  - Sensitivity:  
0.7500 
  - Sensitivity:  0.6250 
 
  - Specificity:  
0.6250 
  - Specificity:  
1.0000 
  - Specificity:  
0.6250 
  - Specificity:  
0.7500 
  - Specificity:  
1.0000 
  - Specificity:  
0.7500 
  - Specificity:  1.0000 
 
  - AROC:         
0.7188 
  - AROC:         
0.7813 
  - AROC:         
0.5625 
  - AROC:         
0.5625 
  - AROC:         
0.7813 
  - AROC:         
0.7969 
  - AROC:         0.7656 
 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.8125 
  - Accuracy:     
0.6250 
  - Accuracy:     
0.7500 
  - Accuracy:     
0.8125 
  - Accuracy:     
0.7500 
  - Accuracy:     0.8125 
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Appendix B.19 ROC curve analysis of sialylation indices (Subset 1) 
Subset 1 
       
Group Complex CA2 CA3 CA4 Hy R Complex + Hy Complex +Hy + R 
AD 0.001521658 0.000637325 0.000650085 0.000234247 0.000702838 0.001425379 0.002224496 0.003649876 
AD 0.003294372 0.001686912 0.00119826 0.000409201 0.002072125 0.0025538 0.005366497 0.007920297 
AD 0.003272873 0.00138003 0.001168956 0.000723887 0.001570447 0.00223436 0.00484332 0.00707768 
AD 0.006246931 0.003549237 0.001835992 0.000861702 0.002663662 0.005403953 0.008910593 0.014314546 
AD 0.000787642 0.000419271 0.000326571 4.18E-05 0.000646285 0.001437844 0.001433927 0.002871771 
AD 0.002572289 0.000904803 0.001250503 0.000416983 0.00106126 0.001017975 0.003633549 0.004651524 
AD 0.002663096 0.001175204 0.001112655 0.000375237 0.00109307 0.001673362 0.003756166 0.005429528 
AD 0.00214586 0.000989622 0.000926901 0.000229337 0.000785892 0.001510717 0.002931752 0.004442468 
CT 0.00078085 0.000328569 0.000320857 0.000131424 0.000338264 0.000425605 0.001119114 0.001544719 
CT 0.006819909 0.003489975 0.00239473 0.000935204 0.00473918 0.007548253 0.011559088 0.019107341 
CT 0.009985394 0.005525554 0.003404209 0.00105563 0.007986952 0.011098823 0.017972345 0.029071168 
CT 0.007299249 0.003075101 0.00307279 0.001151358 0.004707568 0.007521664 0.012006817 0.019528481 
CT 0.003617247 0.001478385 0.00147698 0.000661882 0.002012554 0.003742021 0.005629801 0.009371822 
CT 0.001592984 0.000827424 0.000623098 0.000142462 0.000590929 0.001037433 0.002183913 0.003221346 
CT 0.00182061 0.000807979 0.000729708 0.000282923 0.000644703 0.001315908 0.002465314 0.003781221 
CT 0.000760892 0.000409881 0.000242453 0.000108558 0.000379875 0.000515529 0.001140766 0.001656295 
p-value 0.368115066 0.396114989 0.334667767 0.436343847 0.212702823 0.211613475 0.289702127 0.255883794 
 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  
0.5000 
  - Sensitivity:  0.5000 
 
  - Specificity:  
0.8750 
  - Specificity:  
0.7500 
  - Specificity:  
0.8750 
  - Specificity:  
0.7500 
  - Specificity:  
0.7500 
  - Specificity:  
0.8750 
  - Specificity:  
0.8750 
  - Specificity:  0.8750 
 
  - AROC:         
0.5469 
  - AROC:         
0.5000 
  - AROC:         
0.5313 
  - AROC:         
0.5625 
  - AROC:         
0.4688 
  - AROC:         
0.5156 
  - AROC:         
0.5313 
  - AROC:         0.5313 
 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.6250 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.6250 
  - Accuracy:     
0.6250 
  - Accuracy:     
0.6875 
  - Accuracy:     
0.6875 
  - Accuracy:     0.6875 
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Appendix C 
Appendix C.1 Putative N-glycoforms that were derived from CC patients’ and healthy 
individuals’ blood sera 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
1 1089.5310 1089.5300 -0.0010 -0.9601 Hex5 Na y n/a 
 
2 1171.7538 1171.5831 -0.1707 -145.7199 Hex3HexNAc2 Na y n/a 
 
3 1323.9075 1323.6903 -0.2172 -164.0473 Hex3HexNAc2dHex1 H y n/a 
 
4 1344.9252 1345.6723 0.7471 555.4667 Hex3HexNAc2dHex1 Na y n/a 
 
5 1362.9254 1361.6462 -1.2792 -938.5705 Hex3HexNAc2dHex1 K y n/a 
 
6 1375.9196 1375.6828 -0.2368 -172.0843 Hex4HexNAc2 Na y n/a 
 
7 1416.7992 1416.7094 -0.0898 -63.4000 Hex3HexNAc3 Na y y 
 
8 1456.0142 1457.7359 1.7217 1182.4912 Hex2HexNAc4 Na y n/a 
 
9 1579.8591 1579.7826 -0.0765 -48.4224 Hex5HexNAc2 Na y y 
 
10 1591.0222 1590.7986 -0.2236 -140.5487 Hex3HexNAc3dHex1 Na y n/a 
 
11 1620.9037 1620.8091 -0.0946 -58.3326 Hex4HexNAc3 Na y y 
 
12 1661.9259 1661.8357 -0.0902 -54.2758 Hex3HexNAc4 Na y y 
 
13 1702.0802 1702.8622 0.7820 459.4653 Hex2HexNAc5 Na y n/a 
 
14 1724.1407 1723.8612 -0.2795 -162.0844 Hex4HexNAc2dHex2 Na y n/a 
 
15 1737.1248 1736.8565 -0.2683 -154.4548 Hex4HexNAc2Neu5Ac1 Na y fragment 
 
16 1783.9185 1783.8824 -0.0361 -20.2515 Hex6HexNAc2 Na y y 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
17 1825.0582 1824.9089 -0.1493 -81.7935 Hex5HexNAc3 Na y n/a 
 
18 1835.9286 1835.9249 -0.0037 -2.0117 Hex3HexNAc4dHex1 Na y y 
 
19 1865.9644 1865.9355 -0.0289 -15.5034 Hex4HexNAc4 Na y n/a 
 
20 1906.0998 1906.9620 0.8622 452.3480 Hex3HexNAc5 Na y n/a 
 
21 1938.2262 1938.9770 0.7508 387.3654 Hex3HexNAc3dHex3 Na y n/a 
 
22 1973.2603 1972.9032 -0.3571 -180.9772 Hex3HexNAc5S1 Na y n/a 
 
23 1982.2144 1981.9828 -0.2316 -116.8313 Hex4HexNAc3Neu5Ac1 Na y y 
 
24 1988.1708 1987.9821 -0.1887 -94.8879 Hex7HexNAc2 Na y y 
 
25 2009.2571 2010.0141 0.7570 376.7639 Hex3HexNAc4dHex2 Na y n/a 
 
26 2040.0154 2040.0247 0.0093 4.5491 Hex4HexNAc4dHex1 Na y y 
 
27 2070.0524 2070.0352 -0.0172 -8.2873 Hex5HexNAc4 Na y y 
 
28 2081.0826 2081.0512 -0.0314 -15.0742 Hex3HexNAc5dHex1 Na y n/a 
 
29 2111.1038 2111.0618 -0.0420 -19.8977 Hex4HexNAc5 Na y y 
 
30 2151.3088 2152.0883 0.7795 362.3576 Hex3HexNAc6 Na y n/a 
 
31 2186.1502 2186.0826 -0.0676 -30.9270 Hex5HexNAc3Neu5Ac1 Na y y 
 
32 2192.1386 2192.0819 -0.0567 -25.8559 Hex8HexNAc2 Na y y 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
33 2227.1948 2227.1091 -0.0857 -38.4618 Hex4HexNAc4Neu5Ac1 Na y y 
 
34 2243.9967 2244.1245 0.1278 56.9314 Hex5HexNAc4dHex1 Na y y 
 
35 2256.4668 2255.1404 -1.3264 -587.8047 Hex3HexNAc5dHex2 Na y n/a 
 
36 2274.2584 2274.1350 -0.1234 -54.2513 Hex6HexNAc4 Na y n/a 
 
37 2285.1719 2285.1510 -0.0209 -9.1446 Hex4HexNAc5dHex1 Na y y 
 
38 2301.4826 2301.1249 -0.3577 -155.4041 Hex4HexNAc5dHex1 K y n/a 
 
39 2315.2368 2315.1616 -0.0752 -32.4945 Hex5HexNAc5 Na y y 
 
40 2356.4189 2356.1881 -0.2308 -97.9381 Hex4HexNAc6 Na y n/a 
 
41 2396.1753 2396.1817 0.0064 2.6684 Hex9HexNAc2 Na y n/a 
 
42 2412.4529 2412.1556 -0.2973 -123.2227 Hex9HexNAc2 K y n/a 
 
43 2417.2768 2418.2137 0.9369 387.5695 Hex5HexNAc4dHex2 Na y n/a 
 
44 2431.1978 2431.2089 0.0111 4.5705 Hex5HexNAc4Neu5Ac1 Na y y 
 
45 2472.3893 2472.2355 -0.1538 -62.2229 Hex4HexNAc5Neu5Ac1 Na y n/a 
 
46 2489.2782 2489.2508 -0.0274 -11.0166 Hex5HexNAc5dHex1 Na y y 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
47 2501.4300 2500.2668 -1.1632 -465.0296 Hex3HexNAc6dHex2 Na y n/a 
 
48 2519.4264 2519.2613 -0.1651 -65.5144 Hex6HexNAc5 Na y y 
 
49 2547.3744 2547.2563 -0.1181 -46.3788 Hex5HexNAc3Neu5Ac2 Na y fragment 
 
50 2560.4817 2560.2879 -0.1938 -75.6927 Hex5HexNAc6 Na y n/a 
 
51 2571.6228 2571.3039 -0.3189 -124.0171 Hex3HexNAc7dHex1 Na y n/a 
 
52 2591.4095 2592.3029 0.8934 344.7435 Hex5HexNAc4dHex3 Na y n/a 
 
53 2605.2974 2605.2981 0.0007 0.2766 Hex5HexNAc4Neu5Ac1dHex1 Na y y 
 
54 2635.3504 2635.3087 -0.0417 -15.8289 Hex6HexNAc4Neu5Ac1 Na y n/a 
 
55 2646.4292 2646.3247 -0.1045 -39.4986 Hex4HexNAc5Neu5Ac1dHex1 Na y n/a 
 
56 2663.3385 2663.3400 0.0015 0.5578 Hex5HexNAc5dHex2 Na y y 
 
57 2676.3422 2676.3352 -0.0070 -2.6026 Hex5HexNAc5Neu5Ac1 Na y y 
 
58 2681.4390 2682.3846 0.9456 352.6427 Hex4HexNAc6dHex2 H y n/a 
 
59 2689.5491 2690.2839 0.7348 273.2018 Hex4HexNAc5Neu5Ac1S1dHex1 H y n/a 
 
60 2693.5064 2693.3506 -0.1558 -57.8613 Hex6HexNAc5dHex1 Na y y 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
61 2705.6763 2704.3665 -1.3098 -484.0806 Hex4HexNAc6dHex2 Na y n/a 
 
62 2711.6418 2712.2658 0.6240 230.1315 Hex4HexNAc5Neu5Ac1S1dHex1 Na y n/a 
 
63 2718.3647 2717.3618 -1.0029 -368.9411 Hex4HexNAc6Neu5Ac1 Na y n/a 
 
64 2732.6273 2733.3357 0.7084 259.2453 Hex4HexNAc6Neu5Ac1 K y n/a 
 
65 2736.0278 2734.3771 -1.6507 -603.3202 Hex5HexNAc6dHex1 Na y n/a 
 
66 2739.7490 2738.3608 -1.3882 -506.6959 Hex6HexNAc3Neu5Ac1dHex2 Na y n/a 
 
67 2749.5596 2749.3768 -0.1828 -66.4961 Hex4HexNAc4Neu5Ac1dHex3 Na y n/a 
 
68 2754.7314 2754.3347 -0.3967 -144.0003 Hex6HexNAc3Neu5Ac1dHex2 K y n/a 
 
69 2778.3867 2779.3873 1.0006 360.1477 Hex5HexNAc4Neu5Ac1dHex2 Na y n/a 
 
70 2792.3668 2792.3826 0.0158 5.6506 Hex5HexNAc4Neu5Ac2 Na y y 
 
71 2805.4087 2805.4142 0.0055 1.9652 Hex5HexNAc7 Na y n/a 
 
72 2808.3873 2808.3565 -0.0308 -10.9615 Hex5HexNAc4Neu5Ac2 K y n/a 
 
73 2818.6191 2820.4139 1.7948 636.7582 Hex4HexNAc5Neu5Ac1dHex2 Na y n/a 
 
74 2822.4190 2821.3882 -1.0308 -365.2362 Hex5HexNAc7 K y n/a 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
75 2835.4941 2836.3878 0.8937 315.1888 Hex4HexNAc5Neu5Ac1dHex2 K y n/a 
 
76 2850.4400 2850.4244 -0.0156 -5.4576 Hex5HexNAc5Neu5Ac1dHex1 Na y y 
 
77 2875.5028 2875.3391 -0.1637 -56.9435 Hex6HexNAc4Neu5Ac1S1dHex1 Na y n/a 
 
78 2880.4609 2880.4350 -0.0259 -8.9888 Hex6HexNAc5Neu5Ac1 Na y y 
 
79 2892.6719 2891.4510 -1.2209 -422.0691 Hex4HexNAc6Neu5Ac1dHex1 Na y n/a 
 
80 2909.8092 2908.4663 -1.3429 -461.5051 Hex5HexNAc6dHex2 Na y n/a 
 
81 2922.7872 2921.4616 -1.3256 -453.5543 Hex5HexNAc6Neu5Ac1 Na y n/a 
 
82 2925.8219 2925.4452 -0.3767 -128.7370 Hex6HexNAc3Neu5Ac2dHex1 Na y n/a 
 
83 2939.8301 2938.4769 -1.3532 -460.3079 Hex6HexNAc6dHex1 Na y n/a 
 
84 2953.8178 2953.4765 -0.3413 -115.5323 Hex5HexNAc4Neu5Ac1dHex3 Na y n/a 
 
85 2966.5223 2966.4718 -0.0505 -17.0275 Hex5HexNAc4Neu5Ac2dHex1 Na y y 
 
86 2979.7286 2979.5034 -0.2252 -75.5700 Hex5HexNAc7dHex1 Na y n/a 
 
87 3037.7916 3037.5089 -0.2827 -93.0606 Hex5HexNAc5Neu5Ac2 Na y y 
 
88 3054.6198 3054.5242 -0.0956 -31.2913 Hex6HexNAc5Neu5Ac1dHex1 Na y y 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
89 3153.9435 3153.5562 -0.3873 -122.7842 Hex5HexNAc4Neu5Ac3 Na y n/a 
 
90 3185.0339 3183.6032 -1.4307 -449.1960 Hex6HexNAc7dHex1 Na y n/a 
 
91 3198.5942 3198.6029 0.0087 2.7078 Hex5HexNAc5Neu5Ac1dHex3 Na y n/a 
 
92 3211.6706 3211.5981 -0.0725 -22.5707 Hex5HexNAc5Neu5Ac2dHex1 Na y y 
 
93 3216.1354 3215.6182 -0.5172 -160.8213 Hex6HexNAc5dHex4 Na y n/a 
 
94 3224.8470 3224.6297 -0.2173 -67.3692 Hex5HexNAc8dHex1 Na y n/a 
 
95 3228.6410 3228.6134 -0.0276 -8.5405 Hex6HexNAc5Neu5Ac1dHex2 Na y n/a 
 
96 3241.6603 3241.6087 -0.0516 -15.9255 Hex6HexNAc5Neu5Ac2 Na y y 
 
97 3254.9014 3254.6403 -0.2611 -80.2146 Hex6HexNAc8 Na y n/a 
 
98 3329.8075 3329.6611 -0.1464 -43.9652 Hex7HexNAc6Neu5Ac1 Na y n/a 
 
99 3415.8511 3415.6979 -0.1532 -44.8545 Hex6HexNAc5Neu5Ac2dHex1 Na y y 
 
100 3428.9299 3428.7295 -0.2004 -58.4385 Hex6HexNAc8dHex1 Na y n/a 
 
101 3429.8608 3430.7339 1.8040 526.1219 Hex5HexNAc6dHex5 Na y n/a 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
102 3503.6404 3503.7503 0.1099 31.3712 Hex7HexNAc6Neu5Ac1dHex1 Na y n/a 
 
103 3602.8712 3602.7823 -0.0889 -24.6632 Hex6HexNAc5Neu5Ac3 Na y y 
 
104 3616.0508 3615.8140 -0.2368 -65.4924 Hex6HexNAc8Neu5Ac1 Na y n/a 
 
105 3629.7075 3630.8136 1.1061 304.7468 Hex5HexNAc6Neu5Ac2dHex2 Na y n/a 
 
106 3690.9963 3690.8348 -0.1615 -43.7629 Hex7HexNAc6Neu5Ac2 Na y y 
 
107 3777.0170 3776.8716 -0.1454 -38.5090 Hex6HexNAc5Neu5Ac3dHex1 Na y y 
 
108 3790.5323 3789.9032 -0.6291 -165.9700 Hex6HexNAc8Neu5Ac1dHex1 Na y n/a 
 
109 3865.1357 3864.9240 -0.2117 -54.7768 Hex7HexNAc6Neu5Ac2dHex1 Na y y 
 
110 3949.9210 3950.9608 1.0398 263.2356 Hex6HexNAc5Neu5Ac3dHex2 Na y y 
 
111 3976.6976 3976.9876 0.2900 72.9357 Hex6HexNAc8Neu5Ac2 Na y n/a 
 
112 4053.0309 4052.0084 -1.0225 -252.2709 Hex7HexNAc6Neu5Ac3 Na y y 
 
113 4151.6995 4151.0769 -0.6226 -149.9742 Hex6HexNAc8Neu5Ac2dHex1 Na y n/a 
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Continued 
# 
m/z Accuracy Composition Adduct Database Reported Structure 
Experi. Theor. Da ppm      
114 4226.7876 4226.0976 -0.6900 -163.2334 Hex7HexNAc6Neu5Ac3dHex1 Na y y 
 
115 4357.0686 4357.1810 0.1124 25.8069 Hex6HexNAc6Neu5Ac2dHex5 Na y n/a 
 
116 4413.7799 4413.1821 -0.5978 -135.4383 Hex7HexNAc6Neu5Ac4 Na y y 
 
117 4561.4340 4561.2808 -0.1532 -33.5824 Hex7HexNAc6Neu5Ac2dHex5 Na y n/a 
 
118 4588.0070 4587.2713 -0.7357 -160.3498 Hex7HexNAc6Neu5Ac4dHex1 Na y y 
 
119 4590.9089 4591.2914 0.3825 83.3126 Hex8HexNAc6Neu5Ac2dHex4 Na y n/a 
 
120 4761.8258 4761.3605 -0.4653 -97.7098 Hex7HexNAc6Neu5Ac4dHex2 Na y y 
 
121 4935.2062 4935.4497 0.2435 49.3458 Hex7HexNAc6Neu5Ac4dHex3 Na y y 
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Appendix C.2 MALDI-MS spectra profile of N-glycoforms that were derived from 
soluble glycoproteins purified from CC patients’ and health individuals’ blood sera. 
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Appendix C.3 ROC curve analysis of glycosylation indices for differentiating CC patients 
from healthy individuals. 
A-Galactosylation 
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B- Fucosylation 
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C-Sialylation 
 
 
 
